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 S. equi is considered the causative agent of strangles, a very contagious 
disease of the upper respiratory tract of the Equidae. Although S. equi is 
sensitive to some antibiotics, most of the current treatments are ineffective. 
During the recovery period, horses develop a protective immune response 
mostly against the antiphagocytic cell wall-associated M-like protein SeM, 
which encourages the development of efficient vaccines.  
The main purpose of this thesis was to develop and characterise stable 
polymeric particles and study their potential as mucosal S. equi antigens 
adjuvant.  
Non-aggregated and easily dispersible micro and nanospheres based on 
poly-ε-caprolactone (PCL) and poly(lactic acid) (PLA) polymers were 
formulated by the double emulsion (w/o/w) solvent evaporation method 
and fully characterised. BALB/c monocyte macrophages (cell line J774.1A) 
were used in toxicity tests and cellular uptake studies. The influence of 
mucoadhesive polymers (chitosan (CS), glycolchitosan (GCS) and alginate 
(ALG)) and absorption enhancers (spermine (SP) and oleic acid (OA)) in 
particle physicochemical characteristics and consequently in the humoral, 
mucosal and cellular immune responses was as well evaluated.  
The non-toxic cholera toxin B subunit (CTB) is a potent mucosal adjuvant, and 
the oligodeoxynuleotide with repeating C and G motives (CpG) can also be 
used to up-regulate mucosal and cellular immune responses, increasing 
preferentially the T helper type 1 (Th1) cell activity. Therefore, those 
adjuvants were co-administrated with soluble antigen and non-modified PLA 
and PCL particles, in order to assess their eventual synergic effect. Inspite of 
administration route (i.n. and i.m.), S. equi-loaded polymeric systems were 
able to significantly increase systemic and cellular immune responses, when 
compared with free antigens, isolated or co-admixed with CTB or CpG.  
PLA-loaded particles generally induced higher mucosal antibody levels when 
compared with the correspondent PCL. Similar results were attained when 
the immune responses induced by S. equi antigens-adsorbed particles were 
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compared with those elicited by the correspondent entrapped ones. As per 
PCL nanospheres, those formulated with ALG and GCS, seem to induce a 
more balance Th1/Th2 immune response.  
This study also confirmed the potential adjuvant of S. equi antigen-loaded 
PLA nanospheres, and again the mucopolysaccharide GCS induced the most 
prominent immune response.  
SeM recombinant proteins were entrapped in PLA nanospheres and their 
adjuvant potential after i.m. administration in a mouse model was compared 
with that achieved with S. equi extract. In fact, it was possible to observe that 
PLA-GCS and PLA-OA nanospheres are alternative cost-effective 
preparations, able to induce a balanced IgG2a/IgG1 immune response.  
These studies bring new insights into the strangles prevention field as the 
particulate carriers developed during this PhD thesis, mainly those containing 
GCS, are promising adjuvants for a safe vaccine against strangles, with no 
toxicity issues associated to their utilisation, in contrast to other adjuvants that 
have been associated to S. equi antigens. Therefore, the main goal of this thesis 
was accomplished but challenge studies must be done in order to support 
their future utilisation.   
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A gurma é uma doença infecciosa causada pela estirpe altamente virulenta 
Streptococcus equi subsp. equi (S. equi), que afecta os equídeos e se encontra 
disseminada por todo o mundo. Trata-se de uma infecção que afecta o tracto 
respiratório superior, mais especificamente a nasofaringe e a drenagem dos 
gânglios linfáticos.  
O S. equi atravessa as mucosas oral e nasofaríngea, aloja-se nos gânglios 
linfáticos localizados na região da faringe, onde leva à formação de abcessos. 
De um modo geral, a ruptura dos abcessos pode ocorrer internamente, o que 
se traduzirá num corrimento nasal purulento para a bolsa gutural ou para a 
faringe; ou externamente, no caso de abcessos localizados a nível subcutâneo. 
Embora aparentemente saudáveis, muitos animais podem alojar a bactéria 
durante meses, verificando-se elevado risco de contágio durante esse período. 
A resistência do S. equi à fagocitose constitui a principal característica da 
patogénese desta infecção e os factores que mais contribuem para esta 
resistência são a cápsula do ácido hialurónico, a proteína M (SeM) e as 
proteínas segregadas IdeE e Se18.9. 
O combate à gurma passa pelo desenvolvimento de uma vacina eficaz, uma 
vez que, no período de convalescença, 75% dos animais apresentam 
imunidade protectora, que se mantém durante longos períodos de tempo, 
dirigida maioritariamente à SeM. Esta proteína induz a produção de 
anticorpos opsonogénicos IgG e IgA específicos, presentes no soro e nas 
secreções nasais, que vão sucessivamente reconhecer e inactivar a bactéria. 
No entanto, os resultados obtidos com as vacinas actualmente 
comercializadas são decepcionantes, para além de induzirem reacções 
adversas graves. Embora o mecanismo de protecção não se encontre 
completamente esclarecido, o fracasso das vacinas disponíveis parece estar 
associado à ausência da estimulação da resposta imunitária local, ao nível da 
nasofaringe.  
A utilização de micro e nanopartículas poliméricas no desenvolvimento de 
vacinas é actualmente uma das mais promissoras estratégias de luta contra as 
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doenças infecciosas e uma das áreas mais investigadas em Tecnologia 
Farmacêutica. Os antigénios responsáveis pela indução de uma imunidade 
protectora contra vários agentes patogénicos podem ser imobilizados ou 
associados a sistemas de partículas tendo em vista a libertação prolongada 
e/ou pulsada do antigénio, mantendo uma resposta imunológica durante 
semanas a meses. Assim, protegem o antigénio da degradação prematura no 
organismo, permitem a estimulação prolongada do sistema imunitário e 
promovem a interacção entre o antigénio e as células apresentadoras de 
antigénios (APCs). 
Está comprovado que micro- e nanopartículas de PLA e PLGA são bons 
transportadores de antigénios proteícos ou DNA, encapsulados ou 
adsorvidos. Estudos preliminares realizados pelo nosso grupo de investigação 
demonstraram que microesferas de PLGA são potenciais transportadores de 
antigénios do S. equi, uma vez que a incorporação e administração intranasal 
(i.n.) e intramuscular (i.m.) de bactérias mortas ou lisadas resultaram na 
protecção total de ratinhos contra a infecção experimental com uma estirpe 
virulenta do microrganismo. No entanto, tratando-se de uma vacina 
destinada a animais, o polímero PLGA pode comprometer a sua futura 
comercialização, já que se trata de um produto de elevado custo.  
Pelo acima exposto, o objectivo desta tese prende-se com o desenvolvimento 
de partículas transportadoras do antigénio destinadas à administração pelas 
mucosas, formuladas com excipientes capazes de induzir respostas 
imunitárias protectoras contra a infecção.  
O polímero utilizado nestes estudos, poli-ε-caprolactona (PCL), apresenta 
grande potencial pela sua biodegradabilidade, biocompatibilidade, baixa 
velocidade de degradação, hidrofobicidade, estabilidade in vitro, baixa 
toxicidade e baixo custo. A PCL foi utilizada na preparação de 
micropartículas pelo método da emulsão dupla (a/o/a) seguida da 
evaporação do solvente, cuja superfície foi modificada utilizando diferentes 
concentrações e pesos moleculares do CS ou ALG, de modo a avaliar a 
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influência das características da superfície das partículas nas propriedades 
imunoadjuvantes destes transportadores poliméricos (Capítulo 3). 
Produziram-se partículas esféricas, com carga positiva e negativa, cujo 
diâmetro médio variou entre 1,4 e 2,7 µm. A eficiência de adsorção obtida 
para as partículas com carga positiva ou negativa foi muito semelhante (53% e 
54%, respectivamente), não tendo o processo afectado a estabilidade ou a 
integridade estrutural das proteínas constituintes do extracto, o que é um 
pré-requisito para que o antigénio possa desencadear a resposta imunológica 
adequada.  
Como a utilização de solventes orgânicos constitui uma das principais 
desvantagens da utilização do método da emulsificação com evaporação de 
solventes, os resíduos de diclorometano presentes nas microesferas foram 
avaliados por ressonância magnética nuclear, sendo inferiores aos 600 ppm 
permitidos pela legislação aplicável às especialidades farmacêuticas. Além 
disso, em culturas celulares não se observou qualquer toxicidade associada a 
estas partículas. 
Foram estudadas as características físico-químicas das partículas, tais como a 
forma, diâmetro médio, carga eléctrica superficial, capacidade de carga, 
toxicidade, integridade da estrutura proteíca e preservação das propriedades 
antigénicas. As partículas que apresentavam as características físico-químicas 
adequadas foram seleccionadas para estudos de imunização in vivo, de modo 
a avaliar o efeito da composição polimérica, do tipo de associação dos 
antigénios (adsorção ou incorporação), da via de administração (i.n. ou i.m.), 
da natureza do antigénio (extracto enzimático do S. equi ou proteína SeM 
recombinante), assim como da co-administração de diferentes adjuvantes 
(subunidade B da toxina colérica (CTB) e CpG-oligodesoxinucleótidos). 
Seguidamente procedeu-se à caracterização das respostas imunológicas 
humoral e celular induzidas pelos antigénios do S. equi incorporados ou 
adsorvidos à superfície de micro- e nanopartículas de PCL ou PLA, de modo a 
avaliar a influência das características físico-químicas das partículas nas 
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propriedades imunoadjuvantes destes transportadores poliméricos. A estes 
polímeros associaram-se polímeros naturais, mucoadesivos e igualmente 
biocompatíveis, tais como o quitosano (CS) e o alginato (ALG), ou promotores 
da absorção, como a espermina (SP) e o ácido oleico (OA).  
De início, foi investigada a resposta imunológica desenvolvida em ratinhos 
BALB/c vacinados pela via subcutânea (s.c.) com uma única dose de 
partículas formuladas por adsorção, correspondente a 10 µg de SeM. Este 
estudo decorreu durante 300 dias, não se tendo observado quaisquer efeitos 
adversos, nos grupos tratados com microesferas, durante todo o período 
experimental. Mesmo 300 dias após uma administração única de antigénios 
de S. equi adsorvidos à superfície das microesferas de PCL, os grupos 
vacinados com partículas induziram títulos de anticorpos IgG específicos 
mais elevados do que os observados no grupo vacinado com o antigénio em 
solução. Obteve-se uma resposta Th1/Th2 mista, nomeadamente para as 
formulações de PCL com carga superficial positiva. Para além disso, a 
imunização com as microesferas PCL resultou num aumento geral dos níveis 
de citocinas produzidas pelas células do baço, nomeadamente de IFN-γ. 
Após ter sido confirmado o potencial adjuvante das microesferas de PCL, foi 
estudado o efeito da redução do tamanho das partículas e foram comparadas 
as respostas imunológicas sistémicas, locais e celulares induzidas após a 
adminsitração i.n. de duas doses de extracto enzimático do S. equi adsorvido e 
incorporado em nanopartículas de PCL (Capítulo 4). A baixa solubilidade do 
CS a pH fisiológico determinou a sua substituição por um derivado 
hidrossolúvel, o glicolquitosano (GCS), o qual foi dissolvido na fase interna 
da emulsão a/o. Tal como observado no Capítulo 3, preparou-se um outro 
lote de nanopartículas de PCL modificadas pelo ALG, de modo a prolongar o 
tempo de residência das mesmas à superfície da mucosa nasal. 
Formularam-se igualmente partículas de PCL associadas a promotores da 
absorção (SP e OA), a fim de se avaliar o seu efeito nas propriedades 
adjuvantes destes transportadores poliméricos. Todos os sistemas de 
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partículas apresentaram diâmetros médios inferiores a 500 nm. No entanto, 
tanto o diâmetro médio como a captura por macrófagos da linha celular 
J774A.1, foram influenciados pela composição das partículas. As nanoesferas 
contendo antigénios adsorvidos ou encapsulados induziram um aumento dos 
níveis de anticorpos locais e sistémicos, mesmo 12 semanas após a 
administração da primeira dose. As citocinas quantificadas nos sobrenadantes 
de culturas dos esplenócitos dos animais vacinados indicaram o 
desenvolvimento de uma resposta mista Th1/Th2. Tal como esperado, os 
níveis de anticorpos induzidos pelos antigénios incorporados nas partículas 
foram mais baixos do que aqueles quantificados nos fluidos biológicos dos 
animais imunizados com os antigénios adsorvidos à superfície das 
nanoesferas de PCL, o que aliás está de acordo com os perfis de libertação in 
vitro obtido para ambos os sistemas. Ainda que a interpretação global e 
integrada das respostas imunológicas sistémica, local e celular seja 
complicada, é possível verificar que a composição polimérica e o tipo de 
associação do antigénio às partículas determinaram a natureza da resposta 
obtida. Deste modo, é interessante verificar que, embora todos os sistemas 
tenham induzido respostas imunológicas contra os antigénios do S. equi, os 
polissacáridos parecem ter um potencial adjuvante adicional relativamente a 
este sistema de nanoesferas, quando comparados com os promotores da 
absorção estudados. Ainda assim, as nanoesferas de PCL são potenciais 
adjuvantes para os antigénios em estudo, uma vez que não se verificou um 
efeito adicional na co-administração do adjuvante CTB e das nanoesferas 
PCL-PVA.  
No Capítulo 5 descreve-se a comparação do potencial adjuvante das 
nanoesferas de PLA relativamente às nanoesferas de PCL. Este estudo 
confirmou as propriedades adjuvantes das nanoesferas de PLA quando 
associadas às proteínas do extracto do S. equi, sendo de destacar a resposta 
obtida após administração i.n. das partículas formuladas com o GCS. Os 
níveis de anticorpos IgA doseados na solução de lavagem dos pulmões dos 
animais vacinados com as nanoesferas de PLA foram mais elevados do que os 
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quantificados nos correspondentes grupos que receberam as partículas de 
PCL, tendo-se observado a mesma tendência relativamente aos anticorpos 
sistémicos. Estes resultados poderão dever-se à menor velocidade de 
libertação das proteínas de S. equi a partir das nanoesferas de PCL, uma vez 
que o estudo não foi prolongado para além das 12 semanas após a 
administração da primeira dose.  
Finalmente, procedeu-se à incorporação da proteína SeM recombinante em 
nanoesferas de PLA. Tratando-se do primeiro estudo do potencial adjuvante 
de uma proteína do S. equi recombinante purificada associada a 
nanopartículas poliméricas, optou-se pela administração i.m. de duas doses 
de modo a comparar com os resultados obtidos após a imunização dos 
animais, pela mesma via, com nanoesferas de PLA contendo o extracto de S. 
equi. Após as 12 semanas, foi possível concluir que as nanoesferas PLA-GCS e 
PLA-OA contendo o extracto de S. equi constituem uma alternativa viável ao 
antigénio recombinante de elevado custo. Tal como observado para a CTB, o 
CpG administrado com as nanoesferas de PLA-PVA não induziu um aumento 
dos títulos de anticorpos relativamente aos obtidos nos grupos de animais 
vacinados apenas com as nanoesferas, com a excepção das PLA-PVA.  
De uma maneira geral, é possível concluir que o principal objectivo desta tese 
foi atingido, uma vez que foram desenvolvidos e caracterizados sistemas 
alternativos de micro- e nanopartículas capazes de induzir respostas 
imunológicas sistémicas e locais. As partículas formuladas com GCS, 
constituem potenciais adjuvantes a considerar no desenvolvimento de uma 
vacina segura contra a gurma, sem sinais toxicidade associada, 
contrariamente ao verificado no caso dos restantes adjuvantes geralmente 
utilizados com os antigénios de S. equi. Ainda assim, importa referir que a 
composição polimérica adequada à resposta imunológica desejada depende 
do tipo de antigénio de S. equi utilizado. 
Infelizmente não foi possível avaliar a protecção dos animais vacinados contra 
a infecção pela estirpe virulenta S. equi, nomeadamente pelas nanoesferas 
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formuladas com GCS, o que poderia ter confirmado e reforçado os resultados 
obtidos e descritos ao longo desta tese. Juntamente com os ensaios em 
cavalos, esses estudos farão parte do trabalho a ser realizado no futuro, uma 
vez que deles certamente dependerá a aplicação futura destes sistemas.  
 
Palavras-chave: poli-ε-caprolactona, poli(ácido láctico), partículas poliméricas, 
Streptococcus equi subs. equi, adjuvante, vacina. 
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 Strangles                                                                                   
Strangles is an infectious disease that affects the upper respiratory tract, mainly 
the nasopharynx and lymphatic nodes of the Equidae. Foals up to five years old 
are more susceptible to this disease [1, 2]. Nevertheless, it was already reported 
a strangles infection in two humans [3, 4] and one dog [5].  
Streptococcus equi subsp. equi (S. equi) and S. equi zooepidemicus (S. zooepidemicus) 
are the two subspecies of Streptococcus equi, a Lancefield group C Streptococcus. 
The latter are commensal bacteria, frequently found in the upper respiratory 
tract of a variety of animals, such as horses, pigs, cows, dogs and cats. However, 
they can develop a secondary infection, consequence of a viral infection or 
stress. Symptoms of the resulting pathogenic situation are similar to those 
presented by animals suffering of strangles, caused by the virulent strain S. equi. 
This pathogenic agent was firstly identified by Sand and Jenson, in the 19th 
century (1888), and by Schitz in the same year [6, 7]. 
Strangles, from latin strangulina, was reported for 
the first time by Giordano Ruffo, between 1251 and 
1262, in his manuscript De Medicina Equorum, and 
by Alberto Magno, in De Animalibus, in the period 
1258 and 1262 [7]. It is a highly contagious 
worldwide infection, believed to be responsible for 
30% of all reported equine infections [2, 8, 9]. 
Healthy horses are easily infected after ingestion or 
inhalation of environment particles contaminated 
with S. equi. These bacteria cross the oral and 
nasopharynx mucosae, lodge in the lymphatic nodes of pharynge and head 
regions, mainly in retropharyngeal and submandibular lymph nodes, causing 
abscess formation that, with disease progression, will be extremely painful 
(Figure 1.1) [2, 9-11]. 
 
Figure 1.1 – Horse 
infected with S. equi, 
which presents 
swallowed pharyngeal 
lymph nodes (adapted 
from [11]). 
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Infected animals present depression (Figure 
1.2), high fever, swollen lymph nodes and 
acute pharyngitis and rhinitis. These 
abscesses can frequently result in airway 
obstruction, cough and respiratory sounds. 
The drainage of exudate occurs after abscess 
disruption and this mucopurulent liquid 
contains a high amount of infectious S. equi. 
Therefore, at this phase, there is a high risk of 
infection of other horses in contact with the infected animal [2, 13] (Figures 1.3 
and 1.4).  
 
Subcutaneously located abscesses may burst externally. These animals will 
present lesions in the skin that can be confused with a simple injury (Figure 
1.5). In most cases, four to six weeks after the rupture and drainage of abscesses, 
starts up the healing of skin lesions and total recover of the disease, with 
complete elimination of S. equi of animal body [2, 9, 10, 14-16]. 
The S. equi is transmitted through various mechanisms, which, although may 
involve direct contact with nasal secretions or exudate drainage following 
rupture of abscesses, can be often associated with the use of contaminated 
 
Figure 1.2 – S. equi infected horse 
(adapted from [12]). 
 
 
Figure 1.3 – Schematic localisation of 
guttural pouch in Equidae (adapted 
from [11]). 
Figure 1.4 – Nasal secretions 
characteristically presented by S. equi 
infected animals (adapted from [12]). 
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equipment and utensils, since the bacteria can survive in the environment for 
weeks [2, 17].   
 
 
The infected animals have a long period of convalescence and a high level of 
morbidity, leading to a state of chronic illness or even death [1, 2, 10, 13, 17]. 
Indeed, although most cases are benign, about 5% of infections may result in 
more advanced states of the disease, 
consequence of the spread of the bacteria 
by the systemic circulation, with abscess 
formation in other parts of the body, 
particularly at the abdomen, chest and 
joints. The rupture of these abscesses 
(Figure 1.6) will lead to the release of its 
purulent contents, causing the 
pathological situation called 'bastard strangles' that, in most cases, leads to 
animal death [8]. 
The words 'bastard strangles' first appeared in European veterinary literature in 
the seventeenth century, during which the words 'bastard', 'false' and 
'imperfect' were used to refer atypical forms of diseases. However, the poor 
understanding of the etiology of the disease, made difficult the consensual use 
of the words 'bastard strangles' among authors, being then reserved for cases 
involving the formation of abscesses in the retropharyngeal lymph nodes, with 
drainage of its purulent content into the pharynx or the guttural pouch [7]. 
   
Figure 1.5 – Cutaneous lesions observed in the active phase of the disease as a 
consequence of subcutaneously located abscess rupture (adapted from [11]). 
 
 Figure 1.6 – Submandibular 
abscess rupture (adapted from [18]). 
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At the end of the eighteenth century, the term disappeared, being replaced by 
“irregular strangles”, even if expressions like 'abscesses metastases', 'anomalous 
strangles' and 'supressed strangles' were also used. The word 'bastard strangles' 
was again used in the twentieth century, by Hayes and Wortley, both in the 
year 1906, but continued to be applied to denominate different situations, such 
as abscess spreading, disease at a middle stage or abscess formation in the 
retropharyngeal lymph nodes and parotid gland. There were still authors who 
preferred to refer to these cases as "atypical strangles”,”metastatic strangles” 
and “irregular strangles”. Even today the use of that expression is not 
consensual, existing scientists who disagree with its use in the veterinary 
scientific literature [7]. 
 
DIAGNOSTIC 
Animals infected with S. equi have an incubation period of 3 to 15 days, 
followed by abscess maturation and rupture, resulting, in most of the cases, in 
the total recovery of animals. However, the content of abscesses formed in the 
region of the pharynx can lodge in the guttural pouch (Figure 1.7), which may 
occur without any signs of the disease and, apparently, with full recovery of the 
horse [2, 9, 10, 14 -16]. The guttural pouches are unique in Equidae and consist in 
two isolated compartments, placed to the left and right in the throat, and 
communicate with the pharynx by a hole (Figure 1.3). This aperture opens 
intermittently, allowing the release of bacteria into the throat of these animals, 
and hence for the environment (beds, pastures, forage, drinking water, feed, 
utensils). This state of the disease occurs in 10% of infected animals and appears 
to be a consequence of an incomplete drainage of purulent liquid after 
disruption of abscesses present at the guttural pouch or in the lymph nodes 
[19]. As a matter of fact, though apparently healthy, these animals can 
accommodate S. equi for months, constituting a high risk of contamination of 
other horses during that period [2, 9, 10, 14-16, 20]. 
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The anti-S. equi antibodies can be identified in the serum of horses by a variety 
of methods, such as radioimmunoassay, bactericidal indices, mouse protection 
test and gel diffusion precipitin test [2, 9, 10, 14-16]. However, these techniques 
hardly detect the S. equi housed in the guttural pouch, which means that 
animals are identified as healthy for long periods of time, since they do not 
show any clinical signs of disease. Thus, the horse carrying the infectious S. 
equi, harbouring and preserving the organism for months, is the most important 
cause for the maintainance of the disease for prolonged periods of time, since 
the S. equi only survives for some weeks in the environment [10, 14]. 
Consequently, strangles remains an endemic disease worldwide and is of great 
economic importance since, after diagnosis, the infected animals will have to be 
isolated from other horses living in the stable and undergo a disabled and 
controlled mobility, until three negative results are obtained, during a period of 
two weeks. Still, to prevent any outbreaks, it is necessary to monitor the 
animals that have recovered from the disease for extended periods of time, 
since there are cases of animals carrying S. equi for 15 months without showing 
any clinical signs during the last 12 months [20]. As mentioned, the isolation of 
animals is particularly important since the risk factors associated with the 
development of this sub-clinical state of disease are not known. 
Epidemiological studies can help to clarify the reasons why some animals 
become carriers of S. equi, while others wholly eliminate [2]. 
Figure 1.7 – Chondroid in the guttural 
pouch as a consequence of 
mucopurulent liquid accumulation 
and hardening with time (adapted 
from [2]). 
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Currently, the detection of animals carrying the infectious agent is carried out 
by the culture of secretions from the nasopharynx or, preferably, the upper 
respiratory tract and guttural pouches obtained by endoscopy. The latter can 
assess the tissues and the surrounding area, as well as collect samples from the 
washing of these pouches, which will be analysed by laboratory culture 
methods and amplification polymerase chain reaction (PCR) [16, 21]. However, 
the time needed to obtain the results and the cost of diagnosis, associated with 
the variety of mechanisms of S. equi transmission, make it difficult to implement 
the utilisation of these tests on a large scale in the event of an outbreak, as well 
as the rapid identification of animals that have been in contact with the infected 
horse and therefore may develop the disease [22]. Thus, it is essential the 
development of efficient and practical diagnostic tests, capable of direct use in 
the habitat of animals and able to quickly detect the presence of bacteria in 
infected animals, especially those who are in the prolonged period of 
convalescence and those that are true reservoirs of the bacteria. Indeed, these 
two cases are directly related with the main limitations of novel diagnostic tests. 
For example, results obtained in healthy and convalescent animals with the 
latest commercially available enzyme-linked immunosorbent assays (ELISA) 
[23], based on the detection of the main virulence factor of these bacteria (S. equi 
M protein, SeM), were not conclusive [2, 9, 14, 15]. 
The development of these tests requires a complete identification of 
quantitative and qualitative differences between the immune responses of 
animals carrying the S. equi and those identified in animals that have fully 
recovered from the disease, mainly for the absence of clinical signs and the 
elimination of bacteria. This information, in addition to result in a greater 
knowledge of risk factors in the development of persistent infection, may help 
in the prevention or resolution of the problem underlying the horses, 
apparently healthy, that constitute carriers of the bacteria, which will certainly 
contribute to reduce the incidence of this disease [2 , 9, 14]. 
Overall, strangles prevention is based on the quarantine of infected animals and 
in the identification of which may have been in contact with them, to enable 
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their isolation for weeks, preventing recurrent outbreaks of the disease. Having 
in mind the mechanisms of transmission, it is easily expected that the cleaning 
conditions of places where animals are kept, as well as persons who have 
contact with them, are particularly important. 
 
TREATMENT 
Strangles treatment is not consensual in the veterinary community because, 
although S. equi is sensitive in vitro to some antibiotics such as penicillin, 
erythromycin, lincomycin, tetracyclines and chloramphenicol, some prefer to 
allow the progression of the disease, drain the abscesses and eliminate the 
bacteria from animal body, while others may choose to prevent its development 
through the use of antibiotics [1, 2, 24]. 
Most of the treatments are not effective when the animal is already presenting 
the clinical signs of disease and a considerable number of animals recover 
completely within a few weeks without treatment. Moreover, some 
veterinarious believe that treatment with antibiotics contributes to delayed 
abscesses maturation, favouring the systemic spread of the infectious 
microorganism, which is the most serious stage of the disease, mainly resulting 
in death [10, 18]. Thus, although each strangles outbreak has individual 
characteristics, particularly regarding the financial condition of owners, the 
type of animal accomodation, the number of horses infected or in contact with 
the infectious agent and the degree of disease progression, its prevention seems 
to be the priority. The quarantine period should be adopted as soon as it is 
suspected or diagnosed the presence of the pathogen. To help the recuperation 
of animals, usually quite weak, analgesics and anti-inflammatories may be 
administered so that they can again eat and therefore ingest an adequate 
nutritional support, promoting the recovery process. 
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S. equi virulence factors 
Although this is a worldwide endemic disease, little is known about the 
virulence factors of S. equi, although most of the work done in this field has 
been targeted for the study of substances secreted or present at the surface of 
the bacterial cell [8, 25- 27].  
Different isolated S. equi strains showed a great uniformity within their genetic 
composition, in contrast to the high variability showed by S. zooepidemicus 
strains. Recent studies also confirmed that the S. equi is a clone that has evolved 
from S. zooepidemicus [2].  
The pathogenesis of S. equi infections is not fully understood, although the 
study of its genome has contributed for its better understanding [27, 28]. 
The infectious mechanism occurs in three different phases:  
Phase I – S. equi adhesion to the upper respiratory tract mucosa;  
Phase II – S. equi respiratory epithelium invasion; 
Phase III – S. equi resistance to phagocytosis by polymorphonuclear cells. 
  
PHASE I – S. equi ADHESION TO UPPER RESPIRATORY TRACT MUCOSA  
The animals may be contaminated by a variety of transmission mechanisms, 
which seem to be dependent on the ingestion or inhalation of S. equi. The 
microorganism starts by adhering to the upper respiratory tract epithelium and 
then crosses the oral and nasopharyngeal mucosae. Overall, this first step is 
based on the binding of bacteria to the mucosal membrane and appears to be 
critical for the infection development and bacteria colonisation. It involves the 
participation of a series of adhesins already identified, such as the following: 
 
 Fibronectin binding proteins 
During this first phase, fibronectin binding proteins seem to assume particular 
importance and the proteins SFS, ZAG and FNE have been already identified in 
S. equi strains [6, 27, 29-31].  
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The binding of bacterial surface proteins to the fibronectin, a dimeric 
glycoprotein found both in plasma and in the extracellular matrix, appears to be 
one of the mechanisms used by S. equi to establish their association with the 
animal cells and further internalisation. Thus, the identification of S. equi 
proteins involved in these connections has been the subject of several studies in 
order to better understand and possibly control the transmission of these 
bacteria [32-34]. These protein constituents of Gram-positive bacteria, as S. equi, 
able to establish links with fibronectin, have the characteristics usually 
attributed to the bacterial cell wall proteins, of which it is important to highlight 
the signal peptide, the C-terminal domain, that contains the anchor motif (e.g. 
LPXTG) that binds these proteins to the bacterial surface, and the hydrophobic 
domain, followed by a series of positively charged residues. In the C-terminal 
domain there is a region consistituted by repeated residues, responsible for the 
connection to the fibronectin N-terminal fragment (29 kDa), created after its 
digestion with trypsin. Other proteins can also connect through a domain not 
repetitive to another region of the fibronectin molecule [6, 30]. The subspecies S. 
equi bind to the native fibronectin. However, unlike S. zooepidemicus, does not 
recognize the 29 kDa fragment of this protein. 
 
 Lipoproteins 
From the study of the bacterial genome it was possible to assess that the 
lipoproteins constitute about 2% of the proteomes of the genomes of 
Gram-positive bacterial strains. These proteins, after suffering a lipid 
modification, remain anchored in bacterial capsules and participate in 
important functions related to the input of nutrients, cells adhesion, protein 
maturation and transmission of signals in the cell. So, it is possible to predict 
that they are likely to play a key role in the interaction between the bacterial 
and host cells.  
The bacterial lipoproteins are synthesised with type II signal peptides that 
direct them to the protein export route and later to a pathway where they will 
be modified, which requires the involvement of two enzymes and is 
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characteristic of prokaryots. The first is the enzyme prolipoprotein 
diacylglyceryl transferase (Lgt), which transfers a diacylglycerol group of 
membrane phospholipids to a cysteine residue, located in the cleavage region of 
the type II signal peptides. The prolipoprotein signal sequence, situated before 
the modified cysteine, will then be cleaved by lipoprotein signal peptidase 
(Lsp), leaving the lipid anchor unit in the N-terminal of this amended 
lipoprotein. This route appears to occur in Gram-positive bacteria in general, 
and both enzymes Lgt and Lsp are major targets of antimicrobial drugs, since 
they are exclusive of prokaryots and probably play important roles in the 
bacteria virulence and colonisation. Although Lsp and Lgt are not essential for 
the bacterial growth, several studies have shown that they are vital for the 
virulence of various bacterial agents, such as Listeria monocytogenes, 
Mycobacterium tuberculosis and Staphylococcus aureus, in the case of Lsp, and 
Streptococcus pneumoniae, for Lgt [8].  
Three lipoproteins were already characterised: lipoprotein acid phosphatase 
enzyme (Lpp) [35], metal binding lipoprotein (MBL), which is PsaA of 
Streptococcus pneumoniae homologous involved in the uptake of manganese [36], 
and hyaluronate (capsule)-associated protein (PAHs), that seems to be 
implicated in the capture of oligopeptides [37]. Indeed, the capsule hyaluronic 
acid of S. equi participates in the bacterial adhesion to the host cells, being an 
important factor in the first phase of the S. equi pathogenesis. It was observed 
that mutant strains without capsule had lower virulence in mice and horses [38, 
39]. 
These features attracted the attention of Hamilton et al. (2006) to study the 
importance of these proteins in the virulence of S. equi and, if confirmed, if the 
effect was due to a particular lipoprotein or to the path of production of these 
proteins [8]. They studied the role of a lipoprotein in the in vitro colonisation of 
equine epithelial tissues by S. equi, and the development of the disease in a 
mouse model and ponies. The virulence of a mutant strain, deficient in 
lipoprotein maturase, was evaluated, in order to better understand the 
contribution of this lipoprotein for the pathogenesis of this microorganism. As a 
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result, the colonisation of the airway epithelial tissues was reduced after their 
inoculation with the mutant strain above referred, compared with the bacterial 
colonies seen after adding a virulent strain or a mutant strain to the cell culture, 
in which the enzyme Lgt was not synthesised (S. equiLip) in order to identify 
whether the possible effect would be due to the virulent lipoprotein maturase in 
study or the lipoproteins in general, since the Lgt catalyses the first step of the 
lipid modification cascade. In this case, it was observed a decrease of purulent 
mucus production and none of the five infected ponies have shown clinical 
signs of disease, unlike those infected with the virulent strain or inoculated 
with the mutant strain S. equiLip. These results suggest that lipoprotein 
maturase is a component to be considered in the formulation of vaccines for the 
prevention of strangles, since it seems to significantly contribute to S. equi 
virulence [8]. 
 
PHASE II – S. equi RESPIRATORY EPITHELIUM INVASION 
The second phase of the infection mechanism involves the invasion of 
epithelium respiratory tract by S. equi bacteria and their transport to the lymph 
nodes and blood vessels present in lamina propria. The bacterium produces a 
series of degradation enzymes, such as hyaluronidase [40] and cytolitic toxins 
as streptolisin-like hemolysine, which are thought to have an important role in 
this particular phase [41]. 
 
PHASE III – S. equi RESISTANCE TO PHAGOCYTOSIS BY POLYMORPHONUCLEAR 
CELLS. 
 
The resistance to phagocytosis is the main characteristic of the pathogenesis of 
this infection, essential for abscess development. SeM (FgBP with 58 kDa) and 
SzPSe (40 kDa) are bacterial cell wall antiphagocytic proteins called S. equi M 
proteins. They are fibrillar α-helicoidal molecules showing genetic homology 
only between their signal and cell wall associated sequences [42]. These 
proteins are antiphagocytic and opsonogenic, as antiserum is opsonic for their 
strain. Moreover, they have the ability to bind both to IgG and fibrinogen, 
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therefore being designated as M-like fibrinogen binding proteins. They also 
limit the C3b complement factor deposition on bacterial cell surface, which is 
the basis for their antiphagocytic action, as S. equi will not be identified by 
phagocytic cells as a foreign element, [42-44]. The SeM and the SzPSe, when 
isolated from different S. equi geographically located in different places, have 
the same molecular weight. 
The role of SzPSe, the second S. equi M protein, in the virulence of S. equi is not 
yet known. In addition, it was found that SeM is responsible by 70% for 
fibrinogen binding, so that this mechanism can not be predominantly attributed 
to SzPSe M protein. The low homology between cellular wall external domains 
of these proteins suggests that the binding to fibrinogen seems to be dependent 
on the participation of other molecules beyond the linear sequence of amino 
acids [42].  
It is important to mention that S. equi ability to resist killing by neutrophils also 
depends on the expression of the hyaluronic acid capsule [39]. Moreover, the 
factors that most contribute for phagocytosis resistance are: 
• hyaluronic acid capsule; 
•  SeM - which requires the capsule for its function;  
• the secreted proteins: IdeE, which blocks the phagocytosis 
mediated by C3b factor, and Se18.9 that binds to the complement 
regulatory factor H [27]. 
 
 SeM 
Taking into consideration the genetic homology observed between S. equi 
strains, it is easy to see that this bacterium produces a single type of SeM, with a 
molecular weight of 58 kDa [2, 42]. However, Chanter et al. (2000) and Menhan 
et al. (1998) found that SeM is not entirely uniform, which was surprising given 
the recognition of different strains of S. equi by serum obtained from 
convalescent horses [45, 46]. These authors observed genetic differences in 
sequences located immediately after the N-terminal, between 37 and 183 amino 
acids, which appear to be subject to great variability [45, 46]. Forty three SeM 
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alleles were identified, apparently related to geographical distribution, since 
some appear to be typical of North America and Japan, while others have been 
isolated in outbreaks occurred in Europe, Brazil and Australia. Therefore, the 
genetic sequencing of SeM of bacteria isolated in some outbreaks may help to 
better understand the epidemiology of this disease, allowing to identify any 
transmissions occurred during animal transportation around the globe and to 
develop new strategies for controlling the disease [2].  
The SeM proteins are the main protective antigen. They can stimulate the 
production of anti-SeM specific antibodies, which are the basis of the so-called 
bactericidal reaction of the immune serum. It is not known the influence of 
N-terminal sequence variation of SeM of different S. equi strains in the 
protection conferred by vaccines that target this protein, although it may 
explain the modest results obtained in animal protection after being infected 
with these bacteria [11, 36, 42]. Although SeM presents an antiphagocytic 
activity similar to group A M proteins, repetitive regions A and B characteristic 
of this group of proteins are not found in SeM genetic sequences, even if their 
secondary strucuture is similar. The SeM can be called M protein because it 
satisfies the required opsonogenicity typically assigned to this family of 
proteins [42]. In conclusion, SeM is essential to the persistence of the disease, 
not only because it plays an important role in the mechanism of resistance to 
phagocytosis, but also because, apparently, the protective immunity requires 
specific anti-SeM antibodies [42].  
Indeed, previously infected animals develop a protective immune response 
against SeM, presenting immunocomplexes of IgG and IgA anti-SeM, both in 
serum and in nasal secretions. The development of this immune response, 
verified especially during the active phase of the disease, appears to result from 
the continuous inflammatory responses triggered in animals and contribute to 
the genetic variability of SeM, which results from insertion of amino acid 
residues in the genetic sequence. Some authors think that this variation is the 
key for the persistence of the disease and bacteria virulence, since it changes the 
antigenic epitopes and is thus not recognised by the animal body. However, 
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further studies are needed to prove this hypothesis [2]. Combating and 
preventing the serious complications of the disease depend on the development 
of an effective vaccine [1, 36]. The response reflected in the production of 
anti-SeM antibodies has motivated the search for a vaccine based on the units of 
these M proteins [10]. However, taking into account the variability previously 
mentioned, regarding the development of vaccines, an interesting approach 
would be the use of subunits characteristics of strains of the area where the 
outbreak occurred, although this does not constitute a practical approach [6, 
25]. The commonly used vaccines are composed by several subunits, not subject 
to significant variations from strain to strain, or attenuated S. equi bacteria that 
will eventually stimulate immunity against various antigens, resulting in a 
more efficient protection against different S. equi strains. The globalisation of its 
use might allow greater control of this endemic disease.  
Other bacterial cell surface proteins may be subject to such changes and also 
involved in the S. equi virulence [6, 25, 47, 48].  
In summary, while it is possible to identify and study each of these three 
phases, much remains unclear, particularly the mechanisms underlying the 
invasion and binding by S. equi, and their interaction with the phagocytic cells. 
 
 Other antigens important for S. equi resistance to phagocytosis  
Apparently, S. equi strains have a range of antigens that bind to both major 
histocompatibility system (MHC) class II molecules and T cells, resulting in 
their stimulation and immune response direction, with the release of cytokines 
IL1, IL2, IL6 and tumor necrosis factor β (TNF-β), developing the characteristic 
symptoms of the acute phase of flu disease [2].  
Only the antiphagocytic proteins Se18.9, SeM, SePE-I and SePE-H are 
exclusively expressed by S. equi. The latter two are pyrogenic exotoxins, capable 
of inducing strong mitogenic responses in mononuclear cells present in horse 
blood, although only the last one has the ability to cause high fever in these 
animals [49]. Similarly to protein SeM, sera of convalescent horses have 
antibodies specific to those two mitogens, the animal being protected against 
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the effect of SePE-I [39, 49]. These agents may also be important for abscess 
formation and thus for S. equi evolution and ability to redirect the immune 
response triggered upon infection. However, it is unknown if this mitogen will 
be able to induce protection against strangles because, despite the vaccination 
with SePE-I has protected animals against its pyrogenic effect, their infection 
with S. equi was not further evaluated. In addition, there are no published 
results supporting anti-SePE-I antibody production after administration of this 
particular protein [27]. 
Two other  S. equi mitogenic toxins, SPEL and SPEM, were recently identified in 
100% and 72%, respectively, strains of S. equi studied by Waller et al. (2007) [2]. 
These toxins can enhance the immune response induced by SePE-I, being 
necessary to develop opsonogenic antibodies against the three mitogens 
previously mentioned, to confer animal protection [50, 51].  
Currently accepted, the main S. equi virulence factors are the capsule hyaluronic 
acid and the S. equi cell wall antiphagocytic M proteins. 
 
PREVENTION OF THE DISEASE 
Strangles combat seems to be dependent on the development of an effective 
vaccine since 75% of animals in the convalescent period have a protective 
immunity that is maintained for long periods of time, which can go up to 5 
years, directed mostly against the protein SeM. The IgG and IgA specific 
anti-SeM present in serum and nasal secretions, will successively recognise, 
connect to and inactivate the S. equi that invade the animal organism. Thus, this 
protective immune response developed during infection supports the idea that 
a vaccine will be able to prevent strangles infection [1, 2, 9, 10, 17, 36]. 
S. equi isolated from different organisms are genetically and antigenically 
similar, and their protective immunity seems to be specific of this particular 
subspecies. Thus, vaccination with S. zooepidemicus will not give protection for a 
subsequent infection with S. equi, although the two subspecies have a DNA 
homology of more than 92% [42].  
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It is recommended the regular vaccination of horses against strangles and 
despite the development of many research projects since the 80s, directed to the 
development of an effective vaccine, the results obtained are disappointing, 
including the widely used commercially available vaccines. These vaccines, 
consisting of inactivated microorganism or SeM rich extracts, isolated or 
associated to adjuvants, do not have effectively contributed to control the 
disease and to protect horses against S. equi infection, causing serious adverse 
reactions [2, 9, 10, 25, 28, 42, 52].  
The use of vaccines associated to efficient diagnostic tests seems to be the key to 
prevent and control strangles outbreaks [2, 9]. In Portugal no vaccine is 
available and despite the extensive ongoing research, there are only three 
vaccines marketed over the world [14]. 
Strepguard® with Havlogen® (Intervet Ltd), Equivac® S and Equivac 2 in 1 
(Pfizer Animal Health Pty Ltd) vaccines are S. equi enzymatic extracts 
administered by intramuscular route (i.m.) [25, 53, 54]. The former is 
co-administered with the adjuvant Havlogen® in order to reduce adverse 
reactions usually assigned to this type of vaccine, and is currently marketed in 
Canada. The use of Equivac® 2 in 1, an association between tetanus toxoid (TT) 
a S. equi extract, and Equivac® S vaccines are approved in Australia and New 
Zeland.  
Although the mechanism of protection is not fully known, the failure of the 
vaccines currently available seems to be associated with the lack of stimulation 
of local immune responses at the nasopharynx, and therefore to low levels of 
mucosal IgA and IgG subclasses, which are protective antibodies similar to 
those found in convalescent horses [9, 10, 13, 55].  
Generally, the immune response developed locally plays a predominant role in 
protecting the upper respiratory tract against the infection by bacterial agents. 
Furthermore, although the immunity to S. equi is linked to the production of 
high levels of systemic anti-SeM antibodies, it is accepted that these antibody 
titres are not necessarily associated with the protection afforded by their 
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immune response, being predominant the response developed locally [2, 10, 
36]. These facts suggest that these IgA antibodies produced in the respiratory 
tract are extremely important for the prevention and control of this disease, 
particularly at the ports of entry of this bacterial agent, and their action will be 
complemented by systemic antibodies [2, 9, 10, 36, 56, 57]. 
In order to distinguish the types of immune responses, Galan and Timoney 
(1985) conducted a study with ponies, which were treated with proteic 
supernatants obtained in S. equi cultures, associated with the adjuvant 
aluminium hydroxide [24]. In order to verify the protection given to animals, 
these authors induced the disease in ponies and then evaluated their response 
against S. equi extracted proteins, particularly assessing the levels of IgA and 
IgG in serum and in the nasal discharge. Differences were observed at the level 
of specificity of the antibodies produced in serum or at the nasopharyngeal 
mucosa. The IgA was the bacterial isotype predominantly present in nasal 
secretions. The systemic antibodies recognised a variety of proteins present in 
both the extract and supernatant of bacterial culture, not only of S. equi, but also 
of S. zooepidemicus equi. In contrast, the immunoglobulins IgA and IgG of mucus 
recognised only two proteins with molecular weights of 41 kDa and 46 kDa 
present in the enzymatic extract, with no differences between the proteins 
recognised by IgG or by IgA. Moreover, the seric immunoglobulins recognised 
the smaller hydrolytic products of the M protein (29 kDa and 37 kDa). Thus, 
these authors found some specificity for the proteins recognised by serum 
antibodies and those produced at the nasopharynx. This divergence in the 
specificity of the nasal and systemic antibodies may explain differences in local 
and systemic immune responses of horses to S. equi, and supports the 
independence between them [24]. The protection conferred to convalescent 
horses after new infection with S. equi was higher than that developed after the 
first infection, so the authors concluded that the protective immune response 
appears to be associated with nasopharyngeal antibodies. Possibly, the 
immunoglobulins IgG and IgA produced locally not only help to prevent the 
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development of the disease, but also to reduce the entry of the bacterial agent at 
the pharynx.  
Since 1997, it has been approved in the United States of America (USA) the use 
of a vaccine (Pinnacle®, Fort Dodge) based on a genetically modified S. equi 
strain, without capsule and no virulent [58]. This vaccine is administered 
through the nasal route and prevents or reduces the severity of clinical signs 
attributed to this disease. It was developed in order to stimulate systemic and 
mucosal responses, similar to the protective immunity shown by animals 
during the convalescence period. However, although it allowed the stimulation 
of antibodies produced locally at the nasopharynx similar to those found in 
convalescent animals, horses treated with this vaccine showed severe adverse 
reactions, mainly mucopurulent nasal discharges and abscess formation mostly 
in local of injection, but also elsewhere in the animal body, which contributed 
for its rejection by the European authorities [13, 55, 59]. Moreover, animal 
protection was limited to a short period, and therefore the administration of 
repeated doses of the vaccine was necessary [22, 27]. 
In 2004 Equilis StrepE®, (Intervet Ltd) was introduced in the United Kingdom 
(UK) and USA. It is a vaccine based on a live attenuated S. equi, which 
parenteral administration conferred protection to all 
treated animals, but also resulted in important 
reactions at the injection site [60]. Alternatively, an 
intradermal administration (i.d.) in the upper lip 
mucosa was used (Figure 1.8), and conferred only a 
short duration of protection in 50% of treated animals. 
Consequently, it is advised the administration of this 
vaccine every three months only to animals with high 
or moderate risk of S. equi infection, since there were 
reported adverse reactions, mainly swelling of the site 
of infection, fever and, more occasionally, the 
formation of abscesses in the lymph nodes, which disappeared after 3 weeks [2, 
14, 26, 27]. Some treated animals also developed the disease, which may be due 
Figure 1.8 – Equilis 
StrepE® vaccine 
(adapted from [11]). 
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to infection with the virulent bacteria through contact with infected animals or 
the environment, and not induced by the vaccine itself [22]. However, all 
batches of vaccine were withdrawn and are sold only in the African market 
[60]. Even in countries where the vaccine was used with regularity, strangles 
remained as an extremely infectious and endemic disease.  
Taking into account the virulence factors previously mentioned, some 
researchers believe that any resolution of the problem is dependent on the 
stimulation of multiple epitopes in order to induce high levels of antibodies and 
provide greater protection for animals by the administration of vaccines based 
on immunogenic S. equi cell surface proteins [2, 61]. Other authors have tried to 
clarify the molecular mechanisms underlying the pathogenesis of S. equi and 
thus find other virulence factors that may be potential candidates for the 
development of alternative vaccines [1, 6, 29, 31, 59].  
Flock et al. (1999) have been investigating the formulation of a vaccine made by 
subunits based in several S. equi surface proteins previously identified, as it was 
found that vaccination with surface proteins of other Gram-positive bacteria, 
such as Staphylococcus aureus, in their recombinant form, have provided 
encouraging results in experimental models of infection [62, 63]. The specific 
antibodies produced against these proteins seem to have a double protective 
action, as they inhibit the bacterial cell wall adhesion to cell membranes and 
also by present opsonogenic activities [1, 59, 62, 63]. Three S. equi recombinant 
proteins were used for immunisation of mice and horses: SAE, a protein that 
binds specifically to α2-macroglobulin, serum albumin and IgG of the host [64]; 
SPS, a fibronectin-binding protein [6], and FNZ, which is also a 
fibronectin-binding protein of the S. equi zooepidemicus [31], and that occurs in 
the truncated form (FNE) in S. equi. These proteins were studied alone or in 
combination, resulting in a significant protection, which was enhanced by the 
co-administration of FNZ and SPS proteins [1].  
In another study, the same group assessed the level of protection conferred by 
three other types of proteins (15-20 µg per dose)  located in the cell surface, 
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recently described as antigens in a mice strangles model: CNE, a protein that is 
the main factor responsible for S. equi binding to collagen; SclC (24 kDa), which 
presents a sequence of amino acids similar to the collagen [47]; and FNEB, a 
fibronectin-binding protein recently discovered (Figure 1.9) [51, 59, 65]. Animal 
protection was obtained after the administration of the first two above 
mentioned proteins, although the same result was not observed with FNEB (40 
kDa). Co-administration of CNE (67 kDa) and  EAG (19 kDa) led to a 
synergistic effect, contrary to the weak immune response obtained after the 
administration of EAG alone, which seems to be a result of the 
immunostimulatory action of CNE over EAG [59]. However, the CNE alone 
gives a significant immune response and protection, so that the synergistic 
effect may be due to the development of a response directed to two bacterial 
targets. Therefore, these observations allow predicting that the addition of a 
third antigen may also increase the protection level, although this has not yet 
been studied. CNE, SAE, FNZ, SPS and SclC induce the production of specific 
antibodies in animals infected by S. equi, which is a pre-requisite for their use as 
potential vaccine candidates [1, 47]. Probably, these antibodies may also be 
opsonogenic, although this has not yet been confirmed. 
In summary, this group obtained promising results, suggesting that CNE, SclC 
and SAE are, among the recombinant proteins, the most promising for future 
studies of strangles vaccines, being potential alternatives to the use of live 
attenuated bacteria, even if their effectiveness and safety in horses has yet to be 
tested [1, 22, 59].  
According to Waller and Jolley (2007), all currently available vaccines are not 
ideal in terms of safety, efficiency and practical use in the field. Thus, it remains 
necessary to develop a safe and effective vaccine against strangles, able to 
induce a long lasting immune response, which seems to be dependent on the 
concomitant stimulation of serum and mucosal antibodies [2, 9, 10, 27]. 
The development of this vaccine is limited by the incomplete knowledge of S. 
equi protective antigens and mechanisms of humoral and cellular mediated 
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immunity associated with this protection. However, the possibility to consult 
the gene sequences of S. equi and S. zooepidemicus equi allowed the identification 
and expression of immunogenic proteins, which are potential vaccine 
candidates [26].  
Timoney et al. (2007) studied the protection conferred by associations of S. equi 
recombinant proteins, present at its surface or secreted, when administered to 
ponies. The proteins identified in the S. equi genetic library by the serum of a 
pony previously infected, were SeM, recSzPSe, Se73.9(CNE), Se51.9 (adhesion 
protein), Se44.2 (bind to IgG and platelets), Se46.8, Se75.3 (bind to multiple 
ligands), Se110.0, Se42.0 and 18.9 (antiphagocytic). All these proteins are 
present in the bacterial cell surface, except the last two, which are secreted by S. 
equi (Figure 1.9) [27]. This reinforces the idea that the proteins exposed at the 
bacterial surface appear to play a greater role in horse immune response, than 
those which are in the cytosol.  
 
 
 
 
 
It is also required additional studies involving the administration of these 
proteins through the mucous membrane and co-administration with different 
types of adjuvants, including delivery systems, to enhance immune response 
developed by their isolated administration. 
Figure 1.9 – Different types of S. equi cellular surface protein presentations 
(adapted from [27]).  
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Adjuvants used with S. equi antigens 
General aspects 
An effective immune response leads to the production of high levels of 
antibodies and the stimulation of cytotoxic T lymphocytes (CTL). Vaccines have 
the ability to induce the immune system so that, if a second contact with the 
antigen will occur, there is a rapid and extensive immune response, avoiding 
the effect of the pathogenic microorganism [66]. 
 
The immune system can recognise antigens by: 
 
→ Antibodies or immunoglobulins (Ig) - expressed and secreted by B 
lymphocytes, and have the ability to bind to foreign structures, preferably 
those who are in the extracellular environment. This type of recognition 
depends on the native structure of the antigen; 
→ T lymphocytes – recognise antigens captured by other cells and 
presented by the complexes formed between them and proteins of the MHC. 
The mechanism depends on the sequence of antigen units, rather then its 
three-dimensional structure. The T lymphocytes are divided in two groups, 
depending on the type of receptors expressed at their surface, CD8+ (CD8+ 
T-lymphocytes) and CD4+ (CD4+ T-lymphocytes), which determine the class 
of MHC system molecules involved in the complex formation. Thus, CD8+ 
receptors recognise complexes formed between fragments of antigen, usually 
synthesised by the cell (such as viruses), and MHC class I molecules, while 
the CD4+ T-lymphocytes will bind to complexes of peptides, extracellular or 
internalised by cells, and MHC class II molecules [67-69]. 
The cytokines play a key role in the activation, growth and differentiation of 
B and T cells, which interact with each other, and secrete factors that will 
stimulate other types of cells and possibly themselves. The CD4+ T-cells can 
be divided into two subclasses, depending on lymphokines secreted after 
their stimulation and activation. Thus, the cellular immune response is 
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mediated by Th1 (T helper type 1) cells, secreting interleukin 2 (IL2), 
interferon gamma (IFN-γ) and tumor necrosis factor beta (TNF-β), that will 
increase the expression of genes in antigen presenting cells (APCs) and 
activate B cells differentiation and IgG2a secretion. The production of 
cytokines after Th1 cells activation is extremely important for the eradication 
of S. equi pathogen, providing a useful vaccine for the immunisation of S. 
equi carriers. The humoral immune response is mediated by subclass Th2 
cells, producing IL4, IL5, IL6, IL10 and IL13, being the IgG1 isotype primarily 
secreted after B cells activation [69, 70]. 
 
Wu and Russell (1997) showed that systemic and local immune responses are 
able not only to prevent infection, but also induce an immune response at the 
mucosa by the production of immunoglobulins IgA (SIgA) directed to specific 
pathogens [71]. This is of extreme importance especially when this mucosa is 
the port of entry to bacteria, such as S. equi, since the SIgA can block their 
binding to the mucosal surface and stimulate a protective immunity, usually 
more efficient than the systemic IgG antibodies [71, 72]. 
The extensive investigation of mechanisms involved in microorganisms 
recognition and biological interaction between them and immune system cells, 
such as macrophages, dendritic cells and epithelial cells (in the intestine), has 
allowed researchers to predict the adjuvant potential of certain substances and 
thus openned new perspectives for the development of alternatives vaccines to 
conventional forms [56, 73]. These vaccines must be secure, stable, easy to 
produce, store and administer, allowing efficiency at least equal to that 
obtained with their conventional vaccines, when available, and should not elicit 
serious adverse reactions [74]. 
Recent techniques of molecular biology, immunology and biotechnology have 
improved the development of a large number of specific and harmless antigens, 
including recombinant proteins, being one of the current trends for the 
formulation of new vaccines. However, these antigens are weakly 
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immunogenic, requiring multiple administrations and their association with 
adjuvants [56, 66].  
Hence, vaccine adjuvants are needed. Adjuvants can improve the immune 
responses by different mechanisms [66, 68, 74]: 
 
→ Immunomodulation – re-direction of the type of cytokines produced; 
→ Antigens presentation – usually triggered by molecules or complexes 
that interact with the antigen in its native form; 
→ Transport of antigens – usually achieved by the formulation of 
vehicles associated with the antigen, with the ability to interact with 
the APCs;  
→ Cytotoxic T lymphocytes induction – antigens associated to particles 
or to water-in-oil (w/o) emulsions, that bind to MHC classe I molecules 
or brake the cellular membranes; 
→ Antigen depot – micro and nanoparticles, emulsions (w/o) and 
aluminium salts associated to antigens. 
 
The recognition of antigens by APCs is extremely important for their transport 
from peripheral regions to organised lymph tissues. The maturation of 
phagocytic cells leads to their migration to lymph nodes where they can then 
stimulate the B and T lymphocytes [75]. If the lymphatics are not reached, the 
antigen will not be recognised by the immune cells, with no induction of 
immune response [76]. The maturation and activation of phagocytic cells, the 
type of antigen and its presentation to APCs determine the type of immune 
responses induced by these cells [74-78].  
Adjuvanticity depends on the administration routes, since they determine the 
type of APCs that will be stimulated. The intraperitoneal (i.p.) administration 
induces phagocytosis mostly by macrophages, while the i.d. injection led to a 
preferential activation of dendritic cells [66, 75].  
Some antigens in its soluble form are not recognised by APCs and therefore do 
not induce the immune response [56, 74]. Consequently, antigens responsible 
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for the stimulation of these responses against certain pathogens can be 
imobilised or associated to controlled release particulate systems. These are 
captured by APCs, processed and transported to the lymph nodes and other 
organs, by the action of these adjuvants, based on a combination of some of the 
mechanisms previously mentioned [1, 66, 79-81]. 
Particulate antigen carriers such as polymeric microspheres and liposomes, 
seem to be the most suitable adjuvant to fulfill the main objectives: reducing the 
number of doses or the amount of antigen; increasing stability; administration 
by mucosal routes and eliciting an appropriate or stronger immune response, 
especially in the case of purified antigens or those more recently obtained by 
recombinant techniques [66, 82].  
In general, adjuvants can be associated according to their form of presentation 
(Table 1.1), and different types have already been identified for human use, 
while others are in pre-clinical or clinical trials [83-85]. Even so, adjuvants 
already licensed (aluminium salts derived adjuvants in the USA and Europe, 
and emulsion-based adjuvant MF59 and antigen contained into 
immunostimulating reconstituted influenza virosomes (IRIVs) only licensed in 
the European market) do not allow the stimulation of cellular immunity, which 
justifies the continuous research directed to the development and utilisation of 
new adjuvants [56, 84-86]. Despite the variety of adjuvants already identified 
(Table 1.1), some of which stronger than the aluminium salts, their use in 
humans is limited by local or systemic toxicity [66, 83]. 
The choice of an adjuvant depends on the type of antigen, animal species, route 
of administration and adverse reactions often associated [66]. Recently, Merck 
and GlaxoSmithKline have developed two vaccines against human papilloma 
virus, composed by virus-like particles (VLPs) associated, respectively, to 
aluminium or AS04 adjuvant, which is based on aluminium and bacterial lipids 
already approved in Europe. The VLPs are genetically produced 
antigen-containing particles, whose size and shape are similar to those 
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presented by viruses [66]. The vaccine developed by Merck was approved in 
2006 by the US Food and Drug Adminsitration (FDA) [66].   
 
Table 1.1  
Adjuvant examples 
ADJUVANT CLASSES EXAMPLES 
Aluminium hidroxide 
Aluminium or calcium phosphate  
oil/oil (o/o) or w/o emulsions as MF59 and Syntex 
adjuvant formulation (SAF) 
Liposomes 
Micro and nanoparticles (poly(latic-co-glicolic acid) 
(PLGA); chitosan (CS) ) 
Immunostimulating complexes (ISCOMs®) 
Particulate adjuvants 
Virosomes ( IRIVs) 
Non-ionic surfactant vesicles (NISV) 
Muramil-dipeptide (MDP)   
Muramil-tripeptide (MTP) and derivates 
Monophosphoryl lipid A (MPL) 
Trehalose dimicholate (TDM) 
Attenuated bacterial toxins (cholera toxin B subunit 
(CTB), Escherichia coli heat-labile toxin (LT)), subunits and 
mutant toxins (LTK63 e LTR72) 
Polyphosfazen 
Polynucleotides 
C3b complement factor 
CpG-oligodeoxinucleotides (ODNs) 
Saponin derivates (Quil-A, Quil-21) 
Non-ionic co-polymers (POE, POP) 
Cytokines (IL1, IL2, IL4, IL12, IL15, IL18) 
Granulocyte-macrophage colony-stimulating factor (GM-
CSF) 
Interferon-gamma (IFN-γ) 
Carbohydrates (manan, glucan) 
Co-stimulating (CD80, CD86) and MHC system 
molecules 
Streptococcus cell wall components 
Virus and bacteria alive transporters 
Non-particulate adjuvants 
Bacterial DNA 
Mycobacterium vaccae inactivated 
Bordetella pertussis 
Adjuvant association Freund adjuvant (complete and incomplete) 

 Adapted from [66, 69, 83,  87] 
 
A detailed approach to each type of adjuvants mentioned in Table 1.1 is beyond 
the scope of this manuscript. Consequently, the different types of adjuvants 
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already associated to S. equi antigens will be briefly referred, discussing in more 
detail polymeric micro and nanoparticles, since these are the adjuvants chosen 
to deliver S. equi antigens in a controlled manner and therefore to induce full 
protection after their mucosal administration. 
 
Aluminium salts 
The aluminium salts were the first adjuvants to be approved for human use, 
being the only adjuvant regulated in the USA at the present [66, 74, 83, 87]. 
Aluminium hydroxide and aluminium phosphate can be good adjuvants when 
associated with antigen that by itself allow the stimulation of effective immune 
responses (eg tetanus (TT) and diphtheria (DT) toxoids, cell surface hepatitis B 
antigen), although the adjuvant effect obtained with the aluminium hydroxide 
is not sufficient to confer protection in many cases [56, 69]. Their mechanism of 
action is not completely known, though it seems to be due to the antigen depot 
effect in the site of administration, or to the macrophage or eosinophil 
activation, mainly stimulating antibody mediated immunity [66, 69, 83]. 
Aluminium phosphate and hydroxide have been the most used adjuvant in 
vaccines for human use, for the last 80 years. However, regulatory agencies 
defined some criteria that have to be fulfilled previously to the use of any 
adjuvant in humans, which would prevent the regulation of aluminium salts 
nowadays for use in human beings, because of their associated toxicity and side 
effects (Table 1.2) [66, 69, 83].  
Aluminium is excreted by the kidneys, however, in cases of renal failure, it may 
trigger neurotoxicity resulting from their accumulation in the body, which is 
also often associated to Alzheimer's disease. The local toxicity of these 
adjuvants limits their administration through i.m. route, although the i.p. and 
s.c. routes are more effective in stimulating the immune response [66, 88-90].  
The aluminium hydroxide association to other adjuvants, such as TT-entrapped 
microspheres, have been reported by various groups, and induced higher levels 
of antibodies [73, 92, 93]. It is important to mention that the amount of antigen 
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released in vitro from these carriers in the presence of aluminium hydroxide, 
was always lower than that obtained by those microspheres alone [73]. This 
adjuvant has been often associated with S. equi antigens, by several groups 
(Table 1.3) [23, 24, 49, 94, 95]. 
 
 Table 1.2  
 Disadvantages presented by aluminium-based formulations 
DISADVANTAGES 
Failure to stimulate cellular immune responses  
Limited activity when associated to recombinant proteins or other low 
immunogenic antigens   
Variable absorption 
Difficult freeze-drying 
Repeted dose administrations 
Non-stimulation of CTL and mucosal immune responses  
Adverse reactions: 
→ IgE stimulation - allergenic 
→ Granuloma formation 
→ Neurotoxicity 
 
 
Freund’s adjuvant (complete and incomplete) 
It is presented in the form of emulsions and its mechanism of action is due to 
the formation of an antigen depot in the local of administration, able to slowly 
release the antigen and stimulate the antibody production by B cells. Their use 
in humans has been limited by its associated toxicity, including the 
development of inflammatory reactions, granulomas and ulcers. However, its 
application is considered for the prevention of severe diseases [66].  
In addition to aluminium salts, Freund’s adjuvant is one of the most used 
adjuvants associated with S. equi antigens, being mainly administered to 
animals for the production of antiserum for further analysis (Table 1.3). 
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Sucrose acetate isobutyrate 
Sucrose acetate isobutyrate (SAIB) is a nonpolymeric, cheap adjuvant able to be 
aerosolised for intranasal (i.n) administration. It can be dissolved in an 
appropriate solvent, which will evaporate at the mucosal level, resulting in the 
formation of a biodegradable and biocompatible film able to release the 
antigens eventually dissolved in this polymeric solution [96]. 
Nally et al. (2001) studied the intranasal delivery properties of SAIB associated 
to a strong immunogenic SeM peptide (SEMF3), confirming the mucosal 
adjuvant property of this biocompatible excipient [96]. 
 
Monophosphoril Lipid A 
Monophosphoryl lipid A (MPL) is obtained by acidic hydrolysis of lipid A, and 
is the main responsible for the adjuvant effect of the Gram-negative bacteria cell 
wall lipopolissacharide (LPS) [66, 97]. It has the ability to induce Th1 immune 
responses and has been formulated as emulsions, in order to increase its activity 
[87]. This compound presents the lipid A adjuvant properties, but with lower 
toxicity, being already associated to a S. equi fibrinogen binding protein (FgBP) 
in order to assess their immunogenic potential (Table 1.3). 
 
Havlogen® 
It is a polymer of acrylic acid cross-linked with polyallylsucrose, patented by 
the Intervet Ltd Company, and was associated with the S. equi enzymatic 
extract in the Strepguard® vaccine formulation (Intervet, Ltd) (Table 1.3) [53]. 
 
Cholera toxin B subunit (CTB) and E. coli heat-labile toxin 
B subunit (LTB)   
Cholera toxin (CT) and Escherichia coli thermo-labile toxin (LT) are important 
adjuvants for systemic and mucosal immune responses (IgG and IgA), which 
may be administered by different routes, including oral, i.n., intragastric and 
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intravaginal [97-100]. However, in literature there are referred a few cases 
where the Cholera toxin (CT) adjuvant action was not verified when associated 
to certain antigens, such as Group B Streptococcus [101] and Naegleria fowleri 
lysates [102].  
The toxicity and eventual 
accumulation in the central nervous 
system limit their use in humans and 
resulted in the development of 
genetically modified toxins, such as 
LTK63. Even so, CT safety problems 
were not solved by its mutant forms 
(Figure 1.10), as it was already found 
its transport by olfactory nerves to the 
brain and severe inflammatory 
responses [97]. However, the 
induction of a strong mucosal immune 
response has justified its association with recombinant S. equi proteins (Table 
1.3). 
CT has an A and B subunits, being the first involved in the modification of an 
adenylate cyclase regulatory protein, which is associated to the intestinal 
irritations observed in patients with cholera, while the B subunit (CTB) is a 
non-toxic component. CTB has five subunits that support the A subunit, being 
involved in the bacteria binding to cells, inducing a conformational 
modification that allows the toxic component (A subunit) to be introduced into 
the cell (Figure 1.10). 
It was observed that the recombinant non-toxic CTB presents an adjuvant 
activity, even if the administration of higher doses were required. Even so, 
contradictory results have been obtained and therefore further experiments are 
needed in order to determine wether CTB can replace CT as an adjuvant [69, 97, 
98, 100, 103]. 
 
Figure 1.10 – Vibrio cholerae CT and 
Escherichia coli LT mutant properties, 
showing the affected aminoacids 
(adapted from [104]).  
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Immunostimulating complexes (ISCOMs®and ISCOMATRIX®),  
ISCOMs®, described for the first time by Morein (1984), are strong 
immunostimulatory systems used as antigens carriers, improving their 
presentation to B cells and uptake by APCs [66, 105]. They are composed by 
saponins, phospholipids, cellular membrane antigens and cholesterol, among 
which are established hydrophobic interactions, allowing the formation of 
spherical particles with about 40 nm, which may incorporate hydrophobic or 
amphipatic antigens [66, 87].  
Local reactions such as erythema and pain are attributed to the haemolytic 
activity of free saponin or triterpenoides glycosides QS21, used in ISCOMs® 
[105]. The QS21 is one of the 23 constituents of the natural QuilA, a saponin 
from Quillaja saponaria, which high toxicity precludes its application in humans.  
The QS21 has the ability to improve humoral and cellular immune responses 
and has been included in different veterinary vaccines. Among human 
utilisation, its use is reserved for cancer prevention, because in such cases the 
risk-benefit assessment makes it acceptable [66, 87]. 
ISCOMs® maintain the saponins adjuvant action, but avoid adverse reactions 
triggered by those excipients, since the QS21 is linked to cholesterol, which is an 
important approach regarding the formulation of saponin-associated adjuvants 
[66, 87].  
Unlike ISCOMs®, the ISCOMATRIX® does not have the antigen embedded in its 
formulation, being thus the later added. In addition to its great versatility, some 
researchers found that its use induces preferably a Th2 immune response, while 
the system ISCOMs® induced a mixed Th1/Th2 response [66, 106]. The use of 
these systems was discussed recently by Cox et al. (2006) and Pearse et al. (2005) 
[106, 107].  
A vaccine based on ISCOMs® for the protection of horses against influenza is 
licenced since 1998 (EquipTM, Schering-Plough) [87]. 
 
 
S. equi adjuvants 
34 
Table 1.3 
Adjuvants associated to S. equi antigens 
ADJUVANT ANTIGEN 
IMMUNISATION 
ROUTE 
SPECIE REFERENCES 
M protein s.c. 
i.m. 
Rabbits 
Horses 
[94] 
S. equi supernatant 
cultures  
i.m. Ponies [24] 
S. equi enzymatic extract 
and supernatant cultures  
s.c. Mice [95] 
SePE-H  and SePE-I 
recombinant (rec) 
proteins 
i.m. Ponies [49] 
Aluminium 
hidroxide 
 
Rec SzPSe, Se73.9, Se51.9, 
Se44.2, Se46.8, SeM,  
Se75.3, Se42.0, Se110.0 
and Se18.9. 
s.c. Ponies [23] 
M protein (antiserum) s.c. Rabbits [108] 
Inactivated S. equi  i.p. Rats [109] 
SeM (antiserum) s.c. Rabbits [42] 
Freund adjuvant 
(complete and 
incomplete) 
rec Hyalutonate associate 
protein (HAP-GST) 
 Mice [37] 
FgBP s.c. Mice [46] 
MPL/DMT 
FgBP s.c. Mice [110] 
Havlogen®  SeM i.m. Horses [111] 
Cholera toxin (CT) SeM i.n. Ponies [52] 
Sucrose acetate 
isobutyrate 
Péptido da SeM (SeMF3) i.n. Horses [96] 
E. coli B Subunit 
heat-labile  
enterotoxin (LTB)  
rec FNZ, SFS, e EAG i.n. 
s.c. 
Mice 
Horses 
[1] 
ISCOMs® 
(Matrix-S®) 
rec CNE, SclC, EAG, 
FNEB 
i.n. Mice [59] 
ISCOMATRIX® 
(AbISCO) 
rec CNE, SclC, EAG 
(19kDa) 
i.n. 
i.m. 
Ponies [2] 
PLGA 
microspheres 
S. equi i.n. 
i.m. 
Mice [61] 
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Polymeric Micro and nanoparticles  
The therapeutic use of particulate carriers for the development of an immune 
response is currently one of the most promising strategies to combat infectious 
diseases and, hence, one of the areas most investigated in pharmaceutical 
technology [56, 112]. There are many publications that justify its application in 
the induction of local and systemic immune responses, capable of protecting 
animals against certain pathogens [56, 68, 70, 84, 91]. 
 
ANTIGENS 
The antigen entrapped in a polymeric carrier will be captured, processed and 
presented to APCs, such as macrophages or dendritic cells, and then to T 
lymphocytes (CD4+ and CD8+), in association with MHC molecules class I or II, 
depending on the nature of the antigen [69, 87].  
Antigens responsible for the induction of a protective immunity against various 
pathogens may be detained or associated to particulate systems, which have the 
capacity to be modified and associated with other adjuvants in order to achieve 
a prolonged and/or pulsed release of the entrapped antigen [13 , 42, 57]. This 
approach maintains an immune response for periods much longer than those 
observed for antigen release from aluminium salts [66] or Freund’s adjuvant 
[52, 113]. Thus, these polymeric carriers protect antigens from proteolytic 
enzymes, allow the co-entrapment of multiple antigens, promote antigen 
interaction with APCs, directing the delivery of vaccines to a specific target [66, 
91, 113, 114, 115].  
The prolonged and controlled release of antigens entrapped and/or adsorbed 
onto particles surface is fundamental to prevent a considerable loss of antigen 
associated with particles before they are taken up by APCs [73]. These carriers 
can mimic the prime and boost doses normally used in the conventional 
programmes of vaccination, reducing the frequency of administration needed to 
confer an extended protection to animals, which has been extensively 
demonstrated in the literature [42, 56, 74, 114, 116, 117]. Polymeric micro and 
nanoparticles allow the use of new therapeutic agents, such as macromolecules, 
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when compared with other controlled release systems, as implants, patches, 
injections or oral formulations.  
Regardless of the type of antigen used, the vaccine will only be effective if it is 
administered by a desirable route and simultaneously is able to overcome the 
biological barriers and circulating antibodies present in animal’s serum.  
Several studies have shown that polymeric particles are an important type of 
antigen carriers with adjuvant properties. Their particulate nature along with 
the depot effect will determine the induction of the immune response [13, 42, 
57, 66, 113, 114]. However, biodegradable and polymeric particles may present 
some problems, such as low loadings, loss of antigen activity during the 
entrapment process and difficulty in controlling the release of the active 
protein, especially when encapsulating larger and fragile molecules [118, 119, 
120].  
Soluble antigens are internalised by macropinocytosis, while antigens 
entrapped in polymeric particles are phagocytosed and therefore more 
efficiently presented by the MHC molecules, as demonstrated by several 
studies, in which there was even the stimulation of an immune response 
mediated by cells [68, 75]. Antigen presentation and the way it is processed are 
the main points to consider, defining the type and duration of an immune 
response, elicited by the administration of a single dose vaccine [66, 73]. The 
dendritic cells are of great importance within the immune system as they have 
the ability to phagocytose viruses, bacteria, antigens and particles. These cells 
are found in the blood, skin and mucosal surfaces, being the most important 
phagocytic cells of the immune system as they are able to process and display 
antigens to T lymphocytes, through the MHC class I and II molecules, and 
determine the type of immune response (humoral, cellular or tolerance) [75].  
It is important to mention that the characteristics of each delivery system will 
define the type of immune response. While the neutralizing action of antibodies 
is dependent on protein conformation and structure, the recognition of antigens 
by the CTL epitopes is greatly affected by macromolecule degradation [75]. 
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METHODS OF PRODUCTION 
The development of new vaccine carriers is highly dependent on the reduction 
or even prevention of degradation, denaturation and aggregation of antigens, in 
order to ensure the maintenance of their antigenic properties. The extent and 
type of immune responses stimulated depend mainly on the stability of the 
antigen, particularly in the case of single dose vaccines, since inactive antigens 
do not contribute to the preservation of the immune response for long periods 
of time.  
Different antigens present distinctive properties when entrapped in polymeric 
vehicles, so that each system needs to be developed in order to achieve a 
specific immune response [91].  
There are several methods available to produce polymeric particles and their 
choice has mainly to do with the type of polymer and antigen to be used, and 
with the particle size desired. The methods more frequently used are the double 
emulsion water/oil/water (w/o/w) solvent evaporation technique, 
spray-drying and coacervation, which are modified accordingly to the polymer 
and antigens characteristics [75].  
As it is generally accepted, amphipatic substances present the ability to 
surround a drop surface and spontaneously form micelles in aqueous systems, 
due to the intra and/or intermolecular interactions with hydrophobic residues, 
promoting stability by reducing free energy in the interface between the two 
phases, preventing flocculation and coalescence of droplets dispersed in the 
emulsion, resulting in smaller particles with lower polydispersity indices. The 
resultant carriers present a hydrophobic core and can be used as drug depots 
[121-123].  
The double emulsion (w/o/w) solvent evaporation technique requires 
mechanical agitation and the use of organic solvents, such as dichloromethane 
(DCM), which normally does not affect the antigen structure and its 
immunogenic properties, although these aspects have to be confirmed in all 
systems formulated [120]. Protein denaturation can be displayed by sodium 
S. equi adjuvants 
38 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), by the 
presence of higher or lower molecular weights bands, due to protein aggregates 
or fragments, respectively [120].  
Several alternative methods have been developed to reduce the production 
costs, to maintain antigen structure and activity, to avoid the use of organic 
solvents, to obtain a sterile final product and to scale-up the process [56]. 
However, some limitations have risen as it is necessary the entrapment of high 
amounts of macromolecules, without change of their structural integrity or 
antigenic activity. As a result, the adsorption of important proteins in the 
biomedical field onto polymeric particles surface has been studied, providing a 
technical and promising alternative to entrapment, since it has been able to 
induce strong immune responses [56, 66, 87, 116, 124]. The proteins loading by 
adsorption prevents their contact with organic solvents, stress conditions, 
consequence of mechanical agitation, and low pH, resultant from the 
degradation of some polymers, such as poly(lactic acid) (PLA) and PLGA [56, 
91]. This phenomenon is the product of the sequential adsorption of proteins 
with less affinity for adsorbents, and their displacement by those who have 
greater affinity for that surface. The interactions between different types of 
proteins in a mixture and these proteins with the adsorbents surfaces need to be 
clarified for a complete understanding and control of the absorption 
phenomena [66, 75, 87]. Proteins such as TT and albumin adsorb perfectly to the 
surface of PLGA particles, as previously described in the literature [124, 125]. 
Other researchers have chosen the adjustment of process production 
parameters, such as the one used for microparticles preparation by Kazzaz et al. 
(2000), in which they have conducted the replacement of non-ionic polyvinyl 
alcohol (PVA) polymer by anionic sodium dodecyl sulfate (SDS), resulting in 
the development of immune responses, including CTL, by the soluble antigen 
adsorbed onto particle surface [126]. Radiation can be used to sterilise these 
particles, prior to antigen adsorption [91]. 
The stability of the final product, regarding those produced with synthetic 
polymers, will be acceptable if kept at temperatures below their melting point. 
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The modification of the traditionally used polymers is also an interesting 
approach, for example by the use of different ratios of polymers having distinct 
degradation rates and molecular weights [56]. The polymeric carrier’s 
degradation depends on erosion, which will be determined by the polymeric 
composition and molecular weight, porosity, size and loading capacity of 
particles, release rate of entrapped agent, interaction between polymers and 
antigen, and the method of entrapment used in its preparation. The burst 
release can not be too extensive as it reflects the amount of antigen released into 
the extracellular matrix and therefore not available to be taken up by APCs [75]. 
On the other hand, the in vitro characterisation of these polymeric systems is not 
standardized, which constitutes the major obstacle to their approval by the 
regulatory organisations such as the European Medicines Evaluation Agency 
(EMEA) and the FDA.  
One of the most important characterisation assays is related with the 
determination of the amount of antigen actually associated to particle carriers 
and the confirmation that its structure remained intact, throughout the 
production method. Here, a possible aggregation makes it extremely difficult to 
complete the extraction of the protein actually entrapped, in addition to 
possible change of antigen activity and structure during the extraction process. 
The presence of interferents, such as sugars and the commonly used PVA, 
makes it difficult to obtain reproducible and accurate results for protein assays, 
and, thus, these aspects must be confirmed for each system of particles 
produced [91]. Consequently, FDA included the in vitro release tests in the 
guidelines for the approval of vaccines intended for parenteral administration, 
assuming mandatory the detection of at least 80% of the entrapped antigen [83, 
91].  
Vaccines to be used in healthy animals will only be accepted if minimal local 
and systemic side effects result from their administration. Adjuvants to be 
included in veterinary vaccines need to demonstrate the absence of serious 
adverse reactions, indicate the period of accumulation at the site of injection, 
and their elimination from the animal body. In addition, similarly to what is 
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observed for adjuvants to be used in humans, the preparation of those 
formulations should be easy and economic, as well as applicable to a variety of 
vaccines and result in a stable product [87]. Besides the characterisation usually 
performed to pharmaceutical products, the modification of gene expression 
induced by these polymeric carriers should be studied to better understand 
their impact on the molecular mechanisms of recognition and response of the 
immune system cells [56].  
Polymeric composition, size, loading capacity, route of administration and the 
presence of other adjuvants will influence the particles uptake, their transport 
to the lymph nodes and interaction with surrounding tissues [70, 73, 75, 
127-129].  
Katare et al. (2005) performed the first experiment to evaluate the effect of 
particle loading in the type and duration of immune responses elicited by their 
i.m. administration [73]. The higher amount of protein entrapped in PLA 
particles led to increased levels of antibodies and the number of particles 
administered did not appear to have a role in the immune system stimulation. 
Systems presenting lower loadings will require a greater amount of particles in 
order to administer the same dose. Therefore, the APCs may become saturated, 
due to their limited capacity to transport the antigen-loaded particulate systems 
to the lymphatic tissues, although this could also result in a sustained antigen 
release, and consequently in higher antibody titres [70, 73]. On the other hand, a 
higher antigen loading, besides decreasing the number of particulate carriers 
needed to achieve a desired dose, will protect the antigen as it will be less 
susceptible to a possible inactivation due to particle degradation. Moreover, it is 
generally accepted that a larger amount of antigen initially presented to APCs 
promote a sustained immune response and therefore the activation of T 
lymphocytes [73].  
Among the aforementioned characteristics, particle size seems to be the most 
important factor, although contradictory results have been presented in the 
literature [70, 127-129]. For the same size, the route of administration will 
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determine the type of APCs that will be stimulated and, consequently, the 
resultant immune response [73]. The particles size is particularly important as 
generally microparticles smaller than 10 µm seems to be more immunogenic 
than those with larger diameters [75, 120]. Some studies have indicated that 
microparticles with 10-15 µm are not phagocytosed [70, 73], although there are 
reports showing that carriers bigger than 20 µm have successfully induced 
immune responses, which shows that the antigen uptake and processing by 
APCs is not completely dependent on particle phagocytosis [70, 73, 127, 130, 
131]. However, smaller particles or even polymeric fragments can be founded 
between these larger vehicles and can be taken up by APCs [70, 73]. In addition, 
larger particles usually present lower release rates, and therefore contain higher 
amount of antigen to present to the APCs, which will consequently express a 
higher number of MHC molecules at their surface. Other authors think that 
these larger particles will bind to macrophage surface, constituting a depot that 
will continuously release the antigen throughout time [66, 73]. However, 
particles with mean diameters between 50 and 100 µm will present reduced 
adsorption onto phagocytic cells and release the antigen in a limited manner 
due to smaller macrophage size (10-15 µm) [73]. 
Particles with mean diameters of 1 µm are more efficiently presented by MHC 
class I molecules at APCs surface and stimulate the CD8+ T-lymphocytes, 
although particles with 0,04-0,05 µm elicited humoral and cellular immune 
responses, in contrast to the aluminium salts [66].  
Katare et al. (2005) found that particles with 2-8 µm led to a humoral immune 
response for 250 days, significantly higher than that obtained in groups 
immunised with particles larger and smaller than 8 µm and 2 µm, respectively 
[73]. Regarding submicrometric particles, the results were not expected, and 
authors indicated that this could have been due to a more pronounced 
exocytosis [132] or a lower efficiency in antigen processing and presentation 
[133], when compared with the immune response induced by the micrometric 
particles. The release of the smallest particles from the endosomic vesicles to the 
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cytosol contributes to the stimulation of cell mediated immune responses, 
competing therefore with the production of antibodies, consequence of the 
antigen presentation by MHC class II molecules. As a result, the administration 
of a single dose of nanoparticles can result in lower levels of antibodies than 
those stimulated by microparticles [73, 129]. 
Generally, antigens carried by polymeric particles have the ability to escape the 
degradation in the endosomes, reach the cytosol in higher concentrations, than 
those antigens administered in soluble form, being presented by MHC class I 
molecules more effectively and for longer periods of time [68]. 
 
ADMINISTRATION ROUTES 
The extensive research focused on polymeric carriers with different 
composition, morphology and sizes, has allowed the formulation of vehicles to 
be administered through several routes of administration (oral, i.p., i.n., i.d., 
i.m.), aiming to develop single-dose vaccines or to associate different antigens 
in one system [66, 68, 73, 91, 129].  On the other hand, vaccination through the 
mucosa is easier because it does not require the use of needles and syringes, is 
economic and more effective in the stimulation of mucosal immune responses, 
when compared with parenteral routes. Consequently, non parenteral 
immunisation routes are highly desirable [57, 61].  
S. equi main port of entry in the host is the nasal mucosa which, associated with 
the low production costs and easy administration of formulations administered 
through the nose, justify the choice of nasal route as the one preferred for the 
administration of a vaccine against a S. equi infection. Moreover, previous 
studies have shown that the i.n. administration of antigen-loaded polymeric 
particles was capable of inducing not only humoral and cellular immune 
responses, but also local responses spread at different mucosal membranes, 
regardless the targeted one, essential to protect the host against a further 
invasion [2, 71, 72, 124, 134, 135]. 
Particle size influences their deposition at the nasal cavity and mucosal uptake. 
It was observed that particles larger than 5 µm are taken up by Peyer patches 
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and then remained in this area, while carriers with lower mean diameters were 
identified, not only in these patches, but also in mesenteric lymph nodes and 
spleen. Therefore, these latter carriers will preferably induce systemic immune 
responses, while the former will stimulate local immunity associated to the 
mucosas [125, 139, 140]. 
The microentrapment of TT [70], DT [141] and hepatitis B surface antigen has 
been the most studied system for the development of a single dose vaccine [142, 
143]. Indeed, the entrapment of many antigens, as TT and DT, in biodegradable 
polymeric microspheres has been extensively studied for the induction of a 
systemic but also mucosal immune responses, regardless the administration site 
[70, 144, 145]. 
Eyles et al. (1998/1999) showed that antigens entrapped in microspheres were 
able to induce immune responses stronger than those resultant from 
administration of its soluble form [72, 135]. Almeida et al. (1993) found that the 
i.n. administration of TT adsorbed onto PLA microspheres surface, with mean 
diameters ranging from 0.1 to 1.6 µm, induced systemic and local immune 
responses higher than those elicited by their administration through the oral 
route, which remained even 15 weeks after animal vaccination [124]. Wu and 
Russell (1997) obtained a similar pattern, which may be the result of the difficult 
administration of large amounts of antigen to the intestine, as a consequence of 
the dilution effect and stomach low pH [71].  
The administration of nucleic acids by different routes (i.m., oral, i.d., s.c.) 
induced Th1 type immune responses, along with antibodies production and 
CTL stimulation. Therefore, some researchers are developing vaccine 
formulations based on DNA entrapped polymeric particles [75].  
Particle surface modification is also one of the most recent approaches to induce 
phagocytosis [75]. Biodegradable and polymeric particles associated to 
mucoadhesive compounds, as CS [97, 117, 136, 145] and ALG [146] to increase 
the particle residence time in the vicinity of cells, and absorption enhancers, 
such as spermine (SP) and oleic acid (OA), are important approaches in order to 
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overcome, for example, the nasal barriers and increase antigens uptake through 
mucosa [145, 147-149].  
CS surface modified PLGA microspheres developed by Jaganathan et al. (2006) 
have increased nasal uptake of these vehicles [136]. Their particulate form and 
high mucoadhesive properties conferred by CS seem to be key factors for the 
immunostimulating effect of those polymeric carriers [66].  
CS is a co-polymer of β-(1-4)-D-glucosamine and β-(1-4)-N-acetyl-D-
glucosamine, prepared by the alkaline deacetylation of chitin [150, 151], being 
widely used in the pharmaceutical field, since it is a biodegradable, nontoxic 
and positively charged polysaccharide, which safety has already been 
confirmed [152, 153]. It has the capacity to form colloidal particles and entrap 
macromolecules by several mechanisms. Encouraging results have been 
obtained for the tranfection of DNA entrapped in CS nanoparticles [153]. 
However, low solubility at physiological pH is one of its major drawbacks. 
Increasing the internal phase viscosity reduces not only the interaction between 
entrapped proteins and the organic phase, observed at the (o/w) primary 
emulsion interface during homogenisation process, but also its diffusion 
through the aqueous phase, resulting in higher loadings [152]. The CS particles 
are also recognised and captured by cells of the mononuclear phagocytic 
system, due to the opsonisation process, in which serum proteins and 
glycoproteins coat these particulate systems [153]. This polymer increases drug 
bioavailability due to its mucoadhesion property and its ability to open the tight 
junctions, which promotes the paracelular transport [98, 154-156].  
The review of all types of materials used in the formulation of micro and 
nanoparticles is outside the scope of this introduction. Moreover, the adjuvant 
properties of many of these polymeric carriers had already been reviewed by 
several researchers. As a result, PLGA, PLA and PCL polymeric particles will 
be discussed in more detail, as the present study consists mainly in the 
development of polymeric systems for mucosal administration of S. equi 
antigens, mostly based on polyesters [56, 75, 91, 134, 157-160]. These are able to 
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controll release of antigens for prolonged periods of time, avoiding short 
humoral and cellular immune responses, stimulating CTL and overcoming the 
antigenic variation of the causative agent. Aspects related to antigen 
distribution within particles, formulation stability and cost of production will 
also be evaluated as these are important characteristics that have to be taken 
into account when chosing the type particulate system. 
 
Poly(lactic acid) and poly(lactic-co-glycolic acid) 
The synthetic PLGA is the most studied polymer for vaccine formulation [66, 
75, 91]. PLGA is a polyester composed by one or several monomers of D-lactic 
acid, L-lactic acid and/or glycolic acid. It is a well evaluated polymer, widely 
used in the preparation of controlled release systems and its degradation 
properties are already well known [66, 75, 91]. Indeed, there are several 
publications reporting the use of these polymers in different therapeutic areas. 
PLGA polymeric carrier systems, with distinct sizes and morphologies, can 
encapsulate molecules with different physicochemical characteristics. Their 
chemical composition determines the final structure, which can be highly 
crystalline (poly(L-lactic acid) or amorphous (poly(D-,L-lactic-co-glycolic acid) 
[70, 145]. It has been used for decades, in humans and animals, as degradable 
surgical sutures and in the development of peptide controlled delivery systems. 
Among these, some have been tested in clinical trials and 12 products are 
already licensed in 10 different countries by the regulatory agencies [68, 70, 87, 
91, 161]. 
Several studies have shown that PLA and PLGA particles are potential carriers 
for proteins or antigens [70, 75, 91], entrapped or adsorbed [162], preserving 
antigen stability and immunogenicity, which is important since their structure 
has to be maintained in order to stimulate the immune response for extended 
periods of time, avoiding the administration of repeated doses [70, 73, 91]. 
These polymeric vehicles can continuously and slowly release peptides and 
proteins for 1 to 4 months. The development of immune responses and animal 
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protection for over one year after vaccination with PLGA carriers has been 
reported [70, 75, 91].  
DT entrapped in PLGA microparticles with a mean diameter lower than 5 µm, 
were found at the injection site, even 4 weeks after their administration, 
supporting the depot effect commonly associated to their adjuvant properties. 
This study has revealed the transport of these particles by phagocytic cells from 
the injection site to distant lymph nodes [163].  
In addition, PLGA micro (<10 µm) and nanoparticles have the ability to protect 
antigens, such as proteins, peptides and nucleic acids against extracellular 
degradation. These polymeric carriers can be taken up by APCs, such as 
macrophages and dendritic cells, that will process, transport to the lymph 
nodes and present the antigens to T lymphocytes [68, 75, 91, 93, 143]. Although 
biocompatible, a weak inflammatory response also appears to be inherent to 
their adjuvant effect [91].  
After phagocytosis, the intracellular phenomena associated to antigen 
processing will depend on polymeric composition and surface characteristics of 
particles. Positively charged particles are rapidly phagocytosed, leading to the 
formation of phagosomes, resultant from ionic interactions established between 
particle positive charges and negatively charged phagosome membrane. 
Pseudopod formation is no evident during the negatively charge particles 
internalisation, while phagosome maturation and degradation are faster [164]. 
PLGA monomers and their proportion allow the formulation of different 
vehicles with characteristics suitable to several types of antigens, routes of 
administration and type of immune responses required. Since PLA polymer has 
a degradation rate slower than the poly(glycolic acid) (PLG), the association of 
both monomers can be used in the controlled release of antigen, being 
theoretically possible to predict the release rate taking into account their 
individual degradation pattern. On the other hand, monomer optical properties 
also play an important role in polymers degradation, which is faster for PLA 
racemic mixture than for their isolated isomers [66, 73, 143, 165].  
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Particle surface modification with different functional groups or 
macromolecules has been explored to assess their influence on phagocytic cells 
activation and maturation [91]. The i.n. administration of DT-entrapped PLA 
microspheres containing CS has induced higher specific antibodies levels than 
those observed for PLA negatively charged particles [70, 145]. 
PLA and PLGA particles present a negative charge in solution, which is due to 
their terminal carboxylic groups or to the adsorption of hydrolysed PLGA 
oligomers [75]. Still, the production of particles with positive surface charge is 
easily achieved by the addition of cationic molecules as cetyl 
trimethylammonium bromide (CTAB), stearylmine and polyethyleneimine 
(PEI) during the particles formulation [87, 166-169].  
CS surface modified PLGA microspheres were developed by Jaganathan et al. 
(2006), and used in animal vaccination by i.n. route. Mucus layer is anionic at 
neutral pH, being therefore able to interact with positively charged particles, 
leading to a lower particle clearance and hence a prolonged residence time on 
the mucosal surface [74, 136].  
Shen et al. (2006) found that ovalbumin (OVA)-entrapped PLGA particles were 
taken up by dendritic cells, through endocytosis, followed by antigen 
processing in cytosol proteosomes and presentation by MHC class I molecules 
[68]. Thus, antigens carried by PLGA particles were found in the cytosol in 
higher amounts than those obtained when administered in their soluble form or 
adsorbed onto non-degradable carriers (such as latex), which shows that 
particle composition is essential for uptake. Moreover, there was a slow and 
continuous antigen release from PLGA particles, which is important due to the 
rapid turnover of MHC class I molecules at cells surface [68].  
The microentrapment of Bacillus anthracis recombinant antigens has stimulated 
dendritic cells, in contrast to its soluble form [170]. The authors confirmed the 
observations and conclusions of other studies, showing that the adjuvant 
mechanism presented by the particulate system was different from that 
observed when particles and recombinant antigens were administered alone 
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[171].  Enhanced antigen processing and presentation by dendritic cells were 
also obtained by Sun et al. (2003) [172]. In addition, the ability of particles to 
stimulate antibody production was reported by O'Hagan et al. (1991) and 
Eldridge et al. (1991) [173, 174]. Maloy et al. (1994) and Moore et al. (1995) 
observed that systemic and oral administration of PLGA microparticles 
entrapping OVA or human immunodeficiency virus (HIV) gp-120 to mice, led 
to the stimulation of CTL and cellular immune responses, which is extremely 
important as these are weakly induced by new adjuvants [87, 91, 175, 176]. 
Moreover, PLGA micro and nanoparticles have been proved as potential 
adjuvants for the delivery of DNA and recombinant antigens, being able to 
induce humoral, cellular and also mucosal immune responses [66, 70, 75, 89].  
Several studies have shown that particle size has an important role in particle 
uptake by phagocytic cells. In fact, the diameters range presented by PLGA 
particles entrapping pertussis toxin and filamentous haemagglutinin influenced 
the type of immune response obtained, being strong Th1 immune responses 
preferably induced by microspheres, while nanoparticles preferentially 
stimulated Th2 cells pathway [177]. This physical characteristic is another factor 
responsible for the extensive investigation towards the development of PLGA-
based particulate carriers, as it is possible to formulate antigen controlled 
release PLGA systems of similar polymeric composition but different diameters 
[178-181].  Even so, some limitations are still associated to these vehicles, such 
as their high costs of production, the conditions required for their formulation 
under aseptic conditions, the common use of organic solvents during 
preparation method, which can negatively affect antigen structure integrity and 
immunogenicity, besides others drawbacks related with their in vitro and in vivo 
characterisation assays, as well as the complex prediction of particle adjuvant 
effect in humans based on results obtained in a mouse model [75, 91]. Antigen 
aggregation, denaturation, and their adsorption onto tubes used for in vitro 
release studies, have hindered the effective characterisation of some of these 
loaded particulate systems, and their approval by the regulatory authorities 
[182-184]. For example, Nutropin depot® was the first protein controlled 
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delivery system, that was introduced in 1999 on the USA market but 
withdrawn five years later by manufacturer decision based in its high costs of 
production, mainly due to the sterilisation conditions [185]. 
The degradation of glycolic and lactic acids homo and copolymers occurs by 
hydrolysis resulting in the acids above mentioned, which will be eliminated 
from the body by the Krebs cycle. In fact, one of the major disadvantages 
associated to these polymers is the extremely acidic (pH 2-3) surrounding 
media resulting from the accumulation of degradation products, which is not 
indicated for macromolecules, as several antigens are denatured at these pH 
values [91, 120]. This can be overcomed by addition of bases (for example, 
calcium hydroxide and magnesium carbonate) or polyethylene glycol (PEG) to 
the media, or by reducing the polymer hydrolysis rate (increasing the lactic acid 
fraction, for example) [91, 119 , 185].  
The extensive study of PLGA carriers performed by several groups clarified the 
influence of parameters such as molecular weight, formulation technique and 
chemical composition in their adjuvant properties. It was concluded that even 
polymer low molecular weight and high loadings may provide a continuous 
antigen release.  As a result, some limitations initially associated to these 
carriers, such as low loading capacity, high burst release and difficult particles 
dispersion for parentereral administration, have been overcome [91, 186, 187].  
Preliminary studies conducted by our group showed that the i.n. and i.m. 
administration of whole killed S. equi cells or bacterial lysate entrapped in 
PLGA microspheres resulted in a immune response able to protect mice against 
further infection by the virulent strain [61]. These studies have also shown that 
polymeric particulate systems are promising S. equi antigen carriers and 
adjuvants showing a high potential for use in strangles prevention. 
 
 
Poly-ε-caprolactone 
PCL is biocompatible polyester that has not yet been fully explored for antigen 
entrapment. It has a great potential for developing antigen controlled release 
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matrices by its biocompatibility, low degradation rate, hydrophobicity, good 
drug permeability, in vitro stability and low toxicity [68, 73, 120, 144, 188-190]. A 
positive correlation between the hydrophobicity and particle uptake by cells 
was found, whereas cells had greater affinity for PCL particles than for those 
based on PLA [144, 191].  
PCL degradation does not result in media acidification, in contrast to PLA and 
PLGA polymers, which is an advantage as low pH values can adversely affect 
protein structure, and therefore be responsible for cellular and humoral 
immune responses failure [120, 144, 192, 193]. Even so, it is still necessary to 
assess the antigen structure after being associated to PCL polymeric carriers 
[91].  
PCL particles have a slow degradation rate in an aqueous media due to 
polymer hydrophobic and crystalline nature, which prevents the incorporation 
of water in the system, being the antigen release consequence of erosion of 
polymeric matrix [120, 194]. PCL crystallinity is particularly important in the 
development of controlled drug delivery systems, as hydrophilic substances 
will be entrapped only in polymeric amorphous regions. Moreover, high 
loadings are especially important for expensive antigens or when only a small 
amount is available [120].  
The adjuvant properties of PCL microparticles have been studied by some 
groups, and their ability to induce immune responses after parenteral and 
non-invasive administrations has been previously mentioned [72, 117, 124, 135, 
136, 144]. However, vaccine controlled release systems, such as nanospheres 
based on PCL, have not been extensively referred in the literature, probably due 
to aggregation that often occurs after administration. However, some studies 
have suggested that PCL is a potential adjuvant, mainly due to its hydrophobic 
nature responsible for PCL particles higher uptake by APCs [120, 144]. 
PCL was used for the development of levonorgestel controlled release systems, 
which were included in clinical trials in several countries [120].  
Jameela et al. (1996) showed that the i.m. administration of bovine serum 
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albumin (BSA) entrapped in PCL microspheres, associated to incomplete 
Freund’s adjuvant, were able to stimulate systemic humoral immune responses 
[195]. Murillo et al. (2001) demonstrated in a mouse model that Brucella ovis 
antigen extract loaded in PCL microparticles are a potential vaccine to prevent 
the infection induced by this microorganism [196].  The oral administration of a 
single dose of Schistosoma mansoni antigen entrapped in PCL microparticles led 
to a long-lasting immune response, which remained for longer periods than 
that stimulated after an oral and i.n. administration of PLGA microparticles 
loaded with the same antigen [120].   
The double emulsion (w/o/w) solvent evaporation technique is the most 
common method used to produce PCL carriers. In general PCL is dissolved in 
an organic solvent, being after that homogenised in an aqueous phase 
containing a surfactant, to form a w/o emulsion, which will then be added to 
an aqueous continuous phase. The microspheres are hardened after solvent 
evaporation [120].  
Particle surface modification by hydrophilic polymers such as CS will increase 
the w/o/w double emulsion stability, as it will limit the interactions between 
the organic and external phases. Similarly to PLGA particles, the association of 
CS and ALG to PCL carriers can increase nasal mucosa residence, as 
electrostatic interactions will be established with the negatively charged 
epithellium mucus [136].  
Since the production method previously mentioned involves the use of organic 
solvents, particles interior may be sterile, which along with aseptic conditions 
and good laboratory practice adopted during particle production, will result in 
a sterile final product.  
Several groups have shown that this method does not compromise the activity 
and immunogenicity of entrapped antigens, such as ovalbumin [121], BSA 
[197], TT [124] and CTB [131].  Benoit et al. (1999) used double emulsion 
(w/o/w) solvent evaporation method to formulate PCL microparticles, 
evaluating parameters such as polymer and BSA protein concentration, external 
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aqueous phase volume, primary emulsion internal phase viscosity, external 
phase surfactant type (SDS, PVA and Tween 80) and concentration, time of 
homogenisation, salt addition to internal phase (NaCl) and pH (pH 3, 7 or 10) 
[120].  Higher polymer concentrations resulted in larger particles and higher 
loadings. The size increase may be a consequence of particle agglomeration, 
even if a monodisperse particle population with 5 µm of mean diameter has 
been obtained [120, 198]. On the other hand, entrapment efficiency (E.E.) 
increase could be due to the higher viscosity of the organic phase, which 
reduces protein migration from the inner phase to the external one [120]. 
These authors found a significant decrease in E.E. when higher amounts of 
protein were used, without any change in carrier size or loading, which was 
explained by the small amount of polymer available for protein entrappment. 
PVA was selected as the most appropriate surfactant, as emulsions gave 
particles with satisfactory loadings (1.38±0.11% w/w) and sizes (1-10 µm).  
Higher internal phase viscosity led to a small increase in particle size, but did 
not induce any changes in their loadings and E.E., as reported by Jeffery et al. 
(1993) [121], although these results are opposite to those previously published 
by Ogawa et al. (1988) [199]. The use of higher external phase volumes 
increased particle mean diameter and loading, probably due to the formation of 
larger droplets during double emulsion homogenisation. On the other hand, 
prolonged homogenisation has resulted in particle size reduction probably due 
to droplet division during the emulsification process. The NaCl addition into 
the inner phase decreased the amount of protein entrapped in microparticles, 
but it has not induced any changes in particle size. 
Regarding protein release profile, it was obtained a 30% burst release of the 
associated protein, which was followed by a controlled and sustained period 
that lasted for 3 months, and appears to be a consequence of PCL low 
permeability to macromolecules. Moreover, Benoit et al. (1997) have 
demonstrated that protein molecules have affinity to hydrophobic surfaces, 
which indicates that those 30% are probably to be a result of protein desorption 
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from particles surface [120, 200]. Neverthless, this release profile appears to be 
appropriate for vaccine delivery, since particle administration will first mimic 
the first dose and further simulate boost as they will be able to continuously 
release the antigen. 
 
ANTIGEN-LOADED BIODEGRADABLE MICRO E NANOPARTICLES   
The entrapment of different antigens, such as proteins, peptides and viruses, 
has been studied by several research groups, which was already discussed in a 
considerable number of reviews [70, 75, 91, 116, 201, 202].  
One of the main aspects related to pre-clinical trials of new vaccines, adjuvants 
or any drug delivery systems, concerns the evaluation of immune responses in 
animal models [91]. Some examples of in vivo studies performed with antigens 
loaded in polymeric micro and nanoparticles and the type of immune responses 
induced by these systems are listed in Table 1.4. 
 
S. equi adjuvants 
54 
Table 1.4  
Antigen-loaded biodegradable micro and nanoparticles 
ANTIGENS POLYMERS SPECIES IMMUNE RESPONSES 
IMMUNISATION 
ROUTES 
REFERENCES 
PLA 
PLGA 
Guinea pigs IgG s.c. [70] 
PLA+ aluminium 
hydroxide 
Rats IgG ≅ 2 × TT adsorbed onto 
aluminium hydroxide 
i.m. single dose [73] 
PLGA Guinea pigs Systemic IgG  s.c. [127] 
PLA Guinea pigs Systemic IgG  s.c. [127] 
Poly(DL-lactic 
acid)+CS 
Mice Systemic specific IgG i.n. [145] 
PCL+ alpha-
tocopheryol succinate 
esterified to 
polyethylene glycol 
1000 (TPGS) 
Mice Increased immune response  i.n. [203] 
CS Mice Local (IgA) and systemic (IgG) 
Systemic IgG  
Oral 
i.n. 
[204] 
DT 
PCL 
PLGA 
PLGA-PCL 
Mice Systemic IgGPCL>IgGPLGA-PCL; IgGPLGA  
Systemic IgGPCL>IgGPLGA-PCL; IgGPLGA 
i.n. 
 
i.m. 
[205] 
PLA Rats IgG i.m. [73] 
PLA Rats 
Rabbits 
Guinea pigs 
Local (IgA) and systemic (IgG) 
 
i.n. 
[124] 
TT 
CS Mice IgG 
 IgA 
i.n. [206] 
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Hepatitis B virus core  PLGA 
PLGA+MPL 
Mice Th1 immune response higher for 
PLGA+ MPL 
s.c. [207] 
Staphylococcus B enterotoxin PLGA Mice IgG s.c. [174] 
Alginate  Mice 
Rabbits 
Calves 
Systemic IgA  
Local IgA 
Local and systemic IgA  
Oral 
 
s.c.+oral 
[208] 
PLGA Mice Systemic IgG  s.c. [209] 
PLGA Mice IgG s.c. [210] 
OVA 
PLGA Calves Local IgA 
Systemic IgG 
i.n. [211] 
OVA+MDP PLGA Mice  IgG i.d. [212] 
Pig serum albumin ALG Rams Systemic and nasal IgG1  
Non significant IgG2a and IgA levels  
Non significant immune responses  
i.n. 
 
 
oral 
 
[213] 
Salmonella enteric serovar. Abortusovis 
extract 
PCL Mice Protection failure 
s.c. [115] 
Brucella ovis Extract PCL Rams Protective IgG levels s.c. [214] 
Salmonella enterica Polyacrylamide Mice Th1/Th2 
Th1; IgA local 
i.m.  
Oral 
[215] 
Helicobater pylori CS Mice Systemic IgG1 and IgG2a  
Th2/Th1  
oral [216] 
Mycobacterium tuberculosis CS Mice Systemic IgG, IgG1 and IgG2a  
Th1 
s.c. [217] 
Plasmodium falciparum PLGA Mice IgG ≅ positive control s.c. [218] 
DNA (HIV-2 gp140)  CS Mice IgG, IgM and IgA systemic i.d. [221] 
DNA (HPV-16 E7) PLGA Humans Cellular immune responses; IgA i.m., s.c. [219] 
DNA (HIV-1 p55 gag) PLGA+CTAB Mice IgG;CTL i.m. [220] 
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DNA (E1E2 proteins of Hepatitis C virus)  PLGA+CTAB 
Boost E1E2+MF59 
PLGA+CTAB 
Monkeys 
 
Mice 
IgG >IgG with  E1E2/MF59 
Systemic IgG  
i.m. [222] 
Group C meningococcal conjugated 
vaccine 
CS+LTK63 Mice  Systemic IgG  
Nasal IgA  
i.n. [97] 
HIV-1 p55 gag protein PLGA+SDS Mice CTL stimulation i.m. [126] 
rPsaA (Streptococcus pneumoniae 
recombinant adhesin A) 
ALG 
ALG+CTB 
Mice 
Mice 
Systemic IgM and IgA, local IgA  
Systemic IgM and IgA , local IgA > 
ALG 
oral [223] 
Yersinia pestis F1 and V subunits PLA Mice i.m. protection ≅ intratracheal (i.t.) 
protection 
i.m. 
i.t. 
[224] 
Monovalent influenza A subunit H3N2 N-trimethyl CS Mice Total IgG and IgA 
Total IgG 
i.n.  
i.m.  
[225] 
Live porcine rotavirus VP6 recombinant 
protein 
ALG Mice IgG anti-VP6 
Local IgA anti-VP6  
i.p. 
oral 
[226] 
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OUTLINES AND AIMS OF THIS THESIS 
Horse raising industry generate a considerable number of full time jobs and is 
vital for the economy of several countries all over the world, such as 
Australia, New Zealand, England, USA, Brazil, Scotland, Ireland, Canada, 
Sweden and Japan. Strangles is however a worldwide endemic disease that 
often leads to large outbreaks, being considered as one of the most important 
endemic diseases in horses. Treatment with antibiotics is not consensual 
among the veterinary community, being researchers rather directed to the 
development of efficient diagnostic tests and vaccines. As mentioned in the 
previous section, vaccines available in the market have not been able to make 
major improvements in the effective control of this contagious disease. 
Therefore, all over the world there have been major efforts in order to develop 
a new vaccine that have been certainly improved by the S. equi and S. 
zooepidemicus genome-sequencing projects, as they have markedly contributed 
for the identification of bacteria virulence factors.  
Our research group has been previously involved in a project (R&D project, 
SINDEPEDIP, Consórcio Imunopor, P/P/S5) directed to the development of 
a vaccine against S. equi infection. During those experiments, it was observed 
that SeM identification, production and purification using biotechnology 
methods is a complex and highly expensive process. Therefore, cheaper 
antigens, as S. equi whole cells or their lysates were microentrapped in PLGA 
microspheres, being able to induce protection in laboratory animal model. 
These studies also indicate that PLGA microspheres are a potential carrier 
system for the delivery of S. equi antigens, making possible a vaccine 
formulation. However, the use of PLGA in the production of a veterinary 
vaccine can compromise future commercialisation, as it is a truly expensive 
excipient. Therefore, the major goal of this thesis was to develop and fully 
characterise stable alternative polymeric carriers for mucosal delivery of S. 
equi antigens, able to induce humoral, cellular and local immune responses, 
thus protecting animals against strangles. In addition, it is extremely 
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important that vaccinated animals with S. equi antigen-loaded polymeric 
particles do not show any signs of the disease and adverse reactions, which 
are the main disadvantages of those vaccines currently available in the 
market.  
In the other host institution (Centre for Drug Delivery Research, University of 
London School of Pharmacy, UK), where part of the work included in this 
joint PhD thesis was developed, PCL, PLA and CS were already being tested 
giving promising results for the controlled release of several clinically 
relevant antigens, such as DT, TT, hepatitis B surface antigen, as well as 
plasmid DNA.  PCL is cheaper and more hydrophobic compared to 
PLGA/PLA polymers and therefore may have an extended release profile. 
For that reason, PCL  offers a cost-effective alternative and was used for the 
production of plain microspheres by double emulsion (w/o/w) solvent 
evaporation technique (Chapter 3), whose surface was further modified by 
association with the polysaccharides CS and ALG, in order to evaluate the 
influence of particle surface characteristics in the immunoadjuvant properties 
of these polymeric carriers, as it was previously documented that the particles 
surface charge influences their uptake by APCs.  CS and ALG of different 
molecular weight and concentrations were used to assess their influence in 
particle physicochemical characteristics. CS is a polycationic polymer 
produced by chitin deacetylation, which seems to have the ability to 
reversibly open tight junctions, and therefore increases paracellular transport 
across cells. CS and ALG, besides natural, biocompatible, biodegradable and 
mucoadhesive polymers, are able to elicit higher immune responses and 
somehow have the potential to protect proteins from degradation, due to less 
harsh formulation conditions. After full particle characterisation, three 
polymeric systems were chosen for the following in vivo studies. Therefore, 
the total proteins extracted from S. equi cell wall were adsorbed onto those 
selected PCL microspheres, a single dose was administered by s.c. route and 
the elicited humoral and cellular immune responses were studied for 300 
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days. This was the first study focused on S. equi antigens adsorption onto 
polymeric carriers, as a potential vaccine system. 
After confirming the potential adjuvanticity of PCL microspheres, a second 
experiment was performed upon particle size reduction. A comparative study 
was carried out between systemic and local immune responses induced after 
i.n. administration of S. equi enzymatic extract antigens adsorbed and 
entrapped PCL nanospheres (Chapter 4). Particle size is important as in 
general smaller particles are more efficiently taken up by APCs than larger 
ones. Therefore, PCL nanospheres were produced by modification of the 
w/o/w emulsification solvent evaporation method used in Chapter 1.  
Besides the CS attractive properties, its main drawback is the low solubility at 
physiological pH. Consequently, glycol chitosan (GCS) was used in the inner 
phase of w/o first emulsion, during particle formulation due to its good 
solubility in broad range pH aqueous systems. Similarly to PCL microspheres 
developed in Chapter 3, ALG was also used to modify PCL nanospheres in 
order to extend particle residence time in the nasal mucosa. Particle 
association with absorption enhancers (SP and OA) was performed to 
overcome nasal barriers and improve antigen delivery through the mucosal 
surface. Particle physicochemical characteristics, as volume mean diameter, 
morphology, surface charge, loadings and antigens structural integrity and 
antigenicity after either adsorption or entrapment processes, were extensively 
evaluated.  
In Chapter 5 the cellular, humoral and local immune responses induced by 
PLA nanospheres formulated with those mucoadhesive polymers and 
absorption enhancers previously associated to PCL carriers (Chapter 4) were 
evaluated for 12 weeks in an in vivo study performed after mice i.n. 
immunisation, in order to assess polymer influence in the duration and type 
of immune response elicited.  
Besides being a more expensive antigen product, recombinant S. equi SeM 
proteins were entrapped in PLA nanospheres of similar composition than 
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those previously mentioned (PVA, GCS, ALG, SP and OA) and animals were 
vaccinated by i.m. route. The IgG and IgG subtype levels, along with cytokine 
produced after splenocyte co-stimulation with SeM, were assessed and 
compared with those S. equi enzymatic extract antigen-entrapped PLA 
particles (Chapter 6).    
Overall, the main purpose of these extensive in vivo studies was to study the 
possibility of obtaining a fully characterised polymeric particulate adjuvanted 
system for effective nasal immunisation against strangles in a mice model. 
Most of the results described and discussed in this thesis have been submitted 
or accepted for publication in international journals.  
 
References list 
61 
REFERENCES LIST 
 
[1]   Flock M, Jacobsson K, Frykberg L, Hirst TR, Franklin A, Guss B and 
Flock JI. Recombinant Streptococcus equi proteins protect mice in 
challenge experiments and induce immune response in horses. Infect 
Immun 2004;72(6):3228-36. 
[2]   Waller AS, Jolley KA. Getting a grip on strangles: recent progress 
towards improved diagnostics and vaccines. Vet J 2007;173(3):492-501. 
[3]   Breiman RF, Silverblatt FJ. Systemic Streptococcus equi infection in a 
horse handler-a case of human strangles. West J Med 
1986;145(3):385-6. 
[4]   Elsayed S, Hammerberg O, Massey V, Hussain Z. Streptococcus equi 
subspecies equi (Lancefield group C) meningitis in a child. Clin 
Microbiol Infect 2003;9(8):869-72. 
[5]   Ladlow J, Scase T, Waller A. Canine strangles case reveals a new host 
susceptible to infection with Streptococcus equi. J Clin Microbiol 
2006;44(7):2664-5. 
[6]   Lindmark H, Guss B. SFS, a novel fibronectin-binding protein from 
Streptococcus equi, inhibits the binding between fibronectin and 
collagen. Infect Immun 1999;67(5):2383-8. 
[7]   Slater JD. Strangles, bastard strangles, vives and glanders: 
archaeological relics in a genomic age. Equine Vet J 2003;35(2):118-20. 
[8]   Hamilton A, Robinson C, Sutcliffe IC, Slater J, Maskell DJ, 
Davis-Poynter N, Smith K, Waller A and Harrington DJ. Mutation of 
the maturase lipoprotein attenuates the virulence of Streptococcus equi 
to a greater extent than does loss of general lipoprotein lipidation. 
Infect Immun 2006;74(12):6907-19. 
[9]  Sweeney CR, Timoney JF, Newton JR, and Hines MT. Streptococcus 
equi infections in horses: guidelines for treatment, control, and 
prevention of strangles. J Vet Intern Med 2005;19:123-134. 
[10]   Sweeney CR. Strangles: Streptococcus equi infection in horses. Equine 
Vet Ed 1996;8:317-322. 
[11]   Intrevet, Lda; April 2008 Available from: URL: 
http://www.equine-strangles.co.uk/ 
[12]   Equisport; April 2008 Available from: URL: www.equisport.pt 
[13] Timoney JF. Strangles. Vet Clin North Am Equine Pract 
1993;9(2):365-74. 
[14] Newton R, Waller A, King A. Investigation of suspected adverse 
reactions following strangles vaccinations in horses. Vet Rec 
2005;156(9):291-2. 
[15] Chanter N, Newton JR, Wood JL, Verheyen K, Hannant D. Detection 
of strangles carriers. Vet Rec 1998;142(18):496. 
 62 
[16] Timoney JF, Sheoran A, Artiushin S. Detection of strangles carriers. 
Vet Rec 1998;142(23):648. 
[17] Hamlen HJ, Timoney JF, Bell RJ. Epidemiologic and immunological 
characteristics of Streptococcus equi infection in foals. J Am Vet Med 
Assoc 1994;204(5):768-75. 
[18]  Merck Sharp & Dohme; April 2008 Available from: URL:  
www.merckvetmanual.org/mvm/htm/bc/121309.htm 
[19]  Newton JR, Wood JL, Dunn KA, DeBrauwere MN, Chanter N. 
Naturally occurring persistent and asymptomatic infection of the 
guttural pouches of horses with Streptococcus equi. Vet Rec 
1997;140(4):84-90. 
[20] Wood JL, Dunn K, Chanter N, de BN. Persistent infection with 
Streptococcus equi and the epidemiology of strangles. Vet Rec 
1993;133(15):375. 
[21] Newton JR, Verheyen K, Talbot NC, Timoney JF, Wood JLN, Lakhani 
KH, Chanter N. Control of strangles outbreaks by isolation of guttural 
pouch carriers identified using PCR and culture of Streptococcus equi. 
Equine Vet J 2000;32(6):515-26. 
[22] Verheyen K. Getting a grip on strangles. Vet J 2007;173(3):475-6. 
[23] IDEXX laboratories 2008 April 17 Available from: URL: 
http://www.idexx.com/equine /laboratory/sequi_elisa/ 
[24] Galan JE, Timoney JF. Mucosal nasopharyngeal immune-responses of 
horses to protein antigens of Streptococcus equi. Infect Immun 
1985;47(3):623-8. 
[25] Harrington DJ, Sutcliffe I, Chanter N. The molecular basis of 
Streptococcus equi infection and disease. Microbes Infect 2002;4:501-10. 
[26] Timoney JF. Strangles vaccines in trouble again. Equine Vet J 
2007;39(3):196. 
[27] Timoney JF, Qin A, Muthupalani A, Artiushin S. Vaccine potential of 
novel surface exposed and secreted proteins of Streptococcus equi. 
Vaccine 2007;25:5583-90. 
[28] Timoney JF. The pathogenic equine streptococci. Vet Res 
2004;35(4):397-409. 
[29] Lindmark H, Jonsson P, Engvall E, Guss B. Pulsed-field gel 
electrophoresis and distribution of the genes zag and fnz in isolates of 
Streptococcus equi. Res Vet Sci 1999;66(2):93-9. 
[30] Lindmark H, Jacobsson K, Frykberg L, Guss B. Fibronectin-binding 
protein of Streptococcus equi subsp. zooepidemicus. Infect Immun 
1996;64(10):3993-9. 
[31] Lindmark H, Nilsson M, Guss B. Comparison of the fibronectin-
binding protein FNE from Streptococcus equi subspecies equi with FNZ 
from S. equi subspecies zooepidemicus reveals a major and conserved 
difference. Infect Immun 2001;69(5):3159-63. 
References list 
63 
[32] Cue D, Dombek PE, Lam H, Cleary PP. Streptococcus pyogenes serotype 
M1 encodes multiple pathways for entry into human epithelial cells. 
Infect Immun 1998;66(10):4593-601. 
[33] Hanski E, Horwitz PA, Caparon MG. Expression of protein F, the 
fibronectin-binding protein of Streptococcus pyogenes JRS4, in 
heterologous streptococcal and enterococcal strains promotes their 
adherence to respiratory epithelial cells. Infect Immun 
1992;60(12):5119-25. 
[34] Hanski E, Caparon M. Protein F, a fibronectin-binding protein, is an 
adhesin of the group A streptococcus Streptococcus pyogenes. Proc Natl 
Acad Sci USA 1992;89(13):6172-6. 
[35] Hamilton A, Harrington D, Sutcliffe IC. Characterization of acid 
phosphatase activities in the equine pathogen Streptococcus equi. Syst 
Appl Microbiol 2000;23(3):325-9. 
[36] Harrington DJ, Greated JS, Chanter N, Sutcliffe IC. Identification of 
lipoprotein  homologues of pneumococcal PsaA in the equine 
pathogens Streptococcus equi  and Streptococcus zooepidemicus. Infect 
Immun 2000;68(10):6048-51. 
[37] Chanter N, Ward CL, Talbot NC, Flamagan JA, Binns M, Houghton 
SB, Smith KC and Mumford JA. Recombinant hyaluronate associated 
protein as a protective immunogen against Streptococcus equi and 
Streptococcus zooepidemicus challenge in mice. Microb Pathog 
1999;27(3):133-43. 
 [38] Walker JA, Timoney JF. Construction of a stable non-mucoid deletion 
mutant of the Streptococcus equi Pinnacle vaccine strain. Vet Microbiol 
2002;89(4):311-21. 
[39] Anzai T, Timoney JF, Kuwamoto Y, Fujita Y, Wada R, Inoue T. In vivo 
pathogenicity and resistance to phagocytosis of Streptococcus equi 
strains with different levels of capsule expression. Vet Microbiol 
1999;67(4):277-86. 
[40] Sting R, Schaufuss P, Blobel H. Isolation and characterization of 
hyaluronidases from Streptococcus dysgalactiae, S. zooepidemicus and S. 
equi. Zentralbl Bakteriol 1990;272(3):276-82. 
[41] Flanagan J, Collin N, Timoney J, Mitchell T, Mumford JA, Chanter N. 
Characterization of the haemolytic activity of Streptococcus equi. 
Microb Pathog 1998;24(4):211-21. 
[42] Timoney JF, Artiushin SC, Boschwitz JS. Comparison of the sequences 
and functions of Streptococcus equi M-like proteins SeM and SzPSe. 
Infect Immun 1997 Sep;65(9):3600-5. 
[43] Meehan M, Muldowney DA, Watkins NJ, Owen P. Localization and 
characterization of the ligand-binding domain of the 
fibrinogen-binding protein (FgBP) of Streptococcus equi subsp. equi. 
Microbiology 2000;146 (5):1187-94. 
[44] Meehan M, Kelly SM, Price NC, Owen P. The C-terminal portion of 
the fibrinogen-binding protein of Streptococcus equi subsp. equi 
 64 
contains extensive alpha-helical coiled-coil structure and contributes 
to thermal stability. FEMS Microbiol Lett 2002;206(1):81-6. 
[45] Chanter N, Talbot NC, Newton JR, Hewson D, Verheyen K. 
Streptococcus equi with truncated M-proteins isolated from outwardly 
healthy horses. Microbiology 2000;146(6):1361-9. 
[46] Meehan M, Nowlan P, Owen P. Affinity purification and 
characterization of a fibrinogen-binding protein complex which 
protects mice against lethal challenge with Streptococcus equi subsp. 
equi. Microbiology 1998;144(4):993-1003. 
[47] Karlstrom A, Jacobsson K, Flock M, Flock JI, Guss B. Identification of a 
novel collagen-like protein, SclC, in Streptococcus equi using signal 
sequence phage display. Vet Microbiol 2004;104(3-4):179-88. 
[48] Lannergard J, Frykberg L, Guss B. CNE, a collagen-binding protein of 
Streptococcus equi. FEMS Microbiol Lett 2003;222(1):69-74. 
[49] Artiushin SC, Timoney JF, Sheoran AS, Muthupalani SK. 
Characterization and  immunogenicity of pyrogenic mitogens SePE-H 
and SePE-I of Streptococcus equi. Microb Pathog 2002;32(2):71-85. 
[50] Alber J, El-Sayed A, Estoepangestie S, Lammler C, Zschock M. 
Dissemination of the superantigen encoding genes seeL, seeM, szeL 
and szeM in Streptococcus equi subsp. equi and Streptococcus equi subsp. 
zooepidemicus. Vet Microbiol 2005;109(1-2):135-41. 
[51] Proft T, Webb PD, Handley V, Fraser JD. Two novel superantigens 
found in both group A and group C Streptococcus. Infect Immun 
2003;71(3):1361-9. 
[52] Sheoran AS, Artiushin S, Timoney JF. Nasal mucosal immunogenicity 
for the  horse of a SeM peptide of Streptococcus equi genetically coupled 
to cholera toxin. Vaccine 2002;20:1653-9. 
[53]  Vaccine Strepguard. Intervet, Ltd 2008 April 17 Available from: URL: 
http://active.inspection.gc.ca/scripts/database/vetbio_submit.asp?la
ng=e&manufacturer=all&species=5  
[54]  Vaccine Equivac S and Equivac 2 in 1. Pfizer Animal Health Pty Ltd 
2008 April 17 Available from: 
URL:http://www.pfizeranimalhealth.com.au/index.asp?country=AU
&species=OO&lang=EN&drug=PU 
[55] Timoney JF, Mohtar MM. The protective M proteins of the equine 
group C streptococci. Vet Microbiol 1993;37(3-4):389-95. 
[56] Bramwell VW, Perrie Y. Particulate delivery systems for vaccines: 
what can we expect? J Pharm Pharmacol 2006;58(6):717-28. 
[57] Amidi M, Romeijn SG, Verhoef CJHE, bungener LHA, Crommlin DJA, 
Jiskoot W. N-Trimethyl chitosan (TMC) nanoparticles loaded with 
influenza subunit antigen for intranasal vaccination: Biological 
properties and immunogenicity in a mouse model. Vaccine 
2007;25:144-53. 
References list 
65 
[58]  Pinnacle. Fort Dodge; 2008 April 11 Available from: URL: 
http://ftdodge.naccvp.com/view.php?u=country&p=msds&prodnu
m=1003145. 
[59] Flock M, Karlstrom A, Lannergard J, Guss B, Flock JI. Protective effect 
of vaccination with recombinant proteins from Streptococcus equi 
subspecies equi in a strangles model in the mouse. Vaccine 
2006;24(19):4144-51. 
[60]  Equilis StrepE. Intervet, Lda; 2008 April 11 Available from: URL: 
http://www.equine-strangles.co.uk/News.asp 
[61] Azevedo AF, Galhardas J, Cunha A, Cruz P, Goncalves LM, Almeida 
AJ. Microencapsulation of Streptococcus equi antigens in biodegradable 
microspheres and preliminary immunisation studies. Eur J Pharm 
Biopharm 2006;64(2):131-7. 
[62] Flock JI. Extracellular-matrix-binding proteins as targets for the 
prevention of Staphylococcus aureus infections. Mol Med Today 
1999;5(12):532-7. 
[63] Flock JI, Brennan F. Antibodies that block adherence of to fibronectin. 
Trends Microbiol 1999;7(4):140-1. 
[64] Jonsson H, Lindmark H, Guss B. A protein G-related cell surface 
protein in Streptococcus zooepidemicus. Infect Immun 
1995;63(8):2968-75. 
[65] Lannergard J, Flock M, Johansson S, Flock JI, Guss B. Studies of 
fibronectin-binding proteins of Streptococcus equi. Infect Immun 
2005;73(11):7243-51. 
[66] Aguilar JC, Rodríguez EG. Vaccine adjuvants revisited. Vaccine 
2007;25:3752-62. 
[67] Sayegh MH, Watschinger B, Carpenter CB. Mechanisms of T cell 
recognition of alloantigen. The role of peptides. Transplantation 
1994;57(9):1295-302. 
[68]  Shen H, Ackeman AL, Cody V, Giodini A, Hinson ER, Cresswell P, 
Edelson RL, Saltzman M, Hanlon DJ. Enhanced and prolonged 
cross-presentation following endossomal escape of exogenous 
antigens encapsulated in biodegradable nanoparticles. Immunology 
2006;117:78-88. 
[69]  Conacher M, Alexander J, Brewer JM. Niosomes as immunological 
adjuvants. In: Uchegbu IF, editors. Synthetic surfactant vesicles. 
International Publishers Distributors Ltd. Singapore, 2000: pp. 
185-205. 
[70]  Johansen P, Men Y, Merkle HP, and Gander B. Revisiting PLA/PLGA 
microspheres: an analysis of their potential in parenteral vaccination. 
Eur J Pharm Biopharm 2000;50:129-146. 
[71]  Wu HY, Russel MW. Nasal lymphoid tissue, intranasal immunization 
and compartmentalization of the common mucosal immune system. 
Immunol Res  1997;16:187-201. 
 66 
[72]  Eyles JE, Spiers ID, Williamson ED, Alpar HO. Analysis of local and 
systemic immunological responses after intra-tracheal, intra-nasal, 
intra-muscular administration of microsphere co-encapsualted 
Yersinia pestis sub-unit vaccines. Vaccine 1998;16:2000-9. 
[73]  Katare Y, Muthukumaran T, Panda AK. Influence of particle size, 
antigen load, dose and additional adjuvant on the immune response 
from antigen loaded PLA microparticles. Int J Pharm 2005;301:149-60. 
[74] Almeida AJ, Alpar HO. Mucosal immunisation with 
antigen-containing microparticles. In: Gander B, Merkle HP, Corradi 
G, editors. Antigen delivery systems: immunological and 
technological issues. Amsterdam, Harwood Academic Publishers, 
1997: pp. 207-26. 
[75]  Jilek S, Merkle HP, Walter E. DNA-loaded biodegradable 
microparticles as vaccine delivery systems and their interaction with 
dendritic cells. Adv Drug Deliv Rev 2005;37:377-90. 
[76]  Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H. 
Antigen localisation regulates immuneresponses in a dose- and time-
dependent: a geographical view of immune reactivity. Immunol Rev 
1997;156:199-209. 
[77]  Szakal AK, Burton GF, Smith JP, Tew JG. Antigen processing and 
presentation in vivo. In: Spriggs DR, Koff WC, editors. Topics in 
vaccine adjuvant research. Florida, CRC Press, 2001: pp. 11-21. 
[78]  Spriggs DR, Koff WC. Topics in vaccine adjuvant research. Florida, 
CRC Press, 2001. 
[79]  Ludewig B, Barchiesi F, Pericin M, Zinkernagel RM,Hengartner H, 
Schwendener RA. In vivo antigen loading and activation of dendritic 
cells via a liposomal peptide vaccine mediates protective antiviral and 
anti-tumour immunity. Vaccine 2000;19: 23–32. 
[80]  Eyles JE, Bramwell VW, Williamson ED, Alpar HO. Microsphere 
translocation and immunopotentiation in systemic tissues following 
intranasal administration. Vaccine 2001;19: 4732–4742. 
[81]  Eyles JE, Carpenter ZC, Alpar HO, Williamson ED. Immunological 
aspects of polymer microsphere vaccine delivery systems. J Drug 
Target 2003a;11: 509-514. 
[82]  Friede M, Aguado MT. Need for new vaccine formulations and 
potential of particulate antigen and DNA delivery systems. Adv Drug 
Deliv Rev 2005;57: 325–331. 
[83]  Brennan FR, Dougan, G. Non-clinical safety evaluation of novel 
vaccines and adjuvants: new products, new strategies. Vaccine 
2005:23(24):3210-3222. 
[84]  O’Hagan DT, Valiante NM. Recent advances in the discovery and 
delivery of vaccine adjuvants. Nat Rev Drug Discov 2003;2:727– 735. 
[85]  Sesardic D, Dobbelaer R. European Union regulatory developments 
for new vaccine adjuvants and delivery systems. Vaccine 
2004;22:2452– 2456. 
References list 
67 
[86]  Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, Perrie 
Y, Agger EM, Andersen P. Characterization of cationic liposomes 
based on dimethyldioctadecylammonium and synthetic cord factor 
from M. tuberculosis (trehalose 6,60-dibehenate) – a novel adjuvant 
inducing both strong CMI and antibody responses. Biochim Biophys 
Acta 2005;1718: 22–31. 
[87]  Singh M, O´Hagan DT. Recent advances in veterinary vaccine 
adjuvants. Int J Parasitology 2003;33:469-478]. 
[88]  Gupta RK, Aluminium compounds as vaccine adjuvants. Adv Drug 
Deliv Rev 1998; 32:155-172. 
[89]  Gupta RK, Siber GR. Adjuvants for human vaccines—current status, 
problems  and future-prospects. Vaccine 1995;13:1263–1276. 
[90]  Isaka M, Yasuda Y, KozReino Unidoa S, Miura Y, Taniguchi T, 
Matano K, Goto’f  N, Tochikubo K. Systemic and mucosal immune 
responses of mice to aluminium adsorbed or aluminium-non-
adsorbed tetanus toxoid administered intranasally with recombinant  
cholera toxin B subunit. Vaccine 1998; 16(17):1620-1626. 
[91]  Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable 
poly(lactic-co-glycolic acid) microparticles for injectable delivery of 
vaccine antigens. Adv Drug Deliv Rev 2005;57:391-410.  
[92]  Singh M, Li XM, Wang H, McGee JP, Zamb T, Koff W, Wang CY, 
O’Hagan DT. Immunogenicity and protection in small-animal models 
with controlled-release tetanus toxoid microparticles as a single dose 
vaccine. Infect Immun 1997a;65:1716–1721. 
[93]  Raghuvanshi RS, Katare YK, Lalwani K, Ali MM, Singh O, Panda AK. 
Improved immune response from biodegradable polymer particles 
entrapping tetanus toxoid by use of different immunization protocol 
and adjuvants. Int J Pharm 2002;245:109–121.  
[94]  Woolcock JB. Purification and antigenicity of an M-like protein of 
Streptococcus equi. Infect Immun 1974;10(1):116-122. 
[95]  Timoney JF, Trachman J. Immunologically reactive proteins of 
Streptococcus equi. Infect Immun 1985;48(1):29-34. 
[96]  Nally JE, Artiushin S, Sheoran AS, Burns PJ, Simon B, Gilley RM, 
Gibson J, Sullivan S, Timoney JF. Induction of mucosal and systemic 
antibody specific for SeMF3 of Streptococcus equi by intranasal 
vaccination using a sucrose acetate isobutyrate based delivery system. 
Vaccine 2001;19:492-497. 
[97]  Dougan G, Hormaeche C. How bacteria and their products provide 
clues to vaccine and adjuvant development. Vaccine 
2006;24S2:S2/13-S2/19. 
[98]  Baudner BC, Giuliani MM, Verhoef JC, Rappuoli R, Junginger HE, 
Giudice GD. The concomitant use of the LTK63 mucosal adjuvant and 
of chitosan-based delivery system enhances the immunogenicity and 
efficacy of intranasally administered vaccines. Vaccine 
2003;21(25-26):3837-44. 
 68 
[99]  Esquivel-Perez R, Moreno-Frierros L. Mucosal and adjuvant effects of 
cholera toxin and Cry1Ac protoxin on the specific antibody response 
to HIV-1 C4/V3 peptides are different and depend on the antigen 
co-administered. Viral Immunol 2005;18(4):695-708. 
[100]  Isaka M, Yasuda Y, KozReino Unidoa S, Taniguchi T, Matano K, 
Maeyama J, Komiya T, Ohkuma K, Goto N, Tochikubo K. Induction of 
systemic and mucosal antibody responses in mice immunized 
intranasally with aluminium-non-adsorbed diphtheria toxoid together 
with recombinant cholera toxin B subunit as an adjuvant. Vaccine 
2000;18:743-751.  
[101] Hordnes K, Tynning T, Brown TA, Haneberg B, Jonsson R. Nasal 
immunization with group B streptococci can induce high levels of 
specific IgA antibodies in cervicovaginal secretions of mice. Vaccine 
1997;15:1244-1251. 
[102]  Rojas-Hernandez S, Rodriguez-Monroy MA, Lopez-Revilla R, 
Resendiz-Albor AA, Moreno-Fierros L.Intranasal co-administration of 
the Cry1Ac protoxin with amoebal lysates increases protection against 
Naegleria fowleri meningoencephalitis. Infect Immun 
2004;72:4368-4375. 
[103]  Isaka M, Yasuda Y, Taniguchi T, Kozuka S, Matano K, Maeyama J, 
Morokuma K, Ohkuma K, Goto N and Tochikubo K. Mucosal and 
systemic antibody responses against an acellular pertussis vaccine in 
mice after intranasal co-administration with recombinant cholera 
toxin B subunit as an adjuvant. Vaccine 2003;21:1165-73. 
[104]  Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR. A 
dilemma for mucosal vaccination: efficacy versus toxicity using 
enterotoxin-based adjuvants. Vaccine 2002; 20:2431-2438. 
[105]  Waite DC, Jacobson EW, Ennis FA, Edelman R, White B, Kammer R,    
Anderson C, Kensil CR. Three double-blind, randomized trials 
evaluating the safety and tolerance of different formulations of the 
saponin adjuvant QS-21. Vaccine 2001;19: 3957–3967. 
[106]  Pearse MJ, Drane D. ISCOMATRIX adjuvant for antigen delivery. Adv 
Drug Deliv Rev 2005;57: 465–474. 
[107]  Cox E, Verdonck F, Vanrompay D, Goddeeris B. Adjuvants 
modulating mucosal immune responses or directing systemic 
responses towards the mucosa. Vet Res 2006;37:511–39. 
[108]  Boschwitz JS, Timoney JF. Inhibition of C3 Deposition on Streptococcus 
equi subsp. equi by M protein: a mechanism for survival in equine 
blood. Infect Immun 1994;62(8):3515-3520. 
[109]  Wallace FJ, Emery JD, Cripps AW, Husband AJ. An assessment of 
mucosal immunisation in protection against Streptococcus equi 
(‘Strangles’) infections in horses. Vet Immunol Immunopathol 
1995;48:139-154. 
[110]  Meehan M, Lynagh Y, Woods C, Owen P. The fibrinogen-binding 
protein (FgBP) of Streptococcus equi subsp. equi additionally binds IgG 
References list 
69 
and contributes to virulence in a mouse model. Microbiology 
2001;147:3311-3322. 
[111]  Sheoran AS, Sponseller BT, Holmes MA, Timoney JF. Serum and 
mucosal antibody isotype responses to M-like protein (SeM) of 
Streptococcus equi in convalescent and vaccinated horses. Vet Immunol 
Immunopathol 1997;59:239-251. 
[112]  Langer R, Cleland JL, Hanes J. New advances in microsphere-based 
single-dose vaccines. Adv Drug Deliv Rev 1997;28(1):97-119. 
[113]  Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic 
cells as vectors for therapy. Cell 2001;106:271-4. 
[114]  Jaganathan KS, Rao YU, Singh P, Prabakaran D, Gupta S, Jain A and 
Vyas SP. Development of a single dose tetanus toxoid formulation 
based on polymeric microspheres: a comparative study of 
poly(D,L-lactic-co-glycolic acid) versus chitosan microspheres. Int J 
Pharm 2005;294(1-2):23-32. 
[115]  Estevan M, Irache JM, Grillo MJ, Blasco JM, Gamazo C. Encapsulation 
of antigenic extracts of Salmonella enterica serovar Abortusovis into 
polymeric systems and efficacy as vaccines in mice. Vet Microbiol 
2006;118:124-132. 
[116] Gupta RK, Singh M, O'Hagan DT. Poly(lactide-co-glycolide) 
microparticles for the development of single-dose controlled-release 
vaccines. Adv Drug Deliv Rev 1998;32(3):225-46. 
[117]  Singh M, O'Hagan DT. Recent advances in vaccine adjuvants. Pharm 
Res 2002;19(6):715-28. 
[118] Alonso MJ, Cohen S, Park TG, Gupta RK, Siber GR, Langer R. 
Determinants of release rate of tetanus vaccine from polyester 
microspheres. Pharm Res 1993;51:945-53. 
[119] Zhu G, Mallery SR, Schwendeman SP. Stabilization of proteins 
encapsulated in injectable poly(lactide-co-glycolide). Nat Biotechnol 
2000;18:52-7. 
[120] Benoit MA, Baras B, Gillard J. Preparation and characterization of 
protein-loaded poly(epsilon-caprolactone) microparticles for oral 
vaccine delivery. Int J Pharm 1999;184(1):73-84. 
[121]  Jeffery H, Davis SS, O'Hagan DT. The preparation and 
characterization of poly(lactide-co-glycolide) microparticles. II. The 
entrapment of a model protein using a (water-in-oil)-in-water 
emulsion solvent evaporation technique. Pharm Res 1993;10(3):362-8. 
[122]  Lamprecht A, Ubrich N, Hombreiro PM, Lehr C, Hoffman M, 
Maincent P. Biodegradable monodispersed nanoparticles prepared by 
pressure homogenization-emulsification. Int J Pharm 
1999;184(1):97-105. 
[123]  Nakanishi T, Fukshima S, Okamoto K, Suzuki M, Matsumura Y, 
Yokoyama M, Okano T, Sakurai Y and Kataoka K. Development of the 
polymeric micelle carrier system for doxorrubicin. J Control Release 
2001;74:295-302. 
 70 
[124]  Almeida AJ, Alpar HO, Brown MRW. Immune-response to nasal 
delivery of antigenically intact tetanus toxoid associated with 
poly(L-lactic acid) microspheres in rats, rabbits and guinea-pigs. J 
Pharm Pharmacol 1993;45:198-203. 
[125] Alpar HO, Almeida AJ. Identification of some physicochemical 
characteristics of microspheres which influence the induction of the 
immune response following mucosal delivery. Eur J Pharm Biopharm 
1994;40:198-202. 
[126]  Kazzaz J, Neidleman J, Singh M, Ott G, O’Hagan DT. Novel anionic 
microparticles are a potent adjuvant for the induction of cytotoxic T 
lymphocytes against recombinant p55 gag from HIV-1. J Control 
Release 2000;67:347– 356. 
[127]  Johansen P, Estevez F, Zurbriggen R, Merkle HP, Gluck R, Corradin 
G, Gander B. Towards clinical testing of a single-administration 
tetanus vaccine based on PLA/PLGA microspheres. Vaccine 
2001;19:1047–1054. 
[128]  Gutierro I, Hernandez RM, Igartua M, Gascon AR, Pedraz JL. 
Influence of dose and immunization route on the serum IgG antibody 
response to BSA loaded PLGA microspheres. Vaccine 
2002a;20:2181-2190. 
[129]  Gutierro I, Hernandez RM, Igartua M, Gascon AR, Pedraz JL. Size 
dependent immune response after subcutaneous, oral and intranasal 
administration of BSA loaded nanospheres. Vaccine 2002b;21:67–77. 
[130] Hilbert AK, Fritzsche U, Kissel T. Biodegradable microspheres 
containing influenza A vaccine: immune response in mice. Vaccine 
1999;17:1065–1073. 
[131]  O’Hagan DT, Jeffery H, Davis SS. Long-term antibody responses in 
mice following subcutaneous immunization with ovalbumin 
entrapped in biodegradable microparticles. Vaccine 1993a;11:965–969. 
[132]  Panyam J, Labhasetwar V. Dynamics of endocytosis and exocytosis of 
poly(d,l-lactide-co-glycolide) nanoparticles in vascular smooth muscle 
cells. Pharm Res 2003;20:212–220. 
[133]  Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram PL, 
McKenzie IF, Plebanski M. Sizedependent immunogenicity: 
therapeutic and protective properties of nano-vaccines against 
tumors. J Immunol 2004;173:3148–3154. 
[134] Lemoine D, Deschuyteneer M, Hogge F, Preat V. Intranasal 
immunization against influenza virus using polymeric particles. J 
Biomater Sci Polym Ed 1999;10:805-25. 
[135]  Eyles JE, Williamson ED, Alpar HO. Immunological responses to 
nasal delivery of free and encapsulated tetanus toxoid: studies on 
effect of vehicle colume. Int J Pharm 1999;189:75-9. 
[136]  Jaganathan KS, Vyas SP. Strong systemic and mucosal immune 
responses to surface-modified PLGA microspheres containing 
References list 
71 
recombinant hepatitis B antigen administered intranasally. Vaccine 
2006;24(19):4201-11. 
[137]  Davis SS. Nasal vaccines. Adv Drug Deliv Rev 2001;51:21-42. 
[138]  Donovan MD, Huang Y. Large molecule and particulate uptake in 
nasal cavity: the effect of size on nasal absorption. Adv Drug Deliv 
Rev 1998;29:147-55. 
[139]  Butler SM, Tracy MA, Tilton RW. Adsorption of serum albumin to 
thin films of poly(lactide-co-glycolide). J Control Release 
1999;58:335-347. 
[140]  Ying M, Audran R, Thomasin C, Eberl G, Demotz S, Merkle HP, 
Gander B, Corradin G. MHC class I- and class II-restricted processing 
and presentation of microencapsulated antigens. Vaccine 
1999;17(9-10):1047-56. 
[141] Peyre M, Sesardic D, Merkle HP, Gander B, Johansen P. An 
experimental divalent vaccine based on biodegradable microspheres 
induces protective immunity against tetanus and diphtheria. J Pharm 
Sci 2003;92:957–966. 
[142]  Singh M, Li XM, McGee JP, Zamb T, Koff W, Wang CY, O’Hagan DT. 
Controlled release microparticles as a single dose hepatitis B vaccine: 
evaluation of immunogenicity in mice. Vaccine 1997b;15:475–481. 
[143]  Shi L, Caulfield MJ, Chern RT, Wilson RA, Sanyal G, Volkin DB. 
Pharmaceutical and immunological evaluation of a single-shot 
hepatitis B vaccine formulated with PLGA microspheres. J Pharm Sci 
2002;91:1019–1035. 
[144]  Singh J, Pandit S, Bramwell VW, Alpar HO. Diphtheria toxoid loaded 
poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery 
systems. Methods 2006;38(2):96-105. 
[145]  Alpar HO, Eyles JE, Williamson ED, Somavarapu S. Intranasal 
vaccination against plague, tetanus and diphtheria. Adv Drug Deliv 
Rev 2001;51(1-3):173-201. 
[146]  Borges O, Borchard G, Verhoef jC, Sousa A, Junginger HE. 
Preparation of coated nanoparticles for a new mucosal vaccine 
delivery system. Int J Pharm 2005;299:155-66. 
[147]  Miyake M, Minami T, Hirota M, Toguchi H, Odomi M, Ogawara K, 
Higaki K and Kimura T. Novel oral formulation dafely improving 
intestinal absorption of poorly absorbable drugs: utilization of 
polyamines and bile acids. J Control Release 2006;111:27-34. 
[148]  Sugita Y, Takao K, Toyama Y, Shirahatal A. Enhancement of intestinal 
absorption of macromolecules by spermine in rats. Amino Acids 
2007;33:253-60. 
[149]  Ascarateil S, Dupuis L. Surfactants in vaccine adjuvants: description 
and perspectives. Vaccine 2006;24S2:S2-83-S2/85. 
[150]  Aspden TJ, Mason JD, Jones NS, Lowe J, Skaugrud O, Illum L. 
Chitosan as a nasal delivery system: the effect of chitosan solutions on 
 72 
in vitro and in vivo mucociliary transport rates in humans turbinates 
and volunteers. J Pharm Sci 1997;86:509-13. 
[151]  Illum L, Watts P, Fisher AN, Hinchcliffe M, Norbury H, Jabbal-Gill I. 
Intranasal delivery of morphine. J Pharmacol Exp Ther 
2002;301:391-400. 
[152]  Lee ES, Park K, Park IS, Na K. Glycol chitosan as a stabilizer for 
protein encapsulated into poly(lactide-co-glycolide) microparticle. Int J 
Pharm 2007;338:310-6. 
[153] Chellat F, Grandjean-Laquerriere A, Le Naour R, Fernandes J, Yahia L, 
Guenounou M, Laurent-Maquin D. Metalloproteinase and cytokine 
production by THP-1 macrophages following exposure to chitosan-
DNA nanoparticles. Biomaterials 2005; 26: 961–970. 
[154] Borchard G, Luessen HL, de Boer AG. The potential of mucoadhesive 
polymers in enhancing intestinal peptide drug absorption. Part III. 
Effects of chitosan-glutamate and carbomer on epithelial tight 
junctions in vitro. J Control Release 1996;39:131-8. 
[155]  Dodane V, Amin KM, Merwin JR. Effect of chitosan on epithelial 
permeability and structure. Int J Pharm 1999;182:21-32. 
[156]  Kotzé AF, Luessen HL, de Leeuw BJ, de Boer BG, Verhoef JC, 
Junginger HE. N-trimethyl chitosan chloride as a potential absorption 
enhancer across mucosal surfaces: in vitro evaluation in intestinal 
epithelial cells (Caco-2). Pharm Res 1997;14:1197-202. 
[157] Bowersock TL, Martin S. Vaccine delivery to animals. Advanced drug 
delivery reviews 1999;38:167-194. 
[158]  Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug 
delivery: The need for precision in reporting particle size parameters. 
Eur J Pharm Biopharm 2008;69:1–9. 
[159]  Mohanraj VJ, Chen Y. Nanoparticles-a review. Tropical J Pharm Res 
2006;5(1):561-573. 
[160]  Storni T, Kündig TM, Senti G, Johansen P. Immunity in response to 
particulate antigen-delivery systems. Adv Drug Deliv Rev 
2005;57:333– 355. 
[161]  Chong CSW, Cao M, Wong WW, Fischer KP, Addison WR, Kwon GS, 
Tyrrell DL, Samuel J. Enhancement of T helper type 1 immune 
responses against hepatitis B virus core antigen by PLGA nanoparticle 
vaccine delivery. J Control Release 2005;102:85–99. 
[162]  O’Hagan DT, McGee JP, Holmgren J, Mowat AMCl, Donachie AM, 
Mills KHG, Gaisford W, Rahman D, Challacombe SJ. Biodegradable 
microparticles for oral immunization. Vaccine 1993b;11:149–154. 
[163]  Peyre M, Fleck R, Hockley D, Gander B, Sesardic D. In vivo uptake of 
an experimental microencapsulated diphtheria vaccine following sub-
cutaneous immunisation. Vaccine 2004;22:2430–2437. 
References list 
73 
[164]  Thiele L, Merkle HP, Walter E, Phagocytosis and phagosomal fate of 
surface-modified microparticles in dendritic cells and macrophages. 
Pharm Res 2003;20:221–228. 
[165]  Peyre M, Audran R, Estevez F, Corradin G, Gander B, Sesardic D, 
Johansen P. Childhood and malaria vaccines combined in 
biodegradable microspheres produce immunity with synergistic 
interactions. J Control Rel 2004;99:345–355. 
[166]  Denis-Mize KS, Dupuis M, MacKichan ML, Singh M, Doe B, O’Hagan 
D, UImer JB, Donnelly JJ, McDonald DM, Ott G. Plasmid DNA 
adsorbed onto cationic microparticles mediates target gene expression 
and antigen presentation by dendritic cells Gene Ther 
2000;7:2105-2112. 
[167]  Atuah KN, Walter E, Merkle HP, Alpar HO. Encapsulation of plasmid 
DNA in PLGA-stearylamine microspheres: a comparison of solvent 
evaporation and spray-drying methods. J Microencapsulation 
2003;20:387–399. 
[168] Walter E, Merkle HP. Microparticle-mediated transfection of 
non-phagocytic cells in vitro. J Drug Target 2002;10:11– 21. 
[169]  Greenland JR, Letvin NL. Chemical adjuvants for plasmid DNA 
vaccines. Vaccine 2007;25:3731-3741. 
[170]  Westwood A, Healey GD, Williamson ED, Eyles JE. Activation of 
dendritic cells by microparticles containing Bacillus anthracis 
protective antigen. Vaccine 2005;23:3857–3863. 
[171]  Eyles JE, Bramwell VW, Singh J, Williamson ED, Alpar HO. 
Stimulation of spleen cells in vitro by nanospheric particles containing 
antigen. J Control Release 2003b;86:25–32. 
[172]  Sun H, Pollock KGJ, Brewer JM. Analysis of the role of vaccine 
adjuvants in modulating dendritic cell activation and antigen 
presentation in vitro. Vaccine 2003;21:849–855. 
[173]  O’Hagan DT, Rahman D, McGee JP, Jeffery H, Davies MC, Williams 
P, Davis SS, Challacombe SJ. Biodegradable microparticles as 
controlled release antigen delivery systems. Immunology 
1991;73:239-242. 
[174]  Eldridge JH, Staas JA, Meulbroek JA, Tice TR, Gilley RM. 
Biodegradable and biocompatible poly(DL-lactide-co-glycolide) 
microspheres as an adjuvant for staphylococcal enterotoxin B toxoid 
which enhances the level of toxin-neutralizing antibodies. Infect 
Immun 1991;59:2978–2986. 
[175]  Maloy KJ, Donachie AM, O’Hagan DT, Mowat AM. Induction of 
mucosal and systemic immune responses by immunization with 
ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. 
Immunology 1994;81:661–667. 
[176]  Moore A, McGuirk P, Adams S, Jones WC, McGee JP, O’Hagan DT, 
Mills KHG. Immunization with a soluble recombinant HIV protein 
entrapped in biodegradable microparticles induces HIV-specific CD8+ 
 74 
cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine 
1995;13:1741-1749. 
[177]  Conway MA, Madrigal-Estebas L, McClean S, Brayden DJ, Mills KHG. 
Protection against Bordetella pertussis infection following parenteral or 
oral immunization with antigens entrapped in biodegradable 
particles: effect of formulation and route of immunization on 
induction of Th1 and Th2 cells, Vaccine 2001;19:1940–1950. 
[178]  Partidos CD, Vohra P, Jones D, Farrar G, Steward MW. CTL responses 
induced by a single immunization with peptide encapsulated in 
biodegradable microparticles. J Immunol Methods 1997;206:143–51. 
[179]  Partidos CD, Vohra P, Jones DH, Farrar G, Steward MW. Induction of 
cytotoxic T-cell responses following oral immunization with synthetic 
peptides encapsulated in PLG microparticles. J Cont Rel 
1999;62:325-32. 
[180]  Partidos CD, Vohra P, Steward MW. Induction of measles virus 
specific cytotoxic T-cell responses after intranasal immunization with 
synthetic peptides. Immunology 1996; 87:179–85. 
[181]  Nixon DF, Hioe C, Chen PD, Bian Z, Kuebler P, Li ML, Qiu H, Li XM, 
Singh M, Richardson J, McGee P, Zamb T, Koff W, Wang CY and 
O’Hagan D. Synthetic peptides entrapped in microparticles can elicit 
cytotoxic T cell activity. Vaccine 1996; 14:1523–30. 
[182]  Johansen P, Gander B, Merkle HP, Sesardic D. Ambiguities in the 
preclinical quality assessment of microparticulate vaccines. Trends 
Biotechnol 2000;18:203– 211. 
[183]  Sasiak AB, Bolgiano B, Crane DT, Hockley DJ, Corbel MJ, Sesardic D. 
Comparison of in vitro and in vivo methods to study stability of PLGA 
microencapsulated tetanus toxoid vaccines. Vaccine 2000;19:694– 705. 
[184]  Gupta RK, Chang AC, Griffin P, Rivera R, Guo YY, Siber GR. 
Determination of protein loading in biodegradable polymer 
microspheres containing tetanus toxoid. Vaccine 1997;15:672– 678. 
[185] Available April 2008 URL: 
http://www.gene.com/gene/news/press/releases/ 
[186]  Walter E, Dreher D, Kok M, Thiele L, Kiama SG, Gehr P, Merkle HP. 
Hydrophilic poly(dl-lactide-co-gylcolide) microspheres for the 
delivery of DNA to human-derived macrophages and dendritic cells. J 
Control Release 2001;76:149– 168. 
[187] Walter E, Moelling K, Pavlovic J, Merkle HP. Microencapsulation of 
DNA using poly(dl-lactide-co-glycolide): stability issues and release 
characteristics. J Control Release 1999;61:361– 374. 
[188]   Anderson JM, Shive MS. Biodegradation and biocompatability of PLA 
and PLGA microspheres. Adv Drug Deliv Rev 1997;28:5-24. 
[189]  Baras B, Benoit MA, Gillard J. Influence of various technological 
parameters on the preparation of spray-dried 
poly(epsilon-caprolactone) microparticles containing a model antigen. 
J Microencapsul 2000;17(4):485-98. 
References list 
75 
[190] Visscher GE, Robison MA, Argentieri GJ. Tissue response to 
biodegradable injectable microcapsules. J Biomater Appl 
1987;2(1):118-31. 
[191]  Sah H, Chien YW. Degradability and antigen release characteristics of 
polyester microspheres prepared from polymer blends. J Appl Polym 
Sci 1995;58:197-206. 
[192]  Lemoine D, Francois C, Kedzierewicz F, Preat V, Hoffman M, 
Maincent P. Stability study of nanoparticles of 
poly(epsilon-caprolactone), poly(D,L-lactide) and poly(D,L-lactide-co-
glycolide). Biomaterials 1996;17(22):2191-7. 
[193]  Zhang L, Xiong C, Deng X. Biodegradable polyester blends for 
biomedical application. J Appl Polym Sci 1995;56:103-12. 
[194] Chawla JS, Amiji MM. Biodegradable poly(ε-caprolactone) 
nanoparticles for tumor targeted delivery to tamoxifen. Int J Pharm 
2002;249:127-38. 
[195]  Jameela SR, Suma N, Misra A, Raghuvanshi R, Ganga S, Jayakrishnan 
A. Poly(ε-caprolactone) microspheres as a vaccine carrier. Curr Sci 
1996;70:669-671. 
[196]  Murillo M, Grillo MJ, Rene J, Marin CM, Barberán M, Goñi M, Blasco 
JM, Irache JM and Gamazo C. A Brucella ovis antigenic complex 
bearing poly-epsilon-caprolactone microparticles confer protection 
against experimental brucellosis in mice. Vaccine 2001;19(30):4099-106. 
[197]  Hora MS, Rana RK, Nunberg JH, Tice TR, Gilley RM, Hudson ME. 
Release of human serum albumin from poly(lactide-co-glycolide) 
microspheres. Pharm Res 1990;7:1190–1194. 
[198]  Jeffery H, Davis SS, O’Hagan DT. The preparation and 
characterisation of poly(lactide-co-glycolide) microparticles. I. Oil-in-
water emulsion solvent evaporation. Int J Pharm 1991;77:169–175. 
[199]  Ogawa Y, Yamamoto M, Okada H, Yashiki T, Shimamoto T. A new 
technique to efficiently entrap leuprolide acetate into microparticles of 
copoly(lactic:glycolic acid). Chem Pharm Bull 1988;36:1095–1103. 
[200]  Benoit MA, Poulain-Godefroy O, Baras B, Youan BBC, Riveau G, 
Gillard J, Capron A. Study on the antigenicity of microencapsulated 
Sm28-GST from Schistosoma mansoni. Proc Int Symp Control Rel Bioact 
Mater 1997;24:817-818. 
[201]  Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. Biodegradable 
mucoadhesive particulates for nasal and pulmonary antigen and DNA 
delivery. Adv drug deliv rev 2005;57:411-430. 
[202]  Hanes J, Cleland JL, Langer R. New advances in microsphere-based 
single-dose vaccines. Adv Drug Deliv Rev 1997;28:97–119. 
[203]  Somavarapu S, Pandit S, Gradassi G, Bandera M, Ravichandran E, 
Alpar O H. Effect of Vitamin E TPGS on immune response to nasally 
delivered diphtheria toxoid loaded poly(caprolactone) microparticles. 
Int J Pharm 2005;298:344–347. 
 76 
[204] van der Lubben IM, Kersten G, Fretz MM, Beuvery C, Verhoef JC, 
Junginger HE. Chitosan microparticles for mucosal vaccination 
against diphtheria: oral and nasal efficacy studies in mice. Vaccine 
2003;21:1400-1408. 
[205]  Singh J, Pandit S, Bramwell VW, Alpar HO. Diphtheria toxoid loaded 
poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery 
systems. Methods 2006;38(2):96-105. 
[206]  Vila A, Sanchez A, Janes K, Behrens I, Kissel T, Jato JLV, Alonso MJ. 
Low molecular weight chitosan nanoparticles as new carriers for nasal 
vaccine delivery in mice. Eur J Pharm Biopharm 2004; 57:123-131. 
[207]  Chong CSW, Cao M, Wong WW, Fischer KP, Addison WR, Kwon DS, 
Tyrrell DL, Samuel J. Enhancement of T helper type 1 immune 
responses against hepatitis B virus core antigen by PLGA nanoparticle 
vaccine delivery. J Control Release 2005;102:85-99. 
[208] Bowersock TL, HogenEsch H, Suckow M, Guimond P, Martin S, Borie 
D, Torregrosa S, Park H, Park K. Oral vaccination of animals with 
antigens encapsulated in alginate microspheres. Vaccine 
1999;17:1804-1811. 
[209]  Bennewitz NL, Babensee JE. The effect of the physical form of 
poly(lactic-co-glycolic acid) carriers on the humoral immune response 
to co-delivered antigen. Biomaterials 2005;26:2991–2999. 
[210] Coombes AGA, Lavelle EC, Jenkins PG, Davis SS. Single dose, 
polymeric, microparticle-based vaccines: the influence of formulation 
conditions on the magnitude and duration of the immune response to 
a protein antigen. Vaccine 1996;14(15):1429-1436. 
[211] Kavanagh O V, Earley B, Murray M, Foster CJ, Adair BM. 
Antigen-specific IgA and IgG responses in calves inoculated 
intranasally with ovalbumin encapsulated in poly(dl-lactide-co-
glycolide) microspheres. Vaccine 2003;21:4472–4480. 
[212] Puri N, Sinko PJ. Adjuvancy enhancement of muramyl dipeptide by 
modulating its release from a physicochemically modified matrix of 
ovalbumin microspheres: II. In vitro investigation. J Control Release 
2000;69:69– 80. 
[213]  Rebelatto MC, Guimond P, Bowersock PL, HogenEsch H. Induction of 
systemic and mucosal immune response in cattle by intranasal 
administration of pig serum albumin in alginate microparticles. Vet 
Immunol Immunopathol 2001;83:93-105. 
[214] Muñoz PM, Estevan M, Marin CC, De Miguel MJ, Grillo MJ, Barberan 
M, Irache JM, Blasco JM, Gamazo C. Brucella outer membrane 
complex-loaded microparticles as a vaccine against Brucella ovis in 
rams. Vaccine 2006;24:1897-1905. 
[215] Strindelius L, Wikingsson LD, Sjöholm I. Extracellular antigens from 
Salmonella enteritidis induce effective immune response in mice after 
oral vaccination. Infect Immun 2002;70(3):1434-1442. 
References list 
77 
[216] Xie Y, Zhou N, Gong Y, Zhou X, Chen J, Hu S, Lu N, Hou X. Th 
immune response induced by H pylori vaccine with chitosan as 
adjuvant and its relation to immune protection.  World J Gastroenterol 
2007;13(10):1547-1553. 
[217] Zhu BD, Qie YQ, Wang JL, Zhang YZ, Wang QZ, Xu Y, Wang HH. 
Chitosan microspheres enhance the immunogenicity of an 
Ag85B-based fusion protein containing multiple T-cell epitopes of 
Mycobacterium tuberculosis. Eur J Pharm Biopharm 2007;66:318–326. 
[218] Luzardo-Alvarez A, Blarer N, Peter K, Romero JF, Reymond C, 
Corradin G, Gander B. Biodegradable microspheres alone do not 
stimulate murine macrophages in vitro, but prolong antigen 
presentation by macrophages in vitro and stimulate a solid immune 
response in mice. J Control Release 2005;109:62– 76. 
[219] Metzger H. The receptor with high affinity for IgE. Immunol Rev 
1992;125:37-48. 
[220] Jones DH, Corris S, McDonald S, Clegg JCS, Farrar GH. 
Poly(lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic 
and mucosal antibody responses to encoded protein after oral 
administration. Vaccine 1997;15:814-817. 
[221]  Locher CP, Putnam D, Langer R, Witt SA, Ashlock BM, Levy JA. 
Enhancement of a human immunodeficiency virus env DNA vaccine 
using a novel polycationic nanoparticle formulation. Immunology 
Letters 2003;90:67-70. 
[222] O’Hagan DT, Singh M, Dong C, Ugozzoli M, Berger K, Glazer E, Selby 
M, Wininger M, Ng P, Crawford K, Paliard X, Coates S, Houghton M. 
Cationic microparticles are a potent delivery system for a HCV DNA 
vaccine. Vaccine 2004;23:672–680. 
[223] Seo JY, Seong SY, Ahn BY, Kwon IC, Chung H, Jeong SY. 
Cross-protective immunity of mice induced by oral immunization 
with pneumococcal surface adhesin A encapsulated in microspheres. 
Infect Immun 2002;70(3): 1143-1149. 
[224] Eyles JE, Williamson ED, Spiers ID, Alpar HO. Protection studies 
following bronchopulmonary and intramuscular immunisation with 
Yersinia pestis F1 and V subunit vaccines coencapsulated in 
biodegradable microspheres: a comparison of efficacy. Vaccine 
2000;18:3266-3271. 
[225]  Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, 
Huckriede A, Crommelin DJA, Jiskoot W. N-Trimethyl chitosan 
(TMC) nanoparticles loaded with influenza subunit antigen for 
intranasal vaccination: Biological properties and immunogenicity in a 
mouse model. Vaccine 2007;25:144-153. 
[226] Kim B, Bowersock T, Griebel P, Kidane A, BabiReino Unido LA, 
Sanchez M, Attah-Pokua S, Kaushika RS, Mutwiria GK. Mucosal 
immune responses following oral immunization with rotavirus 
antigens encapsulated in alginate microspheres. J Control Release 
2002;85:191–202. 
 
Development of alternative micro and nanoparticulate polymeric 
systems for mucosal delivery of Streptococcus equi antigens 
 
 
 
CHAPTER 2 
 
 
 
 
S. equi ANTIGENS ADSORBED ONTO SURFACE 
MODIFIED POLY-ε-CAPROLACTONE MICROSPHERES 
INDUCE HUMORAL AND CELLULAR SPECIFIC IMMUNE 
RESPONSES 
 
H.F.Florindo, S.Pandit, L.M.D. Gonçalves, H.O.Alpar, A.J.Almeida 
 
Adapted from Florindo et al., Vaccine 2008;26:4168-4177
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
81 
ABSTRACT 
Streptococcus equi subsp. equi is the causative agent of strangles, which is one 
of the most costly and widespread infectious diseases, affecting the 
respiratory tract of Equidae.  In this work, polyvinyl alcohol, alginate and 
chitosan were used in formulations of surface modified poly-ε-caprolactone 
microspheres, which were evaluated after adsorption of S. equi enzymatic 
extract for physicochemical characteristics and in vivo immune responses in 
mice. After subcutaneous immunisation, the formulations induced higher 
lymphokines levels, in accordance with cellular and humoral immune 
responses, as compared to the free antigen, successfully activating the paths 
leading to Th1 and Th2 cells. The obtained results highlight the role of these 
microspheres as an adjuvant and their use to protect animals against 
strangles.  
 
Keywords: Poly-ε-caprolactone microspheres, Streptococcus equi, vaccine 
adjuvant. 
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INTRODUCTION 
Streptococcus equi subsp. equi (S. equi) is a Lancefield group C streptococcus, 
known as the causative agent of equine strangles, which affects the upper 
respiratory tract, more specifically, the nasopharynx and draining lymph 
nodes of horses, donkeys and mules [1, 2]. This disease was first reported by 
Jordanus Ruffus in 1251 and is characterised by an acute, febrile, suppurative, 
purulent pharyngitis, lymphadenitis and abscesses in head and neck, which 
may often burst and exude [2, 3]. S. equi is highly virulent and is transmitted 
through direct contact with the mucopurulent nasal discharges from infected 
horses or by any equipment and food utensils that are usually near these 
animals [2, 4]. Animals affected with strangles have a long convalescent 
period and present a high morbidity level, which can lead to chronic illness or 
even death [1-5]. Although S. equi is sensitive to some antibiotics, most of the 
treatments are ineffective and prevention is the key [1, 2, 6]. S. equi virulence 
factors are the hyaluronic acid capsule and the antiphagocytic cell 
wall-associated S. equi M-like protein (SeM). SeM is known as the major 
protective antigen as it stimulates opsonozing antibodies, which are the basis 
of the so-called bactericidal reaction of immune serum [3, 7, 8]. Indeed, 
previous infected animals develop a protective immune response against 
SeM, as they carry immune complexes consisting of IgG and IgA against this 
protein, both in serum and in nasal secretions. This indicates that to combat 
and prevent serious complications an efficient vaccine must be achieved [1, 7].  
In fact, the strong antibody response has attracted great interest in SeM as a 
potential vaccine component [5]. However, the efficacy obtained with 
commercially available and widely used vaccines, that consist of 
heat-inactivated bacteria or M-protein-rich extracts, is not enough to make 
major improvements in the control of the disease and thus protection of 
horses against S. equi infection [1-3]. The failure of the current vaccines is 
presumably due to the vaccines inability to stimulate local nasopharyngeal 
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antibodies similar to those found in convalescent immune horses, which are 
considered to be more relevant to protection than serum responses [7].  
The therapeutic use of particulate drug carriers for immunisation purposes is 
currently one of the most promising strategies for fighting infectious diseases 
and therefore one of the most investigated areas in pharmaceutical technology 
[9, 10].  
Antigens that are responsible for the induction of protective immunity against 
various pathogens may be immobilised or attached to suitable particulate 
carriers. The carriers have the advantage to be absorbed with greater 
efficiency in the mucosal epithelium as compared to soluble molecules, thus 
providing a long-term depot for the antigen. This is known as the depot 
theory of adjuvant action, and has been shown to induce effective and long 
lasting immunity [10-12]. For example, microentrapment of antigens, such as 
tetanus and diphtheria toxoid, in polymeric and biodegradable microspheres 
has been extensively studied for its application as antigen carriers in the 
induction of systemic but also mucosal immune responses regardless of the 
target site [13-15]. 
The release properties of microspheres can be tailored for the antigen to 
produce a sustained immune response [11, 12], providing a release of antigens 
for weeks to months, a time far exceeding the depot effect of aluminium salts 
[16] or water/oil emulsions such as Freund's adjuvants [9, 17]. Therefore, 
these carriers have the potential to reduce the frequency of vaccination 
required to establish long-term protection [10, 18].  
In addition, our preliminary studies showed that the entrapment of whole 
killed S. equi cells or bacterial lysates, respectively in poly(lactide-co-
glycolyde) (PLGA) microspheres is a potential carrier system for the delivery 
of S. equi antigens. Furthermore, administration of these microspheres by 
nasal and intramuscular (i.m.) routes, leads to an enhancement of immune 
response, causing full protection against the virulent strain upon 
experimental infection [19]. These studies also indicate that polymeric 
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microspheres are a potential carrier system for the delivery of S. equi antigens, 
making possible a vaccine formulation.  
Researchers have been tempted to expand the use of these carriers, however 
high loading of large and fragile molecules into microspheres without loss of 
activity has been difficult to achieve. The adsorption is an important subject in 
biomedical field and its application as drug delivery systems has been studied 
for the last decades, as it appears to be an alternative and ideal technique for 
the loading of proteins onto particles [10, 20, 21]. 
Poly-ε-caprolactone (PCL) has not been extensively explored for the 
entrapment of vaccine antigens but its higher hydrophobicity, in vitro 
stability, lack of toxicity and low cost comparatively with PLGA polymeric 
particles makes it of interest as a matrix for controlled release [14, 22-25]. PCL 
degradation does not generate an unfavourable low pH micro-environmental 
for antigens as PLGA, which can be an advantage for the generation of 
cellular and antibody-mediated responses, crucial for an effective protection 
against SeM [26, 27]. Some studies have demonstrated the potential of PCL 
microparticles to be used as a vaccine delivery system [28-30]. For example, 
Murillo et al. 2006 [31] have shown that PCL microparticles entrapping a hot 
saline antigenic extract of Brucella ovis could be used as an anti-Brucella 
vaccine candidate in a mouse model.  
In this study, the producing parameters were evaluated for their influence on 
particles characteristics such as surface morphology, particle size, zeta 
potential, residual organic solvent concentration, adsorption efficiency and 
protein integrity. But this paper will mainly focus on the characterisation of 
humoral and cellular immune responses induced by S. equi antigens 
associated to surface modified PCL microspheres, in order to evaluate the 
influence of particle surface characteristics on the immunoadjuvant properties 
of these polymeric carriers. 
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MATERIALS AND METHODS 
MATERIALS 
Polycaprolactone (PCL, average molecular weight (MW) 42.5 kDa), polyvinyl 
alcohol (PVA, MW 13-23 kDa, 87-89% hydrolysed), polyethyleneimine (PEI), 
alginate low viscosity (ALG) and sucrose were supplied by Sigma Aldrich 
Co., UK. Chitosan (CS), low MW (LMW, 150kDa), medium MW (MMW, 400 
kDa) and high MW (HMW, 600 kDa) were purchased from Fluka 
Switzerland. Dichloromethane (DCM) was obtained from BDH Laboratory 
Supplies, UK. Bicinchoninic acid (BCA) kit for protein determination was 
provided by Sigma Aldrich Co. U.K, GOSS Scientific Ld. Nuclear Magnetic 
Resonance (NMR) tubes were obtained from WilMAD/Lab Glass and acetic 
acid-d4 from Cambridge Isotope Laboratories, Inc., UK. 
Streptococcus equi subsp. equi (strain LEX) ATCC 53186 was a kind gift from 
Prof. J.F. Timoney (University of Kentucky, USA). 
Other chemicals were used as purchased and reagent grade.  
 
ANIMALS 
All procedures carried out in this study were performed in strict accordance 
with the UK 1986 Animals (Scientific Procedures) Act. Experimentation was 
carried out using groups of 4 female, 6-8 week old BALB/c mice with food 
and drink provided ad libitum. 
 
ANTIGEN PREPARATION 
Antigens were prepared using a modification of a procedure previously 
developed [32]. Briefly, inactivated Streptococcus equi subsp equi cells (strain 
LEX, ATCC 53186) were washed with phosphate buffered saline (PBS, 
OXOID) 50 mM at pH 6.0 and homogenised by two passages at high pressure 
(900 PSI, Avestin Inc., Canada). Lysozyme (3 mg/ml), mutanolysin (93.6 
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Unit/ml) and sucrose (170 mg/ml), all from Sigma Aldrich Co., UK, were 
added to the homogenised cells (0.4 g /ml; wet weight), and the mixture was 
incubated at 37°C for 3 h, under constant agitation. Finally, protoplasts were 
separated by centrifugation at 8,000xg, and supernatants containing the cell 
wall proteins, including the SeM, were stored at -20ºC for further analysis. 
Just prior to its utilisation, the enzymatic extract obtained was dialysed at 4ºC, 
in order to remove sucrose residues. The resultant protein solution was then 
frozen at -20ºC and freeze-dried (Virtis Advantage freeze dryer, UK) to obtain 
a dry powder containing ca. 2.7% (w/w) of SeM among many other proteins, 
including the enzymes used to obtain the extract. The presence of other 
components of bacterial origin different than proteins may not be discarded. 
 
MICROSPHERE PREPARATION  
Polymeric microspheres were aseptically prepared by w/o/w emulsification 
solvent evaporation method using PVA as a stabiliser (Table 3.1) as described 
elsewhere [25]. The polymer PCL was completely dissolved in DCM and an 
internal aqueous phase consisting of 5% (w/v) PVA was emulsified into this 
organic solution, using an ultra-turrax (T25 Janke & Kunkel, 
IKA-Labortechnik) at 24000 rpm for 2 min. To prepare negatively charged 
PCL microspheres, the resulting w/o emulsion was subsequently added 
dropwise to 2.5 % (w/v) PVA (PCL-PVA microspheres) or into 0.75% (w/v) 
low viscosity ALG (PCL-ALG microspheres), while positively charged PCL 
microspheres were prepared using different molecular weights (LMW, MMW 
or HMW) and concentrations of CS (0.5%, 0.75%, 1% w/v) as the external 
phase (PCL-CS microspheres). This dispersion was then homogenised 
(Silverson model L4RT, Chatham Bucks, UK) to create the double w/o/w 
emulsion. The formulations were magnetically stirred for 4 hours at room 
temperature to allow organic solvent evaporation and microspheres 
formation. Sucrose was added to the polymeric particles suspension, which 
were collected by centrifugation (20,000 rpm, 20 min, 10-15°C ; Beckman J2-21 
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Hi speed centrifuge), washed with deionised water and freeze-dried. The 
formulations details are shown in Table 2.1.  
 
Table 2.1 
Summary of PCL negatively (-) and positively (+) charged microsphere composition 
FORMULATION 
ORGANIC 
PHASE 
INTERNAL 
PHASE 
EXTERNAL PHASE 
PCL-PVA 2.5% (w/v) PVA (-) 
PCL-ALG 0.75% (w/v) ALG LV 
PCL-CS0.5L 0.50% (w/v) 
PCL-CS0.75L 0.75% (w/v) 
PCL-CS1L 1.0% (w/v) 
CS LMW 
PCL-CS0.5M 0.50% (w/v) 
PCL-CS0.75M 0.75% (w/v) 
PCL-CS1M 1.0% (w/v) 
CS MMW 
PCL-CS0.5H 0.50% (w/v) 
PCL-CS0.75H 0.75% (w/v) 
(+) 
PCL-CS1H 
PCL 
in DCM 
5% (w/v) 
PVA 
1.0% (w/v) 
CS HMW 
PCL-PVA – polycaprolactone – polyvinyl alcohol microspheres; PCL-ALG - polycaprolactone 
– alginate microspheres; PCL-CS - polycaprolactone – chitosan microspheres; L – low 
molecular weight; M – medium molecular weight; H – high molecular weight. Chitosan 
concentrations: 0.5%, 0.75% and 1.0% (w/v). 
 
MICROSPHERES PHYSICOCHEMICAL CHARACTERISATION 
PARTICLE SIZE ANALYSIS 
The volume mean diameter (VMD) of particles was determined by laser light 
diffractometry, using a Malvern Mastersizer (Malvern Instruments, UK). The 
results obtained are represented as VMD (µm). 
 
ZETA POTENTIAL DETERMINATION 
The determination of the zeta potential of the particles was performed by 
anemometry, using the Malvern ZetaSizer (Malvern Instruments, UK) 
following the dispersion of particles (2-3 mg) in a 10 mM potassium chloride 
solution to produce a dilute suspension. Zeta potential data (mV) were 
obtained from the average of three measurements with a standard deviation 
of ≤ 5%. 
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SCANNING ELECTRON MICROSCOPY STUDIES  
Scanning electron microscopy (SEM, Phillips/FEI XL30 SEM) was used to 
corroborate the size and to analyse particle surface morphology.  Briefly, a 
thin layer of microspheres was mounted onto aluminium stubs using 
adhesive carbon pads as a dry powder. The particle surface was then coated 
with a gold film with a thickness of approximately 20 nm under vacuum in an 
argon atmosphere using a sputter coater (Emscope SC500) prior to SEM 
analysis. 
 
ANTIGEN DESORPTION STUDIES 
Accurately weighed 10 mg samples of antigen-adsorbed PCL-PVA or 
PCL-CS0.75L microspheres were placed in LoBind eppendorf tubes (1 tube 
per time point) and dispersed in 2 ml of a PBS buffer (pH 7.4), containing 5% 
(w/v) of sodium dodecyl sulphate (SDS, BDH UK) and 0.02% (w/v) of 
sodium azide, and shaken in a water-bath at 37ºC. At predetermined 
intervals, one eppendorf tube was collected, centrifuged at 7500 rpm for 10 
minutes (IEC Micromax eppendorf centrifuge, UK) and the supernatants were 
analysed by the BCA protein assay (Pierce, USA) and SDS-PAGE. 
 
RESIDUAL SOLVENT QUANTIFICATION 
Residual DCM present in the particles (PCL-PVA, PCL-CS0.75L, PCL-ALG) 
after freeze-drying was quantified using NMR spectroscopy technique. The 
1H-NMR spectra were measured using a Bruker spectrometer at a 
temperature of 300K, using acetic acid-d4 as a solvent and sodium formate 
(Sigma Aldrich Co., UK) as internal reference.  
 
S. equi ENZYMATIC EXTRACT ADSORPTION 
To adsorb the extract, plain PCL-PVA and PCL-0.75CSL microspheres were 
weighed (10 mg) and dispersed in 900 µl of water. To this suspension, 18.5 
mg/ml enzymatic extract solution (100 µl) was added and particles were 
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incubated at 37ºC, for one hour under constant agitation. Particles suspension 
was then centrifuged (10000 rpm, 5 min; IEC Micromax eppendorf centrifuge, 
UK), the pellet washed twice and then allowed to dry in a dessiccator, while 
the supernatant and the washes were kept frozen at -20ºC until future 
analysis.  
 
ANTIGEN LOADING 
The amount of protein adsorbed onto the PCL-PVA and surface modified 
PCL-0.75CSL particles, expressed as total protein (%w/w) per unit weight of 
microspheres, was determined by a direct and an indirect method. The total 
amount of protein not adsorbed onto particles was quantified in the 
supernatants recovered after particle centrifugation, as mentioned above, 
using the BCA protein assay (Pierce, USA) which can detect 200-1000 µg/ml 
of  protein, by measuring absorbance at 562 nm. To assess the efficiency of 
protein adsorption onto the particles surface, a known mass of the dried pellet 
(5 mg) was digested in 2 ml of 5% (w/v) SDS (BDH UK) 0.1 M sodium 
hydroxide (NaOH, Fisher Co. UK) solution and maintained under magnetic 
stirring, at 37ºC, until a clear solution was obtained. This solution was then 
neutralised to pH 7.0 with 1N HCl and the total protein amount was 
determined using the BCA protein assay. Plain microspheres (without 
antigen) were used as a control. A calibration curve was established using a 
series of protein standards. Four absorption determinations were made for 
each standard, blank, control or test sample.  
The amount of protein effectively adsorbed onto microparticles surface was 
then calculated by subtracting the weight of the S. equi protein extract 
recovered from microspheres from the starting amount of antigen initially 
used during the adsorption process.   
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STRUCTURAL INTEGRITY OF THE ADSORBED ANTIGEN  
Antigen was extracted from freeze-dried microspheres, suspended in PBS (pH 
7.4), after incubation at 37ºC. The structural integrity was assessed by 
SDS-PAGE, compared with native S. equi enzymatic extract proteins and a 
broad range of prestained SDS-PAGE standards (Bio-Rad UK), in order to 
evaluate the effects of the processing procedures in the structural integrity of 
the adsorbed proteins. Samples were loaded onto a 10% (w/v) 
polyacrylamide (Bio-Rad, UK) mini-gel and electrophoresis was performed at 
a constant voltage of 100 V for 120 minutes using a Bio-Rad 300 power pack 
(Bio-Rad, Hercules, CA, USA). After migration, the gel was stained with 
SimplyBlueTM SafeStain solution (Invitrogen, USA), destained, dried and 
imaged using a UVP gel scanning camera. 
 
IN VITRO CYTOTOXICITY OF PCL MICROSPHERES 
Cytotoxicity of PCL microspheres, specifically PCL-PVA, PCL-ALG, 
PCL-CS0.75L, PCL-CS0.75M and PCL-CS0.75H, to mouse BALB/c monocyte 
macrophage cells (J774A.1 cells line, American Type Culture Collection; 
ATCC#TIB-67) was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay [33], in which the absorbance was 
measured at 570 nm using a Dynex MRX Microplate Reader (Dynex, UK). All 
the experiments were carried out in triplicates.  
 
IMMUNISATION STUDIES 
Three groups of female BALB/c mice (25g; n=4/group) were immunised 
subcutaneously on day 1 with a single dose (100 µl) of S. equi enzymatic 
extract equivalent to 10 µg of SeM, either in the free form or adsorbed onto 
either negatively PCL-PVA or positively PCL-CS0.75L charged microspheres, 
respectively.  
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All formulations were prepared freshly and aseptically in a safety cabinet, 
immediately prior to dosing. For sample preparation, the microspheres were 
suspended in PBS pH 7.4 and the freeze-dried extract was diluted in water, in 
order to obtain the desired SeM concentration.  
Tail vein blood samples were collected after 7, 45, 90, 180 and 300 days of 
immunisation. The blood was allowed to clot by overnight incubation at 4oC. 
The serum was separated by centrifugation at room temperature (15,000 rpm, 
10 min) and stored at -20oC until serum humoral immune response (IgG, IgG1 
and IgG2a) was assessed by indirect ELISA.  
On day 300, mice were ethically sacrificed and their spleens were aseptically 
removed in order to study the cellular immune response.    
      
ANALYSIS OF HUMORAL IMMUNE RESPONSE IN SERUM 
The serum was analysed for S. equi specific antibodies using a modification of 
a standard enzyme-linked immunosorbent assay (ELISA) technique [34]. 
Briefly, 96-well ELISA microtiter plates (Immulon 2, flat bottom plates, 
Dynatech, UK) were coated overnight at 4oC with 50 µl of 10 µg/ml S. equi M 
proteins in PBS solution (pH 7.4). The plates were washed three times with 
0.05% (v/v) solution of Tween 20 (Sigma Aldrich Co., UK) and 1% albumin 
from bovine serum (BSA, fraction V, Fisher scientific UK) in PBS (PBST) and 
allowed to dry. Serum samples were added to the wells at a 16-fold dilution 
in PBS, followed by two-fold serial dilutions and subsequently incubated for 1 
hour at 37ºC. Plates were washed three times with the PBST solution and 
antibody binding was detected adding to each well 50 µl of goat anti-mouse 
antibody-horseradish peroxide conjugate (Sigma, Pool Dorset, UK), diluted in 
PBS (IgG (Serotec, UK) diluted 1:1000; IgG subclass 1 (IgG1; Serotec, UK) 
diluted 1:2000; IgG subclass 2a (IgG2a; Serotec, UK) diluted 1:2000). The 
plates were incubated at 37ºC for 1 hour and washed three times with PBST. 
Fresh substrate solution was prepared by dissolving three tablets of 2, 2’-
azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) (ABTS; Sigma Aldrich Co., 
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UK) in 50 ml of citrate buffer, plus 5 µl of hydrogen peroxide (H2O2; Sigma 
Aldrich Co., UK), and added to each well.  The plates were incubated for 10 
min at 37oC for colorimetric reaction development. The citrate buffer was 
prepared in advance using 44% (m/v) 0.10 M citric acid (Fisher Scientific, UK) 
and 56% (m/v) 0.2M di-sodium hydrogen orthophosphate (BDH anala VWR 
international, UK). Absorbance was measured at 405 nm using a Dynex MRX 
Microplate Reader (Dynex, UK) and compared to sera of naive mice, of the 
same age housed under the same conditions. 
Elicitation of humoral immunity was evaluated by serum S. equi 
proteins-specific IgG, IgG1, IgG2a titres, which were expressed as the average 
(± S.D.) of the reciprocal of the dilution at which the absorbance 405 nm was 
5% higher than the strongest negative control reading, and compared at each 
time point by analysis of variance (ANOVA) with significance set at P ≤0.05. 
As an indicator of immune response bias, serum IgG2a/IgG1 ratios were 
calculated on endpoint titres of group sera obtained at the termination of the 
experiment. 
 
SPLENOCYTE CULTURE STUDIES 
Mice were ethically sacrificed and their spleens were aseptically removed and 
placed into ice-cold sterile PBS. A crude suspension of spleen cells was 
prepared in 10 ml of working media RPMI 1640 (Gibco, UK), supplemented to 
a final concentration of 10 % (v/v) FBS (Gibco, UK), 20mM L-glutamine 
(Sigma Aldrich Co., UK), 105U/l of penicillin and 100 mg/l of streptomycin 
(Sigma, Poole, Dorset, UK), by gently grinding the spleen on a fine wire 
screen. The cell suspension was spun at 200 ×g for 10 min, the cell pellet 
resuspended in 10 ml of fresh working media and the centrifugation 
procedure was repeated.  Following this final centrifugation, the cell pellet 
was resuspended in 5 ml fresh working media and then diluted out in 15 ml 
with sterile working media. Using sterile 96-well tissue culture plates (Fisher, 
UK), 100 µl volumes of cells from individual mice were seeded into 100 µl 
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volumes of media containing soluble S. equi enzymatic extract at the 
concentration of 2.5 µg/ml and 5.0 µg/ml. Covered plates were incubated at 
37°C in a humidified incubator at 5% CO2 environment. After 48 hours of in 
vitro re-stimulation of splenocytes with soluble antigen, supernatants were 
obtained and cytokine production was assessed in the culture supernatants 
using DuoSet® ELISA Development kit (R&D Systems Europe, UK) according 
to the manufacturer instructions to assay for IL-2, IL-4 and IL-6 and IFN-γ 
content by sandwich ELISA.  
 
STATISTICAL ANALYSIS 
Statistical analysis was preformed using an ANOVA general linear model 
with SPSS software (Version 13, Microsoft) assuming p-values of P≤0.05 as 
significant. In order to specify the difference between the groups, multiple 
comparisons were also performed following a LSD post hoc test, assuming as 
well a p-value of  ≤ 0.05 as significant.    
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RESULTS AND DISCUSSION 
MICROSPHERE CHARACTERISTICS 
In the present work, the selection of PCL above other polymers was based 
especially on its biodegradability, biocompatibility, slow rate of degradation, 
hydrophobicity, in vitro stability, lack of toxicity and low cost [23, 24]. 
Non-aggregating positively and negatively charged spherical particles were 
produced by (w/o/w) double emulsion solvent evaporation technique. 
Particle size ranged from 1.43 to 2.71 µm, depending on the formulation 
composition, but those made with CS had a narrower size distribution.  
Surface modification of PCL microspheres by CS was confirmed by a 
recorded change in zeta potential. As expected, CS influenced the surface 
charge of the microspheres resulting in high positive zeta potentials, which 
increased with raising concentrations and molecular weights (Table 2.2).  
 
Table 2.2  
Volume mean diameter (VMD) and zeta potential of PCL polymeric 
particles, positively (+) and negatively (-) charged (n=3 ± S.D.) 
FORMULATION 
VMD 
(µm) 
ZETA POTENTIAL 
(mV) 
PCL-PVA 2.71 ± 1.56 -31.2 ± 2.0 (-) 
PCL-ALG 2.51 ± 1.50 -37.5 ± 1.5 
PCL-CS0.50L 2.35 ± 0.91 +16.5 ± 1.7 
PCL-CS0.75L 2.02 ± 0.48 +22.4 ± 1.4 
PCL-CS1.0L 1.88 ± 0.98 +28.4 ± 0.8 
PCL-CS0.50M 2.04 ± 0.87 +23.4 ± 1.2 
PCL-CS0.75M 1.75 ± 1.02 +30.2 ± 1.7 
PCL-CS1.0M 1.52 ± 0.88 +34.8 ± 1.7 
PCL-CS0.50H 1.92 ± 0.87 +25.1 ± 1.6 
PCL-CS0.75H 1.65 ± 0.73 +32.2 ± 1.2 
(+) 
PCL-CS1.0H 1.43 ± 0.89 +39.5 ± 1.3 
 
It is important to mention that the particle size distribution after freeze-drying 
showed an increase of the number of larger particles when compared with the 
non freeze-dried particles (results not shown), which may be due to some 
aggregation, as they were easily dispersible after agitation. Even so, despite its 
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polymeric composition, all of the prepared PCL particles presented a mean 
diameter below 5 µm, and consequently should be efficient in targeting 
antigen presenting cells (APCs), as shown in earlier studies [14, 35, 36]. 
Scanning electron micrographs show the formation of spherical and 
reasonably monodisperse microspheres from PCL polymer, all exhibiting a 
smooth surface morphology (Figure 2.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
 
(B) 
 
(C) 
 
(D) 
 
(E) 
Figure 2.1 - Scanning electron micrographs of the (A) PCL-PVA, (B) PCL-ALG (C) 
PCL-CS0.75L, (D) PCL-CS0.75M and (E) PCL-CS0.75H microspheres. 
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Concentration of the internal phase stabilizer (PVA), PCL molecular weight 
and external phase volume were chosen based on a previous orthogonal 
design study 33 in which the formulations 5% PVA, PCL MMW and 40 ml of 
external phase seem to result in particles with lower mean diameter but also 
with minor dispersion of particle sizes (results not shown). The influence of 
volume ratio dispersion/continuous phase on the microspheres size has been 
contradictory. Some reports show a mean size reduction with decreasing 
continuous phase volume [37, 38], probably associated to a decrease in mixing 
efficiency associated to larger volume, while in other reports no significant 
difference was obtained [39]. 
It has been shown that higher surfactant concentration generally increases the 
stability of the primary emulsion, resulting in a higher loading efficiency. 
Moreover, addition of a surfactant to the external phase will improve the 
stability of the second emulsion, as it limits the exchange between both 
phases. In fact, during solvent evaporation the thin layer of surfactant around 
the droplets prevents their coalescence. Agglomeration is improved by a 
gradual decrease of the volume and consequent increase of the viscosity of 
dispersed phase.  
PVA is frequently used as a colloidal polymeric stabiliser by surrounding 
particles with a hydrophilic polymer layer. Therefore, the increase of PVA 
concentration has been associated with a decrease in particles size and 
polydispersity [37, 38]. However, PVA lacking biocompatibility is its 
disadvantage, since it is not accepted for intravenous administrations (i.v.) 
and, as a result, is replaced by more biocompatible polymers [40]. For the 
antigen-adsorbed microspheres prepared with PVA, the PVA concentration 
did not significantly affect the size and charge of the particles, and therefore 
for its lacking biocompatibility the smaller concentration tested (5%) was 
selected.   
Adsorption efficiency was almost the same for the positively and negatively 
charged particles i.e. 53% and 54%, respectively (Table 2.3). Furthermore, the 
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amount of S. equi enzymatic extract adsorbed onto 1 mg of particles was 100 
µg for the PCL-PVA microspheres and 98 µg for PCL-CS0.75L, which 
corresponds to 2.7 and 2.6 µg of SeM, respectively. This supports the theory 
that the observed differences in size and charge did not to have an influence 
on the extent of the adsorption of the proteins used in this study [41]. 
 
 
Table 2.3 
Total of S. equi enzymatic extract protein adsorbed onto PCL microspheres (mean ± S.D.; n=3) 
FORMULATION 
ADSORPTION EFFICIENCY 
(%) 
S. equi PROTEIN (µg) ADSORBED 
PER mg OF PARTICLES 
PCL-PVA 53.0 ± 2.8  98.0 ± 5.18 
PCL-CS0.75L 54.0 ± 1.6 100 ± 2.96 
 
 
In a preliminary adsorption study of PCL microparticles using ovalbumin as a 
model drug, the adsorption efficiency of ovalbumin was 48% to the negative 
particles and 100% to the PCL-CS0.75L particles (results not shown). In the 
case of the S. equi enzymatic extract these values were not achieved probably 
because of the presence of several proteins, especially lysozyme that will 
certainly compete for adsorption sites. Moreover, protein adsorption is a 
complex process as several interactions may occur between the proteins and 
the surfaces. Proteins are macromolecules with inhomogeneous domains, 
prone to change their conformations after interaction with surfaces. Therefore, 
the prediction of a protein adsorption from a mixture requires a complete 
understanding of the competition between charges, depending upon the pH, 
of electrostatic, van der Waals and steric interactions of the different types of 
proteins in the mixture and of these proteins with the surface [41]. 
Figure 2.2 shows the in vitro total S. equi protein cumulative desorption 
profiles from PCL-PVA and PCL-CS0.75L microspheres. After a remarkable 
burst release of 59% for the negatively charged and 48% for the positively 
charged particles, proteins are slowly desorbed from microspheres 
throughout time.  
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From Figure 2.3B it can be seen that in both supernatants just the thick 
lysozyme band and two light bands were seen. In order to confirm the results 
obtained with the supernatants, particles adsorbed with the S. equi extract 
were also run directly in a SDS-PAGE gel (Figure 2.3A). The difference in 
concentration between the solutions obtained after extraction of adsorbed 
proteins and those containing proteins which were not adsorbed to the 
particles indicates that adsorption really occurred. The native SeM is a 58kDa 
M-like protein [8, 42], and the corresponding band should appear near that of 
the 56 kDa molecular weight marker used. However, only 25 µg of SeM are 
present in 925 µg of S. equi extract solution, which can explain the thinner 
bands seen in lanes 3 and 4, while the extract solution, which was used for 
adsorption of the particles, presented higher concentration (Figure 2.3A). 
These results might support the existence of a selective adsorption of some 
proteins present in the extract solution to the particles. For example, lysozyme 
is mainly recovered in the supernatant, while a thin band around 56 kDa in 
both formulation supernatants maybe detected, revealing preferential 
adsorption. Moreover, no changes in the pattern of protein migration and no 
additional bands revealing fragmentation or aggregation were detected, 
suggesting that their integrity was maintained.  
Figure 2.2 - In vitro desorption profile of protein antigens from PCL-PVA (◊) and 
PCL-CS0.5L () microspheres (mean ± sd; n = 3). 
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Based on the results from SDS-PAGE it can be postulated that the formulation 
by adsorption did not affect the molecular stability and structural integrity of 
proteins presented in the extract, which is a prerequisite for the antigen to 
generate a suitable immune response. In fact, using other pharmaceutics 
formulation methods, processing and storage, proteins could be exposed to 
conditions that have significant effects on their chemical and physical 
stability, leading to aggregation and precipitation. For this reason, the 
adsorption method was proposed in order to avoid protein contact with 
organic solvents, achieving higher antigen loadings and simultaneously 
maintaining their structural integrity. However, hydrophobic interactions 
between proteins and interfaces may lead to structural changes and accelerate 
aggregation of these macromolecules in solution [21, 43].  
Inclusion of sugars, such as sucrose, while processing the particles is 
important to maintain the stability and activity of the proteins during storage 
and desorption from the microspheres surface [44].  
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(A) (B) 
Figure 2.3 - SDS-PAGE (10% gel) of (A) S. equi enzymatic extract solutions before and after 
adsorption onto PCL (MW 40 kDa) microspheres. Lanes: 1) Standard molecular weight 
markers; 2) S. equi enzymatic extract standard solution at 1850 µg/ml; and S. equi proteins 
extracted from adsorbed particles 3) PCL-PVA and 4) PCL-CS0.75L; (B) supernatants 
obtained after centrifugation of particles 5) PCL-PVA and 6) PCL-CS0.75L. 
Chapter 2 
  101 
RESIDUAL SOLVENT QUANTIFICATION 
The use of organic solvents is one of the main disadvantages of using 
emulsion solvent evaporation methods. Only small amounts of these organics 
solvents (≤ 600 ppm) are allowed to remain in the particles after the 
formulation procedure has been ended [45]. In this particular study, DCM 
was used to dissolve PCL. The DCM residues (% w/w) present in the 
freeze-dryed microspheres were assessed by NMR and the organic solvent 
strength showed to be less than 0.04%, thus below the accepted limit.  
 
IN VITRO CYTOTOXICITY OF PCL MICROSPHERES 
Cytotoxicity of PCL-PVA, PCL-ALG, PCL-CS0.75L, PCL-CS0.75M and 
PCL-CS0.75H, to J774A.1 cell line was determined by the MTT assay. For all 
formulations tested, the MTT test (Figures 2.4A and 2.4B) showed no evidence 
of toxicity  and a significant difference was obtained when the viability was 
compared with that of the positive control (PEI) (P<0.01 for the CS 
formulations and P<0.05 for the negatively charged ones).  
 
 
 
 
(A) 
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Figure 2.4 - Cytotoxicity of PCL negatively charged (A) and positively charged (B) 
microspheres to BALB/c mouse monocyte macrophage J774A.1 cell line. 
PEI-polyethyleneimine; PCL-PVA – polycaprolactone – polyvinyl alcohol microspheres; 
PCL-ALG - polycaprolactone – alginate microspheres; PCL-CS0.75 - polycaprolactone – 
chitosan microspheres (0.75%); L – low molecular weight; M – medium molecular weight; 
H – high molecular weight. 
 
 
Furthermore, there is a significant difference (P<0.001), between the viability 
of cells treated with CSLMW and either CSMMW or CSHMW in the particle 
concentration ranges of 0.1-2.5 mg/ml and 0.01-0.1 mg/ml, respectively 
(Figure 2.4B). This observation also led to the selection of the PCL-CS0.75L 
formulation for further studies.  
No significant difference was found between the PCL-CS0.75L formulations 
and both PCL-PVA and PCL-ALG microspheres (P<0.16 and P<0.25) (Figures 
2.4A and 2.4B).  
 
SERUM HUMORAL IMMUNE RESPONSE 
Biodegradable microspheres have enormous potential as antigen carriers and 
immunoadjuvants when delivered by parenteral routes, acting as depots for 
the sustained release of antigens and inducing a significant protection after a 
single-shot vaccination [37, 46, 47]. Protective immunity following an 
(B) 
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infection with S. equi is mediated by serum bactericidal antibody mostly 
directed against the cell wall SeM [3, 8, 19, 43]. This protein induces a very 
strong B and T cells response resulting in protective immunity mediated by 
systemic IgG and secretory IgA [3, 8, 43].  
Despite extensive investigation undertaken in this field, the development of 
an efficient vaccine has still not been achieved. This is due to the fact that not 
only conventional vaccines,  based on live attenuated whole bacteria, but also 
vaccines that specifically target the SeM have shown little efficacy and have 
failed to confer protection against S. equi in horses [8]. 
In this study we aimed at developing a single shot vaccine consisting of S. equi 
enzymatic extract antigens adsorbed onto PCL particles. Since no major 
differences were observed between PCL-PVA and PCL-ALG microspheres, 
the former was selected as the negatively charged formulation for in vivo 
studies, also because PVA is the most common microsphere stabiliser. 
Concerning the positively charged formulations, again no major differences 
were found between formulations. However, the LMW chitosan is the less 
cytotoxic formulation (section In vitro cytotoxicity of PCL microspheres), while 
give rise to lower viscosity solutions, which are easily handled.  
The immune response developed in mice was followed until 300 days after 
animal vaccination and during the trial period. One week after dosing no 
significant differences could be observed among the several groups of mice 
(P>0.05) (Figure 2.5A). However, by day 45 all mice had seroconverted and 
their IgG responses were significantly superior to that of the free antigen 
immunisation group (Figure 2.5A). At this stage, PCL-PVA microspheres 
enhanced the serum anti-S.equi IgG specific titre three-fold in comparison to 
free antigen, while the PCL-CS0.75L formulation was only able to double this 
value. However, the IgG1 responses obtained with CS surface modified PCL 
microspheres were significantly higher than those observed in the groups 
immunised with free antigen or with PCL-PVA microspheres (P<0.005 and 
P<0.03, respectively) (Figure 2.5B). Moreover, the difference between the 
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serum IgG2a titres obtained after immunisation with the positively charge 
particles and the free antigen was statistically significant. But the difference 
was not as pronounced when compared to the PCL-PVA group (P<0.018 and 
P<0.17 respectively) (Figure 2.5C).  
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On day 90 the microsphere-treated groups of mice exhibited higher systemic 
IgG compared to the free antigen group (P<0.001). Serum IgG titres in the 
PCL-PVA group were superior to those of the PCL-CS0.75L group (P<0.001). 
On the other hand, the IgG1 and IgG2a responses of the PCL-CS0.75L group 
were statistically significant when compared to those obtained with the 
PCL-PVA (P<0.04) or the free antigen group (P<0.03).  
A general decrease in serum anti-S. equi IgG and IgG subclass titres was 
detected after this time-point. However, the decrease in immune response 
was slower in the mice groups immunised with PCL-CS0.75L as compared to 
the other groups. The higher level of immune response could be due to 
impaired desorption from the particle surface, consequence of its positive 
charge. Therefore, after day 180 the IgG level was still maintained in 
PCL-PVA group, whereas no significant difference was observed in the free 
antigen group (P<0.06 and P<0.18, respectively). Furthermore, the 
PCL-CS0.75L group exhibited the highest IgG antibody titre among all 
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Figure 2.5 - Serum anti-S. equi specific IgG (A), IgG1 (B) and IgG2a (C) titres after a single 
subcutaneous immunisation of female BALB/c mice with PCL-PVA (PVA) or 
PCL-CS0.75L (CS) microsphere, compared to the free antigen immunisation (FREE). 
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samples tested (P<0.037) from day 180 and onwards, and a significant 
difference was only distinguishable when IgG1 and IgG2a titres where 
compared with the titres induced by the free antigen group (P<0.014).  
Even 300 days after a single dose of S. equi enzymatic extract adsorbed onto 
PCL microspheres, both PCL-PVA and PCL-CS0.75L groups showed a serum 
specific IgG antibody response to S. equi proteins slightly higher than that 
induced by the free antigen. 
It is important to mention that from day 180 to 300 the PCL-PVA formulation 
enhanced the antibody response in terms of peripheral IgG levels, which 
justifies the considerable difference previously mentioned, opposite to that 
obtained by day 180. Mice vaccinated with PCL-CS microspheres continued to 
show the highest IgG1 and IgG2a titres. Nevertheless a significant difference 
was distinguishable only when compared to the free antigen group (P<0.017 
for IgG1 and P<0.08 for IgG2a).  
The generation of a dominant Th1 profile as a consequence of an animal 
vaccination is vital to facilitate the eradication of the microorganism and 
consequently for a successful prevention against strangles [31, 48]. Upon 
conclusion of the experiment (day 300) the ratio between IgG titres 
(IgG2a/IgG1) were suggestive of a more balanced response regarding to the 
CS surface modified PCL microspheres (IgG2a/IgG1 = 0.464) as opposed to 
the PCL-PVA microspheres (IgG2a/IgG1 = 0.333), which exhibited a subclass 
ratio twice as high as that obtained with the free antigen (IgG2a/IgG1 = 
0.125). Our results indicate a Th1/Th2 mixed response, after a single dose of 
S. equi enzymatic extract proteins adsorbed onto PCL microspheres, mainly 
from the positively charged microspheres.  
Strangles is a disease that starts at the respiratory tract, therefore local 
immune response (SIgA) is likely to play an important protective role [19]. For 
that reason, the evaluation of these mucosal antibodies should help to clarify 
the differences found between the immune response induced by PCL 
microspheres. Previous studies have shown that the delivery of antigens 
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adsorbed onto microparticles up-regulate the gene expression of certain 
cytokines [49]. In order to further characterise the importance of the vaccine 
carriers, a study was performed to assess the cytokines produced by 
splenocytes after their induction by S. equi protein antigens.  
 
SPLENOCYTE RESPONSES   
Immunisation of animals with PCL microspheres resulted in a general 
increase of splenocytes responsiveness as observed in terms of lymphokines 
levels, characterised by high levels of IFN-γ production (Figure 2.6). 
Differences observed in IL2, IL4, IL6 and IFN-γ induced by microsphere 
formulations and free antigen were statistically significant (P<0.02).  
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Figure 2.6 - S. equi-specific recall responses after stimulation of splenocytes derived from 
BALB/c mice immunised subcutaneously with S. equi enzymatic extract alone (FREE) or 
adsorbed onto PCL-PVA (PVA) or PCL-CS0.75L (CS) microspheres. Cytokine 
concentration in culture supernatants was determined in splenocyte cultures stimulated 
with 5 µg/ml of soluble S. equi enzymatic extract. 
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Interestingly, in contrast to the small differences between the IgG1 and IgG2a 
antibody titres induced by the particulate formulations of different charge, a 
significant difference between cytokine titres induced by positively and 
negatively charged particles was observed: CS surface-modified particles 
elicited higher IL2 and IFN-γ levels in the vaccinated animals (P<0.03), while 
PCL-PVA microspheres lead to more pronounced amounts of IL4 and IL6 
(P<0.01). Indeed, PCL-CS0.75L microspheres induced a significantly stronger 
cellular immune response when compared to the unmodified PCL 
microspheres (P<0.03).  
Thus, PCL-CS0.75L microspheres induced a strong cell-mediated immune 
response according to both IgG2a/IgG1 ratio and interleukin levels, 
particularly the high levels of Th1-dependent cytokines. The immune 
response was significantly stronger as compared to the unmodified PCL 
microspheres (P<0.03) and for that reason may be a cost-effective vaccine 
alternative to the component vaccines as it might facilitate the eradication of 
S. equi infection (Figure 2.6).  
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CONCLUSIONS 
The present study confirmed that adsorption is an alternative method for the 
production of protein delivery carriers, as it can avoid the possible 
degradation of proteins caused by organic solvents commonly used in the 
solvent evaporation technique. At the same time this method was able to 
achieve higher loadings than those usually reported for the microentrapment 
process. In addition, non-aggregated PCL microspheres adsorbed with S. equi 
enzymatic extract enhanced serum specific IgG, IgG1 and IgG2a antibody 
responses, even 300 days after a single dose administration. Both unmodified 
and CS-surface modified PCL microspheres were capable of eliciting elevated 
type I immune response cytokines, although it was more pronounced in the 
latter. In conclusion, PCL-CS0.75L microspheres are a potential vaccine 
candidate to prevent S. equi infection as in this case humoral and cellular 
responses are needed after host invasion through mucosal infection. 
Evaluation of mucosal immune response (SIgA) may provide further 
information regarding the effectiveness of these carriers for the delivery of S. 
equi vaccine.  
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ABSTRACT 
Streptococcus equi subsp. equi (S. equi) is the causal agent of strangles, a highly 
contagious disease that affects mainly animals of Equidae family.  Infected 
animals present depression, high fever, swallowed lymph nodes and acute 
pharyngitis and rhinitis. The drainage of exudate occurs after abscess capsule 
disruption and this mucopurulent liquid contains a high amount of infectious 
S. equi. Therefore, at this phase, there is a high risk of infection of other horses 
in contact with the infected animal.  
Strangles combat seems to be dependent on the development of an effective 
vaccine, since 75% of animals in the convalescent period have a protective 
immunity that is maintained for long periods of time, which can go up to 5 
years, directed mostly against the protein SeM, although the mechanism of 
protection is not yet fully known. 
The therapeutic use of particulate carriers for the development of an immune 
response is currently one of the most promising strategies to combat 
infectious diseases and, hence, one of the areas most investigated in 
pharmaceutical technology. The goal of the present study was to develop and 
fully characterise poly-ε-caprolactone (PCL) nanospheres suitable for mucosal 
immunisation. PCL (42.5kDa) nanospheres were prepared by the double 
emulsion (w/o/w) solvent evaporation method. Polymer was dissolved in 
dichloromethane and emulsified by homogenisation, with polyvinyl alcohol 
(PVA, 13-23kDa), or a glycochitosan (GCS) solution containing the S. equi 
antigens (S. equi enzymatic extract). The w/o emulsion was emulsified into a 
PVA or alginate (ALG) solution. Absorption enhancers, such as spermine (SP) 
and oleic acid (OA) were also used. Alternatively, S. equi antigens were 
adsorbed onto plain particle surface in order to compare their release profiles 
with those obtained with the entrapped antigen.    
The nanospheres presented a spherical and smooth surface under SEM and 
particle size ranged from 242.57 nm to 450.2 nm, which means that they may 
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be suitable for an adjuvant effect as they would be more readily taken up by 
macrophages and dendritic cells. The entrapment efficiency (E.E.) varied from 
49.2% (PCL-SP) to 84.2 % (PCL-GCS), with no compromise of antigen 
molecular weight by the entrapment process. All PCL nanospheres loaded by 
adsorption presented higher loading capacities than those resulting from S. 
equi antigen entrapment, although the latter presented better controlled 
release properties for vaccine delivery. The SDS-PAGE analysis showed no 
changes in the pattern of protein migration, before and after extraction from 
the nanospheres, suggesting that their integrity was maintained. MTT studies 
showed no evidence of toxicity and analysis by confocal microscopy 
confirmed the uptake of PCL-PVA, PCL-GCS and PCL-SP nanospheres by 
macrophages, rendering them suitable carriers for mucosal vaccination. 
 
Keywords: Poly-ε-caprolactone, nanospheres, strangles, Streptococcus equi, 
vaccine. 
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INTRODUCTION 
Streptococcus equi subsp. equi (S. equi) is the causal agent of strangles, a highly 
contagious disease that affects mainly animals of Equidae family [1, 2].  These 
bacteria cross oral and nasopharynx mucosae, lodge in the lymphatic nodes of 
pharyngeal and head regions, mainly in retropharyngeal and submandibular 
lymph nodes, resulting in abscess formation [2-4]. Infected animals present 
depression, high fever, swollen lymph nodes and acute pharyngitis and 
rhinitis. The drainage of exudate occurs after abscess capsule disruption and 
this mucopurulent liquid contains a high amount of infectious S. equi. 
Therefore, at this phase, there is a high risk of infection of other horses in 
contact with the infected animal [2, 5]. 
Strangles combat seems to be dependent on the development of an effective 
vaccine, since 75% of animals in the convalescent period have a protective 
immunity that is maintained for long periods of time, which can go up to 5 
years, directed mostly against the protein SeM, although the mechanism of 
protection is not yet fully known. As already mentioned, SeM and the capsule 
hyaluronic acid, are the main factors of virulence of S. equi. The IgG and IgA 
specific anti-SeM present in serum and nasal secretions, will successively 
recognise, connect to and inactivate the S. equi that invade the animal 
organism. Thus, this protective immune response developed during infection 
supports the idea that a vaccine will be able to prevent strangles infection [1-4, 
6, 7]. 
The therapeutic use of particulate carriers for the development of an immune 
response is currently one of the most promising strategies to combat 
infectious diseases [8, 9]. In fact, these delivery systems can act as a reservoir 
of the antigen in the APCs, maintaining the presentation of the antigen for 
prolonged periods of time as shown by Audran et al. (2003) [10]. On the other 
hand, Eyles et al. (1998, 1999) demonstrated that antigens entrapped in 
microspheres have the ability to induce stronger immune response than those 
elicited by the antigen in the soluble form, which is thought to be due to their 
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particulate form [11, 12]. As a result, the development of polymeric delivery 
systems can be used to overcome mucosal barriers and release antigens in the 
mucosal tissues for prolonged periods of time.  
The goal of the present study was to develop and fully characterise poly-ε-
caprolactone (PCL) nanospheres suitable for mucosal immunisation, being 
able to release the antigen into lymphoid tissues. Alginate (ALG) and chitosan 
(CS) are mucoadhesive polymers and therefore are able to increase particles 
residence time at the mucosal surface, which can be due to their 
mucoadhesive hydrophilicity and the electrostatic interactions between the 
positively charged CS and the negatively charged mucins [13-17]. On the 
other hand, Schröder and Svenson (1999) have shown that oleic acid (OA) 
vesicles admixed with diphtheria toxoid were able to induce nasal immune 
responses in mice as high as those induced by this antigen co-adjuvantised by 
aluminium [18]. Sugita et al. (2007) have demonstrated that spermine (SP) is a 
polyamine that has the ability to open the epithelium tight junctions and 
therefore increase the intestinal absorption via the paracellular route [19].   As 
a consequence, the first objective was to produce PCL nanospheres containing 
mucoadhesive polymers (glycolchitosan (GCS) and ALG) or absorption 
enhancers (SP and OA), and associate S. equi antigens without compromising 
their structure integrity and antigenicity. 
The adsorbed or entrapped S. equi antigens release profiles were assessed to 
predict the in vivo antigen release from these nanospheres. Besides using 
general agreed biodegradable and biocompatible polymers, cytotoxicity 
studies in a macrophages cell line (J774A.1) were performed to demonstrate 
that these delivery systems produced did not present any impurities, 
resultant either from the production technology or the polymers source. 
Moreover, the influence of particles composition and surface charge was 
evaluated in order to assess their potential to be taken up by those 
macrophages, which is a limiting step for the antigens processing and 
consequently for the development of an effective immune response. 
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MATERIALS AND METHODS 
MATERIALS 
Polycaprolactone (PCL, average molecular weight (MW) 42.5 kDa), polyvinyl 
alcohol (PVA, MW 13-23 kDa, 87-89% hydrolyzed), alginate low viscosity 
(ALG), spermine (SP), oleic acid (OA), glycolchitosan (GCS), sucrose, 
Bicinchoninic acid (BCA) kit were provided by Sigma Aldrich Co. UK. Micro 
BCATM Protein assay kit was supplied by GOSS Scientific Ld and Pierce, UK. 
Dichloromethane (DCM) was obtained from BDH Laboratory Supplies, UK. 
Streptococcus equi subsp. equi (strain LEX) ATCC 53186 were a kind gift from 
Prof. J.F. Timoney (University of Kentucky, USA). 
 
PREPARATION OF PCL NANOSPHERES 
PCL nanospheres were prepared aseptically at room temperature by a 
modification of a double emulsion (w/o/w) solvent evaporation method 
previously reported [20]. In brief, polymer was dissolved in 6 ml DCM  and 
emulsified by homogenisation using an Ultra-Turrax T25 (Janke & Kunkel, 
IKA-Labortechnik) for 3 min at 24,000 rpm, with a 10% (w/v) PVA or a 1% 
(w/v) GCS solution, which contained S. equi antigens (10.0 mg) for the 
preparation of S. equi-entrapped nanospheres. To prepare the S. equi antigens, 
a bacterial culture was harvested and treated with N-acetyl muramidase and 
lysozyme (Sigma Aldrich Co., UK) to extract the cell wall proteins as 
previously described [20]. Absorption enhancers (10 mg), such as SP and OA 
were also used, being the first one dissolved in the PVA solution, while the 
second was previously molecularly dispersed in 1 ml of ethanol and thus 
mixed with DCM.  The w/o emulsion was then added dropwise into 30 ml of 
a 1.25% (w/v) PVA or 0.75% (w/v) ALG solution, and  homogenised for 7 
min at 10,000 rpm using the Silverson homogeniser (Silverson model L4RT, 
UK). The resultant w/o/w emulsion was magnetically stirred at room 
temperature for 4 hours to evaporate the organic solvent. The PCL 
nanospheres were harvested by centrifugation (20,000 rpm, 45 min, 15°C; 
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Beckman J2-21 High speed centrifuge), washed three times with 0.02% (w/v) 
sucrose solution and subsequently freeze-dried (Virtis, UK) to obtain a fine, 
free-flowing dry powder of nanospheres (Table 3.1).   
 
Table 3.1  
PCL nanospheres composition 
 
To adsorb S. equi extract proteins, 20 mg of plain particles (PCL-PVA, 
PCL-GCS and PCL-ALG) were weighed and dispersed in 2 ml of a 1250 
µg/ml protein solution in a LoBind® eppendorf tube (Eppendorf, UK).  
Particles were then incubated for one hour in a water bath at 37ºC, under 
agitation (100 rpm). After incubation, particle suspension was centrifuged at 
7,500 rpm for 10 minutes (IEC Micromax eppendorf centrifuge, UK), the pellet 
washed twice and then allowed to dry in a dessiccator, while the supernatant 
and the washes were kept frozen at -20ºC until future analysis.  
 
PHYSICOCHEMICAL CHARACTERISATION OF PCL NANOSPHERES 
The size and surface charge of nanospheres were determined by Malvern 
ZetaSizer (Malvern Instruments, UK). For zeta potential measurement, a 10 
mM potassium chloride solution (Sigma Aldrich Co., UK) solution was used 
to disperse the particles. Zeta potential data (mV) were obtained from the 
average of three measurements with a standard deviation ≤5%.  
FORMULATION ORGANIC PHASE 
INTERNAL PHASE 
(w/v) 
EXTERNAL 
PHASE 
(w/v) 
PCL-PVA 10 % PVA 1.25% PVA 
PCL-GCS 1% GCS 1.25% PVA 
A
d
s.
 
PCL-ALG 
PCL 
(100 mg) 
in 6 ml DCM 10 % PVA 0.75% ALG 
PCL-PVA 10 % PVA 1.25% PVA 
PCL-GCS 1% GCS 1.25% PVA 
PCL-ALG 10 % PVA 0.75% ALG 
PCL-SP 
PCL 
(100 mg) 
in 6 ml DCM 
10 % PVA + 10% SP 1.25% PVA 
E
n
tr
a
p
p
ed
 
PCL-OA 
PCL (100 mg) 
 6 ml DCM + 10% OA (1ml 
EtOH) 
10 % PVA 1.25% PVA 
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The surface morphology of nanospheres was analysed by scanning electron 
microscopy (SEM, Phillips/FEI XL30 SEM) as previously described [20].  
 
DETERMINATION OF ANTIGEN LOADING 
The total amount (% w/w) of protein entrapped per unit weight of 
nanospheres (loading capacity, L.C.) was directly measured using the 
MicroBCA protein assay, after digestion of 10 mg of particles with 2.5 ml of a 
5% (w/v) sodium dodecyl sulphate (SDS, BDH UK) in 0.1 M sodium 
hydroxide (NaOH, Fisher Co. UK) solution, maintained under magnetic 
stirring at 37ºC until a clear solution was obtained. Moreover, the total 
amount of protein adsorbed onto the surface of particles was determined by 
an indirect method, assessing the protein concentration in the supernatants 
using the BCA protein assay. The integrity of protein structure after its 
adsorption or entrapment was studied by sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE).  
 
IN VITRO RELEASE STUDIES 
Antigen-containing nanospheres were accurately weighed (10 mg), placed in 
three LoBind eppendorf tubes per time point and dispersed in 2 ml of a PBS 
buffer (pH 7.4), containing 5% (w/v) of sodium dodecyl sulphate (SDS, Sigma 
Aldrich, Co. UK) and 0.02% (w/v) of sodium azide. Tubes were incubated in 
a shaking water-bath at 37ºC. At predetermined interval, three eppendorf 
tube were collected, centrifuged at 7,500 rpm for 10 minutes (IEC Micromax 
eppendorf centrifuge, UK) and the supernatants were analysed for protein 
content and integrity by BCA, Micro BCA and SDS-PAGE, respectively.  
 
STRUCTURAL INTEGRITY OF S. equi ANTIGENS 
Dried particles (10 mg) were suspended in 500 µl of a PBS solution, containing 
10% (w/v) of SDS, and incubated for 2 hours at 37ºC in an orbital shaker.  S. 
equi proteins thus extracted from nanospheres, as well as the supernatants 
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obtained after antigen adsorption were loaded onto 10% (w/v) 
polyacrylamide (Bio-Rad, UK) mini-gel and run at a constant voltage of 100 V 
for 120 minutes using a Bio-Rad 300 Power Pack Electrophoresis system 
(Bio-Rad, Hercules, CA, USA). Proteins bands were observed after staining 
with SimplyBlueTM SafeStain solution (Invitrogen, USA).  
 
WESTERN BLOTTING 
The antigenicity of entrapped and adsorbed S. equi antigens was assessed by 
Western blotting [21].  Samples were transferred from the acrylamide gel onto 
the PVDF membrane using Bio-Rad mini Trans-Blot Electrophoretic Transfer 
Cell for 1 hour. The membrane was then washed and blocked by its 
incubation with 10% (w/v) skim milk powder (Merck KGaA, UK) dissolved 
in PBS containing 0.02% (v/v) of Tween 20 (PBST; Sigma Aldrich, Co., UK), 
for one hour under constant agitation in an orbital shaker (100 rpm). The 
membrane was then incubated at room temperature and for one hour with 
rabbit monoclonal anti-SeM diluted in the blocking buffer (1:200), under 
constant agitation. After washing, the blot was incubated with a goat 
anti-rabbit IgG conjugated to phosphatase alkaline (Sigma Aldrich Co., UK), 
diluted 1:1000 in blocking buffer for 1 hour at room temperature. The capacity 
of the anti-serum to recognise S. equi antigens was revealed colorimetrically 
using nitro blue tetrazolinum (NBT) and 5-bromo-4-chloro-3-indolyl-1-
phosphate (BCIP) (Pierce, USA).  
 
IN VITRO CYTOTOXICITY 
BALB/c monocyte macrophages (J774A.1 cells line, American Type Culture 
Collection; ATCC#TIB-67) were used to study the cytotoxicity of PCL 
nanospheres. Cell viability was evaluated by measuring the reduction of 3-(4, 
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) by the 
mitochondrial dehydrogenase of living cells [22]. Cells were treated with 
samples, in triplicate, at different concentrations and incubated for 4 hours. 
MTT reagent was added and, after incubation, the complete media was 
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removed and the absorbance measured at 570 nm at a Dynex MRX Microplate 
Reader (Dynex, UK) after crystals dissolution with DMSO. 
The relative cell viability related to control wells containing non treated cells 
was determined by the following equation: 
 
100% ×=
A
A
Control
Samples
viabilityCell
 
 
Where Asamples is the absorbance value obtained for cells treated with different 
particles formulations, while Acontrol was the reading obtained when cells were 
just incubated with Dulbecco`s modified Eagle’s media (DMEM, Sigma 
Aldrich Co., UK). The % cell viability obtained for treated and untreated cells 
was compared by one-way ANOVA analysis, followed by LSD post hoc test 
using SPSS software (Version 13, Microsoft), assuming the differences as 
significant when P ≤ 0.05. 
 
CELLULAR UPTAKE STUDIES 
Bovine serum albumin fluorescein isothiocyanate (FITC-BSA) was used to 
assess the binding and uptake of PCL nanospheres by BALB/c monocyte 
macrophages (J774A.1). To prepare the dye-entrapped nanospheres, 
FITC-BSA protein was previously dissolved in the internal phase of the first 
w/o emulsion.  The concentration of the FITC-BSA was optimized to 2% 
(w/w) of polymer weight based on preliminary studies. An efficient loading 
in PCL nanospheres was achieved with no leaching of protein during 
incubation in the cell culture medium. ´The cells were previously cultured on 
a 35 mm glass bottom culture dishes with a cover-slip coated with poly-D-
lysine (5×104 cell/well; P35GC-0-10C, MatTek® Corporation, USA) in DMEM 
(Sigma Aldrich Co., UK) supplemented with 4 mM glutamine (Sigma Aldrich 
Co., UK) plus 10% fetal bovine serum (FBS; Gibco BRL, UK), 100 U/ml 
penicillin and 100 µg/ml streptomycin (Sigma, Poole, Dorset, UK). BALB/c 
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cells were sub-cultured during the experimental period and frequently 
checked for viability using Typan blue exclusion assay. For qualitative uptake 
studies, the culture medium was removed and serum free DMEM was added 
to cells. Freeze-dried S. equi-loaded particles (50 µg/ml; 250 µg/ml) 
suspended in DMEM medium were added to cells and left for 60 minutes at 
37ºC in 5% CO2 and 90% relative humidity. The dishes were afterwards 
observed with a Zeiss LSM 510 confocal laser scanning microscope (Carl Zeiss 
Microscope Systems, Germany) with Zeiss LSM Image Browser® 4.0 software 
for the uptake and distribution of particles. Differential interference contrast 
and fluorescence images were obtained and processed using Adobe 
Photoshop® software. 
 
STATISTICAL ANALYSIS 
Differences of significance between groups of in vitro studies were determined 
by analysis of variance (ANOVA) linear model with SPSS software (Version 
13, Microsoft), with significance set at P ≤ 0.05. This analysis was further 
complemented by a multicomparison LSD post hoc test in order to state the 
difference identified between the groups which ANOVA analysis revealed a P 
≤ 0.05. 
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RESULTS AND DISCUSSION 
PCL NANOSPHERES PHYSICOCHEMICAL CHARACTERISTICS 
Nanospheres presented a spherical shape, a surface free of any pores or cracks 
(Figure 3.1) and a narrow particle size distribution particularly PCL-GCS and 
PCL-OA (Table 3.2).  
 
 
 
  
 
  
 
  
Figure 3.1 – Scanning electron micrographs of the (A) PCL-PVA, (B) PCL-GCS, (C) 
PCL-ALG, (D) PCL-SP and (E) PCL-OA nanospheres. 
(A) 
(B) (D) 
(C) 
(E) 
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PCL particle size ranged from 248.4 to 450.2 nm for antigen-adsorbed particles 
and 242.57 to 422.83 nm when S. equi antigens were entrapped in PCL 
nanospheres. 
 
Table 3.2  
Particles size, zeta potential and loading capacity (L.C.) of PCL nanospheres (mean ± S.D.; 
n=6) 
ZETA POTENTIAL (mV) c 
FORMULATION 
VMDa 
 (nm) BP AP 
L.C.   
(% w/w) 
PCL-PVA 248.4 ± 55.80 -30.7 ± 6.90 -32.7 ± 7.10 10.75  
PCL-GCS 450.2 ± 32.65  +38.7 ± 7.20 +5.40 ± 7.50 11.38  
A
d
s.
 b
 
PCL-ALG 287.1 ± 21.19  -51.3 ± 6.72 -52.30 ± 7.60 10.13  
PCL-PVA 242.57 ± 64.19 -32.8 ± 6.20 -34,30 ± 6.72 5.19 
PCL-GCS 422.83 ± 14.46 +31.7 ± 7.43 +21.10 ± 7.65 8.42 
PCL-ALG 264.67 ± 69.26 -53.1 ± 5. 30 -54.90 ± 5.26 5.04 
PCL-SP 348.37 ± 23.36 -27.8 ± 6.50 -23.10 ± 5.46 4.92 E
n
tr
a
p
p
ed
 
PCL-OA 243.40 ± 10.60 -31.60 ± 3.70 - 31.73 ± 2.52 6.50 
aVMD- volume mean diameter; 
bAds.-adsorbed;  
cPCL nanospheres surface charge, before (BP) and after (AP) protein association. 
 
 
When GCS and SP were added as adjuvants and dissolved in the internal 
phase of the first (w/o) emulsion, the size of nanospheres increased.  The 
smallest particles were formed when PVA, ALG and OA were used as 
adjuvants. The 1% (w/v) GCS solution presented a higher viscosity compared 
to PVA, which can thus explain the increase of nanospheres size. On the other 
hand, the polyamine SP forms relatively low viscosity solutions after 
dissolution in the 10% (w/v) PVA solution and therefore an increase of 
particles size was not predictable. In fact PVA is an excellent colloidal 
polymeric stabiliser. As it is well accepted, amphiphilies having the property 
to align at the droplet surface, spontaneously form micelles in an aqueous 
media, due to intra and/or intermolecular interactions with hydrophobic 
moieties, so as to promote stability by lowering the free energy at the interface 
between two phases and resisting coalescence and flocculation of the 
emulsion droplets, resulting in smaller particle diameters and polydispersity 
E 
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[23-25]. The resultant carriers are composed by a hydrophobic core that can be 
used as drugs reservoir. Moreover, the nanospheres surface modification by 
the use of a hydrophilic polymer, such as alginate, will improve the stability 
of the second emulsion, as it limits the exchange between the external phase 
and the organic phase of the first emulsion. 
Nanospheres production was previously optimised using OVA as a model 
drug (results not shown).  Therefore, the amounts and concentration of 
polymers and stabilisers used in the w/o/w double emulsion solvent 
evaporation technique were chosen in order to produce particles that would 
fit within the nanometric range, as well as with a low polydispersity index. As 
a result, despite particles composition, all presented a size lower than 1 µm, 
which means that they may be suitable for an adjuvant effect as they would 
be more readily taken up by the macrophages and dendritic cells [26, 27].  
For nanospheres formulated with SP and OA, the zeta potential is slightly 
more negative compared to control, non-modified PCL nanospheres, whereas 
it became positive when GCS was used due to its cationic polymeric nature, 
despite its inclusion in the inner phase of the double w/o/w emulsion. 
PCL-ALG nanospheres presented a high negative charge which was even 
higher after proteins adsorption (Table 3.2). 
CS has been widely used in the pharmaceutical field due to its unique 
properties as it is a non-toxic, biodegradable and positively charged 
polysaccharide. However, its low solubility at physiological pH constitutes 
one of its important limitations. On the other hand, lysozyme is the principal 
enzyme responsible for CS degradation [28]. This enzyme was present during 
the extraction of S. equi cell wall proteins and remained in the mixture of S. 
equi extract antigens used for PCL particle loading. As a result, a 
biocompatible CS derivative (GCS) was chosen for particles production, as its 
good solubility in a broad range pH aqueous systems makes possible its 
inclusion in the internal phase of w/o first emulsion, being less accessible for 
lysozyme when the PCL nanospheres are suspended in S. equi antigens 
A 
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solution [29, 30]. Surprisingly, no destabilisation of internal aqueous solution 
was observed when S. equi antigens were dissolved in 1% (w/v) GCS 
solution, contrary to that observed immediately after dissolution of S. equi 
enzymatic extract in a 0.75% (w/v) CS solution.  Actually, as already reported 
in the literature, GCS has indeed the ability to protect proteins not only 
during particles formation, but also throughout release in physiological media 
[29]. The increase in viscosity of the inner phase not only reduces the 
interaction between the entrapped proteins and organic phase, in the 
interface, during the homogenisation of the first w/o emulsion, but also 
reduces leakage from the nanospheres, resulting in a higher L.C. [29]. In fact, 
the entrapment efficiency (E.E.) varied from 49.2% (PCL-SP) to 84.2 % 
(PCL-GCS), with no compromise of antigen molecular weight by the 
formulation process (Figure 3.2). It was observed that GCS substantially 
increased the L.C. of S. equi antigens in the nanospheres (Table 3.2). Besides 
PCL-SP lower L.C., particles were very easy to disperse in water evidently 
due to the high hydrophilicity of the molecule. As a result, sample 
preparation for animal dose will not be compromised by the amount of 
particles needed to be administered in order to keep the SeM dose.  
 
 
 
 
 
 
 
 
 
 
In the present work, kinetic studies were undertaken in order to evaluate the 
adsorption capacity of different PCL particles and to estimate the equilibrium 
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Figure 3.2 – SDS-PAGE (10% gel) 
analysis of S. equi enzymatic extract 
solution before and after entrapment 
in PCL (MWT 42.5 kDa) nanospheres. 
Lanes: 1) Standard molecular weight 
marker; 2) S. equi enzymatic extract 
standard solution at 1250 µg/ml; and 
S. equi proteins extracted from 3) 
PCL-PVA, 4) PCL-GCS, 5) PCL-OA, 6) 
PCL-SP and 7) PCL-ALG. 
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time of the adsorption reaction. Protein adsorption seems to be a 
time-dependent phenomena, but one hour was enough to reach the maximum 
amount of protein adsorbed onto the solid particles (results not shown) [3].  
All PCL nanospheres loaded by adsorption presented higher L.C. than those 
resulting from S. equi antigen entrapment. The total protein amount adsorbed 
was 86% (w/w) onto non-modified PCL-PVA nanoparticles, 91% (w/w) onto 
PCL-GCS nanospheres and 81% (w/w) onto PCL-ALG, which supports the 
idea that, for the mixture of proteins studied, both the differences on particle 
size and charge seemed not to have an influence in the adsorption 
phenomena.  
For the antigen-loaded nanospheres to function as controlled release delivery 
systems for the generation of long lasting immune responses, they should not 
only contain suitable high levels of antigen, but also maintain its antigenicity 
[31]. In S. equi antigens entrapped in PCL nanospheres, proteins were exposed 
to potentially harsh conditions, such as shear force, contact with surfactants 
and organic solvent DCM, which can potentate degradation. Denaturation or 
inactivation of proteins during processing causes alteration of their native 
structure, indicated by a shift in band formation higher or lower than the 
standard. Therefore, western blotting (Figure 3.4) was used to evaluate 
antigenicity, and polyacrylamide gel electrophoresis (SDS-PAGE) (Figures 3.2 
and 3.3) was undertaken in order to assess protein integrity after entrapment 
and adsorption in PCL nanospheres.  
SeM is a 58kDa M-like protein therefore, in Figures 3.2 and 3.3, its band may 
be seen near the 56kDa marker [32, 33]. As it can be observed, protein bands 
pattern of migration obtained for native S. equi antigens and those extracted 
from loaded nanospheres are identical, which suggests that protein molecular 
weights were not affected by the entrapment or adsorption techniques used 
for protein association to PCL carriers. In addition, S. equi epitopes necessary 
for immune responses were as well preserved as an antiserum raised against 
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protein SeM still recognise entrapped and adsorbed S. equi antigens (Figure 
3.4).  
 
 
 
 
 
 
 
 
 
 
The total amount of protein adsorbed was similar in particles with different 
composition, size and charge (Table 3.2), but SeM band is stronger in the 
solution obtained after protein extraction from PCL-GCS nanospheres surface, 
which is in accordance with loading results (Table 3.2). Even so, it was 
assessed that 25 µg of SeM are present in 925 µg of S. equi extract solution, 
which can explain the thin band generally obtained. Therefore, adsorption can 
be successfully used for the development of S. equi enzymatic extract vaccine 
formulations using nanospheres, resulting in higher loadings than those 
obtained for the antigens entrapment, with no compromise of its molecular 
structure. 
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Figure 3.3 - SDS- PAGE (10% gel) of S. equi enzymatic extract solutions before and after 
adsorption onto PCL (MWT 40 kDa) nanospheres. Lanes: 1) Standard molecular weight 
markers; S. equi proteins extracted from adsorbed particles 2) PCL-PVA, 3) PCL-GCS and 
4) PCL-ALG; 5) S. equi enzymatic extract standard solution at 1250 µg/ml; and 
supernatants obtained after particles centrifugation 6) PCL-PVA, 7) PCL-GCS and 8) 
PCL-ALG. 
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S. equi antigens remained largely linked to the PCL nanospheres surface for 4 
hours, as until this time point 45% (w/w), 55% (w/w) and 42% (w/w) of the 
adsorbed antigen remained in the surface respectively of PCL-PVA, PCL-GCS 
and PCL-ALG, under physiological conditions (Figure 3.5). Therefore, this 
system is suitable for nasal delivery as the antigen associated to particles will 
not be released to a large extend before antigen-loaded PCL nanospheres are 
taken up by the nasal epithelium and release the antigen in the nasal cavity.  
CS and ALG are bioadhesive polymers, therefore PCL-GCS and PCL-ALG 
nanospheres may resist to the mucociliary clearance in the nose more 
efficiently than PCL-PVA. Besides the mucoadhesive properties, the positive 
charge of PCL-GCS nanospheres may also contribute to its prolonged 
residence time in the nasal mucosa, as it will establish electrostatic 
interactions with the negatively charged mucus that covers the epithelium.   It 
is important to mention that even 30 days after particle incubation in PBS (pH 
7.4) buffer, 22% (w/w) of loaded S. equi protein remained adsorbed onto 
PCL-GCS particles surface, while only 10,7% (w/w) and 12,2% (w/w) were 
still adsorbed in PCL-ALG and PCL-PVA particles, respectively (Figure 3.5) . 
Figure 3.4 – Western blot analysis S. equi antigens extracted from PCL (MWT 42.5 kDa) 
nanospheres blotted against anti-SeM antibody. Lanes: 1) Standard molecular weight 
marker; S. equi proteins extracted from 2) PCL-PVA and 3) PCL-GCS, 4) PCL-OA, 5) 
PCL-SP and 6) PCL-ALG; S. equi proteins removed from the surface of 7) PCL-PVA and 8) 
PCL-GCS; and  9) S. equi enzymatic extract standard solution at 1250 µg/ml; 
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For this reason, in spite of adsorbing a mixture of proteins, it seems that the 
positive charge presented by PCL-GCS particles contributed for a stronger 
interaction between S. equi proteins and PCL particle surface, as it 
significantly released a lower amount of adsorbed antigen.  
 
 
 
All the particulate systems containing S. equi antigens presented a burst 
release that varied from 26% (w/w) for PCL-GCS, to 33% (w/w) for PCL-OA. 
After this time point, all particles presented a sustained release up to 30 days. 
At this time, 40% (w/w) for PCL-OA to 55% (w/w) for PCL-GCS remained 
entrapped, which is in accordance with the degradability of PCL polymer 
(Figure 3.6). For PCL nanoparticles produced with a 14.8 kDa PCL polymer, it 
was not observed a significant change of polymer molecular weight even 140 
days after particles incubation in PBS at 37ºC. PCL nanospheres degrade 
slowly in aqueous media due to their hydrophobic and crystalline nature. The 
cristallinity increases with the decrease of polymer molecular weight [34]. As 
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Figure 3.5 – In vitro cumulative release of S. equi enzymatic extract proteins adsorbed 
onto the surface of different PCL-based nanospheres, for a period of 30 days (mean ± 
S.D.; n=3). 
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a result, it is possible to state that, in the present study the optimisation of the 
process variables and the degradation characteristics of the polymer chosen 
resulted in nanospheres with reasonable L.C. which demonstrated to be able 
to release the entrapped S. equi antigens over an extended period of time, 
especially the PCL-GCS particles.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCL NANOSPHERES IN VITRO CELL VIABILITY ASSAY 
The cytotoxicity of PCL nanospheres was assessed by determining the 
viability of cells using a MTT test on microtitre plates [22]. PCL nanospheres 
showed no cytotoxicity effect on BALB/c cells (J774A.1 cell line) in a 
concentration up to 2.5 mg/ml. Incubation with PCL nanospheres lead to 
viability as high as 117% compared to control cells, which was significantly 
higher (P<0.001) than that obtained with the positive control PEI. The viability 
curve is similar for all PCL nanospheres studied, but PCL-OA led to the 
Figure 3.6 – In vitro cumulative release of S. equi enzymatic extract proteins entrapped in 
different PCL-based nanospheres, for a period of 30 days (n=3, mean ±  S.D.). 
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Figure 3.7 – Viability of mouse BALB/c monocyte macrophage cells (J774A.1 cell line) 
after incubation with increasing concentration of PCL nanospheres (mean ± S.D.; n=3). 
highest reduction in cell viability, being in a range of 93.72% to 99.24% of the 
control cells (Figure 3.7).  
 
 
 
IN VITRO CELLULAR UPTAKE STUDIES 
Particle uptake is determined by several factors, including particle size, 
charge, hydrophobicity, but also by adjuvants associated such as GCS, ALG, 
SP and OA [13, 14, 19, 35]. Particles with hydrophobic surfaces were observed 
generally to be more readily phagocytosed than those with hydrophilic 
surfaces [36, 37]. Despite PLA and PLGA being the most frequently used 
biomaterials  for antigen entrapment, PCL is one of the widely used 
biodegradable polymers due to its biodegradability, biocompatibility, slow 
rate of degradation, hydrophobicity, good drug permeability, in vitro stability, 
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lack of toxicity and low cost [38-40]. A positive correlation was found for the 
hydrophobicity and the uptake of particles by cells, and these cells had higher 
affinity for PCL particles when compared with PLA delivery systems [37, 41]. 
PCL microparticles have been investigated in the literature as a vaccine 
delivery system, but PCL nanospheres used in immunisation studies have not 
been extensively reported, which can be due to the difficulty of producing 
non-aggregating PCL nanospheres. However, the existing studies have 
suggested promising results of this polymer as a matrix of a vaccine adjuvant, 
which is thought to be due to an increase of particles uptake by M cells [37, 
40]. 
The adjuvant effect of PCL and CS microspheres has been studied and their 
ability to induce an immune response following parenteral and 
non-parenteral administration has previously been reported [15, 16, 42]. 
In fact, the cellular uptake of polymeric carriers is a size dependent 
phenomenon, as particles with a mean diameter less than 10 µm are able to be 
taken up by M cells in Peyer’s patches of mice and pigs as previously shown 
by several investigators. In addition, particle size may determine the type of 
immune response induced in animals, as particles with a diameter > 5 µm are 
taken up by Peyer’s patches and remain in their area, and carriers with lower 
diameters were identified not only in Peyer’s patches, but also in mesenteric 
lymph nodes and spleen, and as a result would preferably induce a systemic 
immune response, while the first ones will preferentially elicite a mucosal 
immunity as they remain in IgA inductive environment [43-45]. 
As it can be seen in Figure 3.8, cells tested do not have background in the 
fluorescence emission range of FTIC. Presence of green fluorescent 
nanospheres surrounding the nucleus of several cells could be found in 
PCL-PVA, PCL-GCS and PCL-SP nanospheres. It is important to reinforce 
that differential interference contrast (A, B and D) and fluorescence images (C 
and E) were obtained at Z of 4 µm, in which the nucleus of cells was focused. 
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These observations suggest that one hour was enough to verify that PCL-GCS 
nanospheres were successfully taken up by cells and therefore can function as 
an effective antigen delivery system. In fact, PCL-ALG nanospheres were only 
able to attach to the membrane of cells during the time of experiment, which 
can be due to its high negative charge, as its size is as small as those presented 
by PCL-PVA and PCL-OA. Probably, a prolonged time of observation would 
have permitted to see the particle inclusion in the cytoplasm, as the cellular 
uptake efficiency was previously found to be dependent on incubation time 
[46].  
 
 
 
 
 
 
Figure 3.8 – Cellular uptake of PCL nanospheres entrapping BSA-FITC, by mouse 
BALB/c monocyte macrophage cells (J774A.1) : (A) PCL-PVA; (B) PCL-GCS; (C) 
PCL-ALG; (D) PCL-SP; (E) PCL-OA (mean ± S.D.; n=3). 
(A) (B) (C) 
(D) (E) (C) 
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CONCLUSIONS 
The purpose of this study was to characterise a delivery system based on PCL 
nanospheres associated to S. equi antigens by adsorption or entrapment 
method.  
Particles fitted the nanosize range and S. equi extracted proteins were 
successfully associated without any damage to their structure, although 
adsorption, a very mild process, resulted in a higher L.C.. Macrophages 
(J774A.1 cell line) viability seemed not to be affected by any of the PCL 
particulate systems prepared, and therefore the preparation method did not 
introduce any toxic compounds on particles. It was shown that PCL particles 
modification by the mucoadhesive polymers (ALG and CS) and the 
absorption enhancers (OA and SP) influenced particles uptake. In fact, one 
hour after particles incubation with cells, it was possible to see that the 
positively charged PCL-GCS nanospheres were taken up by macrophages, 
while the negatively charged PCL-ALG were only able to surround cells 
surface.  
Overall, particles size, L.C., controlled release properties and uptake studies 
may predict that these systems are promising carriers for mucosal 
immunisation. As a result, in vivo studies including the assessment of 
systemic, cellular and mucosal immune responses induced in a mouse model 
will be presented in the second part of this report (Chapter 4) [47]. 
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ABSTRACT 
Strangles is a bacterial infection of Equidae family that affects the nasopharynx 
and draining lymph nodes, caused by Streptococcus equi subspecies equi. This 
agent has been reported as responsible for 30% of all worldwide equine 
infectious and is quite sensitive to penicillin and other antibiotics. However, 
prevention is still the best option because the current antibiotic therapy and 
vaccination are often ineffective. As S. equi induces a very strong serum and 
mucosal responses in convalescent horses, an effective and economic strangles 
vaccine is still a priority. In this study, the humoral, cellular and mucosal 
immune responses to S. equi antigens entrapped or adsorbed onto poly-ε-
caprolactone nanospheres were evaluated in mice. Particles were produced by 
a double (w/o/w) emulsion solvent evaporation technique and contained 
mucoadhesive polymers (alginate or chitosan) and absorption enhancers 
(spermine, oleic acid).  The intranasal administration of S. equi antigen-loaded 
nanospheres, particularly those constituted by the mucoadhesive polymers, 
increased the immunogenicity and mucosal immune responses (SIgA) to the 
antigen. The inclusion of cholera toxin B subunit in formulations successfully 
further activated the paths leading to Th1 and Th2 cells. Therefore, these PCL 
nanospheres are potential carriers for the delivery of S. equi antigens to 
protect animals against strangles. 
 
Keywords: Poly-ε-caprolactone, nanospheres, adjuvants, Streptococcus equi, 
mucosal immunisation. 
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INTRODUCTION 
Streptococcus equi subsp. equi (S. equi) is the etiological agent of strangles, one 
of the most costly, commonly diagnosed and widespread infectious disease of 
Equidae worldwide, that has lead to devastating epidemics in stables where 
horses are housed [1, 2].  This is an acute, contagious and deadly respiratory 
tract disease, which typical signs of infection include pyrexia, suppurative, 
mucopurulent nasal discharge, lymphadenitis and abscessation, often in the 
lymph nodes of the head and neck [1-3]. It occasionally affects other lymph 
nodes and organs, resulting in a severe stage of the disease called bastard 
strangles. Because S. equi persists in the environment for only a few weeks, 
the most important factor for the maintenance of infection is the infected 
horse [3, 4]. Even if generally after 4-6 weeks the infected animals recover 
from disease eliminating S. equi from their organism, 10% will constitute long-
term S. equi carriers, harbouring the microorganism for months. The presence 
of the pathogen is not detectable in S. equi long-term carriers and the animals 
do not show any clinical signs of disease [1-6]. On the other hand, although S. 
equi is sensitive in vitro to some antibiotics, its use is not consensual as most of 
the treatments are ineffective when external signs of disease are already 
detectable [3, 7].  
Animals that recover from a S. equi natural infection show a protective 
immunity, mostly against one of the most virulence factor of these bacteria, 
the antiphagocytic cell wall-associated S. equi M-like protein (SeM), that 
seems to remain in 75% of the animals for five years, although the protection 
mechanism is not yet fully understood [3, 8]. In fact, convalescent horses have 
antibodies IgG and IgA against SeM, both in serum and nasal secretions, 
which encourages the development of efficient vaccines. As a result, the 
inclusion of animals in regular vaccination programmes simultaneously with 
an effective diagnostic test constitutes the key for the combat of large 
strangles outbreaks [1, 2]. Bacterins and adjuvant extracts have been widely 
used in the field since the 1980s, although the efficacy of most available 
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vaccines is not sufficient to confer protection against S. equi infection in horses 
[1, 3, 9, 10].  Secretory IgA (SIgA) antibodies locally produced in the 
respiratory tract are extremely important for the prevention and control of 
infection at mucosal sites [11]. However, those vaccines, which specifically 
target the SeM protein, did not show useful protection in horses. Therefore, it 
appears that an effective strangles vaccine must be able to stimulate a 
nasopharyngeal immune response [12, 13].  
Biodegradable particles are of particular interest as technology platforms, for 
the generation of both protective local and systemic immunities. These 
carriers increase the level concentration of antigen over an extended time and 
its uptake by lymph nodes, promoting the interaction between the antigen 
and specific antigen presenting cells (APCs), protect the antigen from 
proteolytic enzymes and have a great ability to gain access to the 
mucosal-associated lymphoid tissue (MALT), when compared to free 
antigens, thus providing a means of target vaccine delivery [14-16]. These 
delivery systems have the capacity to be modified in order to achieve a 
prolonged and pulsatile release of the entrapped antigen, mimicking the 
primary dose and boosters commonly used in the conventional vaccination 
programs, reducing therefore the number of doses needed to be administered 
in order to maintain an eventual immune response for a long period [17-20, 
21, 22]. The efficacy of polymeric carriers in inducing effective immune 
response was reviewed by Lemoine et al. (1999) [23]. 
Polymeric particles induce a mucosal response, after intranasal (i.n.) 
administration, in lymphoid tissues regardless of target site and the response 
is paralleled by the appearance of antibodies in secretions of glands distant 
from the site of immunisation, due to the role of the common mucosal 
immune system (CMIS), which highlights the immunoadjuvant properties of 
these carriers [24]. The modification of polymeric and biodegradable particles 
with mucoadhesive compounds as chitosan (CS) [20, 25-28] and alginate 
(ALG) [29] to extend residence time, and absorption enhancers as spermine  
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(SP) [30, 31] and oleic acid (OA) [25, 32], constitute an interesting approach in 
order to overcome the nasal barriers and improve the delivery of antigens 
administered by mucosal routes [32]. Accordingly, in the present study SP 
was used as a potential adjuvant to improve S. equi absorption through the 
nasal epithelium. In order to overcome CS poor solubility in physiological 
pH, a glycolchitosan (GCS) was used in this work as it is soluble and active as 
an absorption enhancer at pH 7.4 [33].  
Antigens adsorbed and entrapped in particulate systems have been able to 
induce strong immune responses.  
 In a previous work, our group have showed that S. equi enzymatic extract 
proteins adsorbed onto non-aggregated PCL microspheres enhanced serum 
specific IgG, IgG1 and IgG2a antibody responses and elicited an elevated type 
I immune response (Th1) cytokines, even 300 days after a single-dose 
subcutaneous administration [34].  
The purpose of this study is to use PCL nanospheres, modified by different 
adjuvants (GCS, ALG, SP and OA), as potential carriers for S. equi surface 
proteins, and compare their ability to induce both systemic and local 
protective immunities after mucosal administration in a mouse model.  As  
cholera toxin B subunit (CTB) is one of the most potent mucosal adjuvant, 
both S. equi-loaded PCL nanospheres and free S. equi antigens were admixed 
with CTB and the resultant immunogenicity was evaluated and compared 
with the aforementioned formulations [14, 17, 35].   
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MATERIALS AND METHODS 
MATERIALS 
Polycaprolactone (PCL, average molecular weight (MW) 42.5 kDa), polyvinyl 
alcohol (PVA, MW 13-23 kDa, 87-89% hydrolysed), alginate low viscosity 
(ALG), spermine (SP), oleic acid (OA), glycolchitosan (GCS), sucrose, cholera 
toxin B subunit (CTB),  trypsin-chymotrypsin inhibitor, EDTA sodium salt, 
iodoacetic acid  and phenylmethanosulfonyl fluoride solution (PMSF) were 
supplied by Sigma Aldrich Co., UK. Dichloromethane (DCM) was obtained 
from BDH Laboratory Supplies, UK. Streptococcus equi subsp. equi (strain LEX) 
ATCC 53186 were a kind gift from Prof. J.F. Timoney (University of Kentucky, 
USA). 
 
ANIMALS 
Each group of experimentation used in the in vivo studies was composed by 4 
female, 6-8 weeks old BALB/c mice with food and drink provided ad libitum. 
Experiments were performed in strict accordance with the UK 1986 Animals 
(Scientific Procedures) Act.  
 
PREPARATION OF PCL NANOSPHERES 
PCL nanospheres were prepared by double emulsion (w/o/w) solvent 
evaporation technique, as described previously [34]. Briefly, polymer was 
dissolved in DCM and emulsified with a 10% (w/v) PVA or a 1% (w/v) GCS 
solution, which contained the S. equi antigens (10.0 mg) for the entrapment of 
these antigens in nanospheres. Particles containing absorption enhancers (10.0 
mg), such as SP and OA were also prepared.  The w/o emulsion was then 
homogenised with a 1.25% (w/v) PVA or 0.75% (w/v) ALG solution and the 
resultant w/o/w emulsion was magnetically stirred for 4 hours to evaporate 
the organic solvent. The PCL nanospheres were harvested by centrifugation 
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(20,000 rpm, 45 min, 15°C; Beckman J2-21 High speed centrifuge), washed and 
freeze-dried (Virtis, UK). 
Alternatively, S. equi extract proteins were adsorbed onto plain particles 
surface (PCL-PVA, PCL-GCS and PCL-ALG) following the protocol described 
in a previous study [34].  
For i.n. immunisations, 50 µl of a particles suspension in PBS (pH 7.4) 
containing adsorbed or entrapped S. equi antigens equivalent to 10 µg of SeM 
were administered per mice. Plain particles and free antigen were used as 
controls (Table 4.1).  
 
      Table 4.1  
      Design of intranasal immunisation study 
GROUPS FORMULATION 
1 PCL-PVAads. 
2 PCL-GCSads. 
3 PCL-ALGads. 
4 A
d
so
rb
ed
 
PCL-PVAads.+CTB 
5 PCL-PVA 
6 PCL-GCS 
7 PCL-ALG 
8 PCL-SP 
9 PCL-OA 
10 E
n
tr
a
p
p
ed
 
PCL-PVA+CTB 
11 FREE antigens 
12 FREE antigens+ CTB 
 
 
IMMUNISATION SCHEDULE 
Twelve groups of female BALB/c mice (25g; n=4/group) were immunised by 
i.n. route on day 1 and boosted on day 21, by instillation using a micropipette 
tip to administer 50 µl of sample (25 µl in each nostril) containing S. equi 
antigen equivalent to 10µg of SeM, either free, entrapped or adsorbed in 
nanospheres (Table 4.1).  Before each administration, mice were lightly 
anesthetized with 3% of isoflorane in oxygen (300 cm3 min-1). The 
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formulations were delivered slowly onto the nares, so that the mice could 
inhale it in. Controls consisted of plain particles and 10 µg of CTB (Sigma 
Aldrich co., UK) associated to the free antigen or S. equi-loaded nanospheres. 
All the formulations were freshly and aseptically prepared by particles 
dispersion in PBS pH 7.4 in a biological safety cabinet, immediately prior to 
dosing.  
 
COLLECTION OF SAMPLES 
Blood samples were collected in heparinised capillary tubes (Vitrex, 
Denmark) by tail vein bleeding. The blood was incubated overnight at 4ºC 
and the serum was separated by centrifugation at 15,000 rpm for 20 min at 
4ºC, and stored at -20oC until further analysis.  
In order to assess the mucosal immune response, lung and gut secretions 
were collected from the ethically sacrificed animal following a method 
previously reported [36]. Following the culling of animals, the small intestines 
were aseptically isolated, longitudinally sectioned and transferred into a 
Petri-dish which contained 4 ml of ice-cold enzyme inhibitor mix (1mM 
iodoacetic acid, 0.1% (v/v) trypsin inhibitor soybean type 1 and 10 mM EDTA 
sodium salt). These were scraped to expose the mucus and the liquid was 
transferred into a centrifuge tube and stored in acid-bath. Next, the tube was 
sonicated for 30 seconds to release protein from mucin, and centrifuged at 
20,000×g for 30 min at 4ºC. The supernatants were removed and 
centrifugation was repeated in order to obtain a clear sample, which were 
then stored at -70ºC overnight and lyophilised (Virtis Advantage freeze dryer, 
UK) to obtain a dry powder. These samples were then reconstituted with 500 
µl of PBS immediately before the SIgA quantification by ELISA. To collect the 
lung secretions, the trachea and lungs of the sacrificed animal were exposed 
and 5 ml of lavages solution (1mM PMSF, 0.9% (w/v) sodium chloride, 0.5% 
(v/v) tween 20 and 0.1% (w/v) sodium azide) were added into the trachea to 
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inflate the lungs. The liquid was immediately removed and treated as 
aforementioned for the gut washes.    
 
QUANTIFICATION OF SYSTEMIC (SERUM) AND MUCOSAL ANTIBODY 
RESPONSES  
The level of anti- S. equi specific IgG, IgG1, IgG2a antibodies in serum and IgA 
S. equi specific antibodies in lung and gut washes were assessed by indirect 
ELISA using Immulon 2, flat bottom plates (Dynatech, UK) [37]. Each well 
was coated overnight at 4ºC with 1.5 µg/ml S. equi  M proteins in PBS solution 
(pH 7.4). After washing, non-specific protein-binding sites were blocked with 
2% (w/v) bovine serum albumin solution (BSA, Sigma Aldrich Co., UK) in 
PBS and, after 1h incubation at 37ºC, the plates were washed with PBS 
containing 0.05% of tween 20 and 0.1% of BSA, fraction V (washing buffer). 
Serum samples, controls, lung and gut washes were added to the ELISA 
plates at a 32-fold dilution in PBS (100 µl), and serially diluted two-fold with 
the same buffer. After incubating the plates at 37ºC for 2h, these were washed 
before being incubated for 90 min at 37ºC with horseradish peroxide 
conjugate goat antibody (Sigma, Pool Dorset, UK) against mouse IgG 
(Serotec,UK) diluted to 1:1000 in PBS, IgG subclass 1 (IgG1; Serotec, UK) and 
IgG subclass 2a (IgG2a; Serotec, UK) or IgA (Serotec, UK) all diluted to 1:2000. 
After washing, bound antibodies were detected by a colorimetric reaction 
developed by 2-Azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) [ABTS] 
(Sigma Aldrich Co., UK) in citrate buffer and optical densities were read at 
405 nm.  
The serum antibody titres were expressed as the average (mean ± S.D., n=4.) 
of the reciprocal of the dilution at which the optical density (OD) at 405 nm 
was 5% higher than the strongest negative control reading. The IgA titres 
were presented as the absorbance value directly obtained from the optical 
densities resultant from IgA quantification in lung washes.  
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SPLENOCYTE CULTURE STUDIES 
The spleens were aseptically removed from sacrificed animals and a spleen 
cells suspension was prepared as mentioned elsewhere [34]. These cells 
homogenisates (100µl) obtained from the four mice of each group were plated 
individually in 96-well tissue culture plates (Fisher, UK) in triplicate, along 
with 100µl of RPMI 1640 (Gibco, UK)  containing soluble S. equi enzymatic 
extract at the concentration of  2.5 µg/ml. DuoSet® ELISA Development kit 
(R&D Systems Europe, UK) was used to quantify, according to the 
manufacturer’s instructions, the interleukin concentrations (IL-2, IL-4, IL-6 
and IFN-γ) in cell supernatants obtained after 48h of splenocytes stimulation 
with the soluble antigen at 37°C, in a humidified incubator at 5% CO2 
environment. 
 
STATISTICAL ANALYSIS 
Differences of significance between groups of in vitro and in vivo studies were 
determined by analysis of variance (ANOVA) linear model with SPSS 
software (Version 13, Microsoft), with significance set at P ≤ 0.05. This 
analysis was further complemented by a multicomparison LSD post hoc test 
in order to state the difference identified between the groups which ANOVA 
analysis revealed a P≤0.05. 
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RESULTS AND DISCUSSION 
SYSTEMIC IgG ANTIBODY IMMUNE RESPONSES  
The development of new protein carrier systems is highly dependent on the 
reduction or prevention of chemical degradation, denaturation and 
aggregation, in order to preserve their antigenicity [20]. 
Our previous results suggested that PCL microspheres adsorbed with S. equi 
antigens may work as an antigen depot that will release the antigen over a 
long period of time, as the immune response was still maintained 300 days 
after a single subcutaneous (s.c) administration to BALB/c mice [34]. 
A previous manuscript described the preparation and fully characterisation of 
these S. equi-loaded PCL nanospheres (Chapter 3) [38].  Non-toxic 
nanospheres presented a spherical shape and a narrow particle size 
distribution, particularly PCL-GCS and PCL-OA. The mean diameter of 
various batches of PCL nanospheres used in these studies ranged from 242.57 
to 450.2 nm and it was observed that the production method did not affect 
protein structure integrity, which is vital for the development of an efficient 
immune response. The in vitro studies previously performed have showed 
their controlled release properties for vaccine delivery and confirmed their in 
vitro uptake by macrophages [38]. As a result, the purpose of this in vivo study 
was to evaluate whether a mucosal   immunisation of BALB/c mice with 
those S. equi antigens adsorbed onto PCL nanospheres were able to induce 
systemic IgG and IgG subtype antibodies and mucosal SIgA, and compare 
these immune responses with those elicited by the S. equi antigens entrapped 
in the same polymeric system. Two i.n. administrations were conducted to 
confirm the immunogenicity of S. equi antigen-loaded PCL nanospheres. 
In addition to the entrapment technologies believed to enhance the immune 
response by promoting the antigen uptake by APCs or M-cells, 
immunoadjuvants as CTB, can be used in order to up-regulate mucosal 
responses [35, 39]. Therefore, the association of CTB to non modified 
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Figure 4.1 – Serum anti-S. equi specific IgG profile of mice immunised by i.n. route 
with S. equi antigens in solution (FREE), co-administered with CTB (FREE+CTB) and 
entrapped in different formulations of PCL nanospheres (mean ±  S.D., n=4). 
polymeric nanospheres (PCL-PVA) and their administration by a mucosal 
route was expected to improve both local (SIgA) and systemic (IgG) immune 
responses.  
S. equi-specific IgG responses were detected in sera of mice after 2, 4, 7 and 12 
weeks of animal inoculation. No S. equi specific-IgG antibodies was detected 
in serum of animals vaccinated with plain particles (data not shown), which 
emphasised the utilisation of these PCL polymeric systems as an adjuvant for 
S. equi antigens, as they have the ability to change S. equi antigens 
immunogenicity (Figures 4.1 and 4.2).  
 
1
10
100
1000
10000
100000
2 4 7 12
PCL-PVA PCL-GCS PCL-ALG PCL-SP PCL-OA PCL-PVA+CTB FREE FREE+CTB
 
 
Animals vaccinated with S. equi antigen-loaded PCL nanospheres did not 
show at any period any sign of the disease or other severe adverse reactions, 
which is of vital importance as it constitutes one of the major disadvantages of 
S. equi extract-based vaccines [1]. 
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Figure 4.2 - Serum anti-S. equi specific IgG profile of mice immunised by i.n. route 
with S. equi antigens in solution (FREE), co-administered with CTB (FREE+CTB) and 
adsorbed onto different PCL nanospheres (mean ±  S.D.; n=4). 
Two weeks after animal’s vaccination, only S. equi antigen-adsorbed PCL 
nanospheres groups produced serum anti-S. equi IgG specific titre 
significantly higher than those elicited by free antigen, free antigen associated 
with CTB and S. equi antigen-entrapped PCL-PVA nanospheres alone and 
co-administered with CTB (Figure 4.2).  
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PCL-GCS lead to a noticeable higher and more prolonged antibody IgG levels 
of vaccinated animals, and the difference between these titres and those 
induced and quantified in all other animals vaccinated with loaded 
particulate systems  was significant (P<0.001). 
By day 28, not only PCL-PVAads and PCL-GCSads induced significantly 
higher IgG systemic levels (P<0.001), but also S. equi antigens entrapped in 
PCL-ALG and PCL-OA had already seroconverted and their IgG responses 
were significantly superior (P<0.02) than those induced by FREE and 
FREE+CTB. S. equi antigen-adsorbed PCL-PVA nanospheres co-administered 
with CTB markedly enhanced the immunogenicity compared to FREE and 
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FREE+CTB groups (P<0.002), opposite to the specific anti-S. equi IgG titres 
that have resulted from the i.n. immunisation of mice with PCL-PVA 
nanospheres with entrapped S. equi antigens and associated to CTB (P>0.176) 
(Figures 4.1 and 4.2). 
PCL had a MW of 42.5kDa which may justify the slower increase of antibody 
titres in animals vaccinated with S. equi-entrapped PCL nanospheres, as it 
presents a slow degradation rate. 
The second i.n. immunisation enhanced the immune response induced by 
PCL-GCS, as after 7 weeks, the IgG titres of animals vaccinated with these 
nanospheres, as well as by  PCL-ALG and PCL-OA, were significantly higher 
than those obtained from the free antigen and FREE+CTB (P<0.02 for 
PCL-GCS and PCL-ALG, and  P<0.008 for PCL-OA). PCL-PVA and PCL-SP 
induced IgG antibody levels statistically higher than those elicited by the free 
antigen (P<0.05). On the contrary, those IgG levels were different from those 
obtained with the FREE+CTB-treated group (P=0.131) (Figure 4.1).  Moreover, 
in PCL-PVAads and PCL-GCSads-treated groups it was still possible to 
distinguish IgG levels that were statistically different from those assessed in 
sera of animals treated with FREE and FREE+CTB. However, PCL-PVAads 
elicited a systemic IgG immune response that, at this period, was statistically 
higher than that induced by whatever formulations tested, with exception 
only when this formulation was associated to the potent adjuvant CTB 
(Figures 4.2). 
Twelve weeks after the beginning of the in vivo study, all particulate 
formulations enhanced the antibody response in terms of peripheral IgG 
levels, and the difference between these responses and those induced by the 
FREE and FREE+CTB were statistically higher (Figures 4.1 and 4.2). CTB 
admixed with free antigen increased the serum IgG titres by a factor of at least 
4 compared with the antibody levels induced by i.n. administration of 
non-adjuvantised free antigens. It is important to mention that 
co-administration of CTB with S. equi entrapped-PCL-PVA nanospheres did 
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not resulted in a considerable increase of serum IgG antibody levels when 
compared with PCL-PVA group, and therefore it was not identified a 
synergic adjuvant effect from the association of both adjuvants (P=0.107) 
(Figure 4.1). This finding indicates that CTB seems not to have a substantial 
additional adjuvant effect when associated to these carriers with entrapped S. 
equi. On the contrary, i.n. administration of CTB admixed with S. equi 
antigen-adsorbed PCL-PVA nanospheres, significantly increased the IgG 
titres (P=0.018) to one and half times the level induced by nanospheres in the 
absence of this adjuvant (Figure 4.2). Among animals vaccinated with PCL 
nanospheres, the difference between systemic anti-S. equi IgG specific titre 
induced by polymeric carriers was only significant when compared with 
PCL-ALGads-treated group (P<0.004). In fact, this polymeric system induced 
the lowest IgG levels when compared with those quantified in the serum of 
animals vaccinated with other PCL nanospheres.  
Over the trial period, serum IgG antibody levels of animals vaccinated with S. 
equi antigens entrapped or adsorbed onto PCL particles, despite the type of 
antigen association, was significantly higher (P<0.005) than those elicited by 
the control (plain particles), free antigens, or even free antigen adjuvantised 
with CTB, with exception for S. equi-adsorbed PCL-ALG nanospheres, which 
systemic IgG immune response was not different from that elicited by FREE 
or even FREE+CTB solutions (Figures 4.1 and 4.2).  The exact reason for this 
effect remains uncertain but antigens immobilised in particles are taken up 
and processed in a different way, presenting altered properties in terms of 
uptake and trafficking, as compared with soluble proteins [40]. For example, 
Eyles et al. (1998, 1999) [41, 42] and Baras et al. (1999) [43] obtained an immune 
response higher after an i.n. administration of antigen that was entrapped in 
microspheres, when compared with its soluble form. Almeida et al. (1993) 
used tetanus toxoid-adsorbed PLA microspheres ranging from 0.1 to 1.6 µm 
and obtained humoral immune response stronger, even 15 weeks after the 
priming dose, than that obtained after the i.n. immunisation with the soluble 
antigen, which indicates that the presentation of antigen by microspheres 
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enhance its uptake by NALT and eventually by other lymphatic tissues, as the 
spleen [44]. 
Despite the lower serum S. equi-specific IgG responses obtained after animal 
i.n. immunisation with PCL-ALG particles, this natural polymer is known by 
its bioadhesive properties and consequently might enhance a local immune 
response to strangles [45]. 
Even if the second i.n. immunisation generally raises the systemic immune 
response, in this case the antibody levels were not significantly higher, which 
indicates that one single immunisation of PCL nanospheres may be enough to 
induce elevated immune response in a mouse model. 
Moreover, the antibody titre generated by i.n. administration of these 
different PCL nanospheres was higher (P<0.04) than those induced after a 
single dose of PCL microspheres previously studied, which highlights the 
importance of the route of administration and the particle size in the uptake 
and subsequent presentation of the antigen [34]. This makes PCL nanospheres 
especially attractive as a nasal vaccine delivery system, as it elicited strong 
immune responses after a single dose, while most of available nasal vaccines 
need booster vaccination to reach antibody levels as high as those obtained 
with a parenteral administration [11]. The adjuvant activity of these PCL 
nanospheres of different composition was found to be comparable, with the 
exception of PCL-ALGads, as all S. equi antigen-loaded PCL nanospheres 
tested were equally effective, highlighting the significant adjuvant effect of 
these polymeric carriers and the versatility of this approach. 
Similar results were more recently obtained in mice with whole killed S. equi 
cells or bacterial lysates entrapped in PLGA microspheres, which induced 
protective immunity to a strangles murine model, after their i.n. 
administration [40]. In addition, PLGA microspheres modified with CS were 
successfully developed to improve nasal vaccine delivery by Jaganathan et al. 
(2006) [26]. Indeed, as mucus layer is anionic at a neutral pH value, positively 
charged groups on particles surface can promote interaction between mucus 
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and particles, leading to a lower clearance rate of nanospheres and 
consequently to an increase of their contact time with the nasal mucosa [17, 
26, 46].  
 
IgG SUBTYPE PROFILING  
As observed for serum specific anti-S. equi IgG immune response, analysis of 
IgG subclasses in serum collected from mice vaccinated with S. equi 
antigen-adsorbed PCL-PVA or PCL-GCS, two weeks after the prime dose, 
revealed that IgG1 serum titres were significantly higher than those 
quantified in all other groups (P< 0.013 for PCL-PVAads and P< 0.001 for 
PCL-GCSads). In fact the antibody levels induced by PCL-GCS were 
markedly higher than those induced by PCL-PVAads (P<0.001) (Figures 4.3 
and 4.5). 
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Figure 4.3 – Serum anti-S. equi specific IgG1 titres induced after i.n. administration of S. 
equi antigens entrapped in PCL nanospheres to female BALB/c mice, compared to S. equi 
antigens in solution  (FREE) and co-administered with CTB (FREE+CTB) immunisations 
(mean ± S.D.; n=4). 
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Figure 4.5 - Serum anti-S. equi specific IgG1 titres induced after i.n. administration of S. 
equi antigen-adsorbed PCL nanospheres to female BALB/c mice, compared to S. equi 
antigens in solution (FREE) and co-administered with CTB (FREE+CTB) immunisations 
(mean ±  S.D.; n=4). 
Figure 4.4 - Serum anti-S. equi specific IgG2a titres induced after i.n. administration of S. 
equi antigens entrapped in PCL nanospheres to female BALB/c mice, compared to S. equi 
antigens in solution (FREE) and  co-administered with CTB (FREE+CTB) immunisations 
(mean ±  S.D.; n=4). 
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In addition, IgG2a immune responses induced by PCL-GCSads (P<0.010) and 
PCL-ALGads (P<0.035) nanospheres were statistically different from those 
induced by any other vaccinated group in this study (Figures 4.4 and 4.6). 
Moreover, the systemic responses to S. equi were dominated by the IgG1 
subclass.  
At this point, no efficient specific IgG1 and IgG2a response against S. equi 
antigens could be detected in mice vaccinated with S. equi antigens entrapped 
in any of PCL nanospheres.  
CTB enhanced the development of IgG1 and IgG2a to S. equi only marginally 
in mice treated with free or entrapped antigens (Figures 4.3 and 4.4). 
Conversely, inclusion of CTB in the suspension of PCL-PVAads nanospheres 
significantly enhanced anti-S. equi IgG1 titres, 4 weeks after i.n. immunisation, 
compared with S. equi-entrapped nanospheres, PCL-PVAads and 
PCL-ALGads experimental groups (P<0.01) (Figure 4.5). Therefore, only 
antigen adsorbed onto PCL-GCS and PCL-PVA nanospheres surface 
Figure 4.6 - Serum anti-S. equi specific IgG2a titres induced after i.n. administration of S. 
equi antigen-adsorbed PCL nanospheres to female BALB/c mice, compared to S. equi 
antigens in solution (FREE) and co-administered with CTB (FREE+CTB) immunisations 
(mean ±  S.D.; n=4). 
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markedly enhance the immunogenicity in animals, eliciting an anti-S. equi 
IgG1 titres statistically higher when compared with all experimental groups 
(P<0.006), excepting those induced by CTB associated to PCL-PVAads 
nanospheres (Figure 4.5). Serum from mice treated with antigens entrapped 
in PCL-GCS and PCL-OA nanospheres contained higher concentrations of 
anti-S. equi IgG1 and IgG2a than serum collected from animals vaccinated 
with antigen in the free form (P<0.033) (Figures 4.3 and 4.4). PCL-PVAads 
particles induced IgG2a levels statistically higher than those dosed in the 
serum of all treated mice (P<0.01), with exception for specific anti-S. equi 
IgG2a assessed in animals vaccinated with CTB admixed to the S. equi 
adsorbed onto PCL-PVA surface nanospheres (P=0.283). Conversely, at this 
time point the immunisation of mice with PCL-GCSads induced superior 
IgG2a antibody titres compared with S. equi-loaded ALG nanospheres 
(adsorbed and entrapped) (P<0.038) and the free antigen, either alone or 
combined with the adjuvant CTB (P<0.05) (Figures 4.4 and 4.6).    
After boosting, IgG subtypes quantification indicated a decrease of IgG1 
antibodies levels in animals vaccinated with the S. equi-adsorbed polymeric 
particles, while general elevated levels of IgG2a were obtained, and no change 
in these antibody titres was obtained in mice treated with FREE or FREE+CTB 
(Figures 4.5 and 4.6). As a result, PCL-PVAads and PCL-GCSads at this time 
point induced IgG1 and IgG2a titres higher than those elicited by the antigen, 
free or associated with CTB (P<0.04 and P<0.06, respectively). These 
observations were maintained even 12 weeks after the beginning of the study 
(Figures 4.5 and 4.6). After 7 weeks, particulate systems co-administered with 
CTB still induced higher IgG2a levels than all the other experimental groups 
(P<0.03), while IgG1 antibodies were only extremely higher than those 
induced by PVA and ALG formulations (P<0.027), as well as FREE and 
FREE+CTB groups (P<0.001) (Figures 4.3 to 4.6). At the end of the experiment, 
it is important to mention that PCL-PVAads coupled to CTB induced IgG1 
(P<0.008) and IgG2a (P<0.04) levels significantly higher than those elicited by 
the entrapped antigens, except for IgG2a obtained with PCL-PVA and PCL-SP 
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nanospheres. In contrast, CTB co-administered to S. equi antigens entrapped 
in PCL-PVA has markedly elevated the IgG subclass titres relative to the 
antigen-adsorbed particulate systems (P<0.041 for IgG2a and P<0.033 for 
IgG1), including PCL-PVAads+CTB.  
After boosting, entrapped antigens induced a continuous increase of both IgG 
subclasse levels (Figures 4.3 to 4.6). Despite of the serum of all animals treated 
with this S. equi-entrapped systems containing IgG1 and IgG2a levels 
significantly elevated in comparison with those assessed in animals 
vaccinated with the free form (P<0.011 and P<0.06), PCL-GCS nanospheres 
induced IgG1 antibody levels different than those obtained in mice 
immunised with antigen adsorbed or entrapped in PCL-PVA (P<0.027) and 
PCL-ALG (P<0.001) nanospheres. Anti-S. equi IgG1 assessed in the serum of 
animals vaccinated with S. equi-entrapped PCL nanospheres continued to 
increase even 12 weeks after animal immunisation (Figures 4.3). Therefore, 
these antibody titres were still statistically elevated when compared with the 
antigen, either FREE (P<0.001) or co-adjuvantised by CTB (P<0.001). On the 
other hand, IgG2a titres to S. equi in the experimental groups treated with 
antigen entrapped in GCS, ALG and OA nanospheres had raisen to a level 
that was statistically elevated relative to groups PCL-PVA (P<0.045), all 
groups of mice immunised with S. equi-adsorbed PCL carriers (P<0.007), 
including PCL-PVAads+CTB, and PCL-SP (P<0.045) (Figures 4.4 and 4.6). 
Therefore, despite the immune responses induced by antigen adsorbed onto 
PCL nanospheres being higher during the first seven weeks of the study, the 
antibody titres induced by the antigen entrapped in nanospheres 
continuously increased even 12 weeks after the immunisation, which 
supports the hypothesis of the delayed immune responses induced by these 
particulate carriers being due to the slow release and biodegradation of the 
PCL polymer. As a result, it seems that the best system may result from the 
design of a PCL polymeric carrier containing the antigen adsorbed but also 
entrapped, in order to not only induce a high immune response just after the 
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prime dose, but also to maintain the antibody levels for a prolonged period of 
time.  
Yanagitu et al. (1999) have shown that a nasal immunisation was capable of 
inducing both Th1 and Th2 cells, which can inhibit the bacterial attachment to 
the epithelium and the resultant inflammatory cytokine production [47]. 
Overall, mice vaccination with S. equi antigen-loaded PCL nanospheres, in the 
absence of CTB, maintained statistically elevated IgG subtype titres in 
comparison with animals treated with free vaccine (P<0.04) throughout the 
12-weeks schedule, indicating the generation of Th1/Th2 mixed response. In 
fact, by the end point of the experiment the ratio of different anti-S. equi IgG 
subclasses (IgG2a/IgG1) assessed in the serum of treated animals appeared 
not to be markedly influenced by the presence or absence of CTB in the 
vaccine formulation. Serum of mice immunised intranasally with S. equi 
antigens associated (entrapped or adsorbed) with nanospheres, formulated 
with ALG and GCS, contained elevated levels of anti-S. equi IgG1 and IgG2a 
suggestive of a more balanced immune response (IgG2a/IgG1 = 0.35 and 
IgG2a/IgG1 = 0.49, respectively), opposite to those obtained with the 
remaining particulate systems. Mice treated with vaccine formulations 
co-adjuvantised with CTB presented Th1/Th2 mixed immune responses 
slightly more balanced than those induced by the mucoadhesive polymeric 
particles previously mentioned.  
In addition, until this point, having in mind the particles physicochemical 
characteristics, the loading capacity and these humoral in vivo results, GCS 
seems to be an attractive adjuvant for nasal vaccination of mice against 
strangles.  
 
LOCAL IgA IMMUNE RESPONSES  
The mucosal immunisation used to vaccinate animals in this study is known 
to be able to induce, with lower amounts of antigen, not only the production 
of SIgA, but also a systemic antibody and cell-mediated immunity [48]. The 
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systemic and local immune responses induced after an i.n. vaccination 
depends on several factors, namely the antigen nature, the correct selection of 
an adjuvant, the dose volume, the frequency of administration and the 
delivery system [49]. Wu and Russel (1997) have showed that an appropriated 
systemic and local immune responses can not only prevent infection but also 
induce a mucosal immunisation, as a means of inducing SIgA antibodies 
directed against specific pathogens of mucosal surfaces, which is of vital 
importance especially when mucosa constitutes the portal of bacteria entry 
(eg S. equi), as they may block the attachment of this bacteria to the mucosal 
surfaces and stimulates a cross protective immunity more efficiently than 
serum IgG antibody [41, 49]. Larger doses administered into the nose may be 
swallowed, leading to oral delivery. Eyles et al. (1998) have seen that 40% of 
the dose was found in the lung after an administration of 50 µl of labelled 
microspheres, while most of the particles were retained in the nose when 10 µl 
was dosed [41].  Moreover, the efficacy of vaccines to prevent strangles seems 
to be dependent on the induction of a mucosal immune response [13].  
Soluble antigens need to be associated or delivered by adjuvants as, after 
animal i.n. vaccination, they will cross the nasal epithelium, interact with 
dendritic cells, macrophages and lymphocytes, and then be transported to 
posterior lymph nodes. On the other hand, particulate delivery systems are 
taken up by M-cells in the NALT, which transport the antigen preferentially 
to the cervical lymph nodes. As a result, local and distant mucosal immune 
responses can be elicited as a result of the maturation of the precursors of IgA 
mucosal cells in regional lymph nodes or, after being transported, in the 
lamina propria of distant mucosal sites of the CMIS [48]. Accordingly, the 
induction of an immune response at one mucosal surface will induce the 
production of SIgA specific for the antigen at mucosal surfaces far from the 
target, as it has been strengthened more recently by Mestecky et al. (1997) [50]. 
In the present work, the two i.n. immunisations induced elevated S. 
equi-specific IgA antibodies in lung washes of all groups vaccinated with S. 
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equi-loaded PCL nanospheres compared to controls (plain particles, P<0.002) 
or antigen, free (P<0.01) or admixed with CTB (P<0.02) (Figure 4.7). In fact, 
modest SIgA levels were detected in lung washes of animals vaccinated with 
antigen in solution. In addition, i.n. administrations did not induced 
detectable SIgA levels in intestinal contents of all animals (data not shown).  
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The PCL-SP group had the highest SIgA antibody response, besides not being 
statistically different from that assessed in animals immunised with 
PCL-PVA+CTB (P=0.157) (Figure 4.7).  
Among the adsorbed nanospheres, PCL-ALGads group induced the highest 
SIgA antibody response, which was significantly different from those induced 
by all other groups (P<0.01), although PCL-GCSads had also highly enhanced 
this antibody level. Among all the particulate systems tested, only 
non-modified PCL nanospheres (PCL-PVA) formulation did not induce an 
extremely elevated mucosal response after their i.n. administration (Figure 
4.7). These results were expectable, as these natural polymers (GCS and ALG) 
Figure 4.7 – Secretory IgA (SIgA) level in lung washes of mice immunised intranasally 
with different formulations, at the end of the study (mean ± S.D.; n=4). 
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are known by their bioadhesive properties and consequently would probably 
enhance a local immune response to strangles after animal mucosal 
vaccination. In addition, PLGA microspheres modified with CS were 
successfully developed to improve nasal vaccine delivery by Jaganathan et al. 
(2006) [26]. The strong mucoadhesiveness and the particulate nature of these 
carriers are important properties for its immunostimulatory effect. PCL-GCS 
nanospheres are positively charged and therefore are likely to establish 
electrostatic interactions with the negatively charged mucus, and thereby 
prolong the residence time of the antigen in the nasal cavity [17, 26, 46]. The 
factors that most probably contributed for the immunostimulating effect of 
GCS and ALG-based systems, after their i.n. administration, were the 
improved uptake by M-cells at the nasal mucosa and efficient delivery to the 
mucosal lymph nodes, consequence of the prolonged exposure of the antigen. 
Therefore, it is clear from these results that the S. equi antigen-loaded 
nanospheres successfully induced not only a systemic but also a local immune 
response, after i.n. antigen exposure.    
 
SPLENOCYTE CULTURE STUDIES 
It is generally accepted that the way that the antigen is delivered to APCs is 
one key factor for eliciting Th1/Th2 relation [17, 51, 52]. Cytokines released 
from cells play an important role in the activation, growth and differentiation 
of B and T lymphocytes, which interact with each other and secret factors that 
will stimulate other cell types and eventually themselves. T-helper cells can be 
divided in two groups depending on the lymphokines secreted upon their 
activation.  Th1 cells secrete interleukin 2 (IL2), interferon gamma (IFN-γ) and 
tumor necrosis factor beta (TNF-β), that will increase gene expression in APCs 
and activate B cells to differentiate and secrete IgG2a, while Th2 produces IL4, 
5, 6, 10 and 13, being the IgG1 the major isotype elicited from B cells following 
Th2 cells activation. Therefore, Th1 cells are involved in the cell mediated 
immunity, while Th2 cells are related with humoral immunological response 
[53].  
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Previous studies have shown that the delivery of antigens adsorbed onto 
microparticles up-regulated the cytokine gene transcriptions [54]. More 
recently, whole killed S. equi cells or bacterial lysates entrapped in PLGA 
microspheres, after i.n. administration in mice, induced protective immunity 
to a strangles murine model [40]. As a result, the nasal administration of   S. 
equi antigens-loaded particles (adsorbed or entrapped) were undertaken in 
order to assess if PCL, a polymer generally with higher hydrophobicity than 
PLGA, associated with several adjuvants can induce an immune response 
after i.n. administration. 
From figure 4.8 it can be seen that, in general, the particulate systems induced 
an increase of splenocyte response as the differences observed in IL2, IL4, IL6 
and IFN-γ stimulated by nanosphere formulations and free antigen were 
significant (P<0.021).  
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Among the S. equi antigen-adsorbed particles, PCL-PVAads and PCL-GCSads 
induced an elevated IL2 production after spleen cells stimulation with soluble 
antigen (5 µg/ml), which concentration was statistically different from those 
elicited by the remaining experimental formulations (P<0.011), except when 
compared with IL2 levels consequence of antigens-entrapped PCL-PVA 
nanospheres dosing (P=0.67) (Figure 4.8A).  In addition, the differences found 
in IL2 amounts are statistically significant for all tested formulations, with the 
exception of those induced by PCL-ALGads when compared with the ones 
elicited in animals vaccinated with PCL-GCS (P=0.061). Even so, PCL-ALG 
not only elicited the highest IL2 concentration, but also noticeable IFN-γ 
levels, being the latter statistical higher than those induced by all other groups 
(P<0.001) (Figure 4.8B), which is in accordance with the SIgA antibody levels 
(Figure 4.7). Nevertheless, all the differences between IFN-γ levels observed 
Figure 4.8- S. equi-specific recall responses after stimulation of splenocytes derived from 
BALB/c mice immunised subcutaneously with S. equi enzymatic extract in solution 
(FREE), co-administered with CTB (FREE+CTB) and associated (adsorbed or entrapped) to 
PCL nanospheres. Cytokine concentration in culture supernatants was determined in 
splenocyte cultures stimulated with 5 µg/ml of soluble S. equi enzymatic extract: (A) IL2; 
(B) IL4; (C) IL6 and (D) IFN-γ (mean ± S.D.; n=4). 
(D) 
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in Figure 4.8B are significant (P<0.04), except for PCL-GCS nanospheres when 
compared to PCL-OA (P=0.059) and CTB associated to nanospheres treated 
groups (P=0.094).   
Indeed, both Th1-dependent cytokines and their high levels indicate that a 
strong cell-mediated immune response was elicited by the i.n. administration 
of S. equi antigens entrapped in ALG modified PCL-based formulations. The 
generation of Th1 cytokine profile is extremely important to permit the 
eradication of S. equi pathogen, being therefore a useful vaccine for 
therapeutic immunisation of S. equi-long term carriers.  
IL4 production was significantly induced by PCL-SP among the particulate 
systems tested (P<0.001) (Figure 4.8C). Also CTB admixed with S. 
equi-adsorbed PCL-PVA particles elicited IL4 amounts significantly higher 
than all formulations, except those elicited by PCL-SP and PCL-PVAads 
nanospheres (P=0.23) (Figure 4.8C).    
All antigen-loaded nanospheres induced high levels of IL6, but those elicited 
by PCL-GCS were statistically higher than the IL6 concentration assessed in 
sera of all the remaining groups (P<0.001) (Figure 4.8D).   
Despite the differences above mentioned, in accordance with cellular and 
humoral immune responses, S. equi antigens-loaded modified PCL carriers 
gave higher lymphokines levels when compared to the immunological 
responses induced by non-modified particles (PCL-PVA and PCL-PVAads) 
and free antigens, successfully activating the paths leading to Th2 and Th1 
cells, which highlights the role of these nanospheres as an adjuvant and their 
use to protect animals against strangles.  
Altogether, the data suggest that the quality of immune response to S. equi 
antigens is increased by its association to the PCL polymeric carriers 
formulated, mainly to those modified by the mucoadhesive polymers GCS 
and ALG, as not only a pronounced systemic but also local and mixed cellular 
immune responses have been detected after animals i.n. vaccination. 
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CONCLUSIONS 
The purpose of this study was to compare the systemic and mucosal immune 
responses induced after i.n. vaccination of mice with S. equi antigens 
associated (adsorbed or entrapped) to PCL nanospheres with different 
compositions. These antigens were successfully associated to PCL 
nanospheres without causing any damage to the protein structure, although 
adsorption resulted in higher loadings. Even so, both S. equi-adsorbed and 
entrapped nanospheres induced significantly higher specific immune 
responses to S. equi antigens, which were confirmed by cytokine levels. 
Therefore, in a future work, it would be interesting to combine the adsorption 
and entrapment of S. equi antigens in a single PCL polymeric system, in order 
to obtain a combined immune response profile.  Moreover, modified PCL 
nanospheres are potential nasal delivery systems to vaccinate animals against 
strangles, as humoral, cellular and mucosal immune responses were 
noticeable induced.  
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ABSTRACT 
Streptococcus equi subspecies equi (S. equi) infects animals of the Equidae family 
and is the causative agent of strangles, an acute, extremely contagious and 
deadly disease that affects the upper respiratory tract, leading to devastating 
epidemics in stables. This agent is transmitted through a variety of 
mechanisms, most of them without involving direct contact of horses-to-
horses, which makes it difficult to identify and isolate the infected animals 
and to prevent the spreading of this disease, which in addition can last for 3-4 
weeks. Despite efforts directed to the formulation of an effective vaccine, 
prolonged periods of protection associated to absence of serious adverse 
reactions were not yet achieved. Thus, this experimental work is focused on 
the study of mucosal, humoral and cellular immune responses developed in a 
mouse model, after the intranasal administration of S. equi antigens associated 
by adsorption or entrapment to poly(lactic acid) nanospheres, modified by 
mucoadhesive polymers and absorption enhancers. Particles fitted the 
nanometric range and proteins integrity and antigenicity were not affected. 
PLA nanospheres induced a mixed Th1 and Th2 response, being therefore 
potential carriers for the delivery of S. equi antigens. 
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INTRODUCTION 
Streptococcus equi subspecies equi (S. equi) is the causative agent of strangles, 
which is an acute, highly contagious and deadly respiratory disease of horses, 
donkeys and mules, although its presence in humans has been previously 
reported [1,2]. This is a prolonged disease, quickly and easily transmitted, 
leading to large outbreaks and consequently to an important economic 
burden. In some cases, animals present abscesses in other regions of their 
body, mainly in the abdomen and thorax resulting in a stage of the disease 
called ‘bastard strangles’, which often results in animal’s death. Its long 
convalescent period, associated with the long-term S. equi carriers with no 
sign of the disease, constitutes the main reason for the limitations attributed to 
the development of diagnostic tests capable of detecting this agent in infected 
animals, despite the recent and commercial available new diagnostic 
techniques based in enzyme-linked immunosorbent assays (ELISA) methods. 
The infected horse, which can harbour the bacteria for several months, 
constitutes the most important factor for the maintenance of the disease for 
prolonged periods of time.  
S. equi is in fact sensitive to some antibiotics as penicillin, but in most cases 
treatment is not effective in eradicating the microorganism. As a result, in 
order to combat this disease, the development of an efficient vaccine is the 
aim of most of the research related with this subject, as animals that recover 
from a S. equi infection present a prolonged protective immunity, mostly 
directed against the antiphagocytic cell wall associated S. equi M-like protein 
(SeM) which, associated to the hyaluronic acid capsule and the maturase 
lipoprotein, are believed to be the basis of S. equi virulence [3-7]. The 
protection mechanism is not yet fully understood but it seems that the most 
important antibodies for the prevention and combat of this disease are mainly 
those locally produced in the nasopharynx, although it was previously 
demonstrated that serum antibodies are the first to be produced  [3, 4]. 
Specific anti-S. equi antibodies found in serum and produced by B cells will 
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recognise, subsequently bind and inactivate these bacteria. However, horse 
vaccination with bacterins, adjuvanted S. equi extracts and, more recently, 
SeM associated to different adjuvants, did not protect animals against 
infection with S. equi [4, 8-10]. Therefore, several researchers are still 
developing strategies to prevent infection of animals and spreading of the 
disease.  
The main entrance for S. equi is the nasal mucosa which, associated to its easy 
administration and reduced costs of production, justifies the choice of S. equi 
nasal vaccine administration. In addition, previous studies have shown that 
the intranasal (i.n.) delivery of polymeric particles associated to antigens was 
able to induce not only humoral and cellular immune responses, but also 
desirable mucosal immunity, important for the defence after S. equi invades 
the host via the mucosal surface [11-13].  
The purpose of the present research work was to study the immune response 
developed after mouse vaccination with PLA carriers containing entrapped or 
adsorbed S. equi proteins, previously extracted from bacterial wall. PLA 
particles were produced by a double (w/o/w) emulsion solvent evaporation 
technique and the effect of the mucoadhesive polymers (glycolchitosan (GCS) 
[14-16] and alginate (ALG) [17]) and absorption enhancers (spermine (SP) [18] 
and oleic acid (OA) [19]) associated to the PLA particles in the immune 
response following an i.n. administration was evaluated. In fact, we 
hypothesised that these carriers are able to target and be taken up by antigen 
presenting cells (APCs) making it possible to prime the animals prior its 
infection by S. equi, resulting in the stimulation of a cell mediated immunity 
and the formation of memory B cells, which would prevent and combat 
subsequently infections. 
A similar system was previously developed by our group, using instead 
poly-ε-caprolactone (PCL) for particles matrix constitution [20, 21]. That study 
has shown that after i.n. vaccination of mice with S. equi antigens associated to 
PCL nanospheres, either by adsorption or entrapment method, it was induced 
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not only a systemic humoral and cellular immune response, but also secretory 
IgA (SIgA) locally produced antibodies [20]. Therefore, a comparison will be 
established between the mucosal SIgA and serum specific IgG, IgG1, IgG2a 
antibody responses induced by these PLA carriers and those previously 
obtained for the aforementioned PCL nanospheres. 
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MATERIALS AND METHODS 
MATERIALS 
Poly(L-lactic acid) (PLA, average molecular weight (MW) 2.0 kDa) was 
acquired to PolySciences, Inc., UK. Polyvinyl alcohol (PVA, MW 13-23 kDa, 
87-89% hydrolysed), alginate low viscosity (ALG), spermine (SP), oleic acid 
(OA), glycolchitosan (GCS), sucrose, cholera toxin B subunit (CTB), 
trypsin-chymotrypsin inhibitor, EDTA sodium salt, iodoacetic acid and 
phenylmethanosulfonyl fluoride solution (PMSF) were from Sigma Aldrich 
Co., UK. Dichloromethane (DCM) was obtained from BDH Laboratory 
Supplies, UK.  
Bicinchoninic acid (BCA) kit and Micro BCATM Protein assay kit, both for 
protein determination, were supplied by Sigma Aldrich Co. UK, GOSS 
Scientific Ltd and Pierce UK, respectively.  
Streptococcus equi subsp. equi (strain LEX) ATCC 53186 were a kind gift from 
Prof. J.F. Timoney (University of Kentucky, USA). 
 
ANIMALS 
Female BALB/c mice (n=4/ group), 6-8 weeks old with food and drink 
provided ad libitum, were used in the in vivo studies, which were performed in 
strict accordance with the UK 1986 Animals (Scientific Procedures) Act. 
 
PREPARATION OF PLA NANOSPHERES 
The double emulsion (w/o/w) solvent evaporation method, previously 
described elsewhere, was used to prepare PLA nanospheres at room 
temperature, under aseptic conditions with minor modifications [21]. Briefly, 
the organic phase was prepared by the polymer dissolution in DCM, while 
10% (w/v) PVA or 1% (w/v) GCS solution constituted the aqueous phase 
(Table 5.1). The w/o emulsion was prepared by homogenisation using an 
ultra-turrax (T25 Janke & Kunkel, IKA-Labortechnik) for 3 min at 24,000 rpm. 
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For S. equi antigen-entrapped particles (10.0 mg), a previous dissolution of 
these proteins in the aqueous phase was performed. The proteins were 
extracted from the bacteria cell wall using N-acetyl muramidase, lysozyme 
and mutanolysin (Sigma Aldrich Co., UK), as previously reported [21]. In 
order to study the effect of the inclusion of absorption enhancers (10 mg) in 
particles composition, SP was dissolved in the PVA solution, while OA, 
previously dissolved in 1 ml of ethanol, was diluted in the organic phase.  The 
w/o emulsion was then added dropwise into 30 ml of a 1.25% (w/v) PVA or 
0.75% (w/v) ALG solution, and homogenised for 7 min at 10,000 rpm with the 
Silverson homogeniser (Silverson model L4RT, UK), and then maintained at 
room temperature, under constant magnetic stirring for 4 hours, to remove 
the organic solvent and, therefore, allow particles formation (Table 5.1). These 
carriers were separated from the preparation media by centrifugation (15,000 
rpm, 45 min, 15°C; Beckman J2-21 High speed centrifuge) and freeze-dried 
(Virtis, UK) after being washed and dispersed in a cryoprotectant 0.02% 
(w/v) sucrose solution.   
 
Table 5.1 
PLA nanospheres composition 
PLA-PVA – poly(lactic acid) – polyvinyl alcohol nanospheres; PLA-GCS – poly(lactic acid)  – 
glycolchitosan nanospheres; PLA-ALG - poly(lactic acid)  – alginate nanospheres; PLA-SP - 
poly(lactic acid)  – spermine nanospheres; PLA-OA - poly(lactic acid)  – oleic acid 
nanospheres;  
 
 
FORMULATION ORGANIC PHASE 
INTERNAL PHASE 
(w/v) 
EXTERNAL 
PHASE 
(w/v) 
PLA-PVA 10 % PVA 1.25% PVA 
PLA-GCS 1% GCS 1.25% PVA 
A
d
s.
 
PLA-ALG 10 % PVA 0.75% ALG 
PLA-PVA 10 % PVA 1.25% PVA 
PLA-GCS 1% GCS 1.25% PVA 
PLA-ALG 10 % PVA 0.75% ALG 
PLA-SP 
PLA 
(100 mg) 
in 6 ml DCM 
10 % PVA + 10% SP 1.25% PVA 
E
n
tr
a
p
p
ed
 
PLA-OA 
6 ml DCM + 10% OA 
(1ml EtOH) 
10 % PVA 1.25% PVA 
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A S. equi antigen solution (1250 µg/ml; 2 ml) was added to twenty milligrams 
of PLA-PVA, PLA-GCS and PLA-ALG plain particles, in a LoBind® eppendorf 
tube (Eppendorf, UK), and incubated for one hour in a water bath at 37ºC, 
under agitation. This suspension was centrifuged at 7,500 rpm for 10 minutes 
(IEC Micromax eppendorf centrifuge, UK) and the pellet, after being washed 
two times, was dried in a dessiccator, while supernatant and washes were 
kept frozen at -20ºC until future analysis.  
S. equi antigen-adsorbed or -entrapped particles were administered to animals 
as described elsewhere [20]. 
 
CHARACTERISATION OF PLA NANOSPHERES 
The volume mean diameters (VMD) of the S. equi antigens-adsorbed or 
-entrapped PLA nanospheres were determined in double distilled and filtered 
water (0.2 µm Whatman filters) by photon correlation spectroscopy (PCS; 
Malvern ZetaSizer, Malvern Instruments, UK). The zeta potential (mV) of 
particles dispersed in a 10 mM potassium chloride solution (Sigma Aldrich 
Co., UK) was assessed using the same equipment.  
The morphology of the nanospheres was examined and photographed using a 
scanning electron microscope (SEM, Phillips/FEI XL30 SEM), after samples 
have been sputter coated (Emscope SC500) with gold as described before [21]. 
 
DETERMINATION OF ANTIGEN LOADING 
To evaluate the amount of S. equi antigens entrapped or adsorbed on PLA 
nanospheres, a known amount of antigen loaded particles (10 mg) was 
accurately weighed and dissolved in 0.1 M sodium hydroxide (NaOH, Fisher 
Co. UK) solution, containing 5% (w/v) sodium dodecyl sulphate (SDS, BDH 
UK), under magnetic stirring at room temperature. A bicinchoninic acid 
protein assay (BCATM or Micro BCATM Protein assay kit, Pierce, USA) was 
used to determine the S. equi extract proteins concentration. From these 
results, the percentage (w/w) of total protein entrapped or adsorbed per dry 
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weight of nanospheres (S. equi extract proteins loading capacity (L.C.)) was 
determined as described elsewhere [20]. 
 
IN VITRO RELEASE STUDIES OF S. equi EXTRACT PROTEINS FROM PLA 
NANOSPHERES 
The in vitro release study of S. equi antigens from loaded PLA nanospheres 
was carried out, in triplicate, by placing accurately weighed amounts (10 mg) 
of these particles into LoBind eppendorf tubes (three per time point, 
Eppendorf, UK) containing 2 ml of PBS buffer (pH 7.4), 5% (w/v) of SDS 
(Sigma Aldrich, Co. UK) and 0.02% (w/v) of sodium azide. The tubes were 
incubated in a water bath at 37ºC, under continuous shaking. At selected time 
intervals, three eppendorf tubes were collected and centrifuged at 7,500 rpm 
for 10 minutes (IEC Micromax eppendorf centrifuge, UK). The amount of 
protein released was dosed by BCATM and Micro BCATM protein assays. 
 
STRUCTURAL INTEGRITY AND ANTIGENICITY OF S. equi ANTIGENS 
POLYACRYLAMIDE GEL ELECTROPHORESIS (PAGE) 
The molecular weight integrity of adsorbed and entrapped S. equi antigens 
extracted as mentioned in a previous report [21], native S. equi enzymatic 
extract proteins and molecular weight (MW) reference marker (MW 6.0-181.8 
kDa, Invitrogen UK) were determined by polyacrylamide gel electrophoresis 
(PAGE) under denaturating conditions. These samples were loaded onto 12% 
(w/v) polyacrylamide (Invitrogen, UK) mini-gel and run using a Bio-Rad 300 
Power Pack Electrophoresis system (Bio-Rad, Hercules, CA, USA). Proteins 
were visualized by Coomassie blue staining (SimplyBlueTM SafeStain solution, 
Invitrogen, USA). 
 
WESTERN-BLOT 
Western blotting [22] was used to evaluate the antigenicity of both entrapped 
and adsorbed S. equi enzymatic extract antigens in PLA nanospheres. Antigen 
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samples were transferred from the SDS-PAGE gel and treated as described 
earlier [20]. 
 
 
PLA NANOSPHERES IN VITRO CELL VIABILITY ASSAY 
BALB/c monocyte macrophages (J774A.1 cells line, American Type Culture 
Collection; ATCC#TIB-67) were plated in 96-well tissue culture plates (Fisher, 
UK) and cytotoxicity of freeze-dried PLA nanospheres was evaluated, in 
triplicate, by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT; [23]) method as previously performed, using polyethyleneimine (PEI) 
as a positive control [21]. Samples were prepared by particles suspension,  at 
different concentrations (0.01-2.5 mg/ml), in  Dulbecco`s modified Eagle`s 
media (DMEM, Sigma Aldrich Co., UK), supplemented with 4 mM glutamine 
(Sigma Aldrich Co., UK) plus 100 U/ml penicillin and 100 µg/ml 
streptomycin (Sigma Aldrich Co., UK). 
 
IMMUNE RESPONSE 
Four female BALB/c mice per group were vaccinated intranasally, into the 
two nostrils, with S. equi antigens equivalent to 10 µg of SeM per dose, in 50 µl 
of nanospheres suspensions. One group received unadjuvanted antigens, 
while other mice were vaccinated with S. equi antigens associated to the 
mucosal adjuvant CTB (10 µg), by the same route of administration. The 
immune response elicited after i.n. administration of plain particles was as 
well evaluated. Details of immunogens are given in Table 5.2 and all mice 
were anesthetised (3% of isoflorane) prior immunisation. Regardless samples 
composition, all doses were freshly prepared in sterile PBS (pH 7.4), under 
aseptic conditions, just before animal dosing and boosting, respectively, on 
day one and 21. 
 
 
 
Chapter 5 
  193 
Table 5.2 
Immunisation study design 
GROUPS FORMULATION 
1 PLA-PVAads. 
2 PLA-GCSads. 
3 PLA-ALGads. 
4 A
d
so
rb
ed
 
PLA-PVAads.+CTB 
5 PLA-PVA 
6 PLA-GCS 
7 PLA-ALG 
8 PLA-SP 
9 PLA-OA 
10 E
n
tr
a
p
p
ed
 
PLA-PVA+CTB 
11 FREE antigens 
12 FREE antigens + CTB 
BALB/c female mice 6-8 weeks old were vaccinated intranasally at 
weeks 0 and 3. Tail veins blood samples were collected at weeks 2, 4, 
7 and 12 for antibody titres analysis by enzyme-linked 
immunoassay. After 12 weeks of study, animals were ethically 
sacrificed and lung and gut washes were performed at the end of the 
study to assess the local antibodies (SIgA) levels, by ELISA. Spleens 
were aseptically removed and splenocytes were co-stimulated with 
soluble antigen in order to estimate cytokine concentrations. 
 
 
Blood samples were collected from the tail vein after 2, 4, 7 and 12 weeks of 
immunisation and sera separated by centrifugation (15,000 rpm, 20 min at 
4ºC) and stored at -20ºC until tested by antigen specific ELISA for IgG, IgG 
subclass 1 (IgG1) and IgG subclass 2 (IgG2a).  
Lung and gut washes were collected according to the method previously 
reported [20].  Briefly, a gut fraction was removed, longitudinally sectioned 
and scraped into an ice-cold solution (1mM iodoacetic acid, 0.1% (v/v) 
trypsin inhibitor soybean type 1 and 10 mM EDTA sodium salt). Samples 
were vortexed to disrupt all solid material, centrifuged at 20,000×g for 30 min 
at 4ºC, and clear supernatants were freeze-dyed (Virtis Advantage freeze 
dryer, UK).  On the other hand, lung washes were collected by trachea 
cannulation of sacrificed mice. Trachea and lungs were flushed three times 
with 5 ml of lavages solution (1mM PMSF, 0.9% (w/v) sodium chloride, 0.5% 
(v/v) tween 20 and 0.1% (w/v) sodium azide), which were immediately 
removed and similarly treated until tested by ELISA for secretory antibody 
Chapter 5 
 
194 
(SIgA) levels. Before lyophilised, washes were stored at -70ºC with PMSF as a 
protease inhibitor. Lung and gut lavages were reconstituted with PBS (pH 7.4) 
just before ELISA analysis. 
 
QUANTIFICATION OF HUMORAL (IgG AND IgG SUBTYPES) AND MUCOSAL 
(IgA) ANTIBODY IMMUNE RESPONSES 
S. equi specific IgG, IgG1, IgG2a and IgA antibodies, respectively in serum 
samples and in lung/gut washings were detected by ELISA following a 
protocol previously referred [21]. In brief, 96-well plates (Immulon 2, flat 
bottom plates, Dynatech, UK) were coated overnight with 1.5 µg/ml S. equi M 
proteins in PBS solution (pH 7.4) at 4ºC, washed with PBS (pH 7.4) containing 
0.05% of tween 20 and 0.1% of BSA fraction V, and then blocked with 2% 
(w/v) BSA solution (Sigma Aldrich Co., UK) in PBS (pH 7.4).  
The serum samples were 1:32 diluted in PBS (pH 7.4), and 100 µl was added 
in quadruplicate to the wells of coated plates and serially diluted two fold in 
the same buffer. Detection was performed using horseradish peroxide 
conjugate goat anti-mouse IgG (1:1000), IgG1 and IgG2 (1:2000; Serotec, UK) 
diluted in PBS (pH 7.4), and 2, 2’- azino-bis(3-ethylbenzthiazoline-6-sulfonic 
acid) [ABTS] (Sigma Aldrich Co., UK) in citrate buffer was used as enzyme 
substrate. The colour development was stopped with H2SO4 after 5 minutes 
and optical density (OD) values were read at 405 nm. Negative control sera 
obtained from mice prior the beginning of this study were included in each 
plate and the reciprocal of the dilution, at which mean OD was 5% higher 
than the negative control, was used to compare titres.   
For analysis of lung and gut washes, the ELISA method was essentially the 
same, with some exceptions. After freeze-drying, proteins were reconstituted 
with 500 µl of PBS (pH 7.4) and directly added to the plate wells. The 
horseradish peroxide conjugate goat anti-mouse IgA (1:2000; Serotec, UK) was 
used to detect this antibody, and ABTS substrate was then added as 
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mentioned above. The mean OD was determined for each treatment group 
and directly used to compare mucosal response. 
 
SPLENOCYTE CULTURE STUDIES 
After 12 weeks of study, animals were ethically sacrificed and their spleens 
aseptically removed as mentioned elsewhere [21]. Briefly, spleens were 
homogenised in working media RPMI 1640 (Gibco, UK), supplemented to a 
final concentration of 10 % (v/v) fetal bovine serum (FBS, Gibco, UK), 20mM 
L-glutamine (Sigma Aldrich Co., UK), 105U/l of penicillin and 100 mg/l of 
streptomycin (Sigma, Poole, Dorset, UK). Homogenates were centrifuged at 
200 ×g for 10 min, cells were resuspended in the above mentioned working 
media, plated in 96-well tissue culture plates (Fisher, UK), along with 2.5 
µg/ml soluble S. equi enzymatic extract proteins, and incubated for 48 hours 
at 37ºC in a humidified incubator at 5% CO2. Cell supernatants were used for 
estimation of interferon-γ (IFN-γ) interleukine-2 (IL2), interleukine-4 (IL4) and 
interleukine-6 (IL6), by using separate ELISA Kits (DuoSet® ELISA 
Development kit, R&D Systems Europe, UK). 
 
STATISTICAL ANALYSIS 
Statistical analysis was performed on data obtained in the in vitro and in vivo 
studies by one-way analysis of variance (ANOVA), using SPSS software 
(Version 13, Microsoft), followed by LSD post hoc test if ANOVA results were 
found significant (P<0.05).  
 
RESULTS AND DISCUSSION 
PLA NANOPSHERES PHYSICOCHEMICAL CHARACTERISTICS 
PLA particles were spherical, with no cavities and presented a smooth 
surface, as it can be seen in Figure 5.1.  
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No differences were observed between the surface morphologies of 
particulate formulations prepared in the present study. PLA low molecular 
weight solubility in organic solvents, as DCM, and water is higher when 
compared to higher molecular weight polymers, which reduces particle 
precipitation after organic solvent evaporation. SEM confirms PLA 
Figure 5.1 – SEM photographs of (A) PLA-PVA, (B) PLA-GCS, (C) PLA-SP, (D) PLA-OA 
and (E) PLA-ALG nanospheres. 
 
 
(B) 
 
(A) 
 
(E) 
 
(C) 
 
(D) 
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nanospheres formation and that their shape was maintained with no 
detectable aggregation.  
The small differences obtained in size and surface charge between the 
different batches of nanospheres demonstrates the good reproducibility of the 
production method used (Table 5.3). The size of S. equi-adsorbed PLA 
nanospheres was found to increase from 255.8 ± 10.0 nm for PLA-PVA, to 
407.1 ± 56.98, for those formulated with GCS. S. equi entrapped-PLA particle 
size ranges from 205.47 ± 35.99 to 396.0 ± 36.11, being the smallest and highest 
obtained for PLA-OA and PLA-GCS formulations, respectively. When GCS 
was added to the inner phase, it was observed an increase in solution 
viscosity which led to larger emulsion droplets formed during 
homogenisation, and therefore may justify the difference obtained in particle 
size. As a result, despite differences in particles diameters, all formulations 
are suitable for APCs uptake after i.n. administration [24]. 
All particles present a negative surface charge before and after whichever 
protein association method used, with an exception for that containing the 
positively charge polysaccharide (GCS). Even so, PLA-GCS nanospheres zeta 
potential decreased after S. equi protein adsorption, which allows predicting 
that adsorption actually occurred and consequently the mixture of proteins 
used seems to have a net negative surface charge.  
Chitosan (CS) is one of the few polycations naturally available, which may be 
advantageous relatively to others vectors, as liposomes, due to its minimal 
toxicity. In the present study, a CS derivate was chosen for the formulation of 
positively surface charged PLA nanospheres, as lysozyme used for extract 
production has the ability to degrade this natural polymer.  A previous study 
made by our group had shown that the dissolution of GCS and S. equi 
enzymatic extract protein did not result in any destabilisation of the inner 
phase. In addition, GCS kept the biodegradability and biocompatibility 
attributed to CS, but its solubility in a wide range of pH aqueous solutions 
overcomes CS low solubility at basic pH values [25].  
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Table 5.3 
In vitro characteristics of S. equi-adsorbed and -entrapped PLA nanospheres prepared by 
double emulsion (w/o/w) solvent evaporation technique.  
aParticle size as volume mean diameter (VMD) expressed as mean ± S.D. (n=6);  
bPLA nanospheres surface charge, before (BP) and after (AP) protein association (mean ± S.D. 
(n=6)). 
cLoading capacity (L.C.): represents the mean percentage of actual amount S. equi extract 
proteins content ± S.D. (n=6).  
dAds.-adsorbed. 
 
As shown in Table 5.3, particles produced by adsorption procedures showed 
higher antigen loadings than S. equi-entrapped PLA nanospheres, with no 
significant difference in the mean particle diameter. Among adsorbed 
formulations, PLA-GCS nanospheres presented a similar L.C. when compared 
to those formulated with PVA (PLA-PVA) or alginate (PLA-ALG), supporting 
the idea that charge and size do not have an important influence in the 
adsorption of the S. equi protein extract.  
L.C. varied from 5.37 % (w/w) on PLA-SP nanospheres, to 7.84 % (w/w) for 
PLA-OA nanoparticles. Interestingly, OA may have increased the stability of 
the primary emulsion, resulting in the highest L.C. of all S. equi-entrapped 
polymeric nanospheres studied, besides its lower mean diameter (Table 5.3). 
Higher antigen loading may be a result of organic phase viscosity increase, 
which prevents protein migration from the aqueous to the external phase. 
S. equi-entrapped PLA nanospheres were easily dispersed in PBS (pH 7.4), 
especially PLA-SP and PLA-ALG, and therefore it was possible to efficiently 
administer higher amounts of these particles during immunisation studies. 
Nevertheless, Johansen et al. (2000) demonstrated that the number of particles 
ZETA POTENTIAL b (mV) 
FORMULATION 
VMDa 
(nm) BP AP 
L.C. c 
(%W/W) 
PLA-PVA 255.8 ± 10.00 -30.4 ± 7.19 -29.6 ± 8.95 10.32±0.32 
PLA-GCS 407.1 ± 56.98  +36.4 ± 5.03 +5.17 ± 2.05 10.83±0.25 
A
d
s.
d
 
PLA-ALG 346.7 ± 18.50  -41.3 ± 1.55 -39.63 ± 1.07 10.11±0.60 
PLA-PVA 281.1 ± 17.30 -33.7 ± 6.82 -31.63 ± 8.95 6.04±0.24 
PLA-GCS 396.0 ± 36.11 + 37.1 ± 3.43 +31.83 ± 3.10 7.16±0.56 
PLA-ALG 327.0 ± 57.78 -40.7 ± 2. 23 -50.10 ± 4.49 5.56±0.10 
PLA-SP 267.9 ± 16.41 -22.9 ± 4.45 -24.50 ± 2.95 5.37±0.49 En
tr
ap
p
ed
 
PLA-OA 205.47 ± 45.99 -28.33 ± 8.09 - 29.30 ± 7.82 7.84±0.27 
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administrated is not a limiting factor for the stimulation of the immunological 
response [26]. 
For the antigen-entrapped nanospheres to function as controlled release 
delivery systems for the generation of long lasting immune responses, they 
should not only contain suitably high antigen levels, but also maintain their 
antigenicity [27]. Accordingly, the molecular weight and structural integrity 
of entrapped and adsorbed S. equi antigens were studied by SDS-PAGE and 
their antigenicity was confirmed by western-blot analysis. Despite the relative 
chemical and physical harsh conditions imposed to antigens during the 
entrapment method, the structural integrity, antigenicity and immunogenicity 
of the proteins were conserved, including SeM (58kDa), (Figures 5.2 and 5.3), 
confirming the potential of these particles for immunisation studies. The 
adsorption process not only avoids the harsh entrapment process, but also 
extensively increases the amount of protein associated to the PLA 
nanospheres. This is even more important for S. equi enzymatic extract, as it 
contains a mixture of several proteins wherein only 2.70 % (w/w) is attributed 
to SeM [21, 28].  
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Figure 5.2 - SDS-PAGE (12% gel) analysis of S. equi enzymatic extract protein-entrapped or 
-adsorbed PLA (MW 2 kDa) nanospheres. Lanes: 1) Standard markers; 2) Plain S. equi 
antigens at 1250 µg/ml (control); S. equi antigens adsorbed onto 3) PLA-PVA, 4) PLA-GCS 
and 5) PLA-ALG nanospheres; and encapsulated in 6) PCL-PVA, 7) PCL-GCS, 8) PCL-OA, 
9) PCL-SP and 10) PCL-ALG nanospheres. 
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Figures 5.2 and 5.3 suggest that S. equi extract proteins were successfully 
adsorbed onto PLA nanospheres without changes in molecular stability and 
antigenic components of the extract, which can be seen by the absence of 
alterations in the pattern of migration and proteins reaction with specific 
anti-SeM antibody, being a potential vaccine adjuvant for these antigens. 
Our research group has showed that the double emulsion solvent evaporation 
technique has not affected the activity and immunogenicity of S. equi antigens 
incorporated in the internal phase [20, 21, 29].  
 
 
 
 
 
 
 
 
 
Polymeric composition, particle size, antigen loading, route of administration 
and their association with other adjuvants, are the main characteristics that 
influence the interaction with mucosal tissues, particles uptake and their 
subsequent transport to the lymphatic nodes [26, 30]. Among all of these 
physicochemical characteristics, size seems to be the main parameter, 
although it is possible to find contradictory results in the literature. Particle 
size affects deposition in the nasal cavity and uptake by the mucosa. It is 
general agreed that particles with mean diameters less than 10 µm are readily 
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Figure 5.3 - Western blot analysis showing immunoreactivity of S.equi antigens adsorbed 
and entrapped in PLA (MW 2.0 kDa) nanospheres with anti-SeM antibody as described in 
Materials and Methods section. Lanes: 1) Standard markers; 2) Plain S. equi antigens at 
1250 µg/ml (control); S. equi antigens adsorbed onto 3) PLA-PVA, 4) PLA-GCS and 5) 
PLA-ALG nanospheres; and entrapped in 6) PLA-PVA, 7) PLA-GCS, 8) PLA-OA, 9) PLA-
SP and 10) PLA-ALG nanospheres. 
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taken up by cells, whereas those in the nanometric range are more efficiently 
absorbed by lymphoid tissue associated to the nasal mucosa (NALT) [31]. 
Particles with mean size < 500 nm were found to indeed induce higher 
immune responses than larger carriers (> 2 µm) [32]. As a result, particulate 
form, size and successful association to S. equi antigens predict that these PLA 
nanospheres may be extensively taken up by nasal mucosa M cells, as well as 
by dendritic cells or macrophages. In addition, its antigen depot effect will 
enhance the processing and presentation of associated S. equi antigens, 
thereby inducing higher immunological responses [31].  
In order to increase particles stability and prevent their rapid clearance from 
the organism, recent approaches involve particle surface modification with 
hydrophilic polymers, such as CS and ALG. For example, it has been 
observed an increase in the immune response when the surface of PLGA 
nanospheres was modified by CS, consequence of its mucoadhesivity. This 
positively charged particles surface seem to favour interaction between 
particles and cell membranes [15]. 
Figures 5.4 and 5.5 show in vitro release profiles of S. equi antigens adsorbed 
and entrapped in PLA nanospheres, respectively.  It was found 49.25±1.37%, 
45.00±1.31 %, 53.83±1.07 %, 41.76±0.368 %, and 50.63±2.60 % burst release (1 
day) of S. equi extract proteins entrapped in PLA-PVA, PLA-SP, PLA-ALG, 
PLA-GCS and PLA-OA nanospheres, respectively and tends to a plateau after 
10 days, occurring a prolonged antigen release.  This burst release has been 
mentioned in the literature for proteins as BSA and OVA entrapped in PLA 
low molecular weight nanospheres, which increases with the decreasing of 
polymer molecular weight [33].  
Despite this rapid degradation, PLA-GCS nanospheres presented the slowest 
release (P<0.04) of the entrapped S. equi antigens, which may be due to its 
higher mean diameter or, most probably, to the stronger interaction 
established between the positive charge of the surface and proteins. It was 
interesting to verify that PLA-SP nanospheres, regardless of presenting one of 
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the lowest particle diameters and having a high hydrophilicity, slowly 
released S. equi antigens.  
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Even 30 days after PLA particles incubation in the release media, 20-34% of 
the entrapped S. equi extract antigens were still associated to these carriers 
(Figure 5.5). 
The prolonged release of the entrapped or adsorbed antigens is vital in order 
to preserve a considerable amount of antigen in the particles when achieving 
the APCs, as it is well accepted that the higher amount of antigen in particles 
elicits longer immune responses and lymphocytes T activation [34].  
As it was expected, S. equi-adsorbed PLA nanospheres quickly released 
antigens, but remain potential vectors for nasal immunisation as after 4 hours 
there was still 36-58% of the protein adsorbed onto particles surface (Figure 
5.4). Even so, this study confirmed the stronger interactions established 
Figure 5.4 - In vitro cumulative release of S. equi antigens adsorbed onto different 
PLA-based nanospheres, for a period of 30 days (mean ± S.D.; n=3).  
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between PLA-GCS surface and the S. equi protein extract, as this system 
achieved a more prolonged release profile. 
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An interesting approach would be the adsorption and entrapment of these S. 
equi antigens in the same polymeric system, in order to have a higher amount 
of protein released just after their contact with APCs and simultaneously 
maintain a prolonged release, contributing for the renovation of major 
histocompatibility complex (MHC) molecules at APCs surface and therefore 
guarantee a continuous activation of cells of the immune system. 
 
PLA NANOSPHERES IN VITRO CELL VIABILITY ASSAY 
Figure 5.6 shows that all PLA formulations did not have cytotoxic effects to 
BALB/c cells (J774A.1 cell line), which remained more than 90.8 % viable 
when compared to control, at concentrations as high as 2.50 mg/ml. 
Furthermore, these cells viability was significantly higher than that presented 
Figure 5.5 – In vitro cumulative release of S .equi antigens entrapped in different 
PLA-based nanospheres, for a period of 30 days (mean ± S.D.; n=3).  
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by cells treated with PEI (P<0.01). Among PLA formulations, PLA-ALG led to 
the highest cell viability.  
 
Error! 
 
SYSTEMIC IgG ANTIBODY IMMUNE RESPONSE 
Controlled release of S. equi antigens adsorbed and entrapped in PLA carriers 
resulted in high, sustained levels of S. equi-specific IgG antibodies at all time 
points after boosting (Figures 5.7A and 5.8A). Empty nanospheres induced a 
baseline humoral immune response, not statistically different from antibody 
levels observed for the negative control (results not shown). Free S. equi 
antigens delivered in PBS (pH 7.4) resulted in lower levels of anti-S. equi IgG 
antibodies when compared with other groups, being this difference observed 
7 weeks after dosing statistically significant when compared with IgG titres 
induced by all adsorbed particulate systems (P<0.041) and S. equi 
antigens-entrapped PLA nanospheres studied (P<0.036). 
Figure 5.6 - Viability of mouse BALB/c monocyte macrophage cells (J774A.1 cell line) after 
incubation with increasing concentration of PLA nanospheres (mean ± S.D.; n=3). 
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The co-administration of polymeric particles and other adjuvants has been 
proposed and studied by some investigators in order to increase particles 
adjuvant activity [35, 36].  Several studies have showed that CTB by itself 
strongly induces mucosal immune response, but its adjuvant activity was not 
observed when associated to total antigen extracts from several 
microorganisms [37, 38]. When S. equi was associated to CTB, it was observed 
an increase in the humoral response, however not as high as IgG antibodies 
elicited by PLA carriers 7 weeks after animal vaccination (P<0.039). 
Anti-S. equi IgG levels induced by PLA-PVA+CTB were statistically different 
from those assessed in serum of mice vaccinated with either 
antigen-entrapped PLA-ALG (P=0.025) and PVA-OA (P=0.01) nanospheres, 
or any of the adsorbed particulate systems (P<0.048).  On the other hand, S. 
equi antigens adsorbed onto PLA-PVA and co-administrated with CTB 
induced S. equi specific IgG antibodies markedly higher than any of the 
formulations tested (P<0.025), excepting IgG serum titres elicited by 
PLA-PVAads and PLA-GCSads systems.  In fact, these latter particulate 
systems, together with S. equi-entrapped PLA-OA nanospheres, induced the 
highest IgG antibodies 12 weeks after i.n. administration, which was 
statistically different from all other antigen-associated nanospheres (P<0.01).   
It is important to point out that boosters elicited a significant increase in 
antibodies levels, which was maintained at the end of the study by all 
formulations, with an exception for PLA-GCS, PLA-SP and PLA-OA systems, 
as it induced a gradual increase during this trial period. These results are in 
agreement with the in vitro release profiles, especially for the GCS adjuvanted 
nanospheres as this formulation has showed the slowest release rate during 
that study. Likewise, over the end of the trial period, positively charged 
nanospheres adsorbed with S. equi antigens induced IgG titres higher than 
those elicited by PLA-ALGads (P=0.008), while not being statistically different 
from the levels observed for both PLA-PVAads, alone or associated to CTB 
adjuvant. These observations are similarly related with the S. equi proteins 
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release profile from the surface of these positively charged nanospheres. Even 
so, comparing S. equi-entrapped and -adsorbed PLA carriers, it seems that the 
latter elicited a higher S. equi specific humoral immune response, which can 
be due to the higher amount of S. equi antigens that has reached the APCs. As 
a result, besides PLA-GCS higher surface positive charge, when compared to 
the moderate PLA-GCSads charge obtained after proteins adsorption, latter 
formulation induced statistically higher IgG antibody levels even 9 weeks 
after animals boosting.  
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CS has the ability to increase antigen bioavailability due to its mucoadhesion 
and capacity to open tight junctions between cells, promoting the paracellular 
transport [39, 40]. In fact, at neutral pH the mucus layer is negatively charged 
and therefore positively charged particles can interact with mucus, decreasing 
particle clearance from nasal mucosa [15]. 
Several studies have confirmed that PLA and PLGA particles are potential 
carriers for adsorbed or entrapped proteins [27], being able to preserve 
stability and immunogenicity, in order to stimulate a higher immune 
response able to be maintained for prolonged periods of time, and therefore 
avoiding administration of several vaccine doses [34, 41]. 
By IgG titres assessed in the sera of mice treated with PLA nanospheres 
associated to S. equi enzymatic extract antigens, it seems that the nasal 
administration of these vehicles, mainly those with adsorbed antigens, 
contributes to improve uptake and processing of antigens by APCs, as well as 
more efficiently deliver to peripheral lymph nodes. Comparing these humoral 
Figure 5.7 - Serum anti-S. equi specific IgG (A), IgG1 (B) and IgG2a (C) profiles of mice 
immunised by i.n. route with different formulations of S. equi antigens encapsulated in 
PLA nanospheres, compared to the free  antigen (FREE) and co-administered with CTB 
(FREE+CTB) immunisations (mean ± S.D.; n=4). 
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responses with those reported in a previous study using PCL nanospheres, it 
is possible to see that the IgG levels at the end of the study were higher for 
PLA nanospheres, although statistically different only when PCL-PVAads 
and PCL-GCSads titres are compared with those elicited by PLA-PVAads 
(P=0.033) and PLA-GCSads (P=0.008), respectively [20].   
 
 
1
10
100
1000
10000
100000
1000000
2 4 7 12
PLA-PVAads PLA-GCSads PLA-ALGads PLA-PVAads+CTB FREE FREE+CTB
 
 
1
10
100
1000
10000
100000
2 4 7 12
 
Se
ru
m
 
Ig
G
 
tit
re
s 
Time (week) 
A 
Se
ru
m
 
Ig
G
1 
tit
re
s 
Time (week) 
B 
Chapter 5 
  209 
1
10
100
1000
10000
100000
2 4 7 12
 
 
 
Since particles were formulated with the same adjuvants, using the same 
method of production and presented a similar diameter, it seems that the 
difference observed might be due to their main polymeric composition and its 
surface interaction with the S. equi extract. In vitro release studies have shown 
a faster release of S. equi proteins from PLA nanospheres when compared 
with the release profile observed for S. equi proteins desorption from PCL 
nanospheres, resulting in a difference of approximately 10% of protein 
released 30 days after particles incubation in the media. This higher amount 
of antigen released during this period may be responsible for the stronger 
immune response obtained in animals treated with these nanospheres. On the 
other hand, even if S. equi-entrapped PCL nanospheres induced lower IgG 
titres during the first weeks of the study, the total systemic antibody levels 
elicited by S. equi-entrapped PLA nanospheres started to decrease after 12 
weeks, in contrast with the humoral immune response obtained with the PCL 
nanospheres. In fact, at the end of the study, there was a significant difference 
between the IgG titres induced by PLA-OA versus PCL-OA (P=0.008) and also 
Figure 5.8 - Serum anti-S. equi specific IgG (A), IgG1 (B) and IgG2a (C) profiles of mice 
immunised by i.n. route with different formulations of S. equi antigens adsorbed onto PLA 
nanospheres, compared to the free antigen (FREE) and free co-administered with CTB 
(FREE+CTB) immunisations (mean ± S.D.; n=4). 
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PLA-ALG versus PCL-ALG (P=0.033) nanospheres. These results are in 
agreement with the predicted slower and more prolonged antigens release 
from PCL particles due to its higher molecular weight (42.5 kDa vs. 2 kDa), 
which is reinforced by the in vitro release profile obtained in both situations 
[20]. A detailed difference in the immune response induced by both type of 
polymeric particles can be more specified by the analysis of IgG subtype 
antibodies. 
 
IgG SUBTYPE PROFILING 
To assess the predominance of Th1 or Th2 T cell immune response to S. equi 
delivered in the two forms of polymeric carriers, the levels of both IgG 
isotypes were determined, being the IgG2a isotype more related to a Th1 
response, whereas IgG1 isotype antibodies are predominant in a Th2 
pathway. 
Intranasal vaccination with antigen-loaded PLA nanospheres resulted in 
strong IgG1 and IgG2a immune responses, in contrast to antigen isolated in 
its soluble form or co-administered with CTB, being statistically different 
from 4 weeks of immunisation onwards, with the exception of S. equi 
antigens-adsorbed and -entrapped PLA nanospheres formulated with 
alginate, (Figures 5.7B, 5.7C, 5.8B and 5.8C). In fact, IgG2a titres induced by 
antigens-adsorbed and -entrapped PLA-ALG nanospheres, dosed in sera 
collected 7 weeks after immunisation, were not markedly different from those 
obtained with S. equi proteins in solution co-administered with adjuvant CTB. 
The administration of PLA-PVA nanospheres co-admixed to CTB induced 
IgG1 levels, after 12 weeks of animals vaccination, that were not different 
from those detected in animals treated with antigen loaded PLA-PVA, 
PLA-ALG and PLA-OA nanospheres.  
PLA-PVAads+CTB particles induced high IgG1 subtype levels, although 
these were not statistically significant when compared with those resulted 
from i.n. administration of S. equi proteins-entrapped PLA-GCS and PLA-SP 
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nanospheres. On the other hand, Th1 immune response elicited by antigens  
adsorbed onto PCL-PVA nanospheres and admixed with CTB was not 
different from that elicited by these carriers isolated and PLA-SP, being 
inclusively markedly lower than that induced by the positively charged 
PLA-GCSads nanospheres (P=0.024), PLA-PVA (P=0.014), PLA-GCS (P=0.014) 
and PLA-OA (P=0.014) nanospheres.  S. equi antigens released from 
PLA-PVA, PLA-GCS and PLA-OA nanoparticulate systems induced a Th1 
immune response as high as that obtained in animals dosed with PLA-PVA 
nanoparticles co-administered with CTB.  
It is important to mention that while all nanoparticulate formulations studied 
induced IgG1 levels essentially similar after boosting, high titres of IgG2a 
were markedly induced after the second dose of rather antigen-adsorbed and 
-entrapped positively charged PLA nanospheres, and those were further 
sustained during all the trial period.  
Despite S. equi PLA adsorbed nanospheres initially result in elevated Th1 and 
Th2 responses during the first weeks of this in vivo study, it was observed an 
increase of IgG2a subtype levels determined in mice vaccinated with S. equi 
antigen-entrapped PLA nanospheres later from week 7 to 12, probably due to 
a lower release of the entrapped antigens. In general, it seems that these 
particulate systems allowed the development of a more continuous and 
sustained immune response than the correspondent adsorbed ones.  
Overall, all particulate systems with an exception for PLA-ALGads 
nanospheres were able to induce IgG1 and IgG2a titres statistically higher 
than the isolated form of the antigen (P<0.002) or associated to CTB adjuvant 
(P<0.004), which strengths the idea that an i.n. administration of S. equi 
antigens polymer formulated are able to induce both Th1 and Th2 levels, 
being the prevalence of one dependent on particles composition [42]. 
Interestingly, the ratio of different anti-S. equi IgG subclasses (IgG2a/IgG1), 
by the end of the trial period, indicated that PLA nanospheres formulated 
with GCS elicited a more balanced immune response (IgG2a/IgG1= 0.83 for 
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adsorbed and IgG2a/IgG1=1.0 for entrapped antigen), which was more 
equilibrated than those induced in a previous work with the correspondent 
nanospheres composed by PCL polymer (IgG2a/IgG1=0.49). Therefore, these 
positively charged PLA nanospheres can act as a strong immunostimulator 
for locally administered vaccines. Moreover, CTB adjuvanted formulation 
induced an immunity as balanced as that obtained after PLA-OA 
administration (IgG2a/IgG1=0.5), which highlights the role of OA as a 
potential mucosal adjuvant.  
To put it briefly, the i.n. administration of S. equi extract associated to PLA 
nanospheres resulted in a better immune response than the free extract 
proteins or plain nanospheres, supporting the role of these particles as an 
adjuvant for these S. equi antigens. 
 
LOCAL IgA IMMUNE RESPONSES   
An animal recovering from strangles present specific anti-SeM IgG and IgA 
antibodies in the serum and nasal secretions, which seems to be vital for its 
protection against future infections, as they will recognise, attach and 
inactivate the infectious S. equi [3-5].    
Although the mechanism responsible for horse protection is not completed 
understood, the disappointing results obtained with the commercially 
available vaccines seem to result from their failure in stimulate a local 
immune response and therefore, to the low levels of IgA and IgG sub-classes 
founded in the nasopharynx, which are believed to be the protective 
antibodies similar to those found in animals recovering from a natural 
infection [3].  In fact, the mucosal immune response is believed to have an 
important role in the protection of the upper respiratory tract from bacterial 
infections. In addition, even if the immune response to S. equi infection is 
normally characterised by high levels of specific anti-SeM systemic 
antibodies, as those obtained by S. equi-loaded PLA nanospheres in this 
experiment, they seem not to be the main responsible for animals protection, 
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being predominantly the mucosal immune response developed.  Therefore, 
IgA locally produced in the respiratory tract are important for prevention and 
control of this endemic disease, mainly in their port of entry, being apparently 
complemented by systemic immune response [3, 4]. 
In order to further characterise the type of immune response in study, it is 
then essential to assess the mucosal immunity induced by these S. equi 
particulate loaded systems.   
Polymeric particles composition modification is one of the most used 
alternatives, in order to achieve a specific phagocytosis [43, 44]. After 
phagocytosis, the intracellular phenomena related to antigen processing and 
presentation will depend on particle polymeric composition [45]. As a result, 
biodegradable and polymeric nanoparticles associated to mucoadhesive 
polymers, as CS [14, 15, 39] or ALG [17], to increase time of residence of 
particles near the cells, and absorption enhancers, like SP [18, 20, 21] and OA 
[19, 46], are important strategies to overcome nasal barrier [19]. Indeed, as 
mucus layer is anionic at a neutral pH value, positively charged groups on 
particle surface can promote interaction between the mucus and particles, and 
therefore increase the contact time of these surface modified delivery systems 
with the nasal mucosa [23, 47]. 
The SIgA assessed in nasal lavages indicate that S. equi-loaded particulate 
systems, either by adsorption or entrapment, stimulated IgA-secreting cells of 
the NALT and/or draining lymph nodes, as it was obtained levels of SIgA 
statistically higher than those secreted in consequence of unentrapped antigen 
(P<0.003), or even of its co-administration with the mucosal adjuvant CTB 
(P<0.008) (Figure 5.9). These observations suggest that a mucosal response in 
several places distant from the site of immunisation was elicited by i.n. 
antigen exposure, which is characteristic of i.n. immunisation and actually 
constitutes its main advantage. It has been shown that SIgA can function not 
only as first defence line at portal of entry of the microorganisms and viruses, 
but also is more effective in terms of protection than systemic antibodies [48].  
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Analysing the systemic and mucosal immune responses obtained after 
administration of S. equi antigens-loaded PLA nanospheres, it is possible to 
predict that the formulation method used to entrap these antigens preserves 
the epitopes necessary for the immune response (Figures 5.7 and 5.9).  
Among S. equi-loaded nanospheres, SIgA titres observed in Figure 5.9 are not 
markedly different only when those induced by PLA-PVAads and PLA-GCS 
nanospheres are compared with the ones assessed in lung washes of animals 
exposed to PLA-PVA and PLA-OA, respectively.  It is important to mention 
that S. equi-entrapped PLA-SP nanospheres induced the highest SIgA 
antibody titres, which was also obtained in the previous study performed by 
our group with PCL nanospheres formulated with SP, which means that this 
polyamine, as an absorption enhancer, might have significantly increased 
particles uptake by M cells in the NALT and subsequently delivered the 
antigen to the peripheral lymphoid tissues.  
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Figure 5.9 – Secretory IgA (SIgA) level in lung washes of mice immunised intranasally 
with S. equi antigens-entrapped or -adsorbed PLA nanospheres. Plain particles were used 
as control (mean ±  S.D.; n=4). 
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Nevertheless, besides not as high as those induced by these particles, SIgA 
levels identified in nasal lavages of animals exposed to PLA-GCS and 
PLA-OA were extremely higher than those obtained when PLA-PVA 
nanospheres were admixed with the mucosal adjuvant CTB (P<0.01). These 
results point out a strong mucosal adjuvant effect of those formulations, 
mainly those containing GCS and absorbance enhancers, as their i.n. 
administration effectively induced not only a systemic but also a considerable 
mucosal immune response, which justifies their potential use as alternatives 
to CTB adjuvanted systems.     
S. equi-loaded PLA carriers did not induce detectable SIgA levels in intestinal 
contents of animals, which suggests that, though the large volume 
administered in both nostril, it seems that most of the dose was inhaled and 
not swallowed (data not shown), as previously demonstrated by Eyles et al. 
(2000) [13].   
 
SPLENOCYTE CULTURE STUDIES 
Several studies have shown that antigens immobilised in polymeric particles 
are absorbed with greater efficiency and have a greater ability to be presented 
to APCs than soluble molecules, providing a greater concentration of antigen 
at the inductive site [49]. These phagocytic cells will take up and process the 
antigens, and their maturation will lead to its migration to secondary 
lymphatic tissues, where those will be presented to T and B cells by molecules 
of the MHC system [5, 35, 44]. The transport of antigen to APCs and the way 
that it is processed by these cells are the main aspects to consider in the 
definition of the type (Th1/Th2) and duration of the immune response 
elicited after a vaccine administration. Two subsets of T-CD4+ cells, Th1 and 
Th2, can be identified on the basis of the cytokines secreted following their 
stimulation, being the first more involved in the development of a cellular 
immune response, while the latter influences preferentially the humoral 
responses. IL2, IFN-γ and tumor necrosis factor β  (TNF-β) are mainly secreted 
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by Th1 cells and induces class-switching in B cells promoting the synthesis of 
IgG2a, while Th2 cells are essential for antibody-mediated immunity as they 
produce IL4, IL5, IL6, IL10 and IL13, being the isotype IgG1  the one 
preferentially secreted after B cells activation wherein this pathway [27].  
A previous study performed by our group has demonstrated the 
immunostimulatory properties of PCL carriers for S. equi antigens as these S. 
equi antigen-loaded polymeric particles were able to induce not only high 
levels of serum antibodies, but also a considerable cellular immune response 
[20, 21].  
The supernatants of spleen cells stimulated with recall S. equi antigens were 
collected to quantify the cytokines produced in response to stimulations, 
which are shown in Figure 5.10. As it can be seen, i.n. immunisation with 
polymer formulated S. equi antigens was effective at stimulating Th1 and 
Th2-type cytokines production, being the IFN-γ the one detected in higher 
amount and the differences observed in these cytokine titres significant when 
compared with both FREE (P<0.02) and FREE+CTB (P<0.018) vaccinated 
animals. Both S. equi antigens-adsorbed and -entrapped nanospheres elicited 
cytokines levels significantly higher than those obtained in splenocytes 
cultures of mice vaccinated with soluble molecules of antigen, isolated or 
co-administered with CTB, which failed to stimulate elevated cytokine levels, 
with the exception of IL6 cytokines secreted by spleens of mice 
pre-immunised with FREE antigen when compared with those determined in 
PLA-PVAads and PLA-GCSads immunised groups.  
The pattern of IL4 production by cultured splenocytes was markedly different 
from that of the remaining cytokines studied, but still distinct from those 
secreted by cells following their exposure to the antigen soluble groups 
(P<0.02).  
Chapter 5 
  217 
   
1
10
100
1000
10000
PL
A-
PV
Aa
ds
PL
A-
GC
Sa
ds
PL
A-
AL
Ga
ds
PL
A-
PV
Aa
ds
+
CT
B
PL
A-
PV
A
PL
A-
GC
S 
 
PL
A-
AL
G
PL
A-
SP
PL
A-
OA
PL
A-
PV
A+
C
TB
FR
EE
FR
EE
+
C
TB
IL2 IL4 IL6 IFNGAMMA
 
 
 
It is interesting to compare cytokine levels resultant from S. equi-loaded PLA 
nanospheres mice immunisation with the obtained previously with i.n. 
administration of PCL nanospheres. Therefore, all cytokine titres, mainly 
IFN-γ and IL2, were statistically higher for antigen-adsorbed PLA 
nanospheres treated animals, when compared with those induced by 
splenocytes of PCL immunised groups, obtaining the opposite tendency when 
S. equi-entrapped nanospheres were used. These observations can mean that 
the hydrophobic character may have distinguished S.equi-adsorbed PCL 
nanospheres by increasing their uptake, which however may not have been 
enough to overcome the lower amount of antigen released during PCL 
particles degradation relatively to the correspondent PLA ones, as it was seen 
by their in vitro release profiles (Figures 5.4 and 5.5).  
Figure 5.10 – IFN -γ, IL2, IL4, IL6 and IL12 levels produced after stimulation of splenocytes 
derived from mice immunised with S. equi enzymatic extract alone (FREE), 
co-administered with CTB and associated to different PLA-based nanospheres (mean ± 
S.D.; n=4).  
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The outcome of adjuvant synergy obtained with a combination of a 
carrier/depot adjuvant and an immunomodulator adjuvant is a current 
strategy, as it may result in an enhanced and/or biased/balanced immune 
response profile (Th1/Th2), depending on the combination investigated, 
according to the requirements believed to result in a protective immunity [51]. 
CTB admixed with S. equi-loaded PLA-PVA particles elicited Th1 cytokines at 
a significant level, except when IFN-γ amount obtained in PLA-PVAads+CTB 
group is compared with the correspondent levels consequence of mice dosing 
with antigens adsorbed onto PLA-ALG nanospheres. Nevertheless, due to the 
high levels of cytokines induced by particulate systems, together with 
humoral and mucosal response, it is possible to conclude that the association 
of CTB to PLA-PVA nanospheres did not bring a considerable advantage over 
S. equi-loaded PLA nanospheres by themselves.   
Altogether, having in mind IgG subtypes and IgA levels, it can be inferred 
that, for the trial period, nasal immunisation of S. equi-entrapped PLA 
nanospheres induced Th1 and Th2 cytokines profiles, with IgA responses in 
nasal secretions, more effectively than the adsorbed ones, having the 
mucoadhesiveness and positive charge of PLA-GCS an important 
contribution for the immunostimulatory effect observed and may be an useful 
tool for the induction of systemic and mucosal immune responses, which 
highlights its role in the development in a strangles vaccine. The 
immunostimulating effect of PLA nanospheres obtained after their i.n. 
administration may have resulted from their ability to expose the antigen to 
nasal mucosa for prolonged periods of time, improving its uptake by M-cells 
and APCs at this mucosa, to the efficient delivery to mucosal lymph nodes 
and to the stimulation of APCs after uptake. PLA-GCS especially can prolong 
the residence of antigen in the nasal cavity by the electrostatic interaction 
establish between their positive charge and mucus negatively charged, giving 
more time for antigen to be taken up in nasal tissues.   
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CONCLUSIONS 
The purpose of this study was to study the effect of different mucoadhesive 
and absorption enhancers on humoral, cellular and mucosal immune 
responses induced by S. equi adsorbed or entrapped into PLA nanospheres. It 
was shown that both adsorption and entrapment processes can be 
successfully used for the development of S. equi enzymatic extract protein 
drug carriers with no compromise of its molecular structure or 
immunogenicity. 
The association of antigens to PLA polymeric particles was able to change 
their processing and/or presentation by the immune system. All taken 
together, humoral, cellular and mucosal immune responses make it possible 
to predict that the PLA nanospheres by themselves hold a great promise as a 
delivery system for i.n. vaccination against strangles and do not require the 
co-administration of other adjuvants in order to achieve a mucosal and 
balanced Th1/Th2 immune response, fundamental for animals protection 
against S. equi infection.  
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ABSTRACT 
Strangles is an infectious disease caused by Streptococcus equi subspecies equi 
that affects the upper respiratory tract of the Equidae. The control of this 
disease seems to be dependent on its earlier detection and prevention, but 
prolonged animals protection without development of strong and severe side 
effects was not yet achieved. Convalescent horses present a protective 
immune response, mainly against SeM (58 kDa), an antiphagocytic and 
opsonogenic S. equi M-like protein, known as the major protective antigen 
against strangles. SeM and S. equi protein extract-entrapped poly(lactic acid) 
(PLA) nanospheres were developed and their adjuvant potential was studied. 
The effect of absorption enhancers (spermine, oleic acid) and mucoadhesive 
polymers (alginate, glycol-chitosan) were also evaluated. Spherical 
nanometric particles of less than 500 nm were developed, despite particle 
composition, and protein structure was not affected by the solvent 
evaporation method. The humoral immune response induced by nanospheres 
was markedly higher than that elicited by soluble antigens, isolated or 
co-admixed with CpG. IgG and IgG subtypes, along with cytokines titres, 
indicated that nanospheres composed by glycolchitosan developed a more 
balanced Th1/Th2 response for both SeM and S. equi enzymatic extract 
proteins, although those induced by the pure antigen-entrapped particles 
were higher than the S. equi tested vaccines composed by total antigens 
entrapped in polymeric nanospheres. 
 
Keywords: Poly(lactic acid), nanospheres, SeM, vaccines, immune responses. 
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INTRODUCTION 
Strangles, from Latin strangulina, is an infectious disease that affects the upper 
respiratory tract, more specifically, the nasopharynx and lymphatic nodes 
drainage of horses, donkeys and mules [1-3]. Nevertheless, it is not exclusive 
of the Equidae family, as it was as well identified in two humans and one dog 
[4-6]. It is a highly infectious and worldwide endemic infection, representing 
30% of all horse diseases and is caused by Streptococcus equi subspecies equi (S. 
equi) [2, 7]. These bacteria cross the oral and nasal mucosa, lodge in the head 
and neck lymphatic nodes, leading to the formation of abscesses that, with 
progression of the disease, will become painful and consequently prevent 
horses from eating, resulting in a general weak condition [2, 7]. S. equi 
infected horses present high fever, acute rhinitis and pharyngitis, and 
swallowed lymph nodes, which after being mature, will disrupt and release a 
mucopurulent discharge. This liquid contains a high level of infectious 
bacteria that can be inhaled or ingested by healthy horses [2]. The 
convalescence period is usually long, but in most of the cases, 4 to 6 weeks 
after abscess rupture and complete drainage, animals start to recover and will 
completely eliminate S. equi from their organism. However, in some 
circumstances, pharyngeal abscesses content can lodge in horse guttural 
pouch for months, without causing the development of any clinical sign of the 
disease [2, 7]. These apparent healthy horses constitute S. equi carriers, able to 
release the infectious bacteria for their throat and consequently to the 
environment, representing a high risk of contamination for other non-infected 
horses during that period, as they are not easily detected by the diagnostic 
methods commonly used [2, 7, 8]. Therefore, these infectious S. equi carriers 
are the most important cause for the long lasting maintenance of the disease, 
as the causal agent only survives in the environment for some weeks. 
Moreover, strangles is still a worldwide endemic disease with an important 
economical drawback as, after being identified, infected animals require not 
only the conventional treatment (pain killer, analgesics and, in some 
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situations, antibiotics), but also their maintenance in quarantine or with a 
controlled mobility until the complete elimination of the microorganism  is 
confirmed by diagnostic methods. Even so, it is important to follow animals 
for prolonged periods of time as it was already detected the presence of S. equi 
in horses that did not show any clinical sign of the disease for the last 12 
months [2].  
S. equi infected animals treatment seems not to be effective when animals 
already present signs of the disease. In addition, some clinicians believe that 
antibiotics will delay the abscesses maturation, contributing for the systemic 
dissemination of the microorganism to other regions of the body, leading to 
the most dangerous situation of this disease called “bastard strangles”, 
resulting in most of the cases in the death of the animal [7].  
Besides being an endemic disease, few is known about S. equi virulence, but 
most of the work developed in this field has been directed to the study of 
secreted substances or bacterial cell wall proteins [9, 10].  On the other hand, 
S. equi resistance to phagocytosis seems to be the main factor responsible for 
its infectious character.  Hyaluronic acid capsule, cell wall SeM (58 kDa) and 
secreted IdeE and Se18.9 proteins are the main factors that contribute for S. 
equi phagocytosis resistance [10]. SeM and IdeE limit C3b complement factor 
deposition on bacterial surface, while Se18.9 blocks the bind complement 
regulatory factor H [11, 12]. In addition to their antiphagocytic properties, 
SeM proteins are the most protective antigens as they can also induce the 
production of specific opsonogenic antibodies [11]. In fact, convalescent 
animals present a protective immune response mainly directed to SeM, 
presenting IgG and IgA anti-SeM immunocomplexes, both in serum and nasal 
secretions, that have the ability to recognise, bind and inactivate S. equi in 
further infections. Nevertheless, these opsonogenic antigens are not fully 
protective by themselves in horses and, therefore, anti-SeM immunity may be 
complemented by neutralising antibodies against IdeE and Se18.9. On the 
other hand, mucosal antibodies may be more effective than systemic ones, 
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and therefore also this possibility must be taken into consideration [10]. Even 
if the complete protective mechanisms are not yet completely clarified and the 
immunogenic S. equi proteins are not fully identified, it seems that to combat 
and prevent strangles it is mandatory the development of an effective vaccine 
[1, 2, 7, 13].  
In recent studies performed by our group, it was demonstrated that polymeric 
particles were able to change S. equi protein extract processing and/or 
presentation by the immune system, inducing a mucosal and balanced 
Th1/Th2 immune response fundamental for animal protection against S. equi 
infection [14-16]. Therefore, the aim of the present work was to evaluate and 
compare the humoral and cellular immune responses induced by SeM and a 
mixture of S. equi cell wall extracted proteins, entrapped in PLA nanospheres, 
after mice intramuscular (i.m.) vaccination. In order to assess the effect of 
mucoadhesive polymers and absorption enhancers in the resultant immunity, 
glycolchitosan, alginate, spermine and oleic acid were included in particle 
formulations. It is important to emphasise that this is the first study that 
evaluates the adjuvant potential of polymeric particles associated to 
recombinant S. equi proteins. 
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MATERIALS AND METHODS 
PLA NANOSPHERES PREPARATION  
Poly(L-lactic acid) (PLA, 2.0 kDa) with an average of 2000 Da molecular 
weight (MW) was obtained from PolySciences, Inc., UK. Polyvinyl alcohol 
(PVA, MW 13 23 kDa, 87-89% hydrolysed), alginate low viscosity (ALG), 
spermine (SP), oleic acid (OA), glycolchitosan (GCS), sucrose were purchased 
to Sigma Aldrich Co., UK. Dichloromethane (DCM) was obtained from BDH 
Laboratory Supplies, UK. SeM (58 kDa) was obtained from Prof. J.F. Timoney 
(University of Kentucky, USA), being produced in E. coli following a 
previously published protocol [11]. To prepare S. equi enzymatic extract, 
N-acetyl muramidase, lysozyme and mutanolysin (Sigma Aldrich Co., UK), 
were used to extract proteins from S. equi cell wall as previously described 
[14]. 
S. equi enzymatic extract proteins (10 mg) and recombinant SeM protein (0.5% 
theoretical loading) were entrapped in different types of PLA nanospheres by 
double emulsion (w/o/w) evaporation method, as described elsewhere [14]. 
Briefly, antigens were dissolved in 10 % (w/v) PVA solution, and then 
emulsified with a solution of PLA (2 kDa) in DCM (100 mg in 6 ml), by 
homogenisation using an ultra turrax (T25 Janke & Kunkel, IKA 
Labortechnik). This primary w/o emulsion was further added to 30 ml 1.25 % 
(w/v) PVA or 0.75% (w/v) ALG solution and homogenised for 7 min at 
10,000 rpm with the Silverson homogeniser (Silverson model L4RT, UK) to 
form a secondary emulsion (w/o/w). The emulsion was then left under 
magnetic agitation at room temperature to allow DCM evaporation. The 
particles were afterwards washed, frozen and freeze-dried in the presence of 
the lyoprotectant sucrose (10%, w/v), under vacuum, for two days. To study 
the effect of OA, SP and GCS inclusion in the adjuvant properties of PLA 
nanospheres, an OA solution (10 mg/ml in 1 ml of ethanol) was added to the 
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organic phase, while SP and GCS (10 mg/ml) were dissolved in the 10 % 
(w/v) PVA solution, prior to the w/o primary emulsion formation.  
PLA nanospheres volume mean diameter (VMD) was determined by photon 
correlation spectroscopy (PCS; Zetasizer, Malvern Instruments, UK). PLA 
nanospheres dispersed in double distilled water, containing 0.02% Tween 20 
were placed in a cuvette for size measurements.  The zeta potential for S. equi 
antigen-entrapped nanospheres was measured using a Malvern zeta analyser 
(Zetasizer, Malvern Instruments, UK).  
To prepare nanospheres for in vivo studies, particles containing required 
doses of SeM (10 μg) were weighed and dispersed in 100 μl PBS (pH 7.4) 
buffer, just before mice immunisation. 
 
IMMUNISATIONS  
Animals were allowed to acclimate to the new environment for 1 week prior 
being vaccinated and their care and treatment carried out during these in vivo 
studies were performed in strict accordance with the UK 1986 Animals 
(Scientific Procedures) Act. Female 6-8 weeks old BALB/c mice (n=4/group; 
The London School of Pharmacy, UK) were intramuscularly immunised on 
day 1 and boosted on day 21, with 100 μl of either 10 μg of SeM or the 
equivalent amount of S. equi enzymatic extract proteins dissolved in saline, 
entrapped in PLA nanospheres, or admixed with CpG adjuvant (10 μg; 
ODN1826 22.86 mg/ml, Coley Pharmaceutical group, UK). The 
immunogenicity of the S. equi antigen-entrapped PLA nanospheres and CpG 
was also assessed. Tail vein blood samples were collected 2, 4, 7 and 12 weeks 
after immunisation, and spleens were isolated at the end of the experiment for 
immunological assays.  Serum was prepared from clotted blood and stored at 
-20ºC until analysis.       
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QUANTIFICATION OF ANTIGEN SPECIFIC IgG AND SUBTYPES BY ELISA 
The antibody responses (IgG, IgG1 and IgG2a) to SeM or S. equi cell wall 
extracted proteins were determined based on a method previously reported 
[14]. Plates (Immulon 2, flat bottom plates, Dynatech, UK) were coated 
overnight with 1.0 μg/ml SeM protein (or equivalent S. equi extract proteins) 
in 0.1M sodium carbonate buffer (pH 9.6), washed and afterwards blocked 
with a 2% (w/v) bovine serum albumin solution (Sigma Aldrich Co., UK). 
Plates were again washed and sera were tested at 1:32 and 1:64 followed by 
serial two-fold dilutions.  Sera obtained from naive mice were used as a 
control. Horseradish peroxide conjugate goat anti-mouse IgG, IgG1 and IgG2 
(diluted 1:1000) were applied as secondary antibody (Sigma, Pool Dorset, 
UK). Finally, dissolved 2-Azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) 
[ABTS] (Sigma Aldrich Co., UK) in citrate buffer, along with H2O2 was used 
to develop the plates, the colour reaction was stopped after 15 minutes, by 
adding 5N H2SO4 to the wells, and absorbance was read at 405 nm. The titres 
reported are the reciprocal of serum dilutions that gave an optical density 5% 
higher than the strongest negative control reading. 
 
CYTOKINES ASSAYS 
Spleens were aseptically removed 12 weeks after mice immunisation and cell 
homogenisates were prepared as previously described by our group [14]. 
Supernatants obtained 48-h after splenocytes stimulation with 2.0 μg/ml of 
soluble SeM, or equivalent S. equi extract proteins, were used for cytokines 
(IFN-γ, IL2, IL4 and IL6) concentration measurement, by a enzyme-linked 
immunosorbent assay (ELISA; DuoSet® ELISA Development kit, R&D 
Systems Europe, UK). The concentrations, expressed as pg/ml, were 
determined by reference to different cytokines standard curves.   
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STATISTICAL ANALYSIS 
SPSS software (Version 13, Microsoft) was used to analyse the collected data. 
One way analysis of variance (ANOVA) was applied to study the difference 
in antibody response and cytokine profiles between SeM and S. equi 
enzymatic extract proteins particulate formulations. The IgG and IgG 
subtypes immune responses, as well as the cytokine levels secreted by 
splenocytes induced by soluble antigen were compared with those induced 
by their polymer formulated form. If ANOVA results were found significant 
(P<0.05), a LSD multicomparison post hoc test was performed in order to 
specify the difference between the several groups.  
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RESULTS 
PLA NANOSPHERES CHARACTERISATION 
In a recent work developed by our group, it was reported the formulation and 
characterisation of S. equi cell wall extracted proteins successfully entrapped 
in PLA nanospheres containing PVA, GCS, OA, SP or ALG, and no evidence 
of cytotoxicity was obtained for particles suspension, as macrophages 
viability of approximately 100% was observed in all tested sets. Particles 
appeared to be spherical, smooth and fairly homogeneously distributed, 
without the presence of collapsed particles [15]. Table 6.1 summarises the 
main physicochemical characteristics of SeM-loaded PLA nanospheres with 
(PLASeM). 
 
Table 6.1   
In vitro characteristics of SeM protein-loaded PLA nanospheres  
FORMULATIONS VMD
a  
(nm) 
ZETA POTENTIALb 
(mV) 
L.C.c  
(%) 
Se
M
 
PLA-PVASeM 264.1 ± 7.85 -31.8 ± 1.05 0.247 ± 0.004 
PLA-GCSSeM 403.5 ± 4.96 +45.9 ± 2.32 0.384 ± 0.007 
PLA-ALGSeM 360.6 ± 5.55 -50.8 ± 2.39 0.380 ± 0.017 
PLA-SPSeM 282.7 ± 5.98 -22.4 ± 0.56 0.326 ± 0.029 
PLA-OASeM 252.6 ± 4.84 -29.0 ± 1.27 0.456 ± 0.010 
S.
eq
ui
 
pr
ot
ei
n 
ex
tr
ac
td
 PLA-PVAExt 281.1 ±  17.3 -31.6 ±  8.95 6.04 ± 0.242 
PLA-GCSExt 396.0 ±  36.1 +31.8 ±  3.10 7.16 ± 0.561 
PLA-ALGExt 327.0 ±  57.8 -50.1 ±  4.49 5.56 ± 0.104 
PLA-SPExt 267.9 ±  16.4 -24.5 ±  2.95 5.37 ± 0.494 
PLA-OAExt 205.47 ±  45.9 - 29.3 ±  7.82 7.84 ± 0.268 
aParticle size measured by laser diffraction expressed as volume mean (mean ±  S.D.; n=6) 
of 50% particles in that range (VMD); bZeta potential as a measure of PLA nanospheres 
surface charge (mean ± S.D.; n=6); cLoading capacity (L.C.) representing the amount 
(mean ± S.D.;n=6) of S. equi antigens recovered after hydrolysis of PLA nanospheres; 
ddata discussed in Chapter 5. 
 
Similarly to S. equi enzymatic extract-entrapped PLA particles (PLAExt, Table 
6.1), PCS showed that the VMD of SeM-loaded PLA nanospheres was lower 
than 500 nm, although larger particles were obtained when GCS was 
incorporated in the internal phase. It is important to mention that the 
formulation of SeM-entrapped PLA nanospheres showed a higher 
reproducibility between batches, as it can be observed by lower standard 
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deviation (S.D.) obtained with multiple size measurements, compared with 
those resultant from the analysis of PLAExt [15]. Significant differences were 
obtained for PLA nanospheres containing GCS (PLA GCSSeM) and ALG 
(PLA-ALGSeM) when compared with the size presented by the remaining sets 
of particles (P<0.005).  When PLAExt and PLASeM nanospheres are compared, 
no differences in their size are observed concerning the type of antigen 
entrapped in these carriers. The surface charge of PLA nanospheres 
containing SeM protein re-constituted in 10 mM potassium chloride (KCl) 
solution was found to be markedly different between particles with different 
composition, except for the zeta potential obtained for OA formulated PLA 
nanospheres (PLA-OASeM) compared to -22.4±0.56 mV and -31.8±1.05 mV, 
respectively for PLA containing SP (PLA-SPSeM) and PVA (PLA-PVASeM) 
vehicles. Opposite to the VMD, S. equi type of antigen clearly influenced the 
charge of PLA-GCS nanospheres, as the PLA-GCSSeM presented higher 
positive charge when compared with the correspondent S. equi enzymatic 
extract-entrapped PLA nanospheres (PLA-GCSExt; P<0.001). The entrapment 
efficiency (E.E.) of SeM varied from 91.2 % (w/w) to 49.4 (w/w), respectively 
for PLA-OASeM and PLA-PVASeM nanospheres, which corresponded to a SeM 
loading of 4.56±0.167 μg/mg and 2.47±0.004 μg/mg (Table 6.1). 
Table 6.2  
 Vaccination strategies in BALB/c mice  
BALB/c female mice 6-8 weeks old were vaccinated by i.m. route at weeks 0 and 3. Tail veins 
blood samples were collected at  weeks 2, 4, 7 and 12 for antibodies titres  analysis by 
enzyme-linked immunoassay. 
 
ANTIGEN CARRIERS ANTIGEN CARRIERS 
S. equi enzymatic 
extract 
PLA-PVAExt SeM protein 
(58 kDa) 
PLA-PVASeM 
PLA-GCSExt PLA-GCSSeM 
PLA-ALGExt PLA-ALGSeM 
PLA-SPExt PLA-SPSeM 
PLA-OAExt PLA-OASeM 
PLA-PVAExt+CpG PLA-PVASeM+CpG 
Ext SeM 
Ext + CpG SeM+CpG 
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 Marker 
(kDa) 
 
210 
 
125 
 
101 
 
56.0 
35.8 
29.0 
21.0 
7.0 
  
Accordingly, as observed for PLAExt nanospheres, PLA-OA gave the highest 
entrapment of SeM, among all the PLA nanospheres studied. The evaluation 
by SDS-PAGE demonstrated that, similarly to S. equi cell wall proteins [15], 
SeM (58 kDa) retained its structural integrity after the entrapment process, 
which is shown in Figure 6.1, by the maintenance of protein profile before and 
after being loaded in polymeric nanospheres.   
 
 
 
 
 
HUMORAL IMMUNE RESPONSES 
Mice IgG and IgG subtypes serum antibodies elicited after animals’ i.m. 
vaccination on days 1 and 21, with S. equi antigens alone, admixed with the 
potent adjuvant CpG or entrapped in PLA nanospheres, are summarised in 
Figures 6.2 and 6.3. At two weeks post-immunisation, anti-SeM IgG antibody 
levels elicited by PLA-PVASeM, PLA-GCSSeM and PLA-ALGSeM nanospheres 
were above those resultant from the immune response to SeM alone, or even 
co-administrated with the potent adjuvant oligodeoxynuleotide with 
repeating C and G motives (SeM+CpG) (P<0.001) (Figure 6.2A). On the other 
hand, polymeric formulated S. equi extract, along with AO and GCS, induced 
IgG levels statistically higher than those measured in the sera of mice treated 
with the soluble form of the antigen and with its admixture with CpG 
(P<0.026). By this time, PLA-PVASeM nanospheres induced the highest 
Figure 6.1- Assessment of structural integrity of extracted SeM 
from SeM-entrapped PLA (MWT 2.0 kDa) nanospheres using 
SDS-PAGE (12% gel, 100 V, 1h30min). Lanes: 1) Standard markers 
(broad range Biorad® prestained MW marker: 7.1-209 kDa); 2) 
Control sample of unentrapped SeM at 950 μg/ml (same as 
loaded samples); 3) SeM extracted from PLA-PVA nanospheres. 
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immune response among all SeM sets (Figure 6.2A), while PLA-OAExt 
formulation allowed the production of the highest IgG antibodies titre overall 
S. equi enzymatic extract, in solution or in a particulate form (Figure 6.3A). 
Apparently, the size differences did not noticeably affect antibody 
production. Levels of antibodies induced by PLA-PVASeM, PLA-SPSeM and 
PLA-GCSSeM were maintained statistically different than those observed with 
the same dose of SeM and SeM+CpG, one week after boosting. 
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Antibody levels highly increased between weeks 2 and 4 in the group 
immunised with PLA-PVASeM co-administered with CpG 
(PLA-PVASeM+CpG), being at this time point significantly higher than those 
measured in any other group (P<0.011) (Figure 6.2A). In S. equi 
extract-vaccinated groups it was noticeable a considerable increase in IgG 
levels at week 4 and PLA-PVAExt, which along with PLA-OAExt gave higher 
titres than PLA-GCSExt and PLA-SPExt particulate systems (Figure 6.3A). 
Despite these differences, responses assessed in serum of animals treated with 
any of the PLAExt nanospheres were statistically higher than those induced by 
S. equi extract antigens in solution (P<0.006).  By the IgG antibody levels 
induced in mice vaccinated with PLA nanospheres, it can be observed that, at 
this time point, the type of antigen did not induce any significant difference 
between particles with similar composition (Figures 6.2A and 6.3A). 
Nevertheless, PLA-PVASeM particles suspension co-administered with CpG 
adjuvant (PLA-PVASeM+CpG) resulted in IgG production higher than any of 
those obtaining in the remaining immunisation groups (P<0.001). 
Figure 6.2– Geometric means (mean ± S.D.; n=4 ) of anti-SeM IgG (A), IgG1 (B) and IgG2a 
(C) concentrations induced by intramuscular immunisation with different PLA-based 
nanospheres entrapping SeM (10 μg/dose), compared to the free antigen (SeM) and SeM 
co-administered with CpG (SeM+CpG) immunisations. 
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At week 7, only PLA-OASeM immunisation group gave IgG titres not different 
from those obtained with SeM in solution, alone or associated with CpG 
(Figure 6.2A). By this time, although the response elicited in animals 
vaccinated with PLA-PVASeM nanospheres co-admixed with CpG has 
dropped very noticeably, IgG levels were still the highest among all other 
SeM related vaccination groups (P<0.008). On the other hand, all S. equi 
extract-entrapped formulations raised the immune response to antibody titres 
statistically different from those obtained 7 weeks after i.m. administration of 
S. equi cell wall protein in solution, alone or with CpG (P<0.001) (Figure 6.3A). 
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Among S. equi extract-entrapped particulate systems, PLA-PVAExt gave 
higher IgG antibody titres than those elicited by PLA-GCSExt and PLA-SPExt 
formulations, although not being statistically different from those obtained 
with PLA-ALGExt and PLA-OAExt adjuvantised samples. IgG antibody levels 
remained the highest in animals vaccinated with PLA-PVASeM+CpG (P<0.001) 
(Figure 6.2A). It seems that, at this time point it starts to be evidenced that the 
immune response is dependent on the type of antigen, for particle similar 
composition, as responses obtained with PLA-GCSSeM and PLA-SPSeM were 
statistically higher than the correspondent particles entrapping S. equi extract 
(P<0.014 for PLA-GCSSeM vs PLA-GCSExt, P<0.001 for PLA-SPSeM compared 
with PLA-SPExt) (Figures 6.2A and 6.3A). An opposite tendency was obtained 
for S. equi extract-entrapped PLA-ALG and PLA-OA particles, which induced 
higher IgG levels than SeM-loaded PLA nanospheres with similar 
composition (P<0.038 for PLA-ALGExt vs PLA-ALGSeM, P<0.001 for PLA-OAExt 
compared with PLA-OASeM).  
Figure 6.3– Anti-S. equi specific IgG (A), IgG1 (B) and IgG2a (C) titres elicited by 
immunisation groups. Animals were inoculated twice (days 0 and 21) intramuscularly 
with one of the following formulations: S. equi enzymatic extract proteins loaded 1) 
PLA-PVAExt, 2) PLA-GCSExt, 3) PLA-ALGExt, 4)PLA-SPExt, 5) PLA-OAExt and 6) 
(PLA-PVAExt+CpG) nanospheres; 7) S. equi extract alone (Ext);  8) (Ext+CpG) mixture (n=4, 
mean±S.D.).   
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At the end point of the study, PLA-GCSSeM formulation gave IgG levels 
higher than all formulations tested, inclusive PLA-PVASeM+CpG group 
(P<0.005), while PLA-ALGSeM formulation did not elicited IgG levels different 
from those obtained with the i.m. administration of the recombinant protein 
(Figure 6.2A). On the other hand, PLAExt nanospheres immunisation groups, 
besides inducing IgG response higher than those raised by groups vaccinated 
with antigen in soluble form (P<0.001), gave levels of comparable magnitude 
among particulate vaccinated groups. Besides these differences observed 
between SeM and S. equi extract groups during the in vivo study, at the end of 
the experiment significant differences were observed just when those antigens 
were entrapped in PLA-GCS and PLA-ALG. More specifically, levels of IgG 
antibodies elicited by PLA-ALGExt were markedly higher than those resultant 
from PLA-ALGSeM suspension administration (P<0.001). On the contrary, 
PLA-GCSSeM nanospheres, did not only rise IgG titres noticeably higher than 
those assessed in the serum of mice vaccinated with PLA-GCSExt (P=0.001), 
but also elicited the highest response among all immunisation groups 
(P<0.001) (Figures 6.2A and 6.3A). 
 
IgG SUBTYPE PROFILING 
Figures 6.2B, 6.2C, 6.3B and 6.3C show the evolution of IgG subtypes specific 
responses for 12 weeks against S. equi antigens, elicited after mice i.m. 
vaccination. At two weeks post-immunisation, anti-SeM IgG subtypes 
antibody levels elicited by SeM-entrapped PLA nanospheres were higher than 
those assessed when antigen in soluble form was administered to mice, with 
an exception of IgG1 titres induced by PLA-SPSeM nanospheres (Figures 6.2B 
and 6.2C). The enhancement of IgG1 antibodies using PLA-PVASeM, 
PLA-GCSSeM and PLA-ALGSeM nanospheres suspension was similar, besides 
lower than that observed for PLA-PVASeM+CpG group (P<0.01) (Figure 6.2B). 
At this time point, PLA-GCSSeM, PLA-ALGSeM and PLA-SPSeM nanospheres 
improved IgG2a antibody titres, and these were statistically different 
(P<0.001) from that measured in the remaining immunisation groups (Figure 
Chapter 6 
 
244 
6.2C). After boosting, all SeM-entrapped formulations highly enhanced the 
IgG1 response, exception for PLA-OASeM formulation that slightly increase 
the immune response between week 2 and 4 (Figure 6.2B). Nanospheres 
containing SP, PLA-PVASeM and PLA-ALGSeM induced similar IgG1 
antibodies levels.  In the case of PLA-GCSSeM, the improvement in IgG1 
antibody response was the highest, being statistically different from all other 
immunisation groups (P<0.001). This formulation also induced the strongest 
IgG2a response, although not different from PLA-ALGSeM and PLA-SPSeM 
(Figure 6.2C).  At week 7, IgG1 antibody response profile obtained for 
different PLA nanospheres was maintained, except for PLA-SPSeM, which 
antibody titres drastically decreased (Figure 6.2A). Furthermore, the IgG1 
responses obtained with PLA-ALGSeM, PLA-GCSSeM, PLA-PVASeM and 
PLA-PVASeM+CpG were similar 7 weeks after animals’ vaccination. On the 
other hand, at weeks 7 and 12 the enhancement of IgG2a antibody levels 
using SeM-entrapped nanospheres was higher than that observed for the 
soluble form of the antigen (P<0.04), despite its admixture with CpG 
(P<0.049) (Figure 6.2B). CpG co-administration with PLA-PVASeM 
nanospheres induced the highest IgG2a titres from week 7 until the end of the 
experiment, but those were not different from those elicited by PLA-GCSSeM 
formulation. At the end of the experiment, PLA-PVASeM, PLA-GCSSeM and 
PLA-SPSeM improved IgG1 antibodies titres at the same level, but statistically 
higher than that obtained for groups vaccinated with SeM antigen, alone or 
admixed with CpG (P<0.04) (Figure 6.2A). The inclusion of the additional 
adjuvant CpG in PLA-PVASeM nanospheres had a beneficial impact, as this 
formulation was the one that elicited the highest IgG1 antibody levels for 
prolonged periods of time. Even though, the improvement of IgG2a levels 
induced by this formulation was not different from that observed for 
PLA-GCSSeM and PLA-ALGSeM nanospheres (Figure 6.2B).  
The IgG subtype titres demonstrated that S. equi enzymatic extract-entrapped 
nanospheres led to differential degree of enhancement in antibody titres, 
when compared with SeM-entrapped carriers. At two weeks 
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post-immunisation, IgG1 antibodies elicited by PLA-PVAExt formulation were 
statistical different from those assessed in serum collected from mice 
immunised either with soluble antigen (P<0.001), or S. equi extract polymeric 
formulation (P<0.009) (Figure 6.3B).  Nevertheless, the IgG1 response 
obtained with PLA-PVAExt nanospheres were not different from those 
observed when admixture of those particles with CpG was used for 
vaccination. The enhancement of IgG2a antibodies using PLA-SPExt and 
PLA-OAExt was higher than that observed for the remaining immunisation 
groups (P<0.001) (Figure 6.3C). A marked increase was obtained in IgG1 and 
IgG2a levels induced after boosting, and antibody titres were sustained at 
high levels throughout the post-immunisation period (Figures 6.3B and 6.3C). 
IgG1 responses comparable in magnitude were elicited by PLAExt 
nanospheres from week 7 until the end of the experiment (Figure 6.3B). IgG2a 
titres enhancement induced by PLA-SPExt nanospheres was statistically 
significant among all other groups (P<0.001), and these differences persisted 
until week 12, being only similar to antibody levels obtained at the end of the 
study for PLA-OAExt particles suspension (Figure 6.3C). Besides these 
differences, PLA-GCSExt elicited IgG2a response that was markedly higher 
than those determined in PLA-PVAExt (P<0.017) and PLA-ALGExt (P<0.004) 
groups, and not different from that resultant from PLA-PVAExt 
co-administration with CpG. It is important to state that at the end of this 
study, all particulate formulations induced IgG2a levels higher than those 
induced by the soluble antigen, even when associated to CpG adjuvant 
(P<0.001). 
Over the entire period, no improvement was obtained in antibody titres when 
immunising admixture of particles with CpG, as this formulation induced 
IgG1 levels comparable to those assessed in serum of animals vaccinated with 
whichever particulate formulation. On the other hand, PLA-SPExt and 
PLA-OAExt nanospheres gave in fact higher IgG2a titres than those obtained 
by the addition of CpG to PLA-PVAExt nanospheres (P<0.017), which were not 
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different from those elicited by the cationic preparation (Figures 6.3B and 
6.3C). 
CYTOKINES PROFILES 
Cytokine levels can be used to characterise the type of Th2/Th1 immune 
response [17]. From Figure 6.4 it can be seen that formulations successfully 
induced the production of cytokines Th1 and Th2-related. 
Similarly to the IgG2a/IgG1 relation, IL2, IL6, IFN-γ cytokines secreted by 
splenocytes of mice pre-immunised with PLA-ALGSeM formulation were 
markedly different from those obtained in splenocyte cultures of mice 
vaccinated with any other formulation (P<0.003). It is possible to distinguish a 
preferential secretion of Th1 pathway-related cytokines by cells 
pre-stimulated with whichever SeM-entrapped PLA nanospheres. Even so, 
lower difference between the Th1/Th2 type of immune response was 
observed in cytokines quantified in the culture of splenocytes of PLA-OASeM 
nanospheres-immunised group, as the lowest IL2 and IFN-γ titres were 
detected when mice were treated with these formulation (P<0.031).  
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Similarly to SeM-entrapped nanospheres, a mixed Th1 and Th2 immune 
responses were obtained in animals vaccinated with particles containing S. 
equi enzymatic extract, as all of these vaccine formulations induced detectable 
IL2, IL4, IL6 and IFN-γ levels. PLA-OAExt immunised groups produced the 
highest amount of the Th1 cell cytokines IL2 and IFN-γ  quantified in all S. 
equi extract groups tested (P<0.007), which is in agreement with IgG2a titres 
(Figures 6.3C and 6.4). The improvement of IL6 quantified in splenocyte 
cultures of mice that have been vaccinated with PLA-OAExt test group was 
statistically significant among all vaccination groups, except when compared 
with PLA-PVAExt+CpG nanospheres immunised mice. IL4 highest 
concentration was quantified in mice treated with latter formulation (P<0.015) 
(Figure 6.4). 
 
B 
C
yt
ok
in
es
 c
on
ce
nt
ra
tio
n 
(p
g/
m
l) 
Figure 6.4– Cytokines (IFN -γ, IL2, IL4, IL6 and IL12) titres in supernatant of cultured 
splenocytes following their stimulation for 48 hours with 2 μg/ml of recombinant SeM (A) 
or S. equi extract (Ext, B), accordingly to antigen-loaded PLA nanospheres composition 
(mean ± S.D.; n=4).  
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DISCUSSION   
The development of an efficient vaccine is needed to guarantee horse 
protection against S. equi invasion, as 75% of those animals in convalescence 
present a protective immunity that can persist for 5 years or longer, mainly 
direct to SeM, although the nature of this defence is not yet fully understood 
[1, 2, 7, 13]. SeM binds to fibrinogen and prevents C3b factor deposition on 
bacterial surface, resulting in its antiphagocytic properties [11, 12, 18].  This S. 
equi M-like protein is therefore an antiphagocytic protein known as the most 
protective S. equi antigen, due to the specific anti-SeM opsonogenic antibodies 
found in convalescent animals. Consequently, an extensive research has been 
directed to the development of a vaccine based in this protective S. equi 
antigen and it is generally recommend horse vaccination against this disease. 
Nevertheless, despite the development of a high number of research projects, 
since the 1980s, directed to the production of an efficient vaccine, the results 
so far obtained with commercially available and widely used preparations are 
disappointing [2, 11]. These vaccines, frequently based on inactivated S. equi 
or SeM-rich extracts, alone or co-administered with adjuvants, have not only 
not contributed for the control of strangles, and consequently for horse 
protection against S. equi infection, but also induced strong adverse reactions 
[2, 7, 19]. Strepguard® co-administered with Havlogen® (Intervet Ltd), 
Equivac® S and Equivac 2 in 1 (Pfizer Animal Health Pty Ltd) are vaccines 
based on S. equi enzymatic extract proteins administered to animals by an i.m. 
injection in their necks. Since 1997, an avirulent S. equi genetically modified 
(Pinnacle®, Fort Dodge) is being commercialised in USA market. This 
intranasal (i.n.) vaccine has been able to reduce the clinical signs usually 
developed upon a S. equi infection, and was developed in order to stimulate 
systemic and mucosal immune responses comparable to that observed in 
convalescent animals. Despite eliciting the production of nasopharyngeal 
antibodies, Pinnacle® treated animals develop not only a short protective 
immune response, but also strong adverse reactions, which prevented its 
acceptance by EMEA [10, 18, 20]. In 2004, a vaccine consisting of an 
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attenuated strain of S. equi (Equilis StrepE®, Intervet Ltd) was approved in the 
UK and USA. The administration of Equilis StrepE® resulted in a total 
protection of animals, but important adverse reactions were developed in the 
local of injection. As a result, this vaccine is now administered by submucosal 
injection in the upper lip. Besides, a short protection has been achieved in 50% 
of treated animals, which might limit its usefulness [2, 9, 10]. In fact, all 
Equilis StrepE® batches have been recently removed from the market, and its 
utilisation is only authorised in Africa [21]. Therefore, the development of an 
efficient and safe strangles vaccine is still to be achieved.  
Some researchers believe that the effective protection of horses against 
strangles depends on the stimulation of multiple epitopes to induce high 
levels of local and systemic antibodies, which can be achieved by the 
administration of a mixture of S. equi cells wall immunogenic proteins [2, 22]. 
On the other hand, others try to clarify the bacterial infection mechanisms in 
order to identify further virulence factors as potential vaccine candidates [1, 
18, 23].  
The extensive research based on the study of mechanisms involved in the 
recognition of microorganisms and in their interaction with cells of the 
immune system, such as macrophages and dendritic cells, has contributed for 
the crescent identification of new adjuvants and consequently for the 
development of alternative vaccines [24, 25]. More recently, researchers are 
trying to identify new S. equi potent antigens, such as bacterial cell surface 
proteins, alone or in association, suitable for the induction of high level of 
antibodies and animals protection [1, 22].  
Our study compares the immune responses elicited by an economic 
alternative S. equi extract to the highly purified recombinant SeM, when 
carried by polymeric particles. Their particulate form, along with their antigen 
depot effect is the main aspect to consider in the potential adjuvant of 
polymeric nanospheres, which has been extensively referred in the literature 
[24, 26]. The stimulation of a prolonged immune response is dependent on the 
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maintenance of structural integrity of proteins and immunogenicity during 
formulation, storage and also throughout their release to the biological fluids.  
Spherical PLA particles containing PVA, GCS, OA, SP or ALG, presented a 
mean size diameter lower than 500 nm. Larger particles were obtained when 
GCS was used in particles formulation, which can be attributed to the higher 
viscosity of the primary w/o emulsion aqueous inner phase. As it was 
expected, in contrast with all other PLA nanospheres prepared in the present 
work, PLA-GCS nanospheres presented a positive charge, but all values were 
higher which means that the particles did not tend to agglomerate [27]. 
Surface charge influences particle uptake, being the positively charged those 
that are quickly phagocytosed, which seems to be a result of the ionic 
interactions established between positively charged particles and the negative 
charge of phagosomes. Particles containing OA presented the highest loading 
capacity, which in accordance with the results previously obtained by our 
group, when S. equi extract was entrapped in PLA nanospheres with similar 
composition [15]. This absorption enhancer was dissolved in the organic 
phase of the double emulsion w/o/w, and therefore the higher resultant 
viscosity might have prevented protein diffusion from internal aqueous 
phase, contributing for higher entrapment efficiency. PLA nanospheres 
surface modification by ALG is able to stabilise the secondary emulsion by 
limiting interchanges between external aqueous and the organic phase of the 
first emulsion, resulting in an improvement on antigen entrapment as it was 
obtained in our study, comparative to PVA stabilised carriers, which were the 
ones with lower amount of protein entrapment [25, 27]. Therefore, the 
inclusion of additional adjuvants had a beneficial effect in protein 
entrapment. Electrophoresis demonstrated that the protein integrity was 
maintained after entrapment (Figure 6.1). Once again it was evidenced that 
the double emulsion (w/o/w) solvent evaporation technique is safe and 
adequate to preserve S. equi proteins structural integrity and, as shown in 
previous studies by immunoblotting analysis, their immunogenicity [14-16]. 
Several groups have already demonstrated that solvent evaporation technique 
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does not change the activity and immunogenicity of antigens entrapped in the 
inner phase of the double emulsion. Particle physicochemical characteristics 
are in agreement with those normally presented by these types of 
nanospheres [27, 28].  
Previous studies developed by our group have demonstrated the adjuvant 
potential of PLA nanospheres, adsorbed or encapsulated with S. equi 
enzymatic extract proteins, after their i.n. administration, especially when 
compared with those obtained with the S. equi antigens alone [15]. These 
promising results have encouraged us to investigate the use of this vaccine 
delivery system as the first polymeric carriers for the recombinant 
antiphagocytic SeM. Therefore, for the first time, recombinant SeM proteins 
were entrapped in polymeric particles and their immunogenicity was 
evaluated and compared to those elicited with S. equi cells wall proteins. 
Polymeric particles are extremely versatile systems and their formulation with 
polymers with complementary characteristics, their association to adjuvants 
with distinct mechanisms of action, and the entrapment of multiple antigens 
are currently some of the commonly used approaches in order to optimise 
these carriers to obtain the desirable immune responses [24, 29]. As a result, 
PLA nanospheres containing the mucoadhesive polymers GCS [30] and ALG 
[27] to improve the time of particles residence nearby cells, and absorption 
enhancers SP [31] and OA [32, 33] were used in order to evaluate their effect 
in the cellular and systemic immune responses developed against the S. equi 
antigens studied.  
Despite particles composition and the type of antigen, humoral immune 
responses were generally improved by nanospheres suspension, when 
compared with free antigens, and it was not observed the development of 
adverse reactions in any group of test. In order to evaluate the synergic effect 
of the inclusion of a second adjuvant, CpG was chosen as it is a potent 
humoral, but also mucosal and cellular immune responses adjuvant by 
increasing preferentially the activity of Th1 cells. Nevertheless, at the end of 
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the experiment, IgG levels obtained with PLA-GCSSeM nanospheres were 
statistically different from those elicited by CpG adjuvantised formulation 
(P<0.005), and similar levels were induced by all S. equi extract-entrapped 
particulate systems. These results also reflect that the adjuvant effect of 
polymeric carriers tested, more specifically their influence in Th1/Th2 bias in 
immune response, was dependent in part on the type of antigen that is 
entrapped in particles with similar composition, which is generally agreed 
and has been extensively discussed in the literature [34]. Chitosan, besides its 
positive charge, has the ability to open tight junctions, increasing the 
paracellular transport and therefore the amount of antigen taken up by cells 
[35]. Moreover, particles polymeric composition, size, antigen load, route of 
administration and association to other adjuvants are factors that mainly 
influence the uptake of these carriers, their transport to lymphatic nodes and 
interaction with tissues [36]. It is possible to state that, at the end of the study, 
PLA-GCSExt nanospheres induced IgG1 titres statistically higher than those 
elicited by PLA-ALGSeM, but no other difference was obtained among all other 
particulate carriers. PLA-PVASeM, PLA-ALGSeM and PLA-OASeM formulations 
elicited higher IgG2a antibodies levels than the correspondent S. equi extract-
entrapped particles.  
A more balanced IgG2a/IgG1 immune response was obtained after i.m. 
administration of PLA-SPSeM, PLA-GCSExt, PLA-OASeM and PLA-OAExt 
particulate systems. The CpG admixture with S. equi antigens entrapped in 
PLA-PVA nanospheres increased mainly the Th1 immune response pathway, 
contributing for a more equilibrated immunity than of particles alone. Overall 
antibody response, it seems that the co-administration of CpG along with 
PLA nanospheres stabilised with PVA did not led to differential degree of 
enhancement in antibodies titres. Even so, PLA-PVASeM+CpG induced the 
highest IgG1 titres among all other immunisation groups, despite particles 
composition or type of antigen. CpG biased the immune response towards a 
Th1 response relatively to the PLA-PVA nanospheres encapsulated either 
with SeM or S. equi extract proteins, as measured by IgG subclass analysis. 
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Therefore, the addition of this potent adjuvant to the PLA nanospheres 
provided an improvement of antibody response elicited by S. equi antigens-
entrapped PLA-PVA nanospheres alone. Even so, mainly formulation 
containing the mucopolysaccharides GCS and ALG, in the case of SeM, or 
GCS and both absorption enhancers SP and OA, for those entrapping S. equi 
extract, were able to improve IgG2a responses when compared with that 
elicited by PLA-PVA+CpG formulation. From these results it seems that the 
immune response elicited by nanospheres was not influenced by particle size 
differences, as PLA-GCSSeM and PLA-ALGSeM were larger than the remaining 
PLA carriers.  
Cytokines secreted by splenocytes of mice pre-immunised with polymeric 
formulations corroborate the IgG subtypes titres measured in the serum of 
animals. A comparable pattern was obtained after i.n. immunisation of S. equi 
extract-entrapped PLA nanospheres, in a previous study performed by our 
group [15]. IL4 cytokine levels were the lowest when compared with other 
cytokines assessed in splenocytes supernatants, while the concentration of 
IFN-γ was the highest for all particulate formulations. These results indicate a 
predominant Th1 induction, which is in accordance with results previously 
obtained for these S. equi-entrapped carriers after their i.n. administration [15]. 
In fact, other researchers have reported that antigens carried in a particulate 
form favour the stimulation of Th1 immune response [37, 38]. No significant 
levels of cytokines was detected in culture of splenocytes collected from mice 
treated with antigen in the soluble form, which supports that the antigen 
co-delivery in nanospheres was vital for the stimulation of measurable Th1, 
but also Th2 response throughout the period of study. 
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CONCLUSIONS 
The present studied has showed that vaccination with SeM and S. equi extract 
antigens-entrapped in PLA nanospheres containing GCS, OA, SP and ALG 
gave a considerable antibody and cellular immune responses, after i.m. 
administration in mice. In addition, S. equi extract and SeM-loaded PLA-GCS 
nanospheres induced not only IgG and IgG2a subtypes levels, but also IL2 
and IFN-γ cytokines titres at least as high as those elicited by PLA-PVA 
nanospheres admixed with the potent CpG. Results suggest that these PLA 
carriers are suitable to target phagocytic cells such as macrophages or 
dendritic cells, being promising candidates for an effective and safe vaccine 
against strangles, as it did not develop adverse reactions as a consequence of 
S. equi antigens loaded PLA nanospheres.  
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Overview 
A review of the literature brings together some recent ideas about possible 
strategies to control strangles (Chapter 1). In particular, it seems that despite 
extensive efforts regarding prevention of large outbreaks of this endemic 
disease, S. equi infection remains spread worldwide, causing important 
economic loss to horses industry, important for the financial equilibrium of 
some countries, not only due to the cost of treatment and occasionally the 
death of affected animals, but also quarantine measures needed to be adopted 
in order to prevent the contamination of other animals.  
Affected populations present high morbidity levels and infection may cause 
chronic illness. Despite the recent development of new and sensitive 
diagnostic tests which are currently available in the market, strangles long 
convalescent period and S. equi infected animals presenting no signs of the 
disease are limiting the effective contribution of these tests for the control of 
this endemic infection in horses. 
Several research groups in industry and academic institutions all over the 
world are trying to understand the complex pathogenesis of strangles, which 
along with S. equi and S. zooepidemicus genome-sequencing, are contributing 
for the identification of several virulence factors and better understand their 
roles at different stages of this infection. It has been strongly recommended 
that improved strategies to control strangles include the development of 
efficient vaccines, as the commercially available ones have not made major 
improvements in addition to frequently produce strong adverse effects and 
induce poor and short immunity.  
Previous studies have suggested that blood circulating antibodies (systemic 
immune response) are not as important for animal protection as those locally 
produced in the nose and throat mucosae, suggesting the nasal mucosa as a 
promising immunisation route, even if the first response complements the 
latter. As a result, protective immune response may be triggered by using S. 
equi antigens, combined or isolated, associated to a mucosal adjuvant.  
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The therapeutic use of particulate drug carriers for immunisation purposes is 
one of the most promising strategies to combat infectious diseases.  These 
vehicles, among other advantages, are able to release antigen in a sustained 
manner, which allows a depot effect and consequently enhances their 
immunoadjuvant properties. However, the association of protein antigens to 
polymeric particulate carriers often presents limitations related to antigen 
integrity and long-term stability, but previous experiments have shown that 
adequate modifications of those formulation methods are able to minimise 
antigen instability and preserve its biological activity. In fact, S. equi whole 
cells-entrapped in PLGA microparticles maintained their antigenicity as they 
protected mice against an experimental S. equi infection. These results 
obtained in a previous work by our research group have shown that 
particulate systems may be a potential adjuvant for S. equi antigens. 
Moreover, the delivery of S. equi antigens need to receive further attention in 
order to fully characterise the elicited immune responses, as well as to 
develop alternative carriers, cheaper but still effective, for new S. equi 
antigens, as PLGA is an expensive polymer that may compromise the future 
success of this veterinary vaccine.  
Therefore, the major goal of the studies herein presented has been to develop 
alternative polymeric carriers able to be associated to S. equi antigens, isolated 
or in the form of SeM-rich extracts, without compromising their structure 
integrity and antigenic properties, not only during formulation processes, but 
also after their administration in vivo. After obtaining those polymeric 
particles with the desired physicochemical characteristics, in vivo studies were 
performed to assess the effect of polymeric composition, antigen type of 
association, administration route, S. equi protein antigen nature and 
co-administration of different adjuvants in the immune response.  
To the best of my knowledge, Chapter 3 describes for the first time the 
adsorption of S. equi protein antigens onto the surface of particulate carriers. 
Non-aggregate PCL microspheres (< 3 µm) were formulated by (w/o/w) 
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emulsification solvent evaporation method and S. equi enzymatic extract 
proteins were successfully associated to their surface, with no evidence of any 
change in protein pattern of migration. Therefore, non-toxic positively and 
negatively charged particles, stabilised respectively by CS and PVA, were 
administrated by i.m. route to mice in order to evaluate the adjuvant 
properties of those adsorbed systems. This was in fact a preliminary study, in 
order to confirm their immunoadjuvant properties after association to S. equi 
antigens.  The systemic (IgG and IgG subtypes) antibody and cytokine levels 
confirmed that PCL microspheres, despite their surface charge were able to 
enhance significantly the immune response, when compared to the soluble 
antigens. Moreover, cytokines attributed to a predominant Th1 immune 
response were more pronounced when the CS adjuvanted PCL microspheres 
were used. Therefore, once it was confirmed the potential adjuvant of these 
polymeric carriers over 300 days and after one single dose, it was important to 
test those PCL carriers for nasal immunisation in a mice model.  
As size matters, it was performed a scale-down in particles size (Chapter 4), 
and the effect of mucoadhesive polymers (GCS and ALG) and absorption 
enhancers (SP and OA) in their adjuvant properties was further evaluated. 
Composition influenced particle size, but all formulations presented VMD 
lower than 500 nm. In this study, all S. equi antigen-adsorbed or -encapsulated 
PCL nanospheres were able to increase the level of concentration of systemic 
and mucosal antibodies over 12 weeks. Similarly, cytokines produced by 
splenocytes obtained from those immunised groups, after being co-stimulated 
with S. equi proteins, indicated a mixed Th1/Th2 response. As it was 
expected, the antibody profile levels were distinct for adsorbed and 
entrapped systems, which is in accordance with the in vitro release studies 
performed with those nanospheres.  
Besides being extensive and complex the integrations and complete 
comparison of humoral, local and cellular immune response elicited by S. 
equi-adsorbed and -entrapped PCL nanospheres, it is possible to conclude that 
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along with particles composition, the type of antigen association determined 
the nature of the immune responses obtained. In fact, particles presenting 
exactly the same polymeric composition exhibited a different antigen profile 
accordingly to the type of antigen association. Therefore, S. equi 
antigen-entrapped PCL-ALG particles seem to be the one that overall induced 
a more equilibrated immune response, while among the adsorbed systems 
that role seems to better suit the antibodies and cytokines levels induced by 
PCL nanospheres formulated with GCS. It is interesting to see that, besides all 
particulate systems did not fail to induce immune response against S. equi, the 
mucoadhesive polymers presented an additional adjuvant effect over the 
absorption enhancers tested. Moreover, it seems that the formulated PCL 
nanospheres are potent adjuvants as it was not identified a synergic adjuvant 
effect when CTB was co-administered with PCL-PVA carriers.   
The i.n. administration route and nanometric PCL particles (Chapter 4) 
elicited antibodies titres higher than those obtained when PCL microspheres 
were administered by s.c. route (Chapter 3). Therefore, the next experimental 
study was performed using PLA nanometric particulate carriers (Chapter 5).  
The aim was to compare the adjuvant potential of more easily formulated 
PLA particles for S. equi antigens, with that presented in the previous study 
for the hydrophobic PCL (Chapter 4).  Similarly to PCL nanospheres, this 
study confirmed the potential adjuvant of S. equi antigens-loaded PLA 
nanospheres, and again the mucopolysaccharide GCS induced the most 
prominent immune response. Locally produced IgA antibodies elicited by 
PLA nanospheres were higher than those detected in lung washes of mice 
immunised with loaded PCL nanospheres. Similar tendency was observed for 
systemic antibodies. Therefore, the positive relation between hydrophobicity 
and cellular uptake could not be confirmed by our studies, which may be due 
to a slower release of the antigen from PCL nanospheres, as the immune 
responses were followed only till 12 weeks after priming. In order to confirm 
these observations, a long-term study should have been performed, which 
unfortunately was not possible due to time and study cost limitations. In 
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addition, a thorough hydrophobicity characterisation could have helped to 
clarify this point.  
New generation antigens are obtained by biotechnological methods and 
include the production of recombinant proteins previously identified as 
potential virulence factors of strangles causal agent.  SeM is still known as the 
most protective S. equi antigen and apparently a protective immunity requires 
the production of specific anti-SeM antibodies, although the nature of this 
defence is not yet fully understood. This protein has been extensively studied 
and characterised by Prof. Timoney, Kentucky USA. Due to its high cost, a 
small amount was purchased, just the enough to perform a comparative and 
preliminary study (Chapter 6). Besides the nasal mucosa being the desired 
target, the first association of the pure recombinant SeM to polymeric 
particulate carriers would have to be evaluated by i.m. route. Fortunately, 
particle production formulation protocol allowed the formulation of all 
particulate systems used in previous chapters, with a theoretical loading of 
1% (w/w).  At the end of the experiment, PLA-GCS and PLA-OA 
nanospheres containing S. equi enzymatic extract constituted alternative cost-
effective formulation to those loaded with the more expensive antigen 
product SeM, being inclusive able to induce a balanced IgG2a/IgG1 immune 
response. Similarly to CTB, CpG co-administered to S. equi antigens loaded 
PLA-PVA nanospheres generally did not led to differential degree of 
enhancement in antibodies titres when compared with the remaining groups 
vaccinated with particulate systems, except PLA-PVA ones.  
Finally, it is possible to conclude that the main goal of this thesis was 
achieved as an alternative polymeric carrier for delivery of S. equi antigens 
able to induce both mucosal and systemic immune responses was developed 
and characterised.  
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Future directions 
 
Taken together, the results of this thesis confirmed the versatility of polymeric 
particles and indicated their ability to protect S. equi antigens from 
extracellular degradation, but also to be taken up by APCs. Systemic, mucosal 
and cellular immune responses assessed 12 weeks after animal vaccination 
show that polymeric nanoparticles were able to carry and sustain release S. 
equi antigens over an extended period. They also modulate antigens 
processing and/or presentation by the immune system. Additionally, the 
delivery of S. equi antigens associated to polymeric nanoparticles should 
receive further attention in order to characterise the mechanisms responsible 
for their uptake by APCs and strong activity after being loaded in particles. It 
would be interesting to study the body distribution of those particles after 
being administered by i.n. route.  
The particulate carriers developed during this PhD thesis are promising 
adjuvants for a safe vaccine against strangles, with no toxicity issues 
associated to their utilisation, in contrast to other adjuvants that have been 
associated to S. equi antigens. These studies bring new insights into the 
strangles prevention field, but unfortunately the study was not concluded. In 
fact, the results could have been improved if a challenge study had been 
performed. The potent adjuvant properties of polymeric particles formulated 
with GCS could have been confirmed by the experimental infection of 
vaccinated animals, in order to assess in fact, the desired conclusion:  the 
formulation is protective! Unfortunately, those infectious studies were not 
allowed to be conducted in the facilities of London School of Pharmacy, one 
of this PhD host universities, where the in vivo work was developed. Even so, 
these challenge studies must be done in the future in order to further expand 
their use in the development of a strangles vaccine. As it is an expensive and 
time-consuming experiment, GCS adjuvanted polymeric formulation should 
be selected to confirm if the obtained immunity is protective.   
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It is as well accepted that the immunological responses induced by mice and 
horse are different, and therefore the choice should be done in the target 
animal. Therefore, the next step would be the test of this selected S. equi 
antigen-loaded polymeric formulations in a horse model. In fact, this work  
has already contributed for the establishment of a interesting collaboration 
with Prof. Ian-Ingmar Flock, Karolinska Institut, Sweden, whose lab has been 
extensively involved in the identification of potent S. equi protein antigens 
(SclC, CNE, EAG, FNZ, SFS), which have been tested in mice and horses. 
Further application of these particles is expected to be the study of their 
adjuvant properties for those recombinant S. equi antigens, as well as the test 
of the best formulation obtained in this thesis for less expensive S. equi 
enzymatic extract in horses.  
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Appendix I 
 
RESIDUAL SOLVENT QUANTIFICATION 
In order to assess the dichloromethane (DCM) residual solvent present in 
particles after freeze-drying, a Nuclear Magnetic Resonance (NMR) 
spectroscopy technique was undertaken. Briefly, 1 ml of acetic acid-d4 was 
added to plain particles (30 mg) and sodium formate (20 mg; Sigma Aldrich 
Co., UK) previously accurately weighed into the same vessel. Both samples 
(PCL-PVA, PCL-CS0.75L, and PCL-ALG) and standards (5 µl, 10 µl, and 15 µl 
of DCM) were completely dissolved by sonication for 15-30 min, and the 
solution obtained was transferred into a 5 mm NMR tube. The 1H-NMR 
spectra were acquired on a Bruker spectrometer in which the temperature 
was set to 300 K and was recorded a high field proton NMR (≥400 MHz) 
using a 45 degree pulse and a 60 second pulse repetition time. The spectrum 
was referenced by setting the chemical shift of the methyl signals due to 
residual acetic acid to 2.03 ppm. Accurate integrals were obtained for the 
current standard and residual DCM from the spectra. 
 
STRUCTURAL INTEGRITY OF ADSORBED ANTIGENS 
The freeze-dried microspheres were assessed by SDS-PAGE, in order to 
evaluate the effects of processing parameters on the structural integrity of the 
adsorbed proteins. In brief, antigen was extracted from the different 
preparations by dispersing 10 mg of particles in 200 µl of 5% (w/v) PBS-SDS 
(pH 7.4), which were followed by 2 hours of incubation at 37ºC in an orbital 
oven shaker. Samples were then vortexed for 30 seconds in order to get a 
homogeneous dispersion and then heated for 95ºC/3 min, with the Laemmlie 
sample buffer (Bio-Rad, UK).  Formulations (20 µl), S. equi enzymatic extract 
proteins prior to adsorption (10 µl of a 2.5 mg/ml solution) and broad range 
of prestained SDS-PAGE standards (10 µl; Bio-Rad, UK) were loaded onto 
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10% (w/v) polyacrylamide (Bio-Rad, UK) mini-gel and run with a constant 
voltage of 100 V for 120 minutes using a Bio-Rad 300 power pack (Bio-Rad, 
Hercules, CA, USA). The extracted proteins are shown on the gel prior to 
adsorption as a series of broad bands. Gels were visualised using 
SimplyBlueTM SafeStain solution (Invitrogen, USA), and imaged using a UVP 
gel scanning camera. 
 
IN VITRO CYTOTOXICITY OF PCL MICROSPHERES 
Cytotoxicity of PCL microspheres, specifically PCL-PVA, PCL-ALG, 
PCL-CS0.75L, PCL-CS0.75M and PCL-CS0.75H, to Mouse BALB/c monocyte 
macrophage cells (J774A.1 cells line, American Type Culture Collection; 
ATCC#TIB-67) was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay, in which the absorbance was 
measured at 570 nm by Dynex MRX Microplate Reader (Dynex, UK). All the 
experiment was done in triplicates.  
These cells were maintained in 75 cm2 vented  tissue culture flasks, in 
Dulbecco`s modified Eagle’s (DMEM; Sigma Aldrich Co., UK) medium with 4 
mM glutamine (Sigma Aldrich Co., UK) plus 10% fetal bovine serum (FBS; 
Gibco BRL, UK), 100 U/ml penicillin and 100 µg/ml streptomycin (Sigma, 
Poole, Dorset, UK). Briefly, cells (100µl) were seeded in 96-well plate (Fisher, 
UK), at 5000 cells/well in a complete DMEM, and let to attach for 24 hours in 
a humidified incubator at 5% CO2. The media was then removed, and 100 µl 
of diluted antigen, PEI (polyethyleneimine) and plain particles, all previously 
dissolved or suspended in serum free DMEM at different concentrations (5 
mg/ml, 2.5 mg/ml, 1 mg/ml, 0.5 µg/ml, 0.1 µg/ml, 0.025 µg/ml and 0.01 
µg/ml), were loaded onto cells, shaken gently and left for 24 hours at 37ºC in 
a humidified incubator at 5% CO2. A solution (25 µl) of MTT (5 mg/ml; Sigma 
Aldrich Co., UK) was added to cells and the plate was again left in the CO2 
incubator at 37ºC, for 4 hours. The media was then removed with a needle 
and syringe and the cells were washed with 200 µl of sterile PBS (OXOID, 
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UK). After that, 200 µl of dimetilsulphoxide (DMSO; Sigma Aldrich Co., UK) 
were added and pipetted up and down in order to dissolve the eventually 
formed crystals. The plate was subsequently incubated at 37ºC for 5 minutes 
to dissolve air bubbles and after that transferred to a Dynex MRX Microplate 
Reader (Dynex, UK). The optical density of solubilised formazan product was 
determined using a spectrophotometer (with a 550 nm and 620 nm filter as a 
reference). Results were expressed as the percent of cell survival (OD of 
exposed versus OD of control non exposed cells). 
 
Appendix II 
1H-NMR spectra of standards  ((A) 5 µl, (B) 10 µl and (C) 15 µl DCM) and 
samples ((D) PCL-CS0.75L, (E) PCL-ALG, (F) PCL-PVA microspheres) 
(Chapter 3). 
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